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Abstract 
Subtype C HIV-1 is currently responsible for the majority of new infections in the 
world, particularly in parts of Africa where the adult prevalence rate is as high as 
15%.  In  the  absence  of  a  viable  vaccine  in  the  near  future,  the  study  of  new 
neutralising antibodies that can inhibit virus entry is urgently needed. To understand 
the subtype C HIV-1 envelopes, the env gene was cloned directly from 15 patient 
plasma samples obtained  from a  few countries  in  Africa and  in the  UK, and 18 
replication-competent  chimeric  viruses  were  created.  These  envelopes  were  then 
characterised and compared with other envelopes in standard reference panels. We 
then  exploited  the  unique  properties  of  llama  heavy-chain  antibodies  to  create 
antibody  fragments  (VHH)  that  can  recognise  HIV-1  envelopes  and  prevent 
infection. Four VHH that recognise a conformation dependent epitope on gp41 were 
isolated from a llama that was immunised with recombinant gp140 derived from a 
subtype B’/C isolate after panning of the phage libraries on recombinant gp41. These 
VHH were more potent in neutralising subtype C isolates than subtype B isolates. 
Based  on  the  success  of  an  earlier  study  on  VHH  that  recognise  an  epitope 
overlapping the CD4 binding site on gp120, a novel strategy was used to isolate 
variants of the VHH to create a family-specific VHH library. Thirty-one new VHH 
were characterised and grouped according to their neutralisation breadth against 3 
subtype  C  viruses.  The  neutralisation  breadth  of  the  VHH  correlated  with  its 
dissociation  rate  with  gp120,  and  was  found  to  be  dependent  on  3  amino  acid 
residues in the third complementarity determining region of the VHH. These VHH 
may have further use in applications such as HIV-1 microbicides development and 
immunogen design through reverse immunology.  
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1  Introduction 
This  thesis  will  describe  the  characterisation  of  subtype  C  HIV-1  envelope 
glycoproteins obtained from primary isolates, and the subsequent isolation of llama 
antibody fragments that can recognise these envelopes. This chapter will serve to 
introduce the various topics addressed in this thesis. The first section will give a 
scientific  overview  of  the  human  immunodeficiency  virus  type  1  (HIV-1)  and 
acquired  immunodeficiency  syndrome  (AIDS),  with  particular  emphasis  on  the 
molecular virology of HIV-1. The second section will concentrate on the immune 
response  to  HIV-1,  with  particular  attention  to neutralising  antibodies  (Abs)  and 
research work involving vaccines and microbicide development. The third and final 
section will introduce the humoral immune system of camelids and how single-chain 
antibody fragments from llamas can be utilised to inhibit HIV-1 infection. 
 
1.1  HIV-1 and AIDS 
1.1.1  The start of the AIDS pandemic and the discovery of HIV 
The origins of the AIDS pandemic can be traced back to June 1981 when the Centers 
for Disease Control and Prevention (CDC)  in the USA published a report in the 
Morbidity and Mortality Weekly Report on five cases of rare Pneumocystis carinii 
pneumonia in previously healthy young homosexual men in Los Angeles (Centers 
for Disease Control, 1981b). As more cases emerged, reports of this disease being 
associated with a depletion of T-helper cells were described (Gottlieb et al., 1981; 
Masur et al., 1981). In that same  year, reports of a rare and aggressive  form of 
Kaposi’s  sarcoma  in  young  homosexual  men  in  both  New  York  and  California 15 
 
appeared (Centers for Disease Control, 1981a; Hymes et al., 1981), which were also 
associated with a loss of T-helper cells (Stahl et al., 1982). Similar cases were also 
reported in Europe (du Bois et al., 1981; Rozenbaum et al., 1982; Vilaseca et al., 
1982).  This  condition  was  later  officially  named  acquired  immunodeficiency 
syndrome, or AIDS, by the end of 1982 (Centers for Disease Control, 1982). 
In a retrospective article jointly written by R. Gallo and L. Montagnier (Gallo and 
Montagnier,  2003),  they  described  their  search  for  the  causative  agent  of  AIDS 
during  the  early  years  of  the  epidemic.  As  the  cases  of  AIDS  were  observed  to 
transmit through blood and sexual activity, from mother to child, as well as through 
filtered  blood  products  containing  clotting  factors  for  haemophilia,  a  virus  was 
thought  to  be  the  transmissible  agent.    Coupled  with  the  observations  that  the 
depletion of CD4+ T-helper cells was the biological marker in AIDS patients, and 
that  animal  models  with  AIDS-like  wasting  syndrome  that  was  caused  by 
lymphotropic retroviruses were known, a search for a retrovirus or a variant of the 
human leukaemia virus (HTLV) as the causative agent of AIDS was made.  
The first direct association between AIDS and HIV was made in May 1983, when 
the group of Luc Montagnier at the Pasteur Institute in France described the isolation 
of a novel retrovirus from a lymph node of a patient with AIDS-like illness (Barré-
Sinoussi  et  al.,  1983).  Reverse  transcriptase  activity  was  detected  in  the  culture 
supernatant after 15 days of culturing the lymph node lymphocytes, indicating the 
presence  of  a  retrovirus  that  was  then  observable  under  electron  microscopy. 
Antisera to HTLV-1 did not react with cells infected with the novel virus, indicating 
that the new virus was distinct from HTLV. A protein of similar size to the p24 core 
protein of HTLV-1 was found, but was not recognised by antibodies to the HTLV-1 
p24 protein. Based on these observations, Barré-Sinoussi et al. concluded that the 16 
 
novel virus belonged to a general family of T lymphotropic retroviruses, which was 
related  to  but  distinct  from  HTLV.  The  virus  was  subsequently  called 
lymphadenopathy  virus  (LAV).  This  was  then  again  independently  isolated  from 
other patients by another group (Vilmer et al., 1984). 
A year later in May 1984, the group of Robert Gallo reported the isolation of a novel 
retrovirus from individuals with AIDS and evidence of it being the aetiological agent 
for  AIDS  in  a  series  of  articles  (Gallo  et  al.,  1984;  Popovic  et  al.,  1984; 
Sarngadharan et al., 1984; Schupbach et al., 1984). The virus was called human T 
lymphotropic virus type 3, or HTLV-3. In August 1984, Jay Levy et al. (Levy et al., 
1984) reported an additional isolation of retroviruses from patients with AIDS. This 
virus was called AIDS-associated retrovirus, or ARV. 
By 1985,  it was clear through  molecular cloning and  sequencing techniques that 
LAV, HTLV-3 and ARV belonged to the same species (Ratner et al., 1985a; Wain-
Hobson et al., 1985a). The reported nucleotide sequences, together with additional 
genetic and morphological studies (Gonda et al., 1985; Rabson and Martin, 1985; 
Sonigo et al., 1985; Wain-Hobson et al., 1985a), suggested that the AIDS virus is 
more related to the Lentivirus genus of the Retroviridae family than to the Deltavirus 
genus to which HTLV  belongs. In 1986, the  AIDS virus was  named the  human 
immunodeficiency virus, or HIV (Coffin et al., 1986).  
Another  novel  lentivirus,  related  to  but  distinct  from  the  HIV  strains  already 
described, was isolated from West African individuals with AIDS in 1986 by Clavel 
et al. (Clavel et al., 1986). Serological evidence for a novel lentivirus distinct from 
previous HIV isolates had, however, already been presented the year before (Barin et 
al., 1985). This virus was eventually termed HIV-2, while the HIV isolated by Barré-17 
 
Sinoussi  and  colleagues  was  called  HIV-1.  Françoise  Barré-Sinoussi  and  Luc 
Montagnier  subsequently  shared  the  2008  Nobel  Prize  in  Medicine  for  their 
discovery of HIV. 
1.1.2  Epidemiology of HIV today 
With the first identification of AIDS in North America and Europe in the mid-1981, 
it soon became apparent by the mid-1980s that the AIDS epidemic was a global 
phenomenon.  At  a  World  Health  Organisation  (WHO)  meeting  that  was  held  in 
November 1983 to assess the global AIDS situation, which was also the start of the 
global surveillance by the WHO, it was reported that AIDS was present in many 
parts of North and Central  America, Europe, Africa, Australia and Japan (World 
Health Organisation, 1983). In August 1985, there were 15, 948 cases of AIDS in the 
USA alone (Curran et al., 1985). Twenty-six years after the identification of HIV as 
the  cause  of  AIDS,  there  are  an  estimated  33.2  million  people  living  with  HIV 
worldwide in 2007, according to the joint report by the United Nations Programme 
on HIV/AIDS (UNAIDS) and World Health Organisation (UNAIDS/WHO, 2007). 
Figures for 2008 are not yet available at the time of writing.  
Although the global HIV incidence had peaked at the end of the 1990s, there were an 
estimated  2.5  million  new  infections  in  2007  alone,  with  2.1  million  deaths 
(UNAIDS/WHO, 2007). The AIDS pandemic is caused by HIV-1, whereas HIV-2 is 
the cause of a small epidemic limited to relatively few countries in western Africa, 
with  some  presence  in  Portugal  and  also  in  India  (Reeves  and  Doms,  2002; 
UNAIDS/WHO, 2007; van der Loeff et al., 2006). Although the high-risk groups 
include sex workers, men who have sex with men, and intravenous drug users and 
their partners, the main mode of transmission is heterosexual contact. As the global 18 
 
AIDS pandemic is mainly caused by HIV-1, the rest of this thesis will concentrate 
solely on HIV-1.  
Figure 1-1 shows the distribution of regions most affected by the AIDS pandemic, 
and  Table  1-1  gives  the  breakdown  of  HIV  statistics  according  to  geographical 
regions. The worst affected region is sub-Saharan Africa, with an adult prevalence 
rate that is more than 6 times higher than the global average and 68% of the total 
number of infections. In this region, AIDS remains the major cause of death, with 
76% of the global annual AIDS deaths (UNAIDS/WHO, 2007). In eight sub-Saharan 
countries  (Botswana,  Lesotho,  Mozambique,  Namibia,  South  Africa,  Swaziland, 
Zambia and Zimbabwe) the adult prevalence is more than 15% (UNAIDS/WHO, 
2007). The HIV pandemic continues to grow in many countries and regions, such as 
South-East  Asia,  China,  Russia  and  Ukraine  in  Eastern  Europe,  North  America, 
Brazil and Western Europe. South Africa has the highest number of infections in the 
world, and is closely followed by India (UNAIDS/WHO, 2007). 19 
 
 
Figure 1-1. A global view of HIV infection in 2007 and associated subtypes 
With about 33 million people currently living with HIV, the above figure shows the global adult 
prevalence rates. Countries shaded in darker colours have higher adult prevalence rates. The most 
affected region is sub-Saharan Africa, with the highest adult prevalence in Botswana, Lesotho and 
Swaziland. The prevalent subtypes and recombinant forms are shown in square brackets. This figure 
was adapted from the WHO website (www.who.int/hiv/facts).  
 
Table 1-1. Regional HIV statistics for 2007
a 
  People living 
with HIV 
People newly 
infected with 
HIV 
Adult 
prevalence 
(%) 
Sub-Saharan Africa  22.5 million  1.7 million  5.0 
Middle East and North Africa  380 000  35 000  0.3 
South and South-East Asia  4 million  340 000  0.3 
East Asia  800 000  92 000  0.1 
Oceania  75 000  14 000  0.4 
Latin America  1.6 million  100 000  0.5 
Carribean  230 000  17 000  1.0 
Eastern Europe and Central Asia  1.6 million  150 000  0.9 
Western and Central Europe  760 000  31 000  0.3 
North America  1.3 million  46 000  0.6 
Total  33.2 million  2.5 million  0.8 
a Figures obtained from the report: AIDS epidemic update 2007 (UNAIDS/WHO, 2007) 20 
 
1.1.3  Diversity and origins of HIV 
Phylogenetically, HIV-1 can be classified into three divergent lineages, with each 
lineage apparently arising  from  a separate transmission events  from  chimpanzees 
(McCutchan, 2006). These three lineages are group M (major), N (non-major, non-
outlier) and O (outlier). Very recently, a new group P was proposed after an isolate 
was found to group very closely to SIVgor (Plantier et al., 2009). Groups N and O of 
HIV-1 are rare and are limited to a few individuals in Central Africa, whereas Group 
M accounts for over 99% of the world’s infections with extraordinary diversity and 
can be classified into various genetic subtypes (McCutchan, 2006).  
Group M can be divided into 9 subtypes: A, B, C, D, F, G, H, J and K, plus a number 
of  circulating  recombinant  forms  (CRFs).  Subtypes  are  defined  by  significant 
clustering across the genome in phylogenetic analyses whereas CRFs are defined by 
significant clustering plus an identical recombinant structure, both of which require 
three epidemiologically unlinked complete sequences (Robertson et al., 2000). Out 
of these, subtypes  A, B, C, D, CRF01_AE and CRF02_AG dominate the global 
pandemic, with subtype C accounting for around 50% of infections worldwide and 
currently  infecting  more people than  any other subtype especially  in eastern and 
southern Africa and India (Hemelaar et al., 2006; McCutchan, 2006; Taylor et al., 
2008). The geographical distribution of common HIV-1 group M subtypes and CRFs 
is shown in Figure 1-1. 
HIV was thought to have been brought into the human population by several cross-
species transmissions of simian immunodeficiency viruses (SIVs) from chimpanzees 
(SIVcpz) and sooty mangabeys (SIVsm) to cause HIV-1 and HIV-2 respectively (Hahn 
et al., 2000). Although it was commonly thought that SIVs are not pathogenic in 21 
 
their  hosts,  a  recent  study  has  shown  that  SIVcpz  can  cause  AIDS-like 
immunopathology in chimpanzees (Keele et al., 2009). HIV-1 was the confirmed to 
be  derived  from  SIVcpz  from  the  Pan  troglodytes  troglodytes  subspecies  of 
chimpanzees (Keele et al., 2006). They showed that HIV-1 of group M (major or 
pandemic  group)  and  N  (non-major,  non-outlier)  arose  from  two  distinct  SIVcpz 
strains, circulating in two geographically separated chimpanzee populations present 
in west central Africa. HIV-1 of group O (outlier), on the other hand, may have been 
brought into the human population as the result of a cross-species transmission of 
SIVgor in gorillas, as related SIVs have been found in both chimpanzees and gorillas 
(Van Heuverswyn et al., 2006).  
HIV is perhaps the most variable of human pathogens, and it exists as a swarm of 
highly related but non-identical viral genomes known as “quasispecies”. The sources 
of this variation are due to these three factors: The rapid replication rate of the virus, 
which is estimated to produce 10
10 virions per day in an infected individual (Ho et 
al., 1995), the error-prone reverse transcriptase (RT), and the high recombination 
rate due to the alternate copying from the two RNA molecules found in each virion 
(Robertson et al., 1995). These will be discussed in greater detail in Section 1.1.7.2. 
1.1.4  HIV-1 genome  
HIV-1 belongs to the Retroviridae family of viruses, whose members are enveloped 
viruses  with  diploid,  linear,  single-stranded  RNA  genomes  of  positive  polarity, 
which use a virus-encoded reverse transcriptase to convert their genomic RNA into 
DNA. The DNA is subsequently incorporated into the host genomic DNA where it 
resides  as  a  provirus,  and  consists  of  three  main  open  reading  frames,  the  gag 
(group-specific antigen), pol (polymerase) and env (envelope) genes (Coffin et al., 22 
 
1997). Sequencing of the HIV-1 genome in 1985 classified the virus as part of the 
Lentivirus  genus  (Sonigo  et  al.,  1985),  whose  other  members  include  the  sheep 
visna/maedi lentivirus that also cause slow disease syndromes in mammals (Narayan 
and Clements, 1989). 
HIV-1  has  a  diploid  genome  composed  of  two  identical  positive-sense  RNA 
molecules  of  approximately  9  kb  (Ratner  et  al.,  1985b;  Sanchez-Pescador  et  al., 
1985; Wain-Hobson et al., 1985b), and a genomic map is shown in Figure 1-2. The 
gag gene encodes a 55 kDa Gag precursor polyprotein (Pr55
Gag), which is cleaved by 
the viral protease into matrix (MA or p17), capsid (CA or p24), nucleocapsid (NC or 
p7)  and  p6  proteins,  as  well  as  the  two  smaller  spacer  peptides  SP1  and  SP2 
(Henderson et al., 1992). The pol gene encodes the viral enzymes protease (PR or 
p15), reverse transcriptase (RT or p66 and p51) and integrase (IN or p31). These 
enzymes  are  initially  synthesised  as  part  of  a  Gag-Pol  precursor  polyprotein 
(Pr160
Gag-Pol), which is produced by ribosome frameshifting near the 3’ end of gag, 
but cleaved into individual enzymes by the viral protease (Frankel and Young, 1998; 
Swanstrom, 1997; Vogt, 1997). The env gene encodes an Env precursor glycoprotein 
(gp160),  which  is  cleaved  and  processed  by  cellular  enzymes  to  produce  a  non-
covalent complex of a surface glycoprotein (SU or gp120) and a transmembrane 
glycoprotein (TM or gp41) (Allan et al., 1985; Robey et al., 1985; Swanstrom, 1997; 
Veronese et al., 1985). 
The HIV-1 genome also contains genes encoding regulatory and accessory proteins, 
located downstream of the pol gene (Frankel and Young, 1998; Vogt, 1997). The tat 
and rev genes contain two exons each and encode the gene regulatory proteins Tat 
(Transactivator of transcription) and Rev (regulator of virion), whereas the vif, vpr, 23 
 
vpu and nef genes encode the accessory proteins Vif (viral infectivity factor), Vpr 
(viral protein R), Vpu (viral protein U) and Nef (negative factor) (Vogt, 1997).  
The HIV-1 genome is flanked by two long terminal repeats (LTRs) at both the 5’ and 
3’ end of the integrated provirus genome, and are 630-640 bp long (Starcich et al., 
1985; Wain-Hobson et al., 1985b). The LTRs consist of the U3 region that contains 
the  viral  promoter  and  enhancer  sequences,  the  R  region  that  contains  the 
polyadenylation signal, and the transactivation response element (TAR) that serves 
as the binding site for the viral Tat protein (Berkhout et al., 1989; Laspia et al., 
1989).  
The secondary structure of the complete single-stranded RNA genome of HIV-1 was 
recently determined, which can function to regulate the translation and facilitate the 
proper folding of proteins with implications for viral fitness (Watts et al., 2009).   
 
Figure 1-2. Schematic representation of the HIV-1 genomic map 
Open reading frames are represented as rectangles showing their relative positions on the genome, 
and positioned according to the reading frame. The gag, pol and env open reading frames encode 
structural proteins and enzymes, whereas rev and tat encode gene regulatory proteins and vif, vpr, vpu 
and  nef  encode  accessory  proteins.  The  HIV-1  genome  is  flanked  by  two  long  terminals repeats 
(LTRs).  
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1.1.5  HIV-1 structure 
1.1.5.1 HIV-1 virion structure 
The average diameter of a mature HIV-1 virion is about 145 nm (Briggs et al., 2003), 
and is enveloped with host cell-derived lipid bilayer embedded with virus-encoded 
Env  consisting  of  the  surface  glycoprotein  gp120  non-covalently  linked  to  the 
transmembrane glycoprotein gp41. The functional viral envelope spike exists as a 
trimer of gp120/gp41 on the virus surface (Wyatt and Sodroski, 1998; Zanetti et al., 
2006; Zhu et al., 2006). Below the virus envelope is a layer of trimeric MA proteins 
which interacts with the lipid bilayer via amino (N)-terminal myristoyl groups (Hill 
et al., 1996). The MA shell surrounds a cone-shaped core, consisting of hexameric 
CA proteins forming a hexagonal lattice (Briggs et al., 2003; Li et al., 2000; Mortuza 
et  al.,  2004).  The  conical  core  contains  the  nucleocapsid  (NC)  protein,  which  is 
closely associated with the viral genomic RNA. The NC protein is a small, 55 amino 
acid residue-protein, which contains zinc-finger motifs common to many proteins 
that bind nucleic acids (Frankel and Young, 1998). The RNA genome is diploid and 
the two molecules are associated at the 5′ end. Dimerisation is mediated by so-called 
kissing-loop  interactions  between  hairpin  structures  in  the  dimer  initiation  site 
located downstream of the U5 region (Hoglund et al., 1997; Mujeeb et al., 1998; 
Paillart et al., 2004; Paillart et al., 1996). The viral core also contains PR, RT and IN, 
as  well  as  Vpr.  A  schematic  representation  of  a  mature  HIV  virion  is  shown  in 
Figure 1-3. 
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Figure 1-3. Schematic structure of the mature HIV-1 virion. 
The lipid bilayer membrane contains the viral Env spikes made up of trimeric gp120/gp41. The matrix 
protein (MA) forms a layer beneath the membrane. The capsid protein (CA) forms the conical core. 
Within it contains the diploid viral RNA genome, that is associated with the nucleocapsid protein 
(NC), and several other viral proteins such as reverse transcriptase (RT), integrase (IN), protease 
(PR), viral protein R (Vpr) and p6.  
 
1.1.5.2 HIV-1 envelope spike structure 
As the major part of this thesis is focused on the envelope glycoprotein of HIV-1 and 
antibodies  that  can  recognise  them,  this  section  will  aim  to  provide  an  in  depth 
review on what is currently known about the HIV-1 envelope spike. 
The HIV-1 envelope spike is made up of the surface glycoprotein gp120 bound non-
covalently to the transmembrane glycoprotein gp41 (Allan et al., 1985; Helseth et al., 
1991; Robey et al., 1985; Veronese et al., 1985). The functional HIV-1 envelope 
spike  exist  as  a  trimer  of  the  gp120/gp41  heterodimers  (Chan  et  al.,  1997; 
Weissenhorn  et  al.,  1997;  Zanetti  et  al.,  2006;  Zhu  et  al.,  2006).  In  addition  to 
functional trimeric spikes, there is evidence for non-functional spikes on the virus 
surface, such as gp120/gp41 monomers or other oligomeric forms, as well as gp41 
stumps formed after shedding of gp120 (Moore et al., 2006; Poignard et al., 2003).  26 
 
The transmembrane protein gp41 contains a cytoplasmic tail, a membrane-spanning 
domain and an ectodomain (Wyatt and Sodroski, 1998). The ectodomain consists of 
a fusion peptide, an N-terminal helical heptad repeat (N-HR), a loop region, a C-
terminal heptad repeat (C-HR) and a membrane-proximal external region (MPER). 
High-resolution structural data for gp41 in the context of the native envelope spike is 
not yet available, but such structural data is available for the gp41 ectodomain in its 
fusogenic state, revealing a six-helix bundle consisting of a central parallel trimeric 
coiled-coil of the three N-HR helices, surrounded by the three C-HR helices in an 
anti-parallel hairpin fashion (Weissenhorn et al., 1997; Yang et al., 1999). Formation 
of the six-helix bundle is essential for fusion of the cellular and viral membranes.  
Antibody binding studies have indicated that in the context of the functional spike, 
gp41 is relatively occluded from recognition by antibodies (Nyambi et al., 2000; 
Sattentau et al., 1995). Immunising rabbits with an engineered recombinant trimeric 
molecule containing the ectodomain of gp41 and the C1 and C5 regions of gp120, 
and  reported  to  keep  gp41  in  a  pre-fusion  configuration,  has  supported  these 
observations, as  it  failed to elicit  neutralising antibodies (Qiao et al., 2005). The 
MPER is, however, accessible to antibodies, at least on a fusion intermediate form of 
gp41, as demonstrated by the isolation of neutralising antibodies directed against this 
highly conserved region (Muster et al., 1993; Stiegler et al., 2001; Zwick et al., 
2001).  There  are  two  atomic  structures  available  of  fragments  of  the  MPER  in 
complex  with  two  broadly  neutralising  monoclonal  antibodies,  2F5  and  4E10 
(Cardoso et al., 2005; Ofek et al., 2004).  
The surface glycoprotein gp120 consists of five conserved (C1-C5) and five variable 
(V1-V5) regions (Starcich et al., 1986;  Willey  et al., 1986). Data from antibody 
competition studies predicted the variable regions to be located on the outside of 27 
 
gp120, as they were well-exposed to antibodies, whereas the constant regions were 
less  exposed  (Moore  et  al.,  1994a;  Moore  and  Sodroski,  1996). The  C1  and  C5 
regions were concluded to be the regions interacting with gp41, as they were found 
to  be  accessible  to  antibodies  on  recombinant  monomeric  gp120  but  not  in  the 
context of gp120/gp41 constructs (Moore et al., 1994a; Moore et al., 1994b) and 
mutations  in  these  regions  could  abolish  gp120/gp41  interactions  (Helseth  et  al., 
1991).  Similarly,  observations  made  in  mutational  studies  also  indicated  that the 
variable regions mask more conserved sites of gp120, such as the CD4bs (Pollard et 
al., 1992; Wyatt et al., 1993). For example, antibodies to the receptor-binding sites 
have been observed to bind with higher affinity to gp120 with deleted V1, V2 and 
V3 regions (Cao et al., 1997; Moore et al., 1994a; Sullivan et al., 1998; Wyatt et al., 
1995; Wyatt et al., 1993). The V3 region was also found to protrude from the gp120 
core, which could explain its immunodominant properties (Huang et al., 2005). CD4 
binding  was  also  observed  to  be  dependent  on sequences  within  the  C3  and  C4 
regions (Cordonnier et al., 1989; Lasky et al., 1987; Olshevsky et al., 1990). 
Of great interest is the CD4 binding site (CD4bs) on gp120 as blocking this site on 
gp120 effectively prevents the virus from entering a cell. High-resolution structural 
data of a deglycosylated gp120 core liganded to soluble CD4 and an antibody to a 
CD4-induced epitope, 17b, was solved using X-ray crystallography on HXB2 and a 
primary isolate (Kwong et al., 2000; Kwong et al., 1998). A fully glycosylated and 
unliganded SIV gp120 structure was also solved (Chen et al., 2005a). The core of 
monomeric, CD4-liganded gp120 is made up of five α-helices, twenty-five β-strands 
and ten loop segments, all arranged into an outer and an inner domain linked by a 
bridging  sheet.  The  inner  domain  is  made  up  predominantly  by  the  C1  and  C5 
regions  and  is  suggested  to  be  the  gp41  interaction  site,  based  on  its  lack  of 28 
 
glycosylation and its sequence conservation (Kwong et al., 1998; Wyatt et al., 1998). 
The outer domain is thought to be located on the outside of the envelope spike and 
contains the V3, V4 and V5 variable regions (Huang et al., 2005; Kwong et al., 
1998). It is heavily glycosylated, making it less visible to the host immune system 
(Kwong et al., 1998; Wyatt et al., 1998). 
The CD4bs lies at the interface of the outer domain, the bridging sheet and the inner 
domain  (Kwong  et  al.,  1998).  Twenty-six  amino  acid  residues  in  gp120  (on  the 
V1/V2 region, the bridging sheet, a β-strand in the outer domain, and so called CD4-
binding loop on gp120) make contact with twenty-two residues in the D1 domain of 
CD4 (Kwong et al., 1998). The CD4-gp120 interaction is mainly electrostatic but 
also results from 219 van der Waals contacts and twelve hydrogen bonds located 
within two cavities on the surface of gp120 (Kwong et al., 1998). Comparison of the 
CD4-liganded HIV-1 gp120 and the unliganded SIV gp120 structures showed that 
binding of CD4 to gp120 resulted in substantial conformational changes in gp120 
(Chen et al., 2005a), as was previously observed in antibody binding experiments 
(Sattentau  and  Moore,  1991)  and  changes  in  entropy  in  thermodynamic  studies 
(Myszka et al., 2000). Many of the residues involved in CD4 binding are located in a 
long, narrow and hydrophobic cavity made up by the α-helices of the inner domain, 
part  of  the  outer  domain  and  the  β20-β21  ribbon,  explaining  the  relative 
inaccessibility of the CD4bs to many antibodies (Chen et al., 2005a). 
The coreceptor binding site is less clearly defined, due to the lack of crystal structure 
data. The V3 region of gp120 has been shown to be critical for co-receptor binding 
(Bandres et al., 1998; Lapham et al., 1996; Trkola et al., 1996a; Wu et al., 1996) and 
is thought to interact with the N-terminus and second extracellular loop of the co-29 
 
receptor (Brelot et al., 1997; Doranz et al., 1997; Dragic, 2001; Huang et al., 2007a). 
A  comparison  of  the  CD4-liganded  and  unliganded  gp120  core  structure  has 
revealed that the coreceptor binding site is only assembled and presented after CD4 
binding  (Chen  et  al.,  2005a;  Lapham  et  al.,  1996;  Pantophlet  and  Burton,  2006; 
Trkola et al., 1996a; Wu et al., 1996; Wyatt and Sodroski, 1998). 
The  high-resolution  crystal  structures  of  the  HIV-1  envelope  glycoproteins  were 
based on recombinant monomeric gp120 and gp41 in its fusogenic state, and these 
recombinant  proteins  might  not  be  a  good  representation  of  the  envelope 
glycoproteins as they appear in the functional envelope spike. This is supported by 
the  observation  that  antibody  ability  to  bind  to  recombinant  proteins  does  not 
necessarily  correlate  with  ability  to  neutralise  the  corresponding  virus.  Instead, 
neutralisation  has  been  shown  to  depend  on  the  ability  to  recognise  functional 
envelope spike (Fouts et al., 1997; Moore et al., 1995; Moore et al., 2006; Parren et 
al., 1998; Poignard et al., 2003; Sattentau and Moore, 1995). Unfortunately, a high-
resolution structure is not available due to the labile and flexible nature of the spike 
and the high carbohydrate content of a functional envelope spike.  
However, electron microscopy tomography studies of envelope spikes on the surface 
of  chemically  fixed  HIV-1  virions  have  provided  some  insight  into  the  three-
dimensional  nature  of  native  HIV-1  envelope  spikes  and  provided  the  first 
conclusive evidence for the presence of trimers on actual virions (Zhu et al., 2003). 
Heterogeneity  was  observed  among  different  spikes,  possible  reflecting  the 
heterogeneity and the existence of non-functional spikes predicted by observations 
made  using  biochemical  assays  (Moore  et  al.,  2006).  Another  study  using  cryo-
electron microscopy tomography on frozen, unfixed, unstained and hydrated HIV-1 
and SIV particles gave a much better resolution and observed to have an average of 30 
 
14 spikes per virion which clustered together rather than being uniformly dispersed 
on  the  virion  surface  (Zhu  et  al.,  2006).  A  three-dimensional  density  map  is 
reproduced in Figure 1-4A, which shows a multi-lobed structure and a tripod-like 
foot consisting of three well-separated legs.  
Another report using cryo-electron tomography on virion-associated SIV envelope 
spikes revealed a slightly different structure. Instead of tripod-like structures, the 
envelope spike was found to be made up of three distinct gp120 subunits on top of a 
narrow gp41 stalk with the presence of a cavity at the interface of gp120 and gp41  
(Zanetti et al., 2006), as shown in Figure 1-4B.  
A  third  study  on  virion-associated  HIV-1  envelope  spikes  revealed  yet  another 
slightly different shape, but does share the narrow gp41 stalk feature revealed by 
Zanetti et al. (Zanetti et al., 2006). The density map of the HIV-1 envelope spike as 
revealed by Liu et al. (Liu et al., 2008) is shown in Figure 1-4C. Fitting of gp120 
atomic structures into the density map indicates that the variable regions and the 
glycosylated residues of gp120 are located on the outside of the spike, with the V3 
region near the top of the spike, and the CD4 binding site is located about 20Å from 
the top of the spike in a recessed cavity (Liu et al., 2008). Liu et al. also observed 
that the spike undergoes a drastic quaternary conformational rearrangement upon 
binding to sCD4 and the monoclonal antibody 17b, resulting in a vertical upward 
displacement of gp120, a more open spike structure, and exposure of the gp41 stalk 
(Liu et al., 2008). These observations are likely to further the understanding of HIV-
1  interaction  with  cellular  receptors  and  entry  into  target  cells,  which  has 
implications  for  vaccine  design.  However,  due  to  the  differences  in  the  three 
observed  structures, the true structure of the envelope spike still remains unclear 
(Roux and Taylor, 2007; Subramaniam, 2006).  31 
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Figure 1-4. Three-dimensional models of the SIV and HIV-1 envelope spikes 
based on cryo-electron tomography studies 
[A Density map of an unliganded SIV envelope spike constructed by Zhu et al.. Image obtained from 
Nature, 441:847-52. [B] Density map of an unliganded SIV envelope spike constructed by Zanetti et 
al. Image obtained from PLoS Pathogens, 2:e83. [C] Density maps of an unliganded HIV-1 envelope 
spike constructed by Liu et al. Image obtained from Nature 455:109-13. 
 
 
1.1.6  HIV-1 cellular receptors  
Understanding of the cellular receptors for HIV-1 is crucial as the virus needs to 
interact with these receptors in order to gain entry into the host cell. Blocking of 
these interactions, for example through the use of antibodies, can potentially block 
virus infection of the cell. The cellular receptor for HIV-1 was identified to be CD4 
in  1984  (Dalgleish  et  al.,  1984;  Klatzmann  et  al.,  1984),  when  they  found  that 
monoclonal antibodies (mAbs) to CD4 were able to block HIV-1 infection. The CD4 
antigen  is  a  transmembrane  glycoprotein  belonging  to  the  immunoglobulin 
superfamily  of  receptors  (Maddon  et  al.,  1985;  Terhorst  et  al.,  1980),  and  is 
expressed predominantly on T helper cells but to a lesser extent on other cells types 
such  as  monocytes,  macrophages,  dendritic  cells,  eosinophils  and  mast  cells 
(Germain, 2002; Lee et al., 1999; Lucey et al., 1989; Wood et al., 1983). CD4 on T 
helper cells acts as a coreceptor by binding to the non-polymorphic regions of MHC 
class II molecules on antigen-presenting cells (Wang et al., 2001), and is involved in 
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the activation of antigen-driven T cell responses (Germain, 2002). It has a molecular 
mass of 55 kDa and consists of an extracellular part, a transmembrane domain and 
an intracellular domain. The extracellular portion consists of four immunoglobulin-
like domains, D1-D4 (Maddon et al., 1985; Ryu et al., 1990). In the initiation of the 
HIV-1 entry process, the gp120 portion of the envelope spike was discovered to bind 
to the D1 domain only (Kwong et al., 1998).  
It was soon realised that a coreceptor is required for HIV-1 entry, as non-human cells 
engineered to express CD4 only were not susceptible to infection (Lores et al., 1992; 
Maddon et al., 1985) and other human components or cofactors are involved (Weiner 
et al., 1991). This missing coreceptor for HIV-1 entry was identified to be CXCR4 in 
1996, where Feng et al. showed that co-expression of both CD4 and CXCR4 are 
required to render previously non-permissive cells susceptible to infection (Feng et 
al., 1996). However, this was found to support the infection of T cell line-tropic 
isolates of HIV-1 and not with macrophage-tropic strains and primary T-cell tropic 
strains, indicating that yet another co-factor was responsible for mediating entry for 
the latter isolates. The coreceptor for macrophage-tropic HIV-1 was identified by 
several groups to be CCR5, which is also the receptor for various chemokines such 
as RANTES, MIP-1α and MIP-1β (Alkhatib et al., 1996; Choe et al., 1996; Deng et 
al., 1996; Doranz et al., 1996; Dragic et al., 1996). Other coreceptors, such as CCR2 
and CCR3, can also mediate entry of some HIV-1 strains (Choe et al., 1996; Doranz 
et al., 1996).  
Chemokine receptors belong to the superfamily of seven-transmembrane G-protein-
coupled receptors (GPCRs). They are integral membrane proteins that consist of an 
extracellular  N-terminal  domain  followed  by  seven  helical  membrane-spanning 
regions  connected  by  three  intracellular  and  three  extracellular  loops  and  a 33 
 
cytoplasmic tail (Allen et al., 2007). The gp120 portion of the envelope spike was 
found  to  bind  to the  first  and  third  extracellular  domains  of  CCR5  and  CXCR4 
(Brelot et al., 1997; Doranz et al., 1997; Huang et al., 2007a). 
All primary HIV-1 isolates use one or both of CCR5 and CXCR4 as co-receptor 
(Lusso, 2006). In addition, some virus isolates have been shown to use alternative 
chemokine receptors in vitro. At least a dozen other seven-transmembrane GPCRs, 
such as CCR3, CCR2b, CCR8, Strl33 and D6, have been reported to function as co-
receptors  in  vitro  (Clapham  and  McKnight,  2002;  Neil  et  al.,  2005).  CCR3  is 
commonly  used  as  a  minor  coreceptor  for  HIV-1  in  the  central  nervous  system, 
especially in microglial cells (He et al., 1997). 
Before the coreceptors for HIV-1 were discovered, two distinct phenotypes of HIV-1 
were observed with different tropism for CD4+ cells and appear to coreleate with 
clinical severity (Asjo et al., 1986; Cheng-Mayer et al., 1988; Connor and Ho, 1994). 
Viruses with a high turnover phenotype were able to induce syncytia in immortalised 
T cell lines, whereas viruses with a low turnover phenotype and also non-syncytia 
inducing were found to replicate in macrophages but not T cell lines (Collman et al., 
1989; Schuitemaker et al., 1992; Tersmette et al., 1988). With the identification of 
CXCR4  and  CCR5  as  coreceptors  for  HIV-1,  the  confusion  between  replication 
kinetics, syncytia formation and tropism began to clear up (Dittmar et al., 1997). 
Virus isolates are now classified based on coreceptor usage, and are referred to as 
CCR5-  or  CXCR4-using  viruses,  or  R5  and  X4  viruses,  or  R5X4  for  dualtropic 
viruses (Berger et al., 1998). Also, isolates that have been adapted for growth in T 
cell  lines  are  referred  to  as  T  cell  line-adapted  (TCLA),  whereas  viruses  only 
cultured in primary PBMC or macrophages are referred to as primary isolates. CCR5 
using  viruses  were  observed  to  be  preferentially  transmitted  over  CXCR4  using 34 
 
viruses (Margolis and Shattock, 2006; van't Wout et al., 1994), although CXCR4 
using  viruses  have  been  associated  with  lower  CD4+  T  cell  counts  and  faster 
progression to AIDS (Connor et al., 1997a; Daar et al., 2007; Scarlatti et al., 1997; 
Zhu et al., 1993) 
Although coreceptor usage does not differ significantly between the different HIV-1 
subtypes (Moyle et al., 2005; Zhang et al., 1996), the majority of studies on HIV-1 
coreceptor usage and tropism have been carried out on subtype B viruses. However, 
CXCR4  usage  has  been  less  frequently  observed  among  subtype  C  isolates, 
compared  to  among  HIV-1  of  subtype  B,  even  in  isolates  from  individuals  with 
AIDS (Cecilia et al., 2000; Peeters et al., 1999; Ping et al., 1999; Tscherning et al., 
1998). In addition, CXCR4 usage has been reported to be more prevalent among 
subtype D viruses compared to among subtype A viruses (Huang et al., 2007b).  
As most of the studies on coreceptor usage were focused on CCR5 and CXCR4, I 
have investigated the use of CCR3 as a coreceptor by the different HIV-1 subtypes, 
and this is described in Chapter 3 of this thesis. 
1.1.7  HIV-1 life cycle and replication 
1.1.7.1 Virus entry 
The HIV-1 entry process is initiated by attachment of the gp120 subunit of the viral 
envelope  spike  to  the  primary  cellular  receptor  CD4  (Dalgleish  et  al.,  1984; 
Klatzmann et al., 1984). Binding of gp120 to CD4 triggers a series of conformational 
rearrangements  in  gp120  and  in  the  envelope  spike  as  a  whole,  resulting  in  the 
exposure  of  the  coreceptor  binding  site  (Liu  et  al.,  2008;  Myszka  et  al.,  2000; 
Sattentau and Moore, 1991; Sattentau et al., 1993), thus allowing either of the main 
cellular co-receptors CCR5 or CXCR4 to bind to gp120 (Lapham et al., 1996; Trkola 35 
 
et al., 1996a; Wu et al., 1996). The V3 loop, in particular the amount of net positive 
charges on the V3 loop, is the main determinant for co-receptor usage and thereby 
cell tropism (Hartley et al., 2005; Hwang et al., 1991), although sequence changes in 
the V1, V2, C3 and C4 regions of gp120 and in gp41 have been implicated (Aasa-
Chapman et al., 2006b; Boyd et al., 1993; Hartley et al., 2005; Huang et al., 2008).  
Binding of gp120 to CD4 and to the coreceptor results in conformational changes in 
gp41, leading to the formation of a pre-hairpin intermediate which later springs out 
to insert the gp41 fusion peptide into the host cell membrane, resulting in fusion of 
viral and cellular membranes (Doms and Moore, 2000; Gallo et al., 2003; Roux and 
Taylor, 2007). Although the exact mechanism for membrane fusion is unclear, the 
formation of the pre-hairpin intermediate and the insertion of the fusion peptide is 
thought to be followed by the energetically favoured formation of a six-helix bundle 
(Chan  and  Kim,  1998;  Yang  et  al.,  1999).  Formation  of  the  six-helix  bundle  is 
thought to coincide with fusion of the viral and cellular membranes, which is aided 
by the energy release during bundle formation (Melikyan et al., 2000). 
The number and exact stochiometry of envelope spikes required for HIV-1 entry has 
not  been  determined  precisely,  and  was  found  to  require  between  one  to  seven 
functional spikes per virion (Herrera et al., 2006; Sougrat et al., 2007; Yang et al., 
2005). Virus entry can also take place through cell-cell transfer via a virological 
synapse (Jolly et al., 2004; McDonald et al., 2003) or via filopodial bridges (Sherer 
et al., 2007) or long nanotubes (Sowinski et al., 2008), and are all dependent on HIV-
1 envelope glycoprotein and CD4. Such cell-cell spread of virus and its ability to 
evade antibody responses remain unclear. Although the virus is generally thought to 
enter  a  cell  through  fusion  with  the  plasma  membrane,  the  virus  has  also  been 
observed to enter via endocytosis in a pH-independent step (Miyauchi et al., 2009). 36 
 
1.1.7.2 Reverse transcription 
After virus entry, the little understood process of viral core uncoating and formation 
of a reverse transcription complex (RTC) occurs (Aiken, 2006; Nisole and Saib, 
2004).  Uncoating  involves  the  disassembly  of  CA  and  release  of  the  viral 
ribonucleoprotein  complex.  This  process  remains  to  be  elucidated  but  has  been 
suggested to involve both viral and cellular factors (Aiken, 2006), in particular the 
cellular protein cyclophilin A (Franke et al., 1994; Luban et al., 1993; Thali et al., 
1994). The cellular tripartite motif protein TRIM5α can associate with the CA and 
promote its degradation, leading to accelerated core disassembly and uncoating, and 
thus restrict retroviral infection in a species-specific manner (Stremlau et al., 2004; 
Stremlau et al., 2006). The RTCs are large nucleoprotein structures consisting of 
packed  filaments  containing  IN  and  Vpr  (Fassati  and  Goff,  2001;  Nermut  and 
Fassati, 2003) and interacts with the cytoskeleton (Bukrinskaya et al., 1998).   
Reverse  transcription  of  the  viral  genomic  RNA  into  a  double-stranded  DNA 
genome is thought to take place essentially within the RTC by the viral RT, which 
possess both DNA polymerase and RNase H activities to degrade the genomic RNA 
template (di Marzo Veronese et al., 1986; Freed, 2001). The RT polymerase lacks 
any proof-reading ability and is therefore highly error-prone, making approximately 
3.4 × 10
-5 errors per base pair per cycle  to cause the extreme sequence variation 
observed among HIV-1 isolates (Mansky and Temin, 1995). In addition, RT binds 
with low affinity to its template and can hence make frequent jumps between the two 
RNA genomic  molecules. If the two genomic  RNA  molecules are different, this 
ability  results  in  the  generation  of  genetically  recombinant  DNA  genomes,  thus 
contributing to genetic variability (Temin, 1993). 37 
 
The reverse transcription process can be inhibited by a cellular cytidine deaminase 
protein called APOBEC3G, and thus restrict retroviral replication by deaminating 
cytosine residues in the synthesis of the first retroviral DNA strand and leading to 
hypermutation of the viral DNA (Sheehy et al., 2002). In HIV-1, this restriction is 
overcome  by  the  viral  Vif  protein,  which  mediates  polyubiquitylation  and 
proteasomal degradation of APOBEC3G, thus preventing APOBEC3G incorporation 
into virions and its modulation of the reverse transcription process (Sheehy et al., 
2003; Yu et al., 2003). 
1.1.7.3 Nuclear import, integration and transcription 
HIV-1  replication  requires  that  the  virus  enters  the  nucleus.  Once  the  reverse 
transcription is complete, the RTCs are gradually transformed into pre-integration 
complexes (PICs) in a process that is little understood (Nisole and Saib, 2004). The 
PICs contain the viral genomic DNA and viral protein IN (Farnet and Haseltine, 
1991), and are actively imported into the nucleus (Bukrinsky et al., 1992) with the 
help of importin 7 (Zaitseva et al., 2009), and the viral protein Vpr which contains 
nuclear localisation signals (Lu et al., 1993).  
Once the pre-integration complex has been imported into the nucleus, the viral DNA 
is integrated into the cellular genomic DNA and resides as a provirus in the host 
genome (Brown, 1997). This is solely mediated by viral IN (Bushman et al., 1990), 
and shown to specifically integrate into transcriptionally active regions of the host 
genome (Schroder et al., 2002). 
Once integrated into the host genome, the provirus can stay latent or be transcribed 
by  the  cellular  machinery  (Cullen,  1991).  Prior  to  the  production  of  the  viral 
transactivator  Tat,  the  HIV-1  promotor  on  the  5’LTR  is  activated  by  cellular 38 
 
transcription  factors  alone,  resulting  in  low  transcriptional  levels  and  short 
transcripts. Once Tat is produced, it strongly enhances transcriptional activation and 
elongation in a positive feedback loop (Sodroski et al., 1985).  
After transcription, the viral RNAs are polyadenylated, spliced and exported from 
the  nucleus.  The  obtained  transcripts  are  either  unspliced  (9  kb),  incompletely 
spliced (around 4 kb), or fully spliced RNAs (around 2 kb). The primary HIV-1 
RNA transcript or unspliced RNAs are used  for expression of Gag and Gag-Pol 
precursors or packaged into virions as genomic RNA. Incompletely spliced mRNAs 
have the gag-pol region spliced out and can be used for expression of Env, Vif, Vpr 
and Vpu, whereas fully spliced mRNAs have the gag, pol and most of env removed, 
contain  no  intron sequences, and are used to express Tat, Rev and Nef (Robert-
Guroff  et  al.,  1990;  Schwartz  et  al.,  1990).  The  viral  Rev  protein  promotes  the 
nuclear export of unspliced and incompletely spliced viral RNAs by binding to a 
highly structured RNA region called the Rev responsive element (RRE) (Malim et 
al., 1989; Zapp and Green, 1989).  
1.1.7.4 Synthesis, assembly, and processing of viral proteins 
The  Gag  (Pr55
Gag)  and  Gag-Pol  (Pr160
Gag-Pol)  polyproteins  are  synthesised  on 
polyribosomes  in  the  cytoplasm,  and  are  important  for  membrane  targeting  and 
binding,  multimerisation  of  Gag,  encapsidation  of  viral  genomic  RNA  and 
association with viral envelope glycoproteins anchored to the plasma membrane for 
particle budding and release (Freed, 1998; Swanstrom, 1997). The MA protein is 
important  for  membrane  targeting  and  binding  (Hill  et  al.,  1996).  Gag 
multimerisation is mediated by the viral NC protein at the plasma membrane and a 
layer of Gag-particles associated with the inner layer of the plasma membrane that 39 
 
will eventually form a spherical immature virus particle, with the encapsidation of 
viral genomic RNA by NC (Freed, 1998; Ganser-Pornillos et al., 2008; Swanstrom, 
1997). 
The  HIV-1  envelope  glycoprotein,  gp160,  is  first  synthesised  as  a  precursor 
polyprotein  on  the  rough  endoplasmatic  reticulum  (ER)  where  it  undergoes 
glycosylation, folding and oligomerisation (Freed and Martin, 1995; Maggioni and 
Braakman,  2005;  Wyatt  and  Sodroski,  1998).  The  gp160  polypeptide  is  co-
translationally glycosylated in the ER (Swanstrom, 1997), and it contains around 30 
potential N-linked glycosylation sites (Muesing et al., 1985; Ratner et al., 1985b; 
Sanchez-Pescador et al., 1985; Wain-Hobson et al., 1985b), which are made up of 
asparagine-X-serine/threonine  motifs  where  X  is  any  amino  acid  except  proline. 
Proper folding of gp160 is mediated by the isomerisation of disulphide bonds and the 
signal peptide then cleaved (Berman et al., 1988; Land et al., 2003). The gp160 also 
undergoes  oligomerisation  before  exiting  the  ER  and  into  the  Golgi  (Earl  et  al., 
1990; Lu et al., 1995; Pinter et al., 1989; Weiss et al., 1990). Although dimers and 
tetramers have been observed, the functional spike exists as a trimer (Chan et al., 
1997; Pantophlet and Burton, 2006; Weissenhorn et al., 1997; Wyatt and Sodroski, 
1998; Zanetti et al., 2006; Zhu et al., 2006). To prevent the premature interaction of 
gp160 with CD4 in the ER, the viral protein Vpu has been shown to mediate CD4 
degradation through ubiquitin-mediated proteolysis (Margottin et al., 1998). CD4 
cell-surface  expression  is  also  down-regulated  by  the  viral  protein  Nef,  which 
mediates  internalisation  and  degradation  of  CD4  via  clathrin-coated  pits  and 
lysosomes (Malim and Emerman, 2008). 
The oligomeric gp160 is then transferred from the ER to the Golgi, where the newly 
added  N-linked  high-mannose  glycans  are  modified  by  mannosidase  enzymes, 40 
 
initiating the formation of complex N-linked carbohydrate glycans (Kozarsky et al., 
1989; Stein and Engleman, 1990). The variability in glycosylation and processing of 
glycans contributes to the heterogeneity of the HIV-1 envelope. The trimeric gp160 
then  undergoes  endoproteolytic  cleavage  in  the  Golgi  to  form  the  surface 
glycoprotein  gp120  and  the  transmembrane  glycoprotein  gp41  by  cellular  serine 
proteinases (McCune et al., 1988; Stein and Engleman, 1990; Willey et al., 1988). 
Cleavage  occurs  at  a  highly  conserved  lysine/arginine-X-lysine/arginine-arginine 
motif (where X is any amino acid) and is essential for the fusogenic ability of the 
viral envelope spike. After cleavage, gp120 and gp41 associate non-covalently with 
each other. 
The envelope spikes are then directed to the plasma membrane through the secretory 
pathway  and  incorporated  into  virions  (Swanstrom,  1997).  Several  studies  have 
indicated  that  an  interaction  between  the  cytoplasmic  tail  of  gp41  and  the  MA 
domain of Gag is responsible for the recruitment of envelope glycoproteins to Gag 
(Cosson, 1996).  
1.1.7.5 Assembly and budding of virions 
Virus assembly and budding is generally believed to occur at the plasma membrane 
of infected cells (Swanstrom, 1997). However, conflicting reports suggests that the 
location is dependent on cell types. For example, HIV-1 assembles and buds at the 
plasma membrane for T cells, but the same occurs in late endosomes or intracellular 
multivesicular bodies for macrophages (Ono and Freed, 2004).  Real-time imaging 
of  Gag  assembly  in  HeLa  cells  has  further  supported  the  notion  that  HIV-1 
assembles at the plasma membrane (Jouvenet et al., 2008). The viral protein p6 is 
crucial for the release of virus particles, as the deletion of p6 has been shown to 41 
 
cause accumulation of assembled virus particles tethered to the plasma membrane 
(Gottlinger et al., 1991). A recently described protein, tetherin, was found to tether 
virus particles to the cell  surface (Neil et al., 2008), but was antagonised  by the 
presence of the  viral Vpu protein which was previously known to enhance  virus 
release (Terwilliger et al., 1989).  
HIV-1 buds  from the  membrane of  infected cells  in an  immature, non-infectious 
form (Swanstrom, 1997). Upon budding, the viral PR is activated and cleaves the 
Gag precursor Pr55
Gag in a stepwise fashion into the MA, CA, NC and p6 proteins. 
PR also cleaves the Gag-Pol polyprotein Pr160
Gag-Pol, generating PR, RT and IN. 
Cleavage of the Gag and Gag-Pol polyproteins leads to structural rearrangement of 
the individual Gag proteins and the formation of a mature, infectious HIV-1 virion 
containing the characteristic conical core. 
1.1.8  HIV-1 transmission 
HIV-1 can be transmitted along three major routes. The first route is through direct 
exposure  to  HIV-1  positive  blood  or  blood  products,  either  in  donated  blood  or 
contaminated needles, and represents about 5-10% of HIV-1 infections worldwide 
(Hladik and McElrath, 2008). The second route is via mother-to-child transfer, and 
represents about 15% of new infections in 2007 (UNAIDS/WHO, 2007). The final 
route is through sexual contact primarily at the genital and rectal mucosa (Royce et 
al., 1997), and represents the vast majority of all new infections (UNAIDS/WHO, 
2007). Sexual transmission is the focus of discussion in this section. 
The  probability  of  infection  through  sexual  contact  can  vary  greatly,  and  is 
dependent on the viral dose and also on
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the blood via breaks in the epithelium or across intact mucous membranes (Haase, 
2005; Royce et al., 1997).  
In  men,  HIV-1  transmission  across  the  genital  mucosa  occurs  most  frequently 
through the inner foreskin and perhaps also through the penile urethra. The inner 
foreskin is lined by a multilayer stratified squamous epithelium whereas the urethra 
is lined by layers of columnar epithelial cells, both of which contain target cells for 
HIV-1  infection  and  foreskin  explants  were  susceptible  to  HIV-1  infection 
(McCoombe and Short, 2006; Patterson et al., 2002). Circumcision confers a reduced 
risk of HIV-1 infection for men, highlighting the important role of the foreskin in 
HIV-1 transmission (Gray et al., 2007b).  
Transmission to women during vaginal intercourse can occur through the vaginal, 
ectocervical,  or  endocervical  mucosa  (Hladik  and  McElrath,  2008).  The  intact 
vaginal and ectocervical mucosa is made up of several layers of stratified squamous 
epithelium, whereas the endocervix is lined by a single-layer columnar epithelium. 
Studies  on  macaques  have  shown  that  the  vaginal  mucosa  is  sufficient  for  SIV 
transmission (Miller et al., 1992b). Various factors can lead to an increased risk of 
HIV-1 transmission, such as physical abrasion (Baleta, 1998), abnormalities in the 
vaginal  flora  (Sewankambo  et  al.,  1997)  or  genital  ulcers  caused  by  sexually 
transmitted diseases (Weiler et al., 2008). 
Although the  events on  how HIV-1 can  lead to an established  infection when  it 
reaches the epithelium is not clearly understood, studies on explants models have 
shown  that  HIV-1  can  directly  infect  Langerhans  cells,  subepithelial  DCs, 
macrophages and CD4+ T cells (de Witte et al., 2008; Hladik and McElrath, 2008; 
Hladik et al., 2007; Maher et al., 2005; Miller and Shattock, 2003). 43 
 
1.2  The immunology of HIV-1 
1.2.1  Progression of HIV-1 infection 
After mucosal transmission of HIV-1, infection is established locally at the point of 
entry which then  spreads to the draining  lymph nodes and  subsequently to other 
lymphoid tissues via the circulation (Haase, 2005). Once established, natural HIV-1 
infection  is  characterised  by  three  phases,  which  are  also  seen  in  infection  of 
macaques by pathogenic strains of SIV. 
The first phase is the primary acute infection phase, which is associated with intense 
viral  replication,  a  rapid  increase  in  viral  load  and  a  decline  in  CD4+  T  cells, 
especially  the  mucosal  gut-associated  lymphoid  tissue  (GALT)  which  comprises 
most of total body CD4+ T cells (Brenchley et al., 2004; Veazey et al., 1998). Over 
the following weeks, as antiviral immune responses develop in the host, the number 
of circulating CD4+ T cells start to recover and plasma viral load decreases to a set-
point.  
The second phase is the chronic, and in general clinically asymptomatic, infection 
that is characterised by a gradual increase in plasma viral load and a progressive 
decrease in circulating CD4+ T cells that can span for ten years or more in untreated 
patients. Despite the lack of clinical symptoms, persistent viral replication occurs 
throughout this phase (Ho et al., 1995; Wei et al., 1995).  
The  third  phase  is  characterised  by  the  terminal  failure  of  the  immune  system, 
symptomatic infection and onset of AIDS. AIDS is defined, by the CDC, as the onset 
of  immune  deficiency  leading  to  the  occurrence  of  any  of  more  than  twenty 
opportunistic infections or HIV-related cancers with a circulating CD4+ T cell count 
below 200 cells/µl of blood (Centers for Disease Control, 1992).  44 
 
1.2.2  Host immune response to HIV-1 
The  course  of  HIV-1  infection  and  the  rate of  disease  progression  (as  described 
above) vary between individuals, but none of any infected individuals has been able 
to contain the persistent viraemia and to clear the HIV-1  infection. Host genetic 
factors,  such  as  the  CCR5∆32  allele  and  some  human  leukocyte  antigen  (HLA) 
genotypes (Lama and Planelles, 2007), as well as cellular factors that can restrict 
retroviral replication such as TRIM5α, APOBEG3G and Fv1 (Bieniasz, 2004), can 
affect the rate of disease progression in an infected individual. Innate and adaptive 
immune responses play a big role in determining disease progression. In this section, 
only the background of the adaptive host immune response, in particular the humoral 
response, will be discussed. 
Within weeks of the initial primary infection, HIV-1 specific CD8+ T cells emerge 
to help  in controlling the  viraemia, coinciding  with the decline  in  viral  load and 
restoration of circulating CD4+ T cells in humans and macaques (Pantaleo et al., 
1994; Schmitz et al., 1999). However, cellular-mediated immunity soon comes under 
pressure  from  the  selection  of  cytotoxic  T  lymphocyte  (CTL)  escape  mutants  in 
primary  infection  (Borrow  et  al.,  1997).  Research  work  in  cellular-mediated 
immunity has received renewed focus recently after the failure of the STEP vaccine 
clinical trials (Fauci et al., 2008), which will be discussed in Section 1.2.3.1. 
The humoral or antibody response to HIV-1 infection is primarily directed against 
the  gp120,  gp41,  CA  and  MA  viral  proteins,  but  only  antibodies  that  recognise 
gp120  and  gp41  epitopes  are  able  neutralise  HIV-1  infection,  and  this  antibody 
response varies widely between individuals (Burton et al., 2005; Frost et al., 2008; Li 
et al., 2009; Montefiori et al., 2007). Neutralising antibodies can be observed within 45 
 
weeks of initial infection and can help in the control of primary viraemia, and are 
also detectable after acute infection when viral load declines. The initial neutralising 
antibody  response  is,  in  general,  highly  specific  for  the  autologous  early  virus 
variants  and  shows  limited  cross-neutralisation  properties  (Aasa-Chapman  et  al., 
2004; Albert et al., 1990; Ariyoshi et al., 1992; Frost et al., 2005; Gray et al., 2007a; 
Lathey  et  al.,  1997;  Li  et  al.,  2006a;  Moog  et  al.,  1997;  Pellegrin  et  al.,  1996; 
Richman et al., 2003; Wei et al., 2003). Neutralising anti-envelope antibodies are 
thought to constitute only a fraction of the total antibody response, as the majority of 
anti-envelope antibodies are unable to bind functional envelope glycoprotein spikes 
on the virus surface (Moore et al., 2006; Parren et al., 1997; Poignard et al., 2003). 
Neutralisation escape mutants of the virus can be isolated with the emergence of 
neutralising antibodies, which then again prompts the generation of new antibodies 
that are able to neutralise the escape mutants in an evolutionary cycle to control the 
virus  infection  (Burton  et  al.,  2005;  Richman  et  al.,  2003;  Wei  et  al.,  2003).  
Although the neutralising antibody response may be very vigorous, it is probably not 
able to keep up with the high replicative and mutational rates of the virus (Mansky 
and  Temin,  1995;  Perelson  et  al.,  1996;  Richman  et  al.,  2003).  This  selective 
pressure thus helps to drive virus evolution, and contributes to the extreme genetic 
diversity  observed  in  the  env  gene  and  the  variation  in  neutralisation  sensitivity 
amongst the HIV-1 variants. This also  leads to the gradual  broadening of serum 
neutralising activity, sometimes producing broadly neutralising antibodies that are 
often found in long term non-progressors (Braibant et al., 2006; Frost et al., 2005; 
Pilgrim et al., 1997; Richman et al., 2003). However, there may be limits to the 
ability of HIV-1 to continuously evolve to escape neutralising antibody responses in 
the chronic stage (Deeks et al., 2006; Draenert et al., 2006).  46 
 
In addition to being able to directly neutralise virus, anti-envelope antibodies can 
induce  additional  antiviral  immune  functions,  mediated  by  interaction  of  the  Fc 
portion of the antibody with Fc receptors (FcRs) or with complement that can lead to 
the clearance of infected cells (Huber and Trkola, 2007; Perez et al., 2009). Such 
antiviral immune functions can be mediated by both neutralising as well as non-
neutralising antibodies which recognise non-functional spikes present on the virus 
surface (Moore et al., 2006). The relevance of FcR-mediated effector functions in 
vivo has been highlighted by the recent observation that the ability of the broadly 
neutralising mAb b12 to protect macaques against SHIV challenge was reduced if 
mutations  that  impair  FcR  binding  were  introduced  into  the  Fc  portion  of  b12 
(Hessell et al., 2007). 
The  role  of  neutralising  antibodies  in  the  protection  against  HIV-1  infection  is 
further  demonstrated  in  passive  immunisation  studies.  Studies  have  found  that 
macaques  can  be  protected  from  a  SHIV  challenge  through  the  transfer  of 
neutralising antibodies (Gauduin et al., 1997; Veazey et al., 2003), and can also help 
to control the plasma virus load post-infection (Trkola et al., 2005; Yamamoto et al., 
2007). 
1.2.3  HIV-1 vaccines and prevention strategies 
Improvements  in  anti-retroviral  therapy  (ART)  have  advanced  tremendously  in 
recent years, especially with the introduction of highly-active anti-retroviral therapy 
(HAART) in 1996 which helped to reduce mortality and sustain the quality of life in 
infected individuals (Hogg et al., 1998). Although such therapy can control viral load 
and  prevent  progression  to  AIDS,  it  does  not  clear the  infection  completely  and 
issues remain concerning costs and toxicity, especially in Africa where it is needed 47 
 
most. In order to control the HIV-1 pandemic in the world’s most vulnerable regions, 
there is an urgent need for preventive measures to lower transmission rates and to 
protect from  infection. Such strategies  would obviously  include  barriers to block 
transmission, such as condoms, but the Holy Grail to prevent transmission would be 
an effective HIV-1 vaccine.   
1.2.3.1 HIV-1 vaccine development 
Despite  many  years  of  intensive  research  in  HIV-1  vaccine  development,  an 
effective vaccine against HIV-1 is still unavailable. Several features of HIV-1 make 
it a challenging target for vaccine design, in particular its high mutation rate and its 
remarkable genetic diversity. The immune evasive properties of the HIV-1 envelope 
glycoproteins are other major obstacles in vaccine development, as is the ability of 
HIV-1 to remain latent in cells. 
Nevertheless, the observation that passively transferred neutralising antibodies can 
protect macaques against SHIV and SIV challenge (Baba et al., 2000; Mascola et al., 
2000; Shibata et al., 1999; Van Rompay et al., 1998) indicates that antibodies could 
potentially prevent infection once elicited. As T cell responses also play a role in 
controlling  viraemia  in  HIV-1  and  SIV  infection,  it  is  generally  believed  that  a 
successful  vaccine  against  HIV-1  will  need  to  elicit  both  humoral  and  cellular 
immune responses in order to prevent infection, disease, or both (Fauci et al., 2008; 
Letvin, 2006; Walker and Burton, 2008). 
The vaccine candidates that have so far provided the best protection in the macaque 
model are  live attenuated SIVs (Berkley and  Koff, 2007;  Friedrich and  Watkins, 
2008; Koff et al., 2006). Immunising macaques with live attenuated SIV has been 
shown to provide protection against challenge with homologous pathogenic SIV for 48 
 
up  to  more  than  two  years  after  immunisation,  but  was  less  effectvive  against 
heterologous SIV isolates (Daniel et al., 1992; Gauduin et al., 2006; Mansfield et al., 
2008; Nilsson et al., 1998; Whatmore et al., 1995; Wyand et al., 1999; Wyand et al., 
1996). There are safety issues with this approach however, as there is a possibility 
that the virus may revert back to a pathogenic form, or prove to be pathogenic after a 
prolonged  period  of  time  or  in  immunocompromised  individuals,  as  have  been 
observed in macaque studies (Baba et al., 1999; Whatmore et al., 1995).  
Other vaccine candidates include inactivated or killed virus preparations that may be 
safer, but were found to offer only short-lived protection in the macaque model and 
only against an identical viral challenge (Lifson et al., 2004). Non-infectious virus-
like  particles  (VLPs)    were  found  to  offer  a  slightly  broader  immune  response 
(McBurney  et al., 2007). DNA vaccines  encoding HIV-1 proteins are also under 
investigation,  but  they  were  found  to  be  of  low  immunogenicity  in  non-human 
primates compared to in mice (Letvin, 2006; McMichael, 2006), and might be better 
used  as  priming  vaccines  in  various  prime-boost  strategies  (Amara  et  al.,  2001; 
Hanke et al., 1999; Shiver et al., 2002; Wang et al., 2006). Mucosal administration of 
several vaccine candidates have been shown to reduce viral loads in macaques after 
mucosal challenge with SHIV (Belyakov et al., 2001; Bertley et al., 2004; Fuller et 
al., 2002). 
Subunit  vaccines  containing  crude  virus  extracts  or  recombinant  proteins  can  be 
easily produced and are generally thought to be safest. These were also the first HIV-
1 vaccine candidates to enter phase II/III clinical trials in humans. VaxGen (San 
Francisco,  CA,  USA)  produced  two  vaccine  candidates  containing  recombinant 
gp120 derived  from HIV-1 of subtype B and  A/E, which were shown to protect 
chimpanzees against challenge with homologous virus (Berman et al., 1990). Both 49 
 
candidates were brought forward to phase III clinical trials in the USA and/or in 
Thailand, but they did not prevent infection, had no effect on subsequent viral load, 
and did not elicit antibodies that could neutralise primary isolates of HIV-1 in vitro 
(Cohen, 2003; Flynn et al., 2005; Pitisuttithum et al., 2006).  
The failures of efficacy in the VaxGen trials were perhaps not too surprising, given 
what we now know about the immune evasive mechanisms of the HIV-1 envelope 
glycoproteins and the extreme HIV-1 genetic diversity. Great efforts are currently 
focused  on  designing  immunogens  that  can  elicit  a  broader  and  more  potent 
neutralising antibody response required of a vaccine. This includes the generation of 
stable  recombinant  trimeric  envelope  proteins  that  mimic  the  functional  HIV-1 
envelope  spike,  as  well  as  peptide  and  protein  constructs  that  better  present 
conserved epitopes recognised by a handful of broadly neutralising antibodies to the 
HIV-1 envelope glycoproteins (Walker and Burton, 2008; Zwick and Burton, 2007). 
Unfortunately, such an immunogen has yet to be developed.   
In  light of the difficulties  in eliciting a  neutralising antibody response to HIV-1, 
along  with  the  evidence  for  a  role  of  T  cells  in  the  control  of  SIV  and  HIV-1 
infection, much focus has been on developing vaccines that elicit T cell responses, 
which even though they  may  not prevent  infection may contain  viral replication, 
leading to lower viral load set-points and delayed onset of disease (Letvin, 2006; 
Walker and Burton, 2008).  
Merck developed a T-cell based vaccine candidate that went into clinical trials. This 
is based on the incorporation of HIV-1 genes into viral vectors to mimic the efficacy 
of  a  live  attenuated  vaccine.  Their  vaccine  candidate  consists  of  a  replication-
defective adenovirus type 5 vector engineered to express the HIV-1 Gag, Pol and 50 
 
Nef  proteins.  Results  from  a  macaque  model  showed  some  protection  against 
subsequent  viral  challenge  with  pathogenic  SHIV89.6P,  with  immunised  animals 
showing reduced viral load and rarely developed disease (Shiver et al., 2002). This 
vaccine candidate was taken forward for clinical trials in 2004 by Merck and the 
HIV Vaccine Trials Network, and was called the STEP trial. This vaccine candidate 
had been shown to induce CD8+ T cell responses in clinical phase I and II trials of 
safety and immunogenicity in humans. However, the Merck vaccine candidate not 
only failed to prevent infection and to reduce the viral load in subsequently infected 
individuals  in phase III trials, it has enhanced the rate of infection in vaccinated 
individuals  with  pre-existing  high-titre  antibodies  to  adenovirus  of  serotype  5 
(Cohen, 2007a; Cohen, 2007b; Ledford, 2007; Steinbrook, 2007).  
A  vaccine candidate developed  by Sanofi-Pasteur is currently  in clinical efficacy 
trials  in  Thailand,  and  is  based  on  a  canarypox  vector  in  combination  with  the 
recombinant  gp120  vaccine  candidate  developed  by  VaxGen  in  a  prime-boost 
regime.  This  vector  expresses  HIV-1  Gag,  Pol  and  envelope  glycoproteins. 
Unfortunately, the immunogenicity of this vaccine regimen has been shown to be 
fairly  low in clinical phase I and II trials and preliminary data has suggested no 
effect  on  viral  load  in  individuals  who  have  become  infected  (Lee  et  al.,  2004; 
Nitayaphan et al., 2004). 
So far, none of the vaccine strategies have been able to protect macaques against SIV 
challenge (Friedrich and Watkins, 2008; Watkins et al., 2008). The two candidates 
that have completed large-scale efficacy trials in humans have failed to prevent or 
control infection. Moreover, no vaccine candidate has been able to elicit neutralising 
antibodies, in any species, of the breath and potency likely required of a vaccine. The 
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efficacy of  vaccine candidates prior to testing  in costly  human trials, and results 
obtained in animal models do not necessarily correlate with or predict outcome in 
humans (Friedrich and Watkins, 2008; Sattentau, 2008; Walker and Burton, 2008; 
Watkins et al., 2008). Virus transmission in the best available animal model, the 
SHIV/SIV macaque model, is likely to differ substantially from HIV-1 transmission 
in humans (Friedrich and Watkins, 2008; Watkins et al., 2008). For example, the 
artificial virus preparations used in animal models may not be representative of the 
virus  swarms  involved  in  sexual  transmission  of  HIV-1.  Moreover,  the  limited 
number of SIV or SHIV isolates available  may not accurately represent the  vast 
majority of the circulating HIV-1 strains. A vaccine against HIV-1 therefore remains 
elusive.  
1.2.3.2 Topical strategies against HIV-1 
As  a  viable  vaccine  candidate  for  HIV-1  will  not  be  realised  any  time  soon,  an 
alternative would be the use of a topical microbicide to inhibit sexual transmission of 
HIV-1. Microbicides are agents that can be applied topically in the vagina or rectum, 
and are advantageous over the use of condoms, which is largely male-controlled and 
may not be compatible with marriage, nor can it be combined with reproduction. As 
microbicides  could  potentially  be  inexpensive,  readily  available  and  socially 
acceptable,  they  could  offer  a  promising  preventive  intervention  for  sexual 
transmission of HIV-1 (Balzarini and Van Damme, 2007; Klasse et al., 2008; Klasse 
et al., 2006; Lederman et al., 2006). 
Similar to HIV-1 vaccine development, there are many challenges to overcome in 
HIV-1 microbicide development. Firstly, a microbicide must be effective against the 
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genetic  heterogeneity  observed  among  HIV-1  isolates  (Taylor  et  al.,  2008). 
Secondly, a  microbicide  must be safe to use. A potential  microbicide should not 
cause  inflammation  or  have  adverse  effects  on  the  resident  microflora  or  the 
structural  integrity  of  the  mucosal  epithelia  that  might  increase  the  risk  of 
transmission.  Thirdly,  an  effective  microbicide  needs  to  be  stable  at  a  range  of 
temperatures, easy to use, inexpensive, readily accessible, compatible with condom 
use, acceptable to users and sexual partners, and yet retain its potency in the presence 
of semen (Balzarini and Van Damme, 2007; Klasse et al., 2008; Klasse et al., 2006; 
Lederman et al., 2006; Neurath et al., 2006; Shattock and Moore, 2003). Finally, 
there  are  the  same  issues  as  for  vaccines  with  efficacy  evaluation  and  result 
correlation  between  in  vitro  experiments,  animal  models  and  actual  human  trials 
(Grant et al., 2008; Klasse et al., 2006; van de Wijgert and Shattock, 2007). Current 
evaluation  models  include  the  human  explants  models  (Cummins  et  al.,  2007), 
humanised mice models (Denton et al., 2008), and the macaque vaginal transmission 
model (Ambrose et al., 2008; Harouse et al., 2001; Lederman et al., 2004; Veazey et 
al., 2003). 
Compounds being evaluated as microbicides include detergents and surfactants that 
inactivate free virus by disrupting the viral envelope, and may also be active against 
other sexually transmitted pathogens,  including  enveloped  viruses  such as  herpes 
simplex virus (Lederman et al., 2006). Nonoxynol-9 was the first such compound to 
be  tested  in  clinical  trials,  which  was  originally  developed  in  the  1960s  as  a 
spermicide used in lubricants and to coat condoms, and was shown to demonstrate 
anti-HIV-1 activity in vitro and in animal models (Hicks et al., 1985; Miller et al., 
1992a). Although signs of inflammation could be detected when using nonoxynol-9 
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nonoxynol-9 not only had no effect on HIV-1 incidence, but had increased the risk of 
transmission in some cases by disrupting the membranes of the epithelium and the 
recruitment of target cells to the site due to inflammation (Fichorova et al., 2001; 
Hillier et al., 2005; Roddy et al., 1998; Van Damme et al., 2002). Another surfactant 
called C31G (Savvy) went  into phase III clinical trials  but  it did  not reduce the 
incidence  of  HIV-1  and  might  have  increased  the  hazards  of  receiving  HIV-1 
(Feldblum et al., 2008). 
Other microbicides being tested in clinical trials involve other modes of activity. One 
big  category  is  the  use  of  anionic  polymers  or  polyanions  which  can  bind  to 
positively  charged  regions  of  gp120,  such  as  the  V3  region  and  the  co-receptor 
binding site (Moulard et al., 2000). The first of these is cellulose sulphate, or known 
as Ushercell, which had shown good activity against HIV-1, HSV, HPV, Neisseria 
gonorrhoeae,  Chlamydia  trachomatis  and  Gardnerella  vaginalis  in  preclinical 
studies (Anderson et al., 2002; Christensen et al., 2001; Malonza et al., 2005; Simoes 
et al., 2002). Unfortunately, Ushercell failed to protect against HIV-1 infection in 
phase III trials, and might even possibly enhance the risk of infection (Van Damme 
et al., 2008). The second polyanion to enter clinical trials was Carraguard, which is a 
sulphated polysaccharide extracted from a red seaweed that has been shown to have 
anti-HIV-1  activity  in  vitro  (Schaeffer  and  Krylov,  2000),  but  again  did  not 
demonstrate any efficacy  in phase III trials (The Population Council, 2008). The 
failure of these two candidates was thought not to be surprising, as they had been 
shown to have limited potency in vitro, especially against CCR5-using viruses and in 
the presence of semen (Grant et al., 2008; Hartley et al., 2005; Neurath et al., 2006). 
A  third  polyanion,  PRO  2000/5,  which  is  a  synthetic  naphthalene  sulphonate 54 
 
polymer in clinical efficacy trials, has been shown to be active against HIV-1 in vitro 
(Keller et al., 2006) and against SHIV in the macaque model (Weber et al., 2001).  
Another class of molecules being considered for use as candidate microbicides are 
HIV-1  specific  entry  inhibitors  that  specifically  bind  to  gp120  or  gp41.  These 
include plant lectins which recognise glycans on the viral envelope. One of these is 
cyanovirin-N, which has been shown to prevent infection of macaques after vaginal 
SHIV  challenge  (Tsai  et  al.,  2004).  MAbs  to  gp120  and  gp41  are  also  being 
considered (Lederman et al., 2006) and have already been determined to be effective 
in macaques (Veazey et al., 2003). These include the mAbs b12, 2G12 and 2F5, 
which will be discussed in Section 1.2.4.2. Other entry inhibitors under consideration 
include small molecules such as BMS-378806 which binds to gp120 (Wang et al., 
2003), gp41 peptides which can inhibit virus entry such as T-20 (Klasse et al., 2008), 
RNA aptamers that bind to gp120 (Dey et al., 2005), CD4 mimics (Martin et al., 
2003),  CCR5  ligands  such  as  RANTES  (Lederman  et  al.,  2004),  the  CCR5 
antagonist  Maraviroc  (Fatkenheuer  et  al.,  2005),  as  well  as  the  CXCR4-binding 
small-molecule  AMD3465  (Klasse  et  al.,  2008).  An  innovative  but  controversial 
microbicide agent involves the genetic engineering of live commensal bacteria, such 
as  the  human  vaginal  isolate  of  Lactobacillus  jensenii,  to  secrete  a  two-domain 
version of CD4 or produce the lectin cyanovirin-N that can inhibit HIV-1 in vitro 
(Chang et al., 2003; Pusch et al., 2006).  
With disappointing results in all clinical efficacy trials completed to date, increasing 
efforts  are  being  made  to  develop  microbicides  containing  existing  antiretroviral 
drugs such as the NRTIs and NNRTIs (Grant et al., 2008; Klasse et al., 2008). Rectal 
application of Tenofovir has been shown to protect macaques from SIV infection 
following rectal challenge (Cranage et al., 2008). However, the outcome of the use 55 
 
of  therapeutic  drugs  in  microbicides  and  its  contribution  to  the  spread  of  drug 
resistance remains uncertain (Wilson et al., 2008).  
Just  like  the  field  of  HIV-1  vaccine  development,  research  work  to  produce  an 
effective anti-HIV microbicide is still in a very nascent stage. 
1.2.4  Role of neutralising antibodies in tackling HIV-1 
As  mentioned  in  Section  1.2.2,  neutralising  antibodies  are  produced  by  the  host 
immune response to an HIV-1 infection in an effort to clear the disease. Although 
HIV-1  quickly  evolves  its  envelope  glycoprotein  to  escape  neutralisation,  some 
individuals known as long term non-progressors (LTNP) are able to produce broadly 
cross neutralising antibodies (bcnAbs) that are able to keep viraemia levels in check 
(Braibant et al., 2006).  
1.2.4.1 Antigenic profile of the HIV-1 envelope glycoprotein 
The structure of the HIV-1 envelope spike has been introduced earlier in Section 
1.1.5.2.  This  section  will  introduce  the  antigenic  profile  of  the  HIV-1  envelope 
glycoprotein and means to evade recognition by antibodies. 
Since the envelope spike exists as a trimer of gp120/gp41 heterodimer, the antigenic 
profile of gp120 possess a non-neutralising face that is located on the inner domain 
of gp120 and a neutralising face that is exposed in the context of the envelope spike 
(Kwong  et  al.,  1998;  Moore  and  Sodroski,  1996;  Wyatt  et  al.,  1998).  The  non-
neutralising  face  is  normally  buried within the trimer and  interacts with gp41 or 
other gp120 protomers, but can become exposed on shed gp120 or on non-functional 
spikes on the virus surface (Moore et al., 2006; Poignard et al., 2003). The non-
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non-neutralising  anti-gp120  antibodies  (Moore  and  Sodroski,  1996;  Wyatt  et  al., 
1998). On the other hand, the neutralising face of gp120 which includes parts of the 
bridging sheet and the inner and outer domains, including the V2 and V3 regions 
(Wyatt et al., 1998), contains the receptor-binding sites and epitopes for a number of 
neutralising antibodies (Moore and Sodroski, 1996; Pantophlet and Burton, 2006). 
However,  conserved  and  functionally  important  regions  of  gp120,  such  as  the 
CD4bs, are often occluded from antibody recognition (Pantophlet and Burton, 2006). 
The V3 region is particularly immunogenic but typically elicit only isolate-specific 
antibodies (Hartley et al., 2005; Pantophlet and Burton, 2006). 
Much  of  gp41  is  almost  completely  occluded  from  antibody  recognition  in  the 
context  of  the  HIV-1  envelope  spike,  as  it  is  masked  by  glycans,  gp120,  and 
interactions with other gp41 molecules within the trimer (Nyambi et al., 2000; Qiao 
et al., 2005; Sattentau et al., 1995). However, several regions of gp41 have been 
found to be highly immunogenic and a large number of anti-gp41 antibodies have 
been isolated from infected individuals (Binley et al., 1996; Gnann et al., 1987; Xu et 
al., 1991). As these immunodominant regions are thought to be exposed only on non-
functional or disassembled spikes, or on gp41 in the post-fusion state, the majority of 
anti-gp41 antibodies are non-neutralising. The membrane-proximal external region 
(MPER) of gp41, which is located adjacent to the transmembrane domain of gp41 
and is the recognition site for the two well characterised broadly neutralising mAbs 
2F5 and 4E10, is usually not well exposed but can be accessible to antibodies on a 
fusion intermediate form of gp41 (Muster et al., 1993; Stiegler et al., 2001; Zwick et 
al.,  2001).  However,  immune  response  against  the  MPER  is  relatively  small   
(Braibant et al., 2006; Dhillon et al., 2007; Li et al., 2007). 57 
 
As can be seen, the HIV-1 envelope spike is highly complex and possesses a number 
of strategies to evade neutralising antibodies. As previously mentioned, the env gene 
is highly diverse due to the high mutation rate, and neutralising antibodies are often 
strain specific (Pantophlet and Burton, 2006). The glycan shield renders the outside 
of the envelope spike less visible to the immune system and its position is constantly 
evolving to escape neutralising antibodies (Cheng-Mayer et al., 1999; Wei et al., 
2003). The variable regions of gp120 are thought to mask both the receptor and 
coreceptor binding sites (Sullivan et al., 1998; Wyatt et al., 1995; Wyatt et al., 1993). 
Unliganded  gp120  is  also  thought  to  posses  a  high  degree  of  conformational 
flexibility and potent neutralising antibodies were found to recognise most of the 
different conformations (Myszka et al., 2000; Yuan et al., 2006). The presence of 
non-functional  spikes  on  the  virus  surface,  such  as  gp41  stumps,  gp120/gp41 
monomers and uncleaved gp160, and shed gp120 may all serve to divert the antibody 
response (Moore et al., 2006; Poignard et al., 2003; Zwick and Burton, 2007).  
Therefore,  targeting  the  least  conformationally  variable  regions  of  the  functional 
envelope  spike  may  produce  a  potent  neutralising  antibody  and  be  valuable  in 
vaccine design. Such regions could be identified by studying broadly and potently 
neutralising antibodies to the HIV-1 envelope glycoproteins. 
1.2.4.2 Neutralising antibodies to HIV-1 
As  previously  discussed,  most  of  the  anti-envelope  antibodies  developed  during 
HIV-1 infection are non-neutralising but studies on the humoral response in LTNP 
can give insights into the types of neutralising antibodies that are needed to control 
viraemia. Most of the neutralising antibodies from infected individuals with broadly 
neutralising sera were found to bind to the CD4bs on gp120, to gp120 epitopes not 58 
 
present  on  monomeric  gp120,  or  to  carbohydrate  epitopes  on  gp120,  but  these 
neutralising  antibodies  did  not  bind  to  the  MPER  of  gp41,  or  to  the  V1/V2/V3 
regions of gp120 (Dhillon et al., 2007; Li et al., 2007; Yuste et al., 2006). It was also 
found that broadly neutralising sera from most LTNP contain antibodies that were 
able to compete with the monoclonal antibody b12 for binding to the CD4bs, and 
with the monoclonal antibody 2F5 for binding to the MPER (Braibant et al., 2006) 
Only a handful of mAbs have been found to be broadly neutralising across various 
HIV-1 subtypes (Zwick and Burton, 2007). Two of these broadly neutralising mAbs 
are directed against gp120. The mAb b12, which binds to an epitope that in part 
overlaps a subset of the CD4bs (Barbas et al., 1992; Burton et al., 1991; Burton et 
al., 1994; Zhou et al., 2007), and 2G12, which recognises a carbohydrate motif on 
gp120 (Buchacher et al., 1994; Sanders et al., 2002a; Scanlan et al., 2002; Trkola et 
al., 1996b).  Another two broadly  neutralising  mAbs, 2F5 and 4E10, are directed 
against the MPER of gp41 (Buchacher et al., 1994; Muster et al., 1993; Stiegler et 
al., 2001; Zwick et al., 2001). The Fab fragment X5 (Moulard et al., 2002), which 
recognises an epitope on gp120 that is better exposed after CD4 binding also display 
some neutralising activity across HIV-1 subtypes.  
The  mAb  b12 (also referred as IgG1b12)  is one of the  most extensively studied 
mAbs  to  HIV-1  envelope.  It  was  initially  isolated  in  1991  as  an  Fab  fragment, 
through  panning  of  a  combinatorial  phage  library  displaying  monoclonal  Fab 
fragments  from  an  asymptomatic  HIV-1-infected  individual  on  recombinant 
monomeric  gp120  (Burton  et  al.,  1991)  and  has  since  been  expressed  as  a  full 
immunoglobulin.  The  mAb  b12  has  been  shown  to  be  able  to  neutralise  a  large 
proportion of HIV-1 isolates from a wide range of subtypes (Barbas et al., 1992; 
Binley et al., 2004; Burton et al., 1994; Pantophlet and Burton, 2006) and to protect 59 
 
macaques against SHIV challenge (Parren et al., 2001; Veazey et al., 2003). The 
crystal  structure  of  b12  in  complex  with  gp120  has  confirmed  that  b12,  which 
possess an unusually long and protruding heavy-chain CDR3, binds to an epitope 
that overlaps part of the CD4 binding site and revealed that b12 binds to gp120 only 
with  its  heavy-chain  (Zhou  et  al.,  2007).  Amino  acid  residues  in  all  three 
complementarity  determining  regions  (CDRs)  of  b12  make  contact  with  the 
functionally conserved CD4 binding loop and the outer domain of gp120.  
The  mAb  2G12  is  also  broadly  neutralising,  and  recognises  a  cluster  of 
oligomannose residues on gp120. It has an unusual structure in that it has undergone 
a domain-swap, where the heavy-chain variable regions of each Fab have swapped 
positions  so  that  they  interact  with  the  light-chain  variable  region  of  the 
neighbouring  arm  (Buchacher  et  al.,  1994;  Sanders  et  al.,  2002a;  Scanlan  et  al., 
2002; Trkola et al., 1996b). This antibody has shown efficacy in monkey models 
when used in combination with other mAbs (Baba et al., 2000; Hofmann-Lehmann 
et al., 2001), and also in humans through intravenous administration (Trkola et al., 
2005). Although 2G12 is able to neutralise many of the viruses tested, it does not 
neutralise subtype C viruses (Binley et al., 2004).  
The mAbs 2F5 (Buchacher et al., 1994; Muster et al., 1993) and 4E10 (Stiegler et al., 
2001; Zwick et al., 2001) target adjacent epitopes on the conserved MPER gp41. The 
mAb  2F5  binds  to  an  epitope  overlapping  the  conserved  sequence  ELDKWA 
(Muster  et  al.,  1993;  Ofek  et  al.,  2004),  whereas  4E10  recognises  the  epitope 
NWF(D/N)IT (Cardoso et al., 2005; Zwick et al., 2001) which is just C-terminal to 
the 2F5 epitope. The epitopes for both 4E10 and 2F5 have been shown be slightly 
hydrophobic and possibly membrane-bound (Alam et al., 2007; Haynes et al., 2005; 
Sanchez-Martinez  et  al.,  2006).  In  neutralisation  studies,  2F5  was  not  able  to 60 
 
neutralise  most subtype C  viruses as they  lack the DKW  motif required  for 2F5 
recognition (Binley et al., 2004), whereas 4E10 was able to neutralise most viruses 
tested (Binley  et al., 2004; Li  et al., 2005; Li  et al., 2006b) and  is possibly the 
broadest neutralising mAb to HIV-1 described to date.  
Other similar mAbs that target the CD4 binding site of gp120 and the MPER of gp41 
were isolated. These are the mAbs m14 (Zhang et al., 2004b), F105 (Clayton et al., 
2007), and Z13 (Zwick et al., 2001), but they were found to display less broad and 
potent neutralisation activity compared to b12, 2F5 and 4E10.  
All  of  the  broadly  neutralising  mAbs  reported  in  the  literature  to  date  are  from 
individuals infected with HIV-1 of subtype B (Zwick and Burton, 2007), which may 
explain why the mAbs 2G12 and 2F5 do not recognise viruses from subtype C. As 
most  circulating  strains  are  currently  of  subtype  C,  new  broadly  neutralising 
antibodies with better coverage of the circulating strains are needed.  
1.2.4.3 HIV-1 immunogens and vaccine design 
Efforts  are  being  made  to  design  an  immunogen  that  is  able  to  elicit  broadly 
neutralising antibodies like those described in the previous section. The envelope 
constructs should mimic the functional envelope spike (Pantophlet and Burton, 2006; 
Phogat and Wyatt, 2007), as previous attempts at using HIV-1 envelope glycoprotein 
constructs as immunogens (such as gp120 monomers or gp140 monomers or gp140 
trimers)  has  typically  elicited  only  antibodies  with  weak  neutralisation  activity 
against heterologous isolates. Recombinant oligomeric gp140  molecules are gp160 
molecules that have been truncated just before the transmembrane region of gp41 
(Beddows et al., 2005; Chakrabarti et al., 2002; Earl et al., 2001; Grundner et al., 
2005; Jeffs et al., 2004; Kim et al., 2005; Li et al., 2006c; Sanders et al., 2002b; 61 
 
Selvarajah et al., 2005; Srivastava et al., 2002; Yang et al., 2000; Yang et al., 2001; 
Zhang et al., 2001). However, it is thought that none of these recombinant constructs 
fully  mimic the  functional  viral  spike (Pancera  and  Wyatt, 2005; Pantophlet and 
Burton, 2006; Schulke et al., 2002).  
Other envelope constructs have also been engineered, such as deglycosylated gp120 
and gp120 with deleted immunodominant variable regions, gp120 locked in a CD4-
bound conformation, and masking of non-neutralising regions (Barnett et al., 2001; 
Dey et al., 2007; Kim et al., 2003; Pantophlet and Burton, 2003). Various scaffolds 
that hold the MPER neutralising epitopes are also under evaluation (Law et al., 2007; 
Zwick,  2005),  as  is  presenting  envelope  glycoproteins  in  the  context  of  VLPs 
(Crooks  et  al.,  2007).  A  trimeric  construct  of  the  MPER  of  gp41  was  also 
constructed and used to immunise rabbits, but was not able to produce neutralising 
antibodies (Hinz et al., 2009). 
To  deal  with  the  heterogeneity  of  the  HIV-1  sequence,  polyvalent  immunogens 
consisting of envelopes from different subtypes are also being considered and was 
shown to produce antibodies with better cross reactivity (Chakrabarti et al., 2005; 
Cho  et  al.,  2001;  Zwick  and  Burton,  2007).  Perhaps  some  envelopes  are  also 
conformationally presented in a better way. Rabbits immunised with a recombinant 
gp140 derived from an HIV-1-infected individual, whose serum was found to be 
broadly  neutralising,  were  also  found  to  produce  antibodies  with  cross-subtype 
reactive neutralising activity (Zhang et al., 2007).  
In light of the recent failures in vaccine clinical trials, more attempts are needed to 
design  an  appropriate  immunogen  that  is  able  to  elicit  broadly  neutralising 
antibodies. Reverse immunology, in which antigens can be engineered from epitopes 62 
 
recognised  by  neutralising  antibodies,  is  another  strategy  that  can  be  utilised  to 
design such an immunogen. For that to happen, more broadly neutralising antibodies 
are needed to characterise the relevant epitopes on the envelope glycoprotein for use 
in immunogens. 
 
1.3  Single-chain camelid antibodies 
As discussed earlier, more broadly neutralising antibodies are needed to understand 
and to interrogate epitopes on the HIV-1 envelope glycoprotein that can then be used 
to  design  immunogens  which  can  elicit  such  broadly  neutralising  antibodies,  in 
particular against subtype C viruses. We decided to exploit the unique characteristics 
of the llama immune system to isolate antibodies that can neutralise diverse strains 
of HIV-1, and these are described in Chapters 4 and 5 of this thesis. This section will 
give an introduction on camelid antibodies and single-chain antibody fragments in 
particular, and methods to isolate antibodies of interest. 
1.3.1  Basic  features  and  properties  of  camelid  single-chain 
antibodies 
Conventional IgG antibodies found in higher vertebrates are composed of a pair each 
of heavy chains and light chains. The heavy chains consist of a constant domain 
(CH), which is organised into three constant domains (CH1-CH3), and one variable 
domain (VH). A hinge region connects the CH1 and CH2 domains. The light chains 
are  composed  of  one  constant  (CL)  and  one  variable  domain  (VL).  The  antigen 
binding region or paratope is formed by the paired VH and VL domains.  63 
 
Hamers-Casterman et al. reported in 1993 that members of the Camelidae family 
were  able  to  produce  fully  functional  antibodies  that  are  devoid  of  light  chains, 
called  heavy-chain  antibodies,  in  addition  to  conventional  antibodies  (Hamers-
Casterman  et  al.,  1993).  The  Camelidae  family  includes  the  camel  (Camelus 
bactrianus), dromedary (Camelus dromedarius), llama (Lama glama), alpaca (Lama 
pacos), guanaco (Lama guanicoe) and vicuna (Lama vicugna). These heavy-chain 
antibodies also lack the first constant domain (CH1) of the constant region of the 
heavy  chain  (Figure  1-5).  The  antigen-binding  properties  of  the  heavy-chain 
antibodies are provided by one single fragment, the variable region of the heavy-
chain (Hamers-Casterman et al., 1993), and has been termed the VHH. A schematic 
representation of the camelid heavy-chain antibody is shown in Figure 1-5. 
The heavy-chain IgG fraction has been estimated to constitute up to 50% of the total 
serum IgG content in camelids, and IgA, IgD and IgM fractions do not appear to lack 
the light chains (Maass et al., 2007; Nguyen et al., 2001). The residues involved in 
antibody effector functions, mediated by binding of the Fc to complement and Fcγ 
receptors are conserved  in the  heavy-chain  antibodies,  indicating that they retain 
their ability to mediate effector functions (Vu et al., 1997). 
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Figure 1-5. Schematic representations of camelid heavy-chain antibody 
Conventional mammalian IgG consist of two heavy chains made up of three constant domains (CH1-
CH3) and one variable domain (VH), and two light chains made up of a constant (CL) and a variable 
(VL) domain. Camelid heavy-chains lack the light chains and the first constant domain of the heavy 
chains. Their variable domain has been termed the VHH.  
 
 
 
Figure 1-6. Schematic representation of VHH domains 
Like conventional VH domains, the VHH domain of heavy-chain antibodies contains four framework 
regions (FR1-FR4) and three complementarity-determining regions (CDR1-CDR3).  
 
Sequence and structural analysis of the VHH reveal that they share many features 
with  VH  domains  on  conventional  antibodies  (Harmsen  and  De  Haard,  2007; 
Harmsen  et  al.,  2000;  Muyldermans  et  al.,  2001;  Vu  et  al.,  1997). The  VHH  is 
organised  into  four  relatively  conserved  framework regions,  FR1-FR4,  and  three 
hypervariable  complementarity-determining  regions,  CDR1-CDR3,  which 
determines  antigen  specificity  (Figure  1-6).  On  average,  camelid  VHH  display 
longer CDRs compared to the conventional VH counterparts (Harmsen et al., 2000; 
Muyldermans et al., 1994; Vu et al., 1997). The CDR3 loops of llama VHH are on 
average 15 amino acids long, compared to an average of 12 amino acids in humans 65 
 
and 9 amino acids in mouse (Vu et al., 1997). The extent of somatic hypermutation is 
found to be higher in VHH compared to in VH, resulting in an overall increased 
sequence diversity compared to VH, thus allowing them to exhibit diverse antigen-
binding  properties  (Harmsen  and  De  Haard,  2007;  Muyldermans  et  al.,  2001; 
Nguyen et al., 2000). 
Despite their single-domain nature and small size of approximately 14 kDa, VHH 
have characteristics in terms of affinity and specificity that are similar to those of 
conventional antibodies (van der Linden et al., 1999), and the size of the interface 
surface areas are also similar (De  Genst et al., 2006). The VHH of  heavy-chain 
antibodies have been shown to have a preference for binding into active site clefts 
using its protruding CDR3 (De Genst et al., 2006; Lauwereys et al., 1998) and to be 
able  to  recognise  cryptic  epitopes  typically  occluded  to  conventional  antibodies 
(Stijlemans  et  al.,  2004),  compared  to  conventional  antibodies  which  tend  to 
recognise planar or convex surfaces.  
1.3.2  Exploitation of VHH in medical research 
The single domain and the diverse antigen-binding properties of VHH make them a 
very  useful  tool  in  medical  research,  and  VHH  have  many  biotechnological  and 
therapeutic applications. Individual VHH can be easily isolated from phage display 
libraries, without the need for random recombination of the VH and VL domains in 
conventional antibody Fab fragments (Harmsen and De Haard, 2007). Selected VHH 
can then be readily cloned and expressed to high levels in bacteria or yeast (Frenken 
et  al.,  2000).  Furthermore,  VHH  have  been  shown  to  be  thermally  and 
conformationally  stable,  exhibiting  thermodynamic  stabilities  that  have  not  been 
observed for functional conventional antibody fragments, such as the retention of 66 
 
binding  properties  at    temperatures  up  to  90°C  and  fully  reversible  refolding  of 
structure after denaturation through chemically induced unfolding (Dumoulin et al., 
2002; Perez et al., 2001; van der Linden et al., 1999). The stability and solubility of 
VHH also allows for engineering of multivalent and bispecific molecules, and these 
have  been  shown  to  exhibit  better  binding  and  neutralising  properties  than  their 
monovalent counterparts (Coppieters et al., 2006; Els Conrath et al., 2001; Roovers 
et al., 2007).  
These unique properties of VHH allow it to have diverse applications against a wide 
range of biological targets in biomedical research. VHH have been used to target the 
fungus Malassezia furfur implicated in the formation of dandruff (Dolk et al., 2005), 
and to target human lysozyme to inhibit amyloid fibril formation (Dumoulin et al., 
2003).  Other  applications  include  cancer  therapy  (Cortez-Retamozo  et  al.,  2004; 
Roovers et al., 2007) and infectious diseases (Baral et al., 2006; Garaicoechea et al., 
2008;  Harmsen  et  al.,  2007;  Kruger  et  al.,  2006;  van  der  Vaart  et  al.,  2006). 
Biotechnological applications include immune-affinity chromatography (Verheesen 
et al., 2003) and  intracellular targeting and tracing of antigenic structures within 
living cells (Rothbauer et al., 2006).  
1.3.3  VHH to target HIV-1 
Given the unique properties of VHH, such as its small size and diverse antigen-
binding properties and wide applications, VHH can also be used to target the HIV-1 
envelope spike to inhibit virus entry. Coupled with the VHH preference for binding 
to active site clefts with their protruding CDR3 loops, VHH may be ideal candidates 
to bind into the CD4 and coreceptor binding sites. The broadly neutralising mAbs 
b12,  2F5  and  4E10  were  all  found  to  possess  long  CDR3  loops.  The  stability, 67 
 
solubility,  ease  of  cloning  and  high  production  yield  of  VHH  makes  it  an  ideal 
candidate for microbicide development in the prevention of HIV-1. 
A previous PhD student in the lab, Anna Forsman, has isolated three VHH which 
show  potency  against  cross-subtype  HIV-1  (Forsman  et  al.,  2008).  These  were 
isolated from a llama immunised with recombinant monomeric gp120 derived from a 
subtype B’/C primary isolate. A functional selection approach was used to pan for 
VHH with competitive elution with soluble CD4, in a bid to increase the likelihood 
of isolating VHH that can target the CD4 binding site. The three isolated VHH (C8, 
D7 and A12 VHH) were found to recognise an area around the CD4 binding site of 
gp120 and were able to bind with high affinities, thus inhibiting virus entry into host 
cells. These VHH were found to target various primary isolates of subtypes B and C, 
some of which were not recognised by the mAb b12. Broadly neutralising antibodies 
are usually isolated from infected individuals and this is the first report of obtaining 
such antibodies from an immunised animal.  
1.4  Approach to this thesis 
Based on the initial success in isolating VHH that can inhibit HIV-1 entry, more 
neutralising VHH would be useful. These can have further applications in therapy as 
entry inhibitors or prevention reagents in microbicides, and can also be useful in the 
design of an HIV-1 vaccine by defining neutralising and non-neutralising epitopes in 
reverse immunology. MAbs to the HIV-1 envelope glycoproteins may be useful in 
the  design  of  an  HIV-1  vaccine  as  they  can  help  define  neutralising  and  non-
neutralising epitopes. MAbs able to neutralise a wide range of HIV-1 isolates can 
provide information about vulnerable, conserved and functionally important sites on 
the HIV-1 functional envelope spike, such as the receptor-binding sites.  68 
 
Therefore, the aim of this thesis is to utilise the non-conventional immune system of 
llamas to generate more VHH against the HIV-1 envelope spike, in particular to 
primary isolates of subtype C.  
Chapter 3 will describe the isolation and cloning of gp120 and gp160 envelopes from 
individuals in Africa and in the United Kingdom who are infected with subtype C 
HIV-1, and the insertion of these envelope fragments into HIV-1 backbone vectors 
to produce chimeric viruses that are replication competent. These envelopes are then 
characterised  with  various  antibodies,  and  are  used  as  neutralisation  targets  in 
subsequent chapters. Chapter 4 will describe the isolation of four different anti-gp41 
VHH from a llama that was immunised with trimeric gp140 derived from the same 
subtype B’/C recombinant that is mostly of subtype C in its envelope. Chapter 5 will 
describe the creation of C8- and D7-family specific VHH libraries, from the original 
immune library of the llama used to isolate the C8, D7 and A12 VHH, to create more 
VHH that are able to recognise the CD4 binding site of gp120. The CDRs of these 
VHH are then analysed and amino acid residues that are important for binding to 
HIV-1 are postulated. 
But first, the materials and methods will be described in Chapter 2, and the final 
chapter, Chapter 6, will discuss and summarise the findings of this thesis.  69 
 
2  Materials and Methods 
2.1  Materials 
This section provides details of the buffers and solutions, recombinant proteins and 
antibodies used in this study. 
2.1.1  Buffers and solutions 
The buffers and solutions used in this study are listed in Table 2-1. 
2.1.2  Recombinant HIV-1 envelope glycoproteins 
Recombinant gp120 derived  from the HIV-1 subtype B’/C (CRF07_BC) primary 
isolate CN54 (Su et al., 2000), produced in a baculovirus expression system, was 
kindly  provided  by  I.  Jones,  Reading  University,  UK,  through  the  European 
Microbicide Project (EMPRO). Recombinant gp140 CN54 and gp140 derived from 
the HIV-1 subtype A primary isolate 92UG037 (Jeffs et al., 2004), produced in a 
Chinese  hamster  ovary  (CHO)  cell  system,  were  kindly  provided  by  S.  Jeffs, 
Imperial College London, UK. Recombinant gp120 derived from the HIV-1 subtype 
B TCLA isolate IIIB (Popovic et al., 1984), produced in a baculovirus expression 
system,  was  obtained  from  the  Centralised  Facility  for  AIDS  Reagents  (CFAR, 
catalogue number EVA607) at the National Institute for Biological Standards and 
Control (NIBSC), Herts, UK. Recombinant gp120 derived from the HIV-1 subtype 
C primary isolate 92BR025 (Gao et al., 1996), were cloned, expressed and purified 
as  detailed  in  Section  2.7.1.1.  Recombinant  gp41∆  from  subtype  B  HIV-1  MN, 
consisting  of  only  the  ectodomain  region  (aa  546-682,  16-28kDa)  of  gp41,  was 
obtained  from  CFAR  (catalogue  number  ARP680).  Full  length  recombinant  IIIB 
gp41  that  was  expressed  in  an  yeast  system  (catalogue  number  R65890)  was 
procured from Biodesign International (Saco, Maine, USA). Recombinant trimeric 70 
 
gp140 96ZM651.02, 92UG037.A9 and Bx08 (Moog et al., 1997) were obtained from 
Polymun Scientific GmbH, Vienna, Austria, as part of the Bill & Melinda Gates 
Foundation Collaboration for AIDS Vaccine Discovery (CAVD). 
2.1.3  Monoclonal antibodies to HIV-1 gp120 and gp41 
Monoclonal antibodies b12 (Burton et al., 1991) were kindly provided by D. Burton, 
Scripps Institute, La Jolla, USA. MAbs 2G12 (Buchacher et al., 1994), 2F5 (Muster 
et al., 1993) and 4E10 (Stiegler et al., 2001) were obtained from Polymun Scientific 
GmbH,  Vienna,  Austria,  as  part  of  the  Bill  &  Melinda  Gates  Foundation 
Collaboration  for  AIDS  Vaccine  Discovery  (CAVD).  Mouse  mAb  1577  which 
targets gp41 peptide 735-752 (CFAR catalogue number ARP317, original source M. 
Ferguson),  and  human  mAbs  50-69D  and  98-6D  (CFAR  catalogue  numbers 
ARP3222  and  ARP3223  respectively,  original  source  S.  Zolla-Pazner)  were  all 
obtained from the Centralised Facility for AIDS Reagents (CFAR), NIBSC. MAb 
50-69D reacts to a conformational dependent epitope on gp41, whereas mAb 98-6D 
reacts with aa 644-663 of gp41. 
2.1.4  Sera and plasma from HIV-1-seropositive individuals 
Quality control (QC) sera 1, 2, and 6 from subtype B HIV-1-seropositive individuals 
have been described previously (McKeating et al., 1989). Plasma from individuals 
infected with subtype C HIV-1 was kindly provided by D. Yirrel, Glasgow, UK for 
envelope  cloning.  Serum  and  plasma  samples  were  heat-inactivated  to  destroy 
complement by incubation at 56°C for 1 h prior to use in neutralisation assays. 
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Table 2-1.  Buffers and solutions 
Buffer/solution  Composition 
2 × tryptone/yeast (TY) 
medium 
1.6% (w/v) tryptone, 1% (w/v) yeast extract, 0.5% 
(w/v) NaCl 
Luria-Bertani (LB) medium  1% (w/v) tryptone, 0.5% (w/v) yeast extract, 0.5% 
(w/v) NaCl 
LB agar  LB medium plus 1.5% (w/v) agar 
Phosphate buffered saline 
(PBS) 
137 mM NaCl, 3 mM KCl, 10 mM Na2HPO4, 2 mM 
K2HPO4, pH 7.4 
PBS-T  0.05% (v/v) Tween 20 in PBS 
Super optimal broth with 
catabolite repression (SOC) 
2% (w/v) tryptone, 0.5% (w/v) yeast extract, 10 mM 
NaCl, 2.5 mM KCl, 10 mM MgCl2, 10 mM MgSO4, 
20 mM glucose 
Tris acetate EDTA (TAE)  40 mM Tris-HCl, 20 mM sodium acetate, 1 mM 
EDTA, pH 7.8 
Tris buffered saline (TBS)  20 mM Tris-HCl, 120 mM NaCl, pH 7.6 
TBS-T  0.05% (v/v) Tween 20 in TBS 
TMT/BS  4% (w/v) milk powder and 10% (v/v) bovine serum 
(BS) in TBS-T 
TMT/GS  4% (w/v) milk powder and 10% (v/v) goat serum 
(GS) in TBS-T 
Transfer Buffer  25mM Tris, 192mM Glycine, 0.1% SDS 
His elution buffer  50 mM Na2HPO4, 300 mM NaCl, 150 mM 
imidazole, pH 7.0 
His equilibrium buffer  50 mM Na2HPO4, 300 mM NaCl, pH 8.0 
His pre-elution buffer  50 mM Na2HPO4, 300 mM NaCl, 10 mM imidazole, 
pH 7.0 
FACS buffer  0.1% azide, 1%FCS in PBS 
w/v,  weight/volume;  v/v,  volume/volume;  Tris,  tris-(hydroxymethyl)aminomethane;  EDTA, 
ethylenediaminetetraacetic  acid;  Imidazole,  1,3-diazole;  Tween  20,  polyoxyethylene  sorbitan 
monolaurate. 
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2.1.5  Recombinant sCD4 
Recombinant soluble CD4 (sCD4) consisting of the extracellular domains D1-D4 of 
human CD4 expressed in Sf21 cells in a baculovirus expression system was obtained 
from R&D Systems (Minneapolis, USA, catalogue number 514-CD-050/CF). 
2.2  Cell culture techniques 
2.2.1  Cell lines and culture media 
The TZM-bl cell line (Derdeyn et al., 2000; Platt et al., 1998; Wei et al., 2002), 
previously designated JC53-bl (clone 13), is a HeLa cell line which stably expresses 
human CD4, CXCR4 and CCR5 and contains Tat-responsive firefly luciferase and 
β-galactosidase  genes  under  control  of  the  HIV-1  promoter.  TZM-bl  cells  were 
obtained  through  the  NIH  AIDS  Research  and  Reference  Reagent  Programme 
(catalogue number 8129) from J. C. Kappes, X. Wu and Tranzyme Inc, and cultured 
in Dulbecco’s Modified Eagle Medium (DMEM; Invitrogen) containing 10% (v/v) 
foetal calf serum (FCS).  
The NP2 cell lines (Soda et al., 1999) are human glioma cell lines expressing human 
CD4 and either of the HIV-1 chemokine co-receptors, CCR3 (NP2/CD4/CCR3) or 
CXCR4 (NP2/CD4/CXCR4) or CCR5 (NP2/CD4/CCR5). NP2 cells were cultured 
in DMEM (Invitrogen) containing 5% (v/v) FCS.  
The 293T cell line, of human embryonic kidney origin (Graham et al., 1977), was 
cultured in DMEM GlutaMAX (Invitrogen), which is DMEM containing L-analyl-
L-glutamine instead of L-glutamine, supplemented with 10% (v/v) FCS. The use of 
DMEM  GlutaMAX  minimises  ammonia  build-up  in  cell  cultures,  as  L-analyl-L-
glutamine does not degrade into ammonia like L-glutamine.  73 
 
The H9 (HUT78) cell line, which is of human cutaneous T cell lymphoma origin 
(Mann et al., 1989), was cultured in Roswell Park Memorial Institute (RPMI) 1640 
medium (Invitrogen) supplemented with 10%
 (v/v) FCS.  
2.2.2  Mammalian cell line maintenance 
All  cells  were  grown  in  cell  culture  flasks  at  37°C  in  a  humidified  atmosphere 
containing  5%  CO2,  except  for  293T  cells,  which  were  kept  in  a  humidified 
atmosphere containing 10% CO2. Cell lines were passaged every 2-5 days and split 
at a ratio of 1:3-1:10 depending of the cell line and cell density. For adherent cell 
lines, cell monolayers were disrupted and removed by treatment with trypsin-EDTA 
(0.25% (w/v) trypsin, 1 mM EDTA; Invitrogen) at confluency, prior to passaging. 
Trypsinisation was performed  by washing cells  once  in sterile PBS,  followed  by 
incubation with approximately 4 ml of trypsin-EDTA (Invitrogen) at 37°C. Once 
cells had detached from the flask, fresh culture medium was added and cells were 
diluted in the appropriate growth medium to the desired density and split into an 
appropriate  number  of  flasks.  NP2  cells  engineered  to  express  CD4  were 
occasionally  passaged  in  selective  medium  containing  1  mg/ml  Geneticin  G418 
sulphate (Invitrogen) to maintain stable CD4 expression, and 1ug/ml puromycin for 
CXCR4 and CCR5 selection.  
2.2.3  Freezing and thawing of cells 
Adherent cells were trypsinised and then pelleted by centrifugation at 325 g for 10 
min, and approximately 10
7 cells/ml were resuspended in the appropriate cell culture 
medium containing 20% (v/v) FCS and 10% (v/v) dimethyl sulphoxide (DMSO). 
Resuspended cells were aliquoted into cryovials and subsequently transferred to -
80°C. To allow for slow freezing, vials were put into a polystyrene box. The next 74 
 
day, the vials were transferred to the vapour phase of liquid nitrogen, for long-term 
storage. When needed, cryovials containing frozen cells were transferred from the 
vapour phase of liquid nitrogen to a 37°C water bath. Once thawed, cells were added 
to 10 ml of growth medium and pelleted at 325 g for 10 min. Pelleted cells were 
resuspended in growth medium, transferred to cell culture flasks and kept at 37°C. 
2.2.4  Transfection of 293T cells 
A day before transfection, 293T cells were plated in a 6-well dish at a density of 
4x10
5  cells/well.  The  following  day,  the  medium  was  replenished  before 
transfection. Six µl of Fugene-6 (Roche, Germany) was premixed with 4 µg of DNA 
in 200 µl of serum-free Opti-MEM (Invitrogen, UK) for 15 min at room temperature, 
and  then  added  dropwise  to  each  well.  After  overnight  incubation  at  37°C,  the 
medium was replenished and harvested 42 h later.  
2.2.5  Preparation of peripheral blood mononuclear cells (PBMC) 
Buffy coats from the blood bank (Brentwood blood transfusion centre, London) were 
diluted 1:1 (v/v) in sterile PBS. Forty-five ml of the diluted Buffy coat were then 
layered onto 15ml of Lymphoprep (Nycomed, Norway) in 50 ml falcon tubes, and 
then centrifuged at 1500 g for 30 min without brakes. The lymphocytes layer was 
harvested, washed twice with sterile PBS by centrifugation at 800 g for 10 min. The 
cells were then incubated with 10 ml of red blood cell lysis buffer (Sigma, UK) for 
10 min at RT. Lymphocytes were then harvested by centrifugation, and diluted into 
RPMI. The cells were resuspended at a concentration of 10
6 cells/ml in RPMI-10% 
FCS containing phyto-haemagglutinin (PHA, Murex, UK) at a final concentration of 
20U/ml and grown  for 3 days at 37°C. The cells  were then centrifuged  and 10
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cells/ml  was  resuspended  in  RPMI  supplemented  with  20U/ml  of  IL-2  (Roche, 
Germany).  
2.3  Virus stocks and manipulations 
2.3.1  HIV-1 strains 
HIV-1 IIIB (Popovic et al., 1984) and HIV-MN (Gallo et al., 1984), which are T-cell 
line adapted (TCLA) CXCR4-using subtype B lab strains, were originally isolated 
from the PBMC of HIV-1 seropositive individuals in the 1980s. These were obtained 
from the Centralised Facility for AIDS Reagents (CFAR) as cell-free cell-culture 
supernatant from infected H9 cells. 
HIV-1 BaL (Gartner et al., 1986) and HIV-1 SF162 (Cheng-Mayer and Levy, 1988), 
originally isolated from human infant lung tissue and adult brain tissue respectively, 
are  both  subtype  B  CCR5-using  strains  propagated  in  PBMC.  These  were  also 
obtained  from  the  Centralised  Facility  for  AIDS  Reagents  (CFAR).  PBMC-
propagated HIV-1 primary isolates 92UG037 and 92BR025 were obtained from the 
WHO-UNAIDS collection of primary isolates (Gao et al., 1994).  
HIV-1 subtype B and subtype C reference panels of envelope clones (Li et al., 2005; 
Li et al., 2006b) from acute and early HIV-1 infections were obtained through the 
NIH  AIDS  Research  and  Reference  Reagent  Programme  (ARRRP;  catalogue 
numbers 11227 and 11326). The reference panels were designed for use as Env-
pseudotyped viruses to facilitate standardized Tier 2/3 assessments of HIV-1-specific 
neutralizing antibodies (Mascola et al., 2005). The Env-pseudotyped viruses exhibit 
a neutralization phenotype that is typical of most primary HIV-1 isolates, and they 
are all CCR5-using. No clone is unusually sensitive or resistant to neutralization. 
The gp160 genes were cloned  from  sexually  acquired, acute/early  infections and 76 
 
comprise  a  wide  spectrum  of  genetic,  antigenic  and  geographic  diversity  within 
subtype B and C. 
The subtype B panel consists of gp160 clones  6535.3, QH0692.42, SC422661.8, 
PVO.4,  TRO.11,  AC10.0.29,  RHPA4259.7,  THRO4156.18,  REJO4541.67, 
TRJO4551.58, WITO4160.33 and CAAN5342.A2, whereas the  subtype  C panels 
consists of clones Du156.12, Du172.17, Du422.1, ZM197M.PB7, ZM214M.PL15, 
ZM233M.PB6,  ZM249M.PL1,  ZM53M.PB12,  ZM109F.PB4,  ZM135M.PL10a, 
CAP45.2.00.G3 and CAP210.2.00.E8. The subtype C gp160 clones 93MW965.26 
and 96ZM651.02 were kindly provided by D. Montefiori (Duke University Medical 
Centre,  Durham,  USA)  through  the  Comprehensive  Antibody  Vaccine  Immune 
Monitoring Consortium (CA-VIMC) as part of the CAVD. These HIV-1 envelope 
pseudotyped  viruses  were  produced  in  293T  cells  by  co-transfection  with  the 
pSG3∆env plasmid, and are then capable of a single round of infection in TZM-bl 
cells. 
Replication-competent  chimeric  molecular  clones  CA6  and  CB7,  which  contain 
subtype C gp120 held  in the pHXB2∆env vector (McKeating et al., 1993), were 
kindly provided by M. Aasa-Chapman (UCL, London, UK). 
A collection of 20 HIV-1 subtype C infected plasma samples were obtained from 
David Yirell (Specialist Virology Centre in Glasgow, Scotland), with randomised 
patient  ID  numbers  given  from  C20  to  C39.  Replication  competent  chimeric 
molecular clones C202, C222, C250, C261, C271, C281, C291, C344, C351, C361, 
C381  and  C391  contain  HIV-1  Env  gp120  from  the  patients  and  held  in  the 
pHXB2∆env vector. Similar molecular clones C27b, C27d, C33.52, C37.42, C38d, 
C38g, C38.22, and C38.32 containing HIV-1 Env gp160 from the patients were also 77 
 
produced and held in the pNL43∆env vector (Zheng and Daniels, 2001). The cloning 
and characterisation of these viruses are described in Chapter 3.  
 
Table 2-2. HIV-1 isolates and molecular clones used in this study 
Virus  Subtype  Type
a  Source
b  Geographical origin 
IIIB  B  TCLA  PBMC  USA 
MN  B  TCLA  PBMC  USA 
BaL  B  PBMC  Lung  USA 
SF162  B  PBMC  Brain  USA 
QH0692.42  B  PSV  ccPBMC  Trinidad 
PVO.4
   B  PSV  ccPBMC  Italy 
92BR025.C1  C  MC   ccPBMC  Brazil 
93MW965.26  C  PSV  No info.  Malawi 
96ZM651.02  C  PSV  No info.  Zambia 
ZM214M.PL15  C  PSV  Plasma  Zambia 
aTCLA, T cell line-adapted isolate; PBMC, Primary PBMC-propagated isolate; PSV, pseudotyped 
viruses containing full-length envelopes; MC, molecular gp120 clone slotted into pHXB2∆env.  
bSource  of  original  isolate.  ccPBMC,  co-cultured  PBMC;  for  molecular  clone,  the  envelope  was 
cloned directly from ccPBMC. 
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2.3.2  Growth of viral stocks 
HIV-1 BaL and SF162 were propagated in PHA-stimulated PBMC. Approximately 
1-2 x10
7 PBMC (pooled from two donors) were incubated with virus at 37°C in a 
total  volume  of  1-2  ml.  After  2  h  of  incubation,  growth  medium  (RPMI  1640 
supplemented with 10%
 (v/v) FCS and 20 U/ml of interleukin-2) was added to the 
cells to a total volume of 10 ml. Virus production was monitored by evaluating the 
p24 content in the cell culture supernatant using the Vironostika HIV Uni-Form II 
Ag/Ab  p24  assay  (bioMérieux,  Marcy  l'Etoile,  France)  as  per  manufacturer’s 
protocol. After 6-7 days, the cells were pelleted by centrifugation at 325 g for 10 min 
and co-cultured (in fresh growth medium) with fresh, uninfected PHA-stimulated 
PBMC from two donors at a 1:1 ratio. Cell density was adjusted to approximately 1-
2 x 10
6 cell/ml. This procedure was repeated every 6-7 days for 4 weeks or until a 
sufficient volume and titre of virus had been obtained. The p24 content of the cell 
culture supernatant was monitored throughout. At the peak of p24 production, the 
cell culture supernatant was harvested by centrifugation of the cultures at 325 g for 
10 min. The supernatant was subsequently filtered (0.45 µm) and stored in liquid 
nitrogen in 0.5 ml aliquots.  
Laboratory-adapted CXCR4-tropic strains of HIV-1 (IIIB and MN) were grown in 
H9 cells. A virus stock was thawed and incubated with 10
6 H9 cells for 2 h at 37 °C, 
after which it was resuspended in 5 ml of RPMI supplemented with 10% (v/v) FCS, 
and allowed to incubate for 3 days at 37 °C. The infected cells were then centrifuged 
and  allowed  to  incubate  with  a  further  5x10
6  cells  for  2  h.  The  cells  were 
resuspended in 12 ml of media for another 3 days, until syncytia were visible under 
the  microscope. The cells were then pelleted and the supernatant, containing the 
virus particles, was aliquoted and stored in liquid nitrogen.  79 
 
2.3.3  Production of HIV-1 envelope pseudotyped viruses and virus 
from replication-competent molecular clones in 293T cells 
HIV-1 envelope pseudotyped viruses were produced in 293T cells by co-transfection 
with the pSG3∆env plasmid, which contains the entire HIV-1 genome except for the 
env gene. For each 10 cm cell culture dish of 293T cells, 4 µg of envelope clone and 
8  µg  of  pSG3∆env  was  used.  Virus  stocks  from  replication-competent  HIV-1 
molecular clones were also prepared by transfection of 293T cells. Transfection of 
293T cells was carried out as described in Section 2.2.4. The virus-containing cell 
culture supernatant was harvested at 48-72 h after transfection, and filtered through a 
0.45 µm filter. It was then aliquoted into cryovials and stored in liquid nitrogen. 
2.3.4  HIV-1 p24 intracellular immunostaining 
HIV-1  infection  of  NP2  cells  was  detected  using  in  situ  intracellular  p24 
immunostaining  as  previously  described  (Sonza  et  al.,  1991).  The  cell  culture 
medium was removed and the cells were fixed for 10 min at room temperature using 
200 µl per well of an ice-cold mixture of methanol and acetone (at a 1:1 ratio). The 
cells were then subsequently washed twice in PBS+1% FCS. The fixed cells were 
then incubated with 200 µl per well of an equal mixture of mouse anti-p24 mAbs 
38:96K and EF7 (corresponding to reagents ADP365 and ADP366 at the Centralised 
Facility for AIDS Reagents, NIBSC) at 1:40 dilution in PBS+1% FCS, for 1 h at 
room  temperature.  After  another  two  washes  in  PBS+1%  FCS,  the  cells  were 
incubated  with  200  µl  per  well  of  a  goat  anti-mouse  immunoglobulin  antibody 
conjugated  to  β-galactosidase  (Southern  Biotechnology  Associates,  Birmingham, 
USA; catalogue number 1010-06) at 2.5 µg/ml in PBS+1% FCS, for 1 h at room 
temperature. The stained cells were then washed twice in PBS+1% FCS and once in 
PBS, and subsequently incubated with 200 µl per well of β-galactosidase substrate 80 
 
solution  (0.5  mg/ml  5-bromo-4-chloro-3-indolyl-β-galactopyranoside  in  PBS 
containing 3 mM potassium ferricyanide, 3 mM potassium ferrocyanide and 1 mM 
MgCl2)  at  37°C  overnight.  Cells  infected  with  HIV-1  will  develop  a  deep-blue 
colour, and individual or grouped stained cells were counted under the microscope as 
focus-forming unit (FFU). 
2.3.5  Titration of virus stocks on NP2 cells 
HIV-1  titres  were  assessed  on  NP2/CD4/CXCR4  cells  or  NP2/CD4/CCR5  cells, 
depending on the co-receptor usage of the HIV-1 strain. Cells were split and 2x10
4 
cells were seeded per well in a 48-well plate, and allowed to incubate overnight at 
37°C. A vial containing the viral stock was thawed and 10-fold serially diluted in 
DMEM+10% FCS. One hundred µl of the serial dilutions were allowed to incubate 
with cells in duplicate wells for 2 h at 37°C. The cells were then washed once with 
medium and incubated with 500 µl of DMEM+10% FCS per well for 48-72 h at 
37°C.  The  medium  from  each  well  were  then  removed  and  fixed  with  ice  cold 
methanol/acetone.  Virus  infection  was  detected  with  intracellular  HIV-1  p24 
immunostaining  as  described  in  Section  2.3.4.  Focus  forming  units  (FFU)  were 
counted microscopically and the virus titre determined as FFU/ml. 
2.3.6  Neutralization assays on NP2 cells 
NP2 cells were plated overnight in 48-well cell culture plates at a density of 2 x 10
4 
cells per well. Virus (100 FFU) was then incubated in triplicates with 2-fold serial 
dilutions of test antibody (from 25 µg/ml) or serum (from 1:10 dilution) in 100µl 
DMEM+10% FCS for 2 h at 37°C. The cells were then gently washed once with 
DMEM+10% FCS and incubated with 500 µl of DMEM+10% FCS per well, and 
incubated  for 3 days at 37°C. The cells were then  fixed and  virus  infection was 81 
 
detected with HIV-1 p24 intracellular immunostaining as described in Section 2.3.4. 
FFU were counted microscopically and neutralisation titres were determined as the 
antibody  concentration  (or  dilution)  required  to  give  50%  reduction  of  infection 
(IC50) compared to a negative control antibody (or normal human serum).  
2.3.7  Detection of infection of TZM-bl cells 
TZM-bl  cells  contain  the  integrated  reporter  gene  for  firefly  luciferase,  which  is 
induced in trans by viral Tat protein soon after infection. Luminescence production 
was detected using the Bright-Glo Luciferase Assay System (Promega) according to 
the manufacturer’s instructions. Briefly, 100 µl of cell culture medium was removed 
from each well, and 100 µl per well of Bright-Glo reagent was subsequently added. 
Lysis was allowed to occur for 2 min and luminescence (in relative light units; RLU) 
was then detected using a GloMax 96 Luminometer (Promega). 
2.3.8  Titration of virus stocks on TZM-bl cells 
Viral stocks were five-fold serially diluted in cell culture medium in quadruplicate 
wells,  in  a total of 100 µl per well. This was  performed  in opaque 96-well  cell 
culture  plates  (Nuclon,  Nunc).  Eight  of  the  wells  contain  100  µl  of  cell  culture 
medium  only  for  virus-controls.  Approximately  1x10
4  newly  trypsinised  TZM-bl 
cells  in  100  µl  of  DMEM+10%  FCS  and  30  µg/ml  diethylaminoethyl  (DEAE)-
dextran (Sigma-Aldrich) were then added to each well, giving a final concentration 
of 15 µg/ml of DEAE-dextran. The plates, containing serially diluted virus and equal 
amounts of TZM-bl cells, were allowed to incubate at 37°C for 48 h. Luminescence 
was then detected as described in Section 2.3.7, and background luminescence (i.e. 
luminescence in wells containing cells but no virus) was subtracted. The dilution 
where 50% of wells were positive, i.e. the TCID50, was calculated using an Excel 82 
 
macro set up by D. Montefiori at the Duke University Medical Centre, Durham, NC, 
USA. 
2.3.9  HIV-1 neutralisation assay on TZM-bl cells 
This assay measures the reduction in luciferase reporter gene expression in TZM-bl 
cells  following  a  single  round  of  virus  infection.  Serial  three-fold  dilutions  of 
monoclonal antibody (starting at 25 µg/ml) or QC serum (starting at 1:10 dilution) 
were prepared in growth medium in duplicate wells of opaque 96-well cell culture 
plates, in a total volume of 50 µl per well. Approximately 200 TCID50 of virus, in 
50  µl  of  growth  medium,  was  then  added  to  each  well,  and  the  plates  were 
subsequently incubated at 37°C. After 1 h of incubation, 1x10
4 newly trypsinised 
TZM-bl cells in 100 µl of growth medium containing 30 µg/ml of DEAE-dextran 
(Sigma-Aldrich) were added to each well. The plates were then incubated at 37°C 
for  48  h,  after  which  the  cells  were  lysed  and  luminescence  was  detected  as 
described in Section 2.3.7. For each plate, 8 wells containing cells only, and another 
8 wells containing cells and virus only, were included. Neutralisation was measured 
as  the  reduction  in  RLU  in  test  wells  compared  to  virus  control  wells  after 
subtraction  of  background  luminescence  (from  cells  only  wells).  The  lowest 
antibody concentration (or serum dilution) required to give 50% reduction in RLU 
(IC50) were determined using the XLFit 4 software (IDBS). A negative control VHH 
(VHH #3; kindly provided by A. Gorlani, Utrecht University, the Netherlands) or 
normal human serum was tested in parallel.  83 
 
2.4  Molecular biology techniques 
2.4.1  Isolation of RNA 
RNA was isolated from plasma of HIV-1 infected individuals using the QIAamp 
Viral  RNA  Mini  Kit  (QIAGEN)  according  to  the  manufacturer’s  instructions. 
Briefly, virus was lysed by the addition of QIAGEN AVL lysis buffer and incubated 
at room temperature for 10 min, in the presence of polyA carrier RNA. RNA was 
then  purified  on  the  QIAamp  Mini  Spin  columns  and  eluted  in  QIAGEN  AVE 
elution buffer. 
2.4.2  Isolation of plasmid DNA 
Five ml of LB medium containing the appropriate antibiotic for selection (typically 
100  µg/ml  of  ampicillin  or  carbenicillin)  was  inoculated  with  a  single  bacterial 
colony  from an agar plate. Cultures were grown overnight at 37°C (or 30°C for 
bacteria with  large  vectors such  as  full-length  HIV-1  molecular  clones or gp160 
clones) with orbital shaking at 250 revolutions per minute (rpm). The bacteria were 
then pelleted  by centrifugation at 3000 g  for 10  min at 4°C. Plasmid DNA was 
isolated  from pelleted bacteria using the  QIAprep Spin Miniprep  Kit (QIAGEN) 
according  to  the  manufacturer’s  instructions.  Briefly,  the  pelleted  bacteria  were 
resuspended in resuspension buffer P1, containing RNase A, and subsequently lysed 
using buffer P2, with gentle inversion to avoid shearing of bacterial chromosomal 
DNA. The lysate was then neutralised and adjusted to high-salt binding conditions 
by the addition of the neutralising buffer N3. The samples were mixed by gentle 
inversion and precipitated SDS, chromosomal DNA, cellular debris, and denatured 
proteins were pelleted by centrifugation at maximum g. The supernatant was added 
to QIAprep Spin columns containing a silica membrane, and adsorbed plasmid DNA 84 
 
was purified in a series of washing steps and eluted in 50 µl of QIAGEN EB elution 
buffer (10 mM Tris-HCl, pH 8.5). 
2.4.3  Restriction enzyme (RE) digestion of plasmid DNA 
Plasmid  DNA  was  digested  using  restriction  enzymes  obtained  from  Promega 
(Southampton, UK) for 1 h under conditions specified by the manufacturer, usually 
at 37°C with an appropriate buffer.  Digested DNA was separated using agarose gel 
electrophoresis.  
2.4.4  Agarose gel electrophoresis of DNA 
DNA fragments were separated according to size by agarose gel electrophoresis. The 
gels were  made with 1% (DNA  fragments >500 bp) or 1.5-2% (DNA  fragments 
<500 bp) agarose (w/v; Roche Diagnostics, Lewes, UK) in 1x TAE buffer containing 
0.5 µg/ml of ethidium bromide (Sigma-Aldrich, Poole, UK). A molecular weight 
marker of appropriate size (GeneRuler 1 kb DNA ladder or GeneRuler 100 bp DNA 
ladder; Fermentas Life Sciences, York, UK) was run in parallel. Electrophoresis was 
carried out in 1x TAE buffer at 100 V for an appropriate amount of time. DNA was 
visualised by illumination with UV light. 
2.4.5  Extraction of DNA fragments from agarose gels 
DNA bands of the expected size were excised from the agarose gel while minimising 
exposure to UV light, and the DNA fragments were extracted using the QIAquick 
Gel Extraction kit (QIAGEN) according to the manufacturer’s instructions. 
2.4.6  DNA ligation  
DNA ligation of the DNA inserts into a vector backbone was carried out using a 2x 
Rapid Ligation Buffer together with T4 DNA ligase (both from Promega), with an 85 
 
appropriate amount of vector and insert DNA. The mixture was allowed to incubate 
for 30 min at room temperature.    
2.4.7  Transformation of competent bacteria 
Ligation reactions were transformed into chemically competent E. coli TOP10 cells 
(Invitrogen,  Paisley,  UK)  by  adding  1  µl  of  ligation  reaction  to  25-50  µl  of 
competent bacteria, followed by incubation on ice for 30 min. The bacteria were 
subsequently subjected to heat-shock at 42°C for 30 s, followed by incubation on ice 
for 1 min and addition of 250 µl of SOC medium (Invitrogen). The bacteria were 
then  incubated  for  1  h  at  37°C  (or  30°C  for  bacteria  transformed  with  vectors 
containing full-length HIV-1 molecular clones or gp160 clones) with orbital shaking 
at  250  rpm,  and  subsequently  plated  onto  LB  agar  plates  containing  100  µg/ml 
ampicillin or carbenicillin. Plates were then incubated overnight at 37°C (or 30°C for 
bacteria transformed with vectors containing full-length HIV-1 molecular clones or 
gp160 clones). 
Electrocompetent E. coli TG1 cells (Stratagene, La Jolla, USA) were transformed by 
adding 1 µl of ligation reaction or plasmid DNA to 40 µl of bacteria. Samples were 
then transferred to 0.1 cm electroporation cuvettes (Bio-Rad Laboratories, Hemel 
Hempstead,  UK),  which  had  been  pre-chilled  on  ice,  and  electroporated  using  a 
MicroPulser electroporator (Bio-Rad Laboratories) according to the manufacturer’s 
instructions (1.7 kV, 200 Ω, 25 µF). After addition of 1 ml of pre-warmed SOC 
medium, the bacteria were incubated for 1 h at 37°C with orbital shaking at 250 rpm 
and subsequently plated onto LB agar plates containing 100 µg/ml of ampicillin (or 
carbenicillin)  and  supplemented  with  2%  glucose.  Plates  were  then  incubated 
overnight at 37°C. 86 
 
2.4.8  DNA sequencing 
Plasmid  DNA  was  sequenced  using  the  CEQ  DTCS  Quick  Start  Kit  (Beckman 
Coulter, High Wycombe, UK) according to the manufacturer’s instructions. Briefly, 
sequencing reactions were carried out in a total volume of 10 µl containing 100 ng of 
DNA, 1.6 pmol of sequencing primer and 1x CEQ DTCS Quick Start master mix. 
Thermal cycling conditions consisted of 30 cycles of 96°C for 20 s, followed by 
50°C for 20 s and 60°C for 4 min. For each sample, the sequencing reaction was 
stopped by the addition of 1 µl of 3 M NaOAc (pH 5.2), 1 µl of 100 mM Na2-EDTA 
(pH 8.0), and 0.5 µl of 20  mg/ml of glycogen. The reactions were then cleaned 
through ethanol precipitation and re-suspended in 20 µl of sample loading solution 
(provided with the CEQ DTCS Quick Start Kit). Resuspended sequencing reactions 
were covered by one drop of mineral oil and plates were loaded onto a CEQ 2000 
DNA Analysis System sequencer (Beckman Coulter). 
Most of the DNA sequencing was  however carried out by the DNA Sequencing 
Service at the Wolfson Institute, University College London, UK, using the BigDye 
Terminator Cycle Sequencing Kit (Applied Biosystems, Foster City, USA). DNA 
sequencing  of  VHH  clones  was  carried  out  by  Ablynx  NV,  Porto,  Portugal. 
Predicted  amino  acid  sequences  were  aligned  using  the  Clustal  W2  multiple 
sequence alignment software (Larkin et al., 2007). 
2.4.9  Determination of nucleic acid concentration 
Nucleic acid concentration and purity was determined spectrophotometrically using 
the  NanoDrop  1000  Spectrophotometer  (Thermo  Fisher  Scientific,  Wilmington, 
USA) by measuring absorbance at 260 nm with prior zeroing of the machine with 
EB solution. 87 
 
2.4.10  Determination of protein concentration 
Protein concentration was determined using a combination of two methods. The first 
was method was spectrophotometry using the NanoDrop 1000 Spectrophotometer 
(Thermo Fisher Scientific) by measuring absorbance at 280nm with prior zeroing 
with PBS. Since protein measurements with spectrophotometry were often prone to 
errors, a second method was employed by running the samples with dilutions of a 
standard amount of BSA in SDS-PAGE and Coomassie staining.  
2.4.11  SDS-PAGE and Coomassie blue staining 
Proteins  were  resolved  using  SDS-polyacrylamide  gel  electrophoresis  (PAGE). 
Separating polyacrylamide gels were made with 15% Bis-polyacrylamide (Bio-Rad 
Laboratories) and 0.1% SDS in 375 mM Tris-HCl (pH 8.8), with 100 µl of 10% 
ammonium  persulphate  (APS)  and  10  µl  of  N’-tetramethylethylenediamine 
(TEMED) per 10 ml of gel, to polymerise. Stacking gels were made with 4% Bis-
polyacrylamide and 0.1% SDS in 125 mM Tris-HCl (pH 6.8), and APS and TEMED 
as above.  
Samples were mixed with sample buffer to a final concentration of 2% (w/v) SDS, 2 
mM  dithiothreitol  (DTT),  4%  (v/v)  glycerol,  40  mM  Tris-HCl  (pH  6.8)  and 
approximately 0.01% (w/v) bromophenol blue, boiled for 5 min, loaded onto gels 
and run at 200 V in running buffer containing 25 mM Tris-HCl, 200 mM glycine and 
0.1% (w/v) SDS. 
Alternatively, proteins were separated on pre-cast NuPAGE Novex 10% Bis-Tris 
gels (Invitrogen) in 3-(N-morpholino) propane sulphonic acid (MOPS) SDS running 
buffer. Samples were mixed with 1x NuPAGE LDS Sample Buffer and 1x NuPAGE 
Reducing Agent and heated to 70°C for 10 min prior to being loaded onto gels and 88 
 
electrophoresed at 200 V. The PageRuler (Fermentas Life Sciences) or BenchMark 
(Invitrogen) pre-stained protein  ladders were run in parallel, as  molecular weight 
markers. 
Gels  were  stained  using  0.1%  Coomassie  Brilliant  Blue  R-250  (Bio-Rad 
Laboratories)  in  10%  acetic  acid  and  40%  methanol  for  1  h  and  subsequently 
destained  in  10%  acetic  acid  and  40%  ethanol  until  an  appropriate  resolution  is 
obtained. 
2.4.12  Western Blots  
Proteins were first separated in polyacrylamide gels as described in Section 2.4.11, 
and then transferred to a Hybond-P PVDF membrane (Amersham/GE, UK) using an 
Amersham  SemiPhor  unit  (Amersham/GE,  UK)  for  semi-dry  transfer.  The 
membrane was first pre-soaked for 30 s in methanol before placing it under the gel 
and in between 4 pieces of blotting paper already soaked in transfer buffer added 
with 10% methanol. The transfer conditions were 60 mA for 1 h. After the transfer, 
the  membrane  was  soaked  in  TBS-T  with  5%  (w/v)  skim  milk  for  1h  at  room 
temperature with shaking. The membrane was then washed with 2 changes of TBS-T 
for 10  min each. To probe the antigens on the  membrane, VHH or antibody (at 
1ug/ml unless otherwise stated) in TBS-T was introduced for 1 h with shaking, and 
then washed off with 3 changes of TBS-T for 10 min each. These were repeated 
again with secondary mAb conjugated with HRP (at 4000-fold dilution). To detect 
the probed samples, 8 ml of ECL detection reagent (RPN2106, Amersham/GE, UK) 
was used on the membrane for 1 min, and the membrane was exposed on an x-ray 
film (Hyperfilm ECL, Amersham, UK) in a dark room for 15-45 s.  89 
 
2.4.13  Enyzme-linked immunosorbent assay (ELISA) 
Opaque 96-well Maxisorp plates (Nunc, Denmark) were coated overnight at 4 °C 
with 1 µg/ml of antigen (unless otherwise stated) in 0.1 M NaHCO3, pH 8.5. After 
washing  3  times  with  TBS-T,  non-specific  protein  binding  was  blocked  by 
incubating wells with 200 µl per well of 4% (w/v) milk powder in TBS for 1 h at 
room temperature. Wells were then washed 3 times with TBS-T and subsequently 
incubated  with  50  µl  per  well  of  serial  dilutions  of  antibody  in  1%  (w/v)  milk 
powder in TBS, for 1 h at room temperature. Each dilution of antibody were assayed 
in duplicate. Blank wells were included, or negative control antibodies were used, 
together with positive controls. This was washed again 3 times with TBS-T, and then 
incubated  for  1  h  with  100  µl  per  well  of  a  detection  antibody  conjugated  with 
alkaline phosphatase (AP) in 1% (w/v) milk powder in TBS. After 3 washes with 
TBS-T, 100 µl per well of Lumi-Phos Plus substrate (Aureon Biosystems) was added 
and  chemiluminescence  was  detected  after  0.5  h  of  incubation  at  37°C.  Blank-
corrected RLU were plotted against the antibody dilution. For detection with horse-
radish  peroxidase  (HRP)  conjugated  antibodies,  the  SureBlue  TMB  Microwell 
Substrate  (Kirkegaard  and  Perry  Laboratories,  Maryland,  USA)  was  added  and 
allowed to develop for 30 min, and the reaction was stopped with the addition of 25 
µl per well of 1 M H2SO4. The A490 was then measured and background subtracted 
values were plotted on a graph against protein concentration. 
2.5  Cloning of subtype C env genes and virus characterisations 
This section will describe most of the procedures used in Chapter 3. 90 
 
2.5.1  Sources of RNA 
HIV-1  gp120  and  gp160  were  amplified  from  viral  RNA  isolated  from  infected 
patient plasma samples as described in Section 2.4.1. These plasma samples were 
infected  with  subtype  C  HIV-1  and  were  obtained  from  David  Yirell  (Specialist 
Virology Centre in Glasgow, Scotland), with randomised patient ID numbers given 
from C20 to C39. 
2.5.2  Primers and primer design 
The primers used to amplify HIV-1 gp120 and gp160 are listed in Table 2-3. Primers 
o_envf and o_envr were designed by Anna Forsman (UCL, London, UK) to target 
nucleotide stretches conserved among most HIV-1 group M subtype A, B, C, and D 
as well as from HIV-1 of group O. Primers fenv3 and renv3, which amplify gp160 
and  contain  restriction  sites  for  XhoI  and  EcoRI  (underlined  in  Table  2-3)  to 
facilitate subsequent sub-cloning, were modified from primers described by Zheng 
and Daniels (Zheng and Daniels, 2001). Primers 125Y and 626L contain restriction 
sites for BstEII and MluI (underlined in Table 2-3) were used to amplify gp120, 
whereas primers 944S and E400010_His were used for gp120 recombinant protein 
expression. The primer 944S contains a natural Kozak sequence and a start codon, 
while the primer E400010_His contains a 6-histidine tag, a stop codon, as well as the 
recognition  motif  (VVQREKR)  for  sheep  polyclonal  antibody  D7324  (Aalto  Bio 
Reagents,  Dublin,  Ireland),  which  recognises  a  conserved  motif  at  the  very  C-
terminus of gp120 (APTKAKRRVVQREKR). These primers were provided by M. 
Aasa-Chapman  (Aasa-Chapman  et  al.,  2006a).  The  nucleotide  position  refers  to 
numbering  on  the  HIV-1  HXB2  genome  (GenBank  accession  number  K03455) 
which corresponds to the 5’-end of the primer.  
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Table 2-3. Primers used for amplification of HIV-1 gp160 and gp120 
Primer  Sequence (5´to 3´)
a  Position
b 
o_envf  TYTCCTATGGCAGGAAGAAGC  5964 
o_envr  TAACCCWTCCAGTCCCCCCTTTT  9096 
fenv3  AGCTCGAGCAGAAGACAGTGGCAATGA  6202 
renv3  CTATGGAATTCTTCGACCACTTGCCCCCCATTT  8827 
626L  GTGGGTCACCGTCTATTATGGG  6326 
125Y  CACCACGCGTCTCTTTGCCTTGGTGGG  7742 
944S  AGAAAGAGCGGCCGCCAGTGGCAATG  6202 
E400010_His  TTAATGATGATGATGATGATGTCTTTTTTCTCTCTGCACCACT  7778 
a. Underlined portions denote the restriction enzyme digestion site. The primers fenv3, renv3, 626L 
and 125Y contain XhoI, EcoRI, BstEII, and MluI digestion sites respectively.  
b. Nucleotide positions according to HXB2 numbering 
 
 
Table 2-4. Primers used for sequencing of HIV-1 gp160 and gp120 
Primer  Sequence (5´to 3´)  Position
a 
gp160 +1  ATGGGGACACAGAGGAATTATC  6234 
gp160 +298  GAGGATGTAATCAGCTTATG  6540 
gp160 -317  CATAAGCTGATTACATCCTC  6559 
gp160 +580  CAAGCCTGTCCAAAGATCTC  6831 
gp160 -600  GAGATCTTTGGACAGGCTTG  6850 
gp160 +901  ATAGGACCAGGACAAACATTC  7155 
gp160 +1198  TGCAGATCAAATATCACAGG  7557 
gp160 +1581  GTCTGGTATAGTGCAACAGC  7859 
gp160 +1881  GCTTGAAGAATCACAAAGCCAG  8159 
gp160 +2191  GTGAGCGGATTCTTAGCACT  8469 
gp160 +2431  GTAGCTGAGGGAACAGATAG  8688 
gp160-C21R  AAGTTCTTGTGGGTTGGGGT  6476 
gp160-C3  CGCAAAACCAGCGGAGCACA  6896 
gp160-C5  TGGCTTAATTCCATGTGTAC  6983 
gp160-C6  AGACTTGATATAGTACCACT  6755 
a. Nucleotide positions according to HXB2 numbering 
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Primers used for DNA sequencing of gp120 and gp160 clones are shown in Table 
2-4. Primers gp160 +1, gp160 +298, gp160 -317, gp160 +580, gp160 -600, gp160 
+901, gp160 +1198, gp160 +1581, gp160 +1881, gp160 +2191, and gp160 +2431 
were designed by K. Aubin (UCL, London, UK). Primers gp160-C21R, gp160-C3, 
gp160-C5, and gp160-C6 were designed by me to cover gaps in the sequences and 
ensure complete sequence coverage for certain isolates when the other sequencing 
primers failed to work. 
2.5.3  RT-PCR 
Specific  first-strand  cDNA  was  synthesised  from  viral  RNA  and  subsequently 
amplified  in a one-step RT-PCR using the Titan One Tube RT-PCR  Kit (Roche 
Diagnostics)  and  primers  o_envf  and  o_envr  (Table  2-3)  according  to  the 
manufacturer’s  instructions.  The  Titan  One  Tube  RT-PCR  Kit  uses  avian 
myeloblastosis  virus  (AMV)  reverse  transcriptase  and  the  DNA  polymerase  mix 
from  the  Expand  Long  Template  PCR  System  (Roche  Diagnostics).  Reverse 
transcription is initiated at the reverse primer. The reaction was carried out in a total 
of 50 µl containing 1x Titan RT-PCR reaction buffer, 1 µl of Titan enzyme mix, 500 
µM  of  each  of  the  four  dNTPs,  300  nM  each  of  forward  (o_envf)  and  reverse 
(o_envr) primers, 5 mM of DTT, 5 U of RNase inhibitor, and up to 1 µg of RNA. 
For the reverse transcription step, the reaction mix was incubated at 48°C for 30 min. 
The reverse transcription step was immediately followed by the PCR step, which 
consisted  of  initial  denaturation  at  96°C  for  5  min,  followed  by  35  cycles  of 
denaturation at 96°C for 1.5 min, annealing at 60°C for 1 min and elongation at 68°C 
for 10 min, followed by a final elongation step of 20 min at 68°C. Negative control 
reactions  containing  no  template  RNA  were  included  in  each  RT-PCR  run  to 93 
 
monitor possible contamination. Control reactions where reverse transcription was 
not carried out, containing the enzyme mix from the Expand Long Template PCR 
System instead of the Titan enzyme mix were also included to exclude amplification 
from genomic DNA. A 1-5 µl aliquot from the RT-PCR was taken forward to a 
second round of PCR using nested primers, to amplify gp120 or gp160. 
2.5.4  PCR amplification of gp120 and gp160 
Full-length HIV-1 gp120 and gp160 was amplified from proviral DNA or plasmid 
DNA in two rounds of PCR using the Expand Long Template PCR System (Roche 
Diagnostics). In addition to Taq DNA polymerase, the Expand Long Template PCR 
System enzyme  mix contains the Tgo DNA polymerase, which  has proofreading 
activity. The first round of PCR was carried out in a total of 50 µl containing 1x 
Expand Long Template Buffer 3, 500 µM of each of the four dNTPs, 300 nM each 
of the forward (o_envf) and reverse primer (o_envr), 3.75 U of the Expand Long 
Template enzyme mix and 300-500 ng of template genomic DNA. It consisted of an 
initial denaturation step of 5 min at 96°C, followed by 35 cycles of denaturation at 
96°C for 1.5 min, annealing at 60°C for 1 min and elongation at 68°C for 10 min, 
followed by a final elongation step of 20 min at 68°C.  
A  1-5  µl  aliquot  from  the  first  round  of  PCR  amplification  (or  from  RT-PCR 
amplification) was taken forward to a second round of PCR using nested primers that 
amplified gp120 or gp160. If the gp120 was going to be cloned into the pcDNA3.1-
TOPO expression vector (Section 2.7.1.1) for recombinant protein expression in a T7 
RNA  polymerase-recombinant  vaccinia  virus  system,  gp120  was  amplified  using 
primers 944S and E400010_His. If the gp120 was going to be slotted into cloning 
vectors (Section 2.5.5), gp120 was amplified from the outer PCR product, or re-94 
 
amplified  from  selected  gp120  clones  held  in  the  pcDNA3.1-TOPO  expression 
vector,  using  primers  125Y  and  626L.  Full-length  gp160  was  amplified  using 
primers fenv3 and renv3. The nested PCRs consisted of an initial denaturation step 
of  5  min  at  96°C,  followed  by  35  cycles  of  denaturation  at  96°C  for  1.5  min, 
annealing  at  52°C  (primers  fenv3/env3),  55°C  (primers  944S/E400010_His),  or 
57°C (primers 125Y/626L) for 1 min, and elongation at 68°C for 5 min, followed by 
a final elongation step of 10 min at 68°C. For primers that had not been previously 
described, the PCR conditions were optimised by varying annealing temperatures 
and elongation times. Negative control reactions containing no template DNA were 
included  in  each  PCR  to  monitor  possible  contamination.  PCR  products  were 
separated using agarose gel electrophoresis and DNA fragments of the expected size 
were purified from the gel as described in Sections 2.4.4 – 2.4.5 . 
2.5.5  Cloning of amplified gp120 into expression vectors 
Gel-purified  gp120  92BR025  amplified  using  primers  944S/E400010_His  was 
ligated into the expression vector pcDNA3.1-TOPO (Invitrogen) according to the 
manufacturer’s protocol. The ligation reactions were subsequently transformed into 
chemically  competent  TOP10  bacteria.  Screening  of  pcDNA3.1-TOPO  plasmids 
carrying  an  insert  of  the  expected  size  was  carried  out  by  restriction  enzyme 
digestion  followed  by  agarose  gel  electrophoresis  (refer  to  molecular  techniques 
described in Section 2.4). Clones producing functional gp120 when transfected into 
T7 RNA polymerase-recombinant vaccinia virus-infected 293T cells (Section 2.2.4) 
were sequenced for verification. 95 
 
2.5.6  Cloning of amplified gp120 and gp160 into cloning vectors 
Gel-purified gp120 and gp160 clones were ligated into pCR2.1-TOPO (Invitrogen) 
cloning vectors according to the manufacturer’s protocol. Competent bacteria were 
transformed with the ligation reactions (Section 2.4.7) and plated onto LB/ampicillin 
plates  added  with  40  µl  of  40  mg/ml  of  5-bromo-4-chloro-3-indolyl-β-
galactopyranoside  (X-gal)  in  N,N´-dimethylformamide  (Promega).  As  successful 
cloning of an insert into the pCR2.1-TOPO vectors interrupts the coding sequence of 
β-galactosidase, recombinant clones were identified by blue/white colour screening. 
Clones containing an insert of the correct size were subsequently identified using 
restriction enzyme digestion (Section 2.4.3) and agarose gel electrophoresis. 
2.5.7  Sub-cloning of gp120 into the pHXB2∆ ∆ ∆ ∆env backbone 
To  generate  chimeric  infectious  HIV-1  molecular  clones  containing  heterologous 
gp120, full-length gp120 was sub-cloned from the pCR2.1-TOPO vectors into the 
pHXB2∆env  vector  (McKeating  et  al.,  1996),  by  means  of  the  BstEII  and  MluI 
recognition sites present in primers 626L and 125Y respectively. The pHXB2∆env 
backbone  is  based  on  HIV-1  HXB2  (subtype  B)  and  allows  incorporation  of 
heterologous gp120 sequences from amino acid residue 38 to six amino acids before 
the gp120/gp41 junction. The gp120 DNA fragment was extracted from the pCR2.1-
TOPO cloning vectors by double digestion with BstEII and MluI. Digested plasmid 
DNA  was  separated  using  agarose  gel  electrophoresis  and  the  gel-purified  DNA 
fragments of the expected size were then  ligated  into the pHXB2∆env  backbone 
(which had also been digested with the BstEII and MluI enzymes and gel-purified) 
using T4 DNA ligase (Promega). For some virus isolates, the gp120 contained an 
internal BstEII recognition site. Partial restriction digests were then carried out and 
bands of the expected size were purified from the gel and ligated into pHXB2∆env. 96 
 
2.5.8  Sub-cloning of gp160 into the pNL43-based C2 cassette 
The C2 cassette (Zheng and Daniels, 2001), which is based on the infectious HIV-1 
NL4.3 (subtype B) molecular clone, was used to generate chimeric infectious HIV-1 
molecular clones containing heterologous full-length env genes. Full-length gp160 
was extracted from the pCR2.1-TOPO vectors by double digestion with enzymes 
XhoI and EcoRI, whose recognition sites were present in primers fenv3 and renv3 
respectively. Digested gp160 fragments were then gel-purified and transferred into 
the similarly digested and gel-purified pNL43-based C2 cassette using the T4 DNA 
ligase (Promega). 
2.5.9  Production  of  infectious  gp120/HXB2  and  gp160/NL43 
chimeras 
The gp120-pHXB2∆env and gp160-pNL43∆env ligation reactions were transformed 
into competent bacteria (Section 2.4.7). Clones containing inserts of the correct sizes 
were identified through restriction enzyme digestion and used for virus production in 
293T cells as described  in Section 2.3.3. Clones producing  infectious virus were 
identified by titration of the cell culture supernatant from transfected 293T cells onto 
NP2/CD4/CCR5  or  NP2/CD4/CXCR4  target  cells,  as  described  in  Section  2.3.5. 
Clones producing  infectious  virus were then sequenced (Section 2.4.8) using the 
sequencing primers listed in Table 2-4.   
2.5.10  Envelope sequence manipulations and analysis 
Chromatograms from the sequencing reactions were analyzed using Sequencher 4 
software (Gene Codes Corp., Ann Arbor, MI) and individual sequence fragments for 
each  env  clone  were  assembled  and  edited  from  a  minimum  of  two  different 
sequencing reactions to ensure full coverage. These curated sequences are available 
from  GenBank,  and  the  accession  numbers  are  listed  in  Table  3-3.  Protein 97 
 
translations and deduced Env amino acid sequences were aligned using Clustal W2 
(Larkin et al., 2007) and comparatively analyzed. The alignments were fed into the 
SeqPublish  tool  found  on  the  Los  Alamos  National  Laboratory  (LANL)  HIV 
database website (www.hiv.lanl.gov) to produce publication ready alignments. The 
number of potential glycosylation sites  for each clone was checked using the N-
GlycoSite tool (Zhang et al., 2004a) from the LANL HIV database. The variable 
loops on gp120 were determined by the positions of the cysteine residues, and the 
number of amino acid residues within the variable loops was counted.  
2.5.11  Phylogenetic tree construction 
The DNA sequence for the gp120 portions of the viruses were first aligned based on 
the Hidden Markov model (HMM) to the curated DNA alignments on the LANL 
HIV database, and the  subtype assignment was  confirmed  by clustering with the 
subtype  reference  alignments  (Leitner  et  al.,  2005).  This  consists  of  4  different 
strains for each HIV-1 subtype and recombinant forms. A phylogenetic tree using the 
maximum likelihood approach was then constructed with the PhyML tool (Guindon 
and Gascuel, 2003). Pairwise distance matrices were calculated using the General 
Time  Reversible (GTR) algorithm with a transition/transversion ratio of 2.0. The 
consistency of the phylogenetic clustering was tested using bootstrap analysis with 
100  replicates.  DNA  sequences  from  Li’s  African  subtype  C  standard  reference 
panel,  consisting  of  Du123.6,  Du151.2,  Du156.12,  Du172.17,  Du422.1, 
ZM197M.PB7,  ZM214M.PL15,  ZM215F.PB8,  ZM233M.PB6,  ZM249M.PL1, 
ZM53M.PB12,  ZM55F.PB28a,  ZM106F.PB9,  ZM109F.PB4,  ZM135M.PL10a, 
CAP45.2.00.G3, CAP210.2.00.E8 and CAP244.2.00.D3 (Li et al., 2006b) were also 
included in the phylogenetic tree analysis for comparison. The tree is rooted with 
three subtype D strains (NDK, ELI and 94UG114).  98 
 
2.6  Anti-gp41 VHH from gp140-immunized library 
2.6.1  Immunization of animal and library construction 
Immunisation  of  llamas  and  construction  of  phage  libraries  expressing  the  VHH 
repertoires of the immunised llamas were carried out by staff of Ablynx, NV, Ghent, 
Belgium  as  part  of  the  EMPRO  Consortium.  One  adult  Lama  glama  (L48)  was 
immunized subcutaneously with recombinant CN54 gp140 (kindly provided by Ian 
Jones,  Reading  University).  The  llama  received  six  intramuscular  injections  at 
weekly intervals. Each injection consisted of a freshly prepared 4.5 ml water-in-oil 
emulsion, prepared by vigorous mixing of 2 volume units of antigen (50 or 100 µg) 
with 2.5 volume units of the adjuvant Stimune  (CEDI Diagnostics, Lelystad, the 
Netherlands), and was administered intramuscularly in the neck divided over two 
spots. One hundred µg of the immunogen was administered on days 0 and 7, and 50 
µg on days 14, 21, 28 and 35. Preimmune sera was obtained on day 0. Four days 
after the last antigen injection (on day 39 post-immunisation), a 150 ml blood sample 
and a lymph node biopsy were collected as the source of B cell containing tissues. 
After  another  four  days  (on  day  43  post-immunisation)  a  second  150  ml  blood 
sample was collected. ELISAs were carried out on the titrated sera to determine the 
presence of an appropriate immune response against the immunogen (gp140 CN54). 
Total  RNA  was  isolated  from  peripheral  blood  lymphocytes  and  lymph  node 
biopsies  collected  post-immunisation  by  acid  guanidinium  thiocyanate-phenol-
chloroform extraction. The total RNA isolated from the two different tissues was 
pooled and reverse transcribed into cDNA using oligo-dT primers with SuperScript 
III First-Strand Synthesis System for RT-PCR (Invitrogen). The VHH repertoires 
were  amplified  in  two  rounds  of  PCR.  In  the  first  PCR,  the  repertoire  of  both 99 
 
conventional  (1.6  kb)  and  heavy-chain  (1.3  kb)  antibody  gene  segments  were 
amplified  using  a  forward  primer  specific  for  the  leader  sequence  and  a  reverse 
oligo-dT  primer.  To  allow  for  efficient  separation  of  cDNA  fragments  encoding 
conventional and heavy-chain antibodies, the resulting PCR product was then treated 
with the BglI restriction enzyme, since the gene segment coding for the CH1 domain, 
present  only  in  conventional  antibodies,  contains  a  unique  BglI  recognition  site. 
Following  restriction  enzyme  digestion  and  agarose  gel  electrophoresis  and 
purification, the resulting 1.3 kb fragment was used as a template in a nested PCR 
using a mixture of forward primers specific for the FR1 region of VHH, which also 
introduced a SfiI recognition site, and a reverse oligo-dT primer. The resulting PCR 
products were subsequently treated with SfiI and BstEII (naturally occurring in FR4) 
restriction  enzymes  and  separated  using  agarose  gel  electrophoresis.  The  VHH-
encoding DNA fragment (400 bp) was extracted from the gel and 330 ng was ligated 
into 1 µg of the pUC-derived phagemid vector pAX050, followed by transformation 
into electrocompetent E. coli TG1 cells.  
To obtain recombinant bacteriophages expressing the VHH as fusion proteins with 
the  bacteriophage  gene  III  product,  the  transformed  TG1  cells  were  grown  to 
logarithmic phase and then infected with helper phage M13KO7. The phage particles 
were precipitated with polyethylene glycol 6000 (PEG; Sigma-Aldrich) to remove 
free VHH as described in Section 2.6.2.4. From each library, a colony PCR using an 
M13 reverse primer and a gene III primer was carried out on 24 randomly picked 
colonies, and the proportion of clones containing an insert of the correct size was 
estimated. 100 
 
2.6.2  Bio-panning and selection for anti-gp41 VHH  
The panning of the phage display library on immobilised antigens will be described 
in this section. An overview of this method is shown in the figure below.  
 
Figure 2-1. Schematic overview of the phage panning process 
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2.6.2.1 Plate preparation and phage binding 
Maxisorp plates (Nalgene) were separately coated with gp41 and gp41∆ at 5, 1 and 
0.2  µg/ml  concentration  in  PBS  in  a  total  volume  of  100  µl/well.  Different 
concentrations  of  antigens  were  used  to  determine  the  optimum  concentration  to 
elute  out  phage  binders.  Negative  control  wells  containing  only  PBS  were  also 
included. After an overnight incubation at 4°C, the plates were washed four times 
with PBS-T, and non-specific protein binding was subsequently blocked by filling 
the wells with 1% (w/v) casein in PBS and incubating for 1 h at room temperature 
and orbital shaking at 200 rpm. After the blocking step, the plates were washed four 
times with PBS-T. 
Phages, expressing the cloned VHH repertoires as prepared earlier, were then diluted 
1:10  in  0.2%  (w/v)  casein  in  PBS  and  subsequently  pre-incubated  at  room 
temperature for 10 min to allow for unspecific binding. One hundred µl of diluted 
phages were then incubated with wells containing immobilised gp41 or gp41∆ for 1 
h at room temperature with orbital shaking at 200 rpm, and thereafter the wells were 
washed 20 times in PBS-T to remove unbound or unspecifically bound phages. To 
increase  the  stringency  of  the  washing  step,  every  five  washes  the  plates  were 
incubated with PBS-T for 15 min at room temperature and orbital shaking at 200 
rpm. Plates were then finally washed twice in PBS. 
Bound phages were eluted using a variety of methods; namely trypsin, glycine and 
antibody competition. Trypsin elutes out every bound phage through the digestion of 
the gene III product at the base of the VHH on the phage, and this was done by 
incubating 100 µl per well of trypsin (1mg/ml) for 30 min at room temperature and 
orbital shaing at 200 rpm, and then neutralised with 5-fold molar excess (210 uM) of 102 
 
trypsin  blocker,  acetylbenzenesulfonyl  fluoride  (ABSF;  Sigma).  Glycine  elutes 
phages through low pH shock, and was performed by incubating wells with 100 µl 
per well of 1 mg/ml glycine. After 30 min at room temperature and orbital shaking at 
200 rpm, the glycine-eluted phage (100 µl) was transferred to 50 µl of 1 M Tris-HCl 
pH 7.5 for neutralisation. In antibody competition elution, bound phages were eluted 
with  a  high  concentration  (100  µg/ml)  of  mAbs  2F5  or  4E10  to  target  phages 
carrying VHH that target these epitopes.  
2.6.2.2 Titration of eluted phage  
Eluted phages from each well were titrated onto E. coli TG1 cells to determine the 
success of the selection process. Serial dilutions of the output phage were prepared 
(up to 10
-4) by sequentially transferring 10 µl to 90 µl of PBS. A 5 µl aliquot from 
each dilution (dilution factor 20) was used to infect 95 µl of exponentially growing 
TG1 cells (at an optical density at 600 nm of approximately 0.65) in V-bottomed 96-
well microtitre plates. After incubation at 37°C without shaking for 30 min, 5 µl of 
bacteria were  spotted in duplicates onto LB agar plates containing 100 µg/ml of 
ampicillin and 2% (w/v) glucose, and grown overnight at 37 °C.  
2.6.2.3 Amplification and rescue of eluted phage 
Eluted phages from the biopanning were multiplied in TG1 cells and rescued by 
superinfection with helper phage. A 50 µl aliquot of eluted phage was used to infect 
0.5 ml of exponentially growing TG1 cells for 30 min at 37 °C without shaking. The 
cells were then spun down at 4500 x g for 5 min, and then resuspended in 10 ml of 
2xTY  medium  containing  100  µg/ml  of  ampicillin  and  2%  (w/v)  glucose,  and 
subsequently incubated overnight at 37°C and 250 rpm. The overnight culture was 
used to prepare glycerol stocks. To rescue the phages, 1 µl of helper phage M13KO7 103 
 
(corresponding to approximately 10
11 plaque-forming units; PFU) were added to 2.5 
ml of the overnight culture, and allowed to incubate for 30 min at 37 °C without 
shaking.  Cells  were  then  pelleted  and  resuspended  in  50  ml  of  2xTY  medium 
containing 100 µg/ml of ampicillin and 25 µg/ml kanamycin and incubated at 37°C 
overnight with shaking at 250 rpm. 
2.6.2.4 Phage precipitation 
After the rescue of the phages, the cells were pelleted and 40 ml of the supernatant 
(containing free phages) were added to 10 ml of 20% (w/v) polyethylene glycol 6000 
(PEG; Sigma-Aldrich) and 2.5 M NaCl, and then incubated on ice for 30 min. The 
precipitated  phages  were  then  spun  for  15  min  at  4500  x  g  at  4  °C,  and  the 
supernatant removed. The pellet was then resuspended into 1 ml of PBS for washing, 
and pelleted again at maximum speed on a tabletop centrifuge for 5 min to remove 
cell  debris.  The  supernatant  was  collected,  transferred  to  a  new  1.5  ml  tube 
containing 250 µl of 20% (w/v) PEG and 2.5 M NaCl, and incubated on ice for 10 
min.  It  was  then  centrifuged  at  maximum  speed  for  5min,  and  the  pellet  was 
resuspended again in 1 ml PBS. To remove the last bits of cell debris, the suspension 
was centrifuged for 5 min and the supernatant was transferred into a new eppendorf 
tube. These new phage stocks were titrated onto TG1 cells and taken forward to 
subsequent rounds of panning.   
2.6.2.5 Further rounds of selection 
A repeat of the above procedure was carried out in a second round of selection to 
further enrich the phage pool for binders to gp41.  104 
 
2.6.3  Isolation and small scale expression of VHH 
The eluted phages were cloned into expression vectors and individual clones were 
picked and the VHH subsequently expressed in E. coli TG1 cells. 
2.6.3.1 Cloning of VHH repertoire into expression vectors 
Five  ml  of  the  overnight  cultures  were  mini-preped  to  harvest  the  plasmids 
containing the VHH gene fragments. The plasmids were first digested with SfiI at 
50°C for 2 h, followed by BstEII at 50 °C for another 2 h. The digested products 
were gel purified on a 1.5% agarose gel and fragments of about 300 bp were cut out 
and the fragments were ligated into pAX051 for 15 min at room temperature using 
T4 DNA Ligase (Promega). The pAX051 expression vector is a derivative of pUC19 
(Yanisch-Perron  et  al.,  1985)  and  contains  the  LacZ  promoter,  which  enables  a 
controlled  induction  of  expression  using  isopropyl-ß-D-thiogalactopyranoside 
(IPTG). Expression from the pAX051 vector incorporates a 6-histidine and a c-myc-
tag to the C-terminus of the VHH. The ligated mixture (2 µl) was electrotransformed 
into  40  µl  of  electrocompetent  TG1  cells  (Stratagene,  UK),  and  1  ml  of  2xTY 
medium  with  2%  glucose  was  added  for  recovery.  Various  dilutions  of  the 
transformed  cells  were  plated  onto  LB  agar  plates  containing  100  µg/ml  of 
ampicillin and 2% glucose and left to incubate overnight at 37 °C. Ninety-six clones 
from each output were picked and used to inoculate 1 ml of LB medium containing 
100  µg/ml  of  ampicillin  (or  carbenicillin)  and  2%  glucose  in  96-well  deep-well 
plates. Plates were incubated overnight at 37°C with 250 rpm. Glycerol stocks were 
prepared  from  the  overnight  cultures  and  stored  at  -80°C  in  96-well  plates  as 
“masterplates”. 105 
 
2.6.3.2 DNA Fingerprinting 
Colony PCR was performed on the clones selected by using sterile toothpicks to dip 
the cells into a 10 µl PCR mastermix (M13F/M13R standard primers) on a 96-well 
format.  The  PCR  products  were  digested  with  HinfI  for  DNA  fingerprinting  by 
incubating the restriction enzyme for 2-3h at 37 °C and then analyzed on a 2.5% 
agarose (TBE) gel. 
2.6.3.3 Small scale expression of VHH in 96-well format 
The same toothpick used for colony picking was used to inoculate a 96-well plate 
containing 100 µl of 2xTY containing 100 µg/ml of ampicillin and 2% glucose, in 
the exact same well position, and allowed to incubate overnight at 37 °C. The next 
day, 10 µl of the overnight culture was used to inoculate 1 ml of 2xTY containing 
100 µg/ml of ampicillin and 0.1% glucose in 96-deep well plates, whilst the residual 
culture were frozen in glycerol. The deep well plates were incubated at 37 °C with 
shaking at 250 rpm. When the OD600 reached approximately 0.8 (approximately 3 h 
later), 10 µl of 0.1M IPTG was added into each well to induce the production of 
VHH. After 4 h of further incubation at 37 °C with shaking, the cells were pelleted 
by spinning at 4500 x g for 10 min at 4 °C, and the pellet was allowed to freeze 
overnight  after  the  removal  of  the  supernatant.  The  frozen  pellet  was  then 
resuspended in 100 µl of PBS.  The freeze-thaw action allows the escape of the VHH 
trapped in the periplasmic layer of the cells. The periplasmic extracts (containing the 
expressed VHH) was harvested from the supernatant after spinning down to remove 
the spheroplasts, and transferred to new 96-well plates and stored at -80 °C.  106 
 
2.6.4  Large scale expression of VHH 
VHH found to be neutralising or binding were expressed and purified as described in 
this section. Some of the E. coli TG1 produced stocks of VHH were also obtained 
from Ablynx NV (Ghent, Belgium). 
2.6.4.1 Expression of selected VHH 
Glycerol stocks of E. coli TG1 cells containing selected VHH clones (held in the 
pAX051 vector) were used to inoculate 50 ml of LB medium containing 100 µg/ml 
of ampicillin and 2% (w/v) glucose. The cultures were incubated overnight at 37 °C 
and 250 rpm, and a 5 ml aliquot was subsequently used to inoculate 1 litre of 2xTY 
medium containing 100 µg/ml of ampicillin and 0.1% (w/v) glucose. This culture 
was  incubated  at  37  °C  and  250  rpm  until  an  OD600 of  0.7  was  reached.  VHH 
expression  was  then  induced  with  1  mM  of  IPTG  and  the  cultures  incubated 
overnight at 30 °C with 250 rpm. Aliquots of pre-induced and induced samples were 
kept and analysed by SDS-PAGE (Section 2.4.11). After the overnight incubations, 
bacteria were harvested by centrifugation of 4 x 250 ml aliquots at 4000 g for 30 min 
at 4 °C. The pelleted bacteria were then frozen at -80 °C overnight. The day after, the 
bacteria were thawed, resuspended in 4 x 25 ml of PBS, incubated at 8 °C for 1 h at 
250 rpm, and subsequently subjected to centrifugation at 4000g for 30 min at 4 °C. 
The resulting supernatants, corresponding to the VHH-containing E. coli periplasmic 
extracts, were collected. 
2.6.4.2 Purification of expressed VHH 
Expressed VHH were purified from E. coli periplasmic extracts by means of the 6-
histidine-tag using TALON Metal Affinity Resin (Clontech, Mountain View, CA, 
USA),  according  to  the  manufacturer’s  instructions.  Briefly,  the  TALON  Metal 107 
 
Affinity Resin suspension was washed twice in 50 ml of VHH equilibrium buffer. 
Approximately 1 ml of TALON Metal Affinity Resin was subsequently resuspended 
in 50 ml of VHH-containing E. coli periplasmic extract in 50 ml Falcon tubes (BD 
Biosciences, Oxford, UK) and incubated at room temperature for 1 h with head-over-
head rotation. The resin was then pelleted by centrifugation at 700 g for 2 min at 
4°C. The supernatant was discarded and an aliquot was saved for analysis by SDS-
PAGE  (unbound  sample).  The  resin  was  then  washed  twice  in  50  ml  of  VHH 
equilibrium buffer, by incubating the resin with buffer at room temperature for 10 
min with head-over-head rotation followed by centrifugation at 700 g for 2 min at 4 
°C. The resin (approximately 1.5-2 ml per VHH) was then resuspended in a total of 
10 ml of VHH equilibrium buffer and packed into Poly-Prep gravity/flow columns 
(Bio-Rad  Laboratories).  Packed  columns  were  then  washed  twice  with  one  bed 
volume of VHH equilibrium buffer. One bed volume of VHH pre-elution buffer was 
then  added  and  the  eluate  collected.  Bound  protein  was  then  eluted  with 
approximately 4 x 0.5 bed volumes of VHH elution buffer and the eluate collected in 
4 fractions.  
The eluted fractions were analysed by SDS-PAGE and Coomassie blue staining and 
fractions containing the bulk of the eluted VHH were pooled and dialysed for 8 h at 
4°C against 1 litre of PBS using Slide-A-Lyzer Dialysis Cassettes (Pierce Protein 
Research Products, Thermo Fisher Scientific, Rockford, USA) with a molecular cut-
off of 3.5 kDa. After dialysis, the purified VHH were analysed by SDS-PAGE and 
Coomassie  blue  staining  and  the  protein  concentration  was  determined  (Sections 
2.4.10 – 2.4.11). 108 
 
2.6.5  Screening of selected anti-gp41 VHH with ELISA 
The periplasmic extracts and purified VHH were tested for their ability to bind to the 
selecting antigen (either recombinant gp41 or gp41∆) in ELISAs as described  in 
Section 2.4.13. Opaque 96-well Maxisorp plates (Nunc) were coated overnight with 
50 µl of either antigen at 1 µg/ml. After blocking and washing of the plates, 50 µl of 
50-fold  diluted  periplasmic  extracts  were  allowed  to  incubate  for  1  h  with  the 
antigen.  The  positions  of  the  wells  on  the  ELISA  plates  were  matched  with  the 
selected VHH clones on the VHH masterplate. After washing, 100 µl of 0.5 µg/ml 
mouse anti-c-myc mAb (catalogue number 11667149001, Roche Diagnostics) was 
introduced for 1 h to detect the c-myc tagged VHH. After washing as before, 100 µl 
per well of 0.5 µg/ml of an AP-conjugated goat anti-mouse IgG antibody (catalogue 
number 1030004, Oxford Biotechnology) was introduced for another 1 h. After a 
final  washing  step,  100  µl  of  Lumi-Phos  (Lumigen,  Southfield,  MI,  USA)  was 
allowed  to  incubate  at  37  °C  for  30  min.  The  luminescence  (RLU)  was  then 
determined using a plate reader.  
2.6.6  Screening of the selected anti-gp41 VHH in neutralisation 
All the selected VHH were tested for their ability to neutralise HIV-1 using the NP2 
assay described in Section 2.3.6. To enable a fast screening of all the selected VHH, 
they were tested at a single dilution (1:10) of periplasmic extracts with 100 FFU of 
virus per well. Viruses included in the preliminary neutralisation screening include 
IIIB, MN, 92Br025 and 92UG037. In the TZM-bl  cell-based  neutralisation assay 
(Section 2.3.9), 50 µl of VHH-containing periplasmic extract was pre-incubated 200 
TCID50 of virus, per well. Irrelevant (negative control) E. coli periplasmic extracts 
were included on each plate.   109 
 
2.6.7  Western Blot of anti-gp41 VHH 
The recombinant gp41 antigen was first resolved in polyacrylamide gels and then 
transferred to a PVDF membrane as described in Sections 2.4.11 and 2.4.12. After 
washing of the membranes, 1 µg/ml of purified VHH in TBS-T supplemented with 
4% (w/v) skim milk was introduced for 1 h with shaking to probe the antigens on the 
membrane. These were then washed off  and 0.5 µg/ml of  mouse anti-myc  mAb 
(Roche)  in  TBS-T  supplemented  with  4%  (w/v)  skim  milk  was  introduced  for 
another hour. After washing, the antibody was probed with a 4000-fold diluted anti-
mouse IgG conjugated with HRP (NXA931, Amersham/GE, UK). ECL detection 
reagent (Amersham/GE, UK) was then used and the membrane exposed on an x-ray 
film.   
A  modified  Western  Blot  was  carried  out  whereby  the  purified  VHH  was  first 
resolved in the polyacrylamide gels and then transferred to a PVDF membrane. Its 
ability to bind antigen in solution form was determined by incubating the membrane 
with  1  µg/ml  of  recombinant  gp41  in  PBS.  Captured  gp41  by  the  VHH  on  the 
membrane  was  probed  with  an  anti-gp41  mouse  mAb  (ARP  317,  NIBSC)  and 
detected with a 4000-fold diluted anti-mouse IgG conjugated with HRP. This was 
then visualised on an x-ray film after addition of ECL detection reagent. 
2.6.8  Flow cytometry of HIV-1 infected cells 
H9 T-cells chronically infected with HIV-1 MN were used in this assay. Cells (5x10
5 
cells/tube) were washed once with 4 ml of PBS (by spinning at 250 x g for 5 min, 
then re-suspending), and then washed again with 4 ml of FACS buffer. Blocking of 
the cells was carried out using 10% goat serum in FACS buffer for 10 min at 4 °C. 
The cells were then spun down and resuspended in 20 µl of VHH (at 1 µg/ml), and 
allowed to incubate for 1 h at 4 °C. The cells were then washed twice in FACS 110 
 
buffer, and resuspended in 50 µl of 10-fold diluted mouse anti-c-myc mAb (Roche), 
and allowed to incubate for another hour at 4 °C. After 2 more washes in FACS 
buffer, a sheep anti-mouse Ab conjugated with FITC (at 10 µg/ml) was introduced 
for 1 h at 4 °C. The cells were again washed twice with FACS buffer, and then once 
with PBS. The cells were fixed with 3.8% formal saline and stored at 4 °C prior to 
analysis.  Cells  were  acquired  using  a  Becton  Dickinson  FACS  LSRII  (BD 
Biosciences, San  Jose, CA) and the data analyzed using  FlowJo (Tree Star, Inc, 
Ashland, OR). The anti-gp41 mAb (ARP317) was used as a positive control, and a 
negative control was performed without any primary Ab. H9 cells without HIV-1 
MN infection were run concurrently as negative controls.  
2.6.9  VHH competition with each other for binding to gp41 in ELISA 
VHH competition with each other was also assayed by ELISA. A set of the anti-
gp41 VHH were first biotinylated, as described in Section 2.7.1.2, and allowed to 
compete with unbiotinylated anti-gp41 VHH in ELISA. Opaque 96-well Maxisorp 
plates (Nunc) were coated overnight with 1 µg/ml of gp41 in 0.1 M NaHCO3, pH 
8.5. After washing four times with TBS-T, non-specific protein binding was blocked 
by incubating wells with 200 µl per well of 4% milk powder in TBS for 1 h at room 
temperature. Wells were then washed four times with TBS-T. Serial dilutions of the 
different unbiotinylated VHH  in 1%  milk powder  in TBS were  introduced at 50 
µl/well and allowed to bind to gp41 in duplicates. Biotinylated VHH at an optimum 
concentration (0.005 µg/ml) were then introduced at 50 µl/well to compete with the 
unbiotinylated VHH for binding to gp41. Bound biotinylated anti-gp41 VHH was 
then detected with 100 µl of 0.5 µg/ml of an AP-conjugated streptavidin (RPN1234, 
Amersham/GE, UK). Luminescence was detected as above and blank-corrected RLU 
were plotted against VHH concentration. The A12 VHH, which recognise the CD4 111 
 
binding site of gp120, was added as a negative control; and the mAb 2F5 was used to 
determine if any of the VHH binds to the MPER of gp41. 
2.6.10  Epitope mapping of anti-gp41 VHH 
To determine the possible binding sites on gp41, the anti-gp41 VHH were tested on a 
set  of  15-mer  linear  peptides,  with  11  amino  acid  overlaps  between  sequential 
peptides, from the MN strain (catalogue ARP7113 from NIBSC). The peptides were 
coated onto Maxisorp plates at 10 µg/ml in 0.1 M NaHCO3, pH 8.5, and an ELISA 
was carried out as described in Section 2.6.5. 
In a separate attempt to determine the epitopes of the anti-gp41 VHH, these VHH 
were sent to Hans Langedijk (Pepscan Presto BV, The Netherlands) for testing on 
their  proprietary  combinatorial  peptide  arrays.  In  a  variation  of  the  ELISA,  this 
involved the testing of the VHH for its ability to bind to a proprietary collection of 
short 20-mer linear and cyclic peptide fragments overlapping by 19 amino acids of 
gp41 of subtype A and C (MW965 and UG037). 
2.6.11  Denaturing gp41 ELISA 
To determine if the anti-gp41 VHH recognise linear or conformational dependent 
epitopes, a denaturing ELISA was carried out. Gp41 was denatured by diluting 1 
µg/ml of the antigen in 1% SDS/50 mM dithiothreitol (DTT, Sigma Aldrich) with 
0.1 M NaHCO3, pH 8.5 and incubating for 10 min at 100°C. Two parallel Maxisorp 
plates were set up, one coated with 1 µg/ml of gp41 in 0.1 M NaHCO3, pH 8.5 
(untreated) and the other coated with the denatured gp41. Coating of the plates was 
allowed to progress overnight at 4°C, as before. The VHH were then added on, as 
described in Section 2.6.5. 
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2.7  Creation and characterisation of C8- and D7-family specific 
VHH library 
2.7.1  Preparation of recombinant gp120 antigen 
This part describes the steps involved in preparing the recombinant gp120 for use as 
an antigen in the panning for C8- and D7-family specific VHH library. 
2.7.1.1 Expression of recombinant gp120 
Recombinant gp120 derived from HIV-1 92BR025 was expressed as described by 
Aasa-Chapman et al. (Aasa-Chapman et al., 2004) using a bacteriophage T7 RNA 
polymerase-recombinant  vaccinia  virus  system  (Fuerst  et  al.,  1986).  Primers 
E400010_His  (Table  2-3)  specific  for  subtype  C  gp120  envelopes  were  used  to 
amplify the gp120 fragments from HIV-1 92BR025, which is a Brazilian subtype C 
virus. The primer E400010_His incorporates a 6x histidine tag at the C-terminus of 
the  product  for  downstream  purification  of  the  expressed  protein.  Following  the 
procedures as described in Sections 2.4.6 and 2.4.7, the gp120 DNA fragments were 
first  subcloned  into  TOPO  vectors  before  cloning  into  a  mammalian  expression 
vector pcDNA3.1-TOPO (Invitrogen, UK). Sequencing was carried out to verify that 
the clone contained the correct sequence in the correct orientation. 
Exponentially dividing 293T cells, seeded the day before at a density of 4 x 10
5 cells 
per well of a 6-well plate, were washed once in serum-free DMEM and subsequently 
overlaid with 2 ml per well of serum-free DMEM. Cells were then incubated with 
approximately 4 x 10
4 50% tissue culture infectious doses (TCID50) per well of T7 
RNA  polymerase  recombinant  vaccinia  virus  (vTF7-3,  American  Tissue  Culture 
Collection number VR-2153) at 37°C. After 2 h of incubation, cells were washed 
once in DMEM, overlaid with 2 ml per well of DMEM/GlutaMAX supplemented 113 
 
with 10% (v/v) of FCS, and subsequently transfected with the gp120-pcDNA3.1-
TOPO plasmids. Transfections were carried out as described in Section 2.2.4 using 4 
µg  of  plasmid  DNA  and  12  µl  of  FuGENE  6  (Roche  Diagnostics).  Cell  culture 
supernatants  were  harvested  72  h  after  transfection,  treated  with  NP40  detergent 
(Sigma-Aldrich) to inactivate vaccinia virus, filtered and stored at -20°C. To monitor 
residual infectious vaccinia virus, cell culture supernatants were titrated onto Vero 
cells  (African  green  monkey  kidney)  and  cytopathic  effects  were  observed 
microscopically.  The  gp120-containing  cell  culture  supernatants  were  then  used 
directly in an enzyme-linked immunosorbent assays (ELISA) as described in Section 
2.4.13. If a high expression titre was achieved, the gp120 was purified using Ni 
Sepharose 6 Fast Flow (GE Healthcare, Little Chalfont, UK) by means of the 6-
histidine-tag encoded by primer, according to the manufacturer’s instructions. 
2.7.1.2 Biotinylation of recombinant gp120 
One  hundred  µg  of  both  92BR025  and  IIIB  gp120  recombinant  proteins  were 
dialyzed  using  Microcon  YM-50  Centrifugal  Filter  Units  (Milipore,  UK)  with  a 
50kDa cut-off to remove contaminating proteins and buffers  in the solution. The 
concentrated protein residue was washed 3 times with 300 µl of 50 mM carbonate 
buffer at pH 8.0, and harvested by spinning the inverted columns into new eppendorf 
tubes. Biotin was added in a 6x molar excess ratio using the EZ-Link Biotinylation 
kit (Pierce, UK) and allowed to incubate for 2 h at 4°C. The NHS groups of biotin 
will interact with any free NH2 groups on a protein. The reaction mixture was then 
put back into new YM-50 filter units, and washed 3 times with 200 µl of PBS. The 
biotinylated recombinant proteins were eluted out by spinning the inverted columns 
into new eppendorf tubes.  114 
 
The 5 different anti-gp41 VHH described in Chapter 4 were also biotinylated in a 
similar way for testing in competitive binding to gp41 in ELISA (Section 2.6.9). 
2.7.1.3 Gp120 functionality check 
The recombinant gp120 proteins were then checked for the successful integration of 
biotin  and  also  for  the  non-disruption  of  integral  epitopes  that  are  essential  for 
binding to VHH. ELISAs were performed as described in Section 2.4.13. Maxisorp 
plates  (Nunc)  were  first  coated  overnight  with  4  different  concentrations  of 
biotinylated and unbiotinylated gp120 samples, and then blocked with 4% skim milk 
in TBS. After washing with TBS-T, biotinylation of the samples were detected with 
HRP-conjugated streptavidin. The substrate was added and allowed to develop for 30 
min, and the reaction was stopped with the addition of 25 µl of 1 M H2SO4. The 
OD490  was  then  measured  and  background  subtracted  values  were  plotted  on  a 
graph against protein concentration. Another set of ELISA was also set up similarly 
as above,  but the  bound gp120 were probed directly with the C8 and D7 VHH, 
followed by mouse anti-c-myc mAb, and the detected with HRP-conjugated donkey 
anti-mouse antibody.  
Western blots were also carried out (as described in Section 2.4.12) by first resolving 
the biotinylated gp120  in polyacrylamide gels, and transferring them onto PVDF 
membranes. The PVDF membranes were then reversibly visualised with the protein 
stain, Ponceau S (Sigma Aldrich), to ensure the successful transfer of proteins. The 
membrane was then washed in water to remove the stain and blocked with 1% skim 
milk. After washing in TBS-T, 0.5 µg/ml of HRP-conjugated streptavidin was then 
introduced to probe for the gp120. This was then visualised on an x-ray film after 
treatment with ECL detecting reagent.  115 
 
2.7.2  Creation of C8- and D7-family specific VHH libraries 
Total RNA (60 µg) that was previously isolated from the PBL pools from llama 44 
(L44), was reverse transcribed into cDNA using random hexamers (SuperScript III, 
Invitrogen, Carlsberg, USA ) and cleaned up with QIAquick PCR purification kit 
(Qiagen, Germany). The llama (L44) was immunised with recombinant CN54 gp120 
and from which the C8, D7 and A12 VHH were isolated from (Forsman et al., 2008). 
(Refer to Section 2.6.1) 
Based on the sequences of the C8 and D7 VHH, unique degenerate reverse primers 
were designed to pull out VHH gene fragments with similar sequences to C8 and D7 
through  nested  PCR.  These  reverse  primers,  C8p  (5’- 
TGAGGAGACGGTGACCTGGGTCCCCTGGCCCCAGTCTGTATAGTCGC)  and  D7p  (5’- 
TGAGGAGACGGTGACCTGGGTCCCCTGGCCCCAGTMGTWRTAATCYGAATTCG), 
extends  into  the  last  4-6  codons  of  the  CDR3  loop  region  (underlined).  In 
conjunction with a framework 1 (FR1) specific primer, the PCR was carried with 
Expand High Fidelity (Roche, UK) using the following programme: 94 ºC for 2 min, 
followed by 28 cycles of 94 ºC for 30 s, 55 ºC for 30 s and 72 ºC for 90 s, and a final 
extension at 72 ºC for 7 min. Twenty-eight cycles were carried out to prevent over 
saturation of the amplified products, and a 300 bp band was cut out after separation 
on an agarose gel. After restriction enzyme digestion with BstEII and SfiI and gel-
purification,  the  digested  DNA  fragments  were  ligated  into  a  phagemid  vector 
(pAX050) for display on filamentous bacteriophage and electro-transformed into E. 
coli TG1 electro-competent cells. The transformed cells were titrated on agar plates 
to determine the library size, and a colony PCR was performed on a selection of 
colonies to determine the presence of DNA inserts in the vector. (Refer to Section 
2.6.1) The creation of these libraries was carried out at Ablynx NV. 116 
 
2.7.3  Bio-panning and Selection for C8 and D7-like VHH 
For the selection of C8- and D7-like VHH, a variation from the previously described 
bio-panning  method  was  used.  Instead  of  antigens  coated  directly  onto  a  solid 
substrate, the biotinylated recombinant gp120 was allowed to bind to the phages in 
solution form, followed by the subsequent capture of the phages-biotinylated gp120 
complexes through the use of neutravidin coated plates.  
2.7.3.1 Plate preparation and phage binding 
Maxisorp plates (Nunc) were coated with 100 µl of neutravidin (5 µg/ml; Pierce 
Biotech) to capture biotinylated-gp120 and allowed to incubate overnight at 4 °C. 
Neutravidin is a neutrally charged derivative of the streptavidin molecule that binds 
to  biotin  with  minimal  nonspecific  binding  through  the  removal  of  carbohydrate 
groups which can bind to lectins. The next day, the plates were washed 3 times with 
PBS-T, and blocked with 200 µl of 1% casein in PBS at room temperature for 1 h 
with shaking, and washed 5 times with PBS-T thereafter.  
Another set of uncoated U-bottom 96 well plates were blocked with 200 µl of 1% 
casein in PBS at room temperature for 1 h with shaking, and then washed 5 times 
with PBS-T. Biotinylated-gp120 (IIIB and 92BR025) were serially diluted to various 
concentrations from 10nM to 0.01nM in PBS supplemented with 0.2% casein and 50 
µl of each of these dilutions were allowed to incubate with 50 µl of 5-fold diluted 
C8- and D7-specific phage library stock (created in Section 2.7.2) in the pre-blocked 
plates.  This  was  to  allow  the  binding  of  the  phages  to  gp120  in  solution  form. 
Negative control blank wells were included where no antigen was added. After 2 h 
of incubation with shaking at room temperature, 75 µl of the gp120/phage mixture 
was applied to the neutravidin coated plates, and allowed to incubate for not more 
than 30 min with shaking at room temperature. The plates were then washed 20 117 
 
times with PBS-T to remove uncaptured phages. Captured phages were eluted with 
100 µl of 1 mg/ml trypsin for 30 min with shaking at room temperature, and then 
neutralized with 5-fold molar excess (210 µM) of trypsin blocker ABSF (Sigma). 
Alternatively, plates were coated with 10 µg/ml of the antibody D7324 (Aalto Bio 
Reagents), a sheep polyclonal antibody raised against a conserved motif at the C-
terminus of gp120. After an overnight incubation at 4°C, D7324-coated plates were 
washed and blocked as described above, and subsequently incubated with serially 
diluted 92BR025 gp120 in cell culture supernatant (from Section 2.7.1.1) in 0.2% 
casein in PBS. Negative control wells containing D7324 only, or D7324 plus cell 
culture supernatant from a negative control transfection experiment (i.e. transfections 
carried out as described in Section 2.7, but without addition of gp120 plasmids) were 
included. After 1 h at room temperature, the plates were washed five times with 
PBS-T. 
2.7.3.2 Titration, rescue and precipitation of phages 
The eluted products from the first round of selection were titrated to determine the 
effectiveness of the selections. The phages were then rescued and precipitated to 
prepare for the second round of selections. These procedures are detailed earlier in 
Sections 2.6.2.2 to 2.6.2.4.  
2.7.3.3 Further rounds of selection 
The second round of selection was similar to the first, but lower concentrations of 
biotinylated gp120 were used, with 10-fold serial dilution steps from 1 nM to 0.1 
pM. The phage stocks used were diluted 50-fold in the second round, instead of 5-
fold dilution in the first round. As in the first round of selection, 50 µl of biotinylated 
gp120 and 50 µl of the diluted phage stocks were allowed to incubate separately on a 118 
 
pre-blocked plate  for 2 h with  shaking. Seventy-five µl of the  mixture was then 
transferred to the pre-blocked neutravidin-coated plates or D7324-coated plates for 
30  min and with shaking. The phages were then  harvested with trypsin, and the 
phages were rescued according to the procedures described above. 
2.7.3.4 Clone isolations and expression of periplasmic extracts 
After 2 rounds of selections, 47 clones were picked from each selected output after 
subcloning into the expression vector pAX051 and their DNA was fingerprinted to 
check for clonal diversity. Periplasmic extracts containing the VHH were grown and 
then harvested for further testing and analysis. These procedures are described in 
Sections 2.6.3.1 to 2.6.3.3. 
2.7.4  Surface plasma resonance 
VHH affinity for recombinant IIIB gp120 was determined by Bart Hoorelbeke at 
Ablynx  NV  (Ghent,  Belgium),  using  surface  plasmon  resonance  techniques.  All 
experiments  were  carried  out  using  a  BIAcore  3000  (BIAcore,  GE  Healthcare, 
Uppsala, Sweden). An estimate of the dissociation rates were first measured for each 
of  the  VHH  in  the  periplasmic  extracts.  A  selected  few  were  then  subsequently 
purified  and  their  affinity  constants  determined.  Briefly,  approximately  2100 
response  units  (RU)  of  biotinylated  gp120  IIIB  was  non-covalently  captured  by 
streptavidin that was pre-immobilised onto a SA sensor chip (BIAcore).  
The  VHH,  serially  diluted  to  80,  60,  40,  20  and  10  nM  in  0.01  M  4-(2-
hydroxyethyl)-1-piperazineethanesulfonic  acid  (HEPES)  pH  7.4,  0.15  M  NaCl,  3 
mM  EDTA  and  0.005%  (w/v)  surfactant  P20  (HBS-EP  buffer;  BIAcore),  were 
injected onto the chip at a flow rate of 45 µl/min for 3 min and were allowed to 
dissociate for 15 min. Regeneration was achieved by washing with 10 mM HCl for 3 119 
 
min. The association rate constants (ka) and dissociation rate constants (kd) were 
computed  from  the  binding  curves  using  the  BIAevaluation  software  (1:1 
interaction).  The  equilibrium  dissociation  constants  KD  were  calculated  as  KD  = 
kd/ka. 
2.7.5  Screening of selected VHH in neutralisation 
Individual VHH were screened for their ability to neutralise HIV-1 using the TZM-bl 
cell-based neutralisation assay as described in Section 2.3.9. Briefly, 50 µl of VHH-
containing periplasmic extract was pre-incubated 200 TCID50 of virus, per well. 
Irrelevant (negative control) E. coli periplasmic extracts were included on each plate. 
Purified VHH samples were tested at a maximum concentration of 25 µg/ml.  
2.7.6  VHH competition with sCD4 for binding to envelope proteins 
in ELISA 
The ability of the VHH to inhibit sCD4 binding to gp120 was evaluated in ELISA. 
Opaque  96-well  Maxisorp  plates  (Nunc)  were  coated  with  sCD4,  blocked  and 
washed, as described in Section 2.4.13. Serial dilutions of VHH in 1%  milk powder 
in TBS were pre-incubated with purified gp120 IIIB at 0.5 µg/ml in 1% milk powder 
in TBS in a separate plate, for 1 h at room temperature. The pre-incubated VHH-
gp120 mixtures were then added to duplicate wells of the sCD4-coated plates (50 µl 
per  well).  Wells  lacking  sCD4  were  included,  as  was  an  irrelevant  VHH,  and 
negative controls. After 1 h at room temperature, the plates were washed 3 times 
with TBS-T and bound gp120 was then detected using 100 µl of 1 µg/ml antibody 
D7324  (Aalto  Bio  Reagents)  and  thereafter,  by  100  µl  of  0.5  µg/ml  of  AP-
conjugated  rabbit  anti-sheep  IgG  antibody  (catalogue  number.  ab6748-1,  Abcam, 
Cambridge, UK). Luminescence was detected as before and blank-corrected RLU 
were plotted against VHH concentration. 120 
 
3  Virus cloning and characterisation 
3.1  Introduction 
This  chapter  describes  the  cloning  of  HIV-1  envelopes  directly  from  primary 
samples obtained from patients. When this project was started in 2005, most of the 
published research and virological studies were performed on subtype B viruses that 
are prevalent in North America and Europe. However, subtype C viruses account for 
more than half of all new infections worldwide, and are prevalent in sub-Saharan 
Africa,  South  Asia  and  Brazil.  There  is  a  need  to  study  and  characterise  the 
envelopes of these viruses to determine the neutralisation sensitivity of circulating 
strains to monoclonal antibodies and for vaccine design studies.  
To achieve this, plasma samples were obtained from patients infected with subtype C 
HIV-1. The env gene was cloned directly from the viral RNA in plasma samples, and 
then subcloned into HIV-1 vectors to produce replication competent viruses. The 
vectors  used  were  pHXB2∆env  and  pNL43∆env,  which  allow  the  insertion  of 
heterogeneous gp120 or gp160 gene respectively (McKeating et al., 1996; Zheng and 
Daniels, 2001). By amplifying the envelopes directly from patient plasma samples, 
we have isolated viral envelopes that have not been through isolation procedures that 
can potentially select for virus strains able to replicate faster in PMBC cultures and 
may omit viruses adapted for replication in in vivo cell types. This facilitated the 
comparison of the proteins encoded by env in each virus at the time of sampling, and 
provided a realistic picture of the circulating envelopes.  
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Other research groups in the world have also recognised the scarcity of subtype C 
envelopes  for  research  in  neutralisation  and  vaccine  studies,  and  had  set  out  to 
characterise the subtype C circulating strains. In the interim period of this research, 
Brown et al. had created a panel of 60 viruses; 10 each from subtypes A, B, C, D, 
CRF01_AE, and CRF02_AG (Brown et al., 2005). The 10 subtype C viruses were 
obtained from 6 different countries; five African and one Indian. However, all the 
isolates were obtained from primary PBMC coculture. Propagation of HIV-1 in cell 
culture can restrict the diversity of the quasispecies present in the original  blood 
sample and can favour the replication of some members of the quasispecies. Li et al. 
then created a reference panel of 12 African subtype C pseudoviruses and deposited 
them  in  the  NIH  AIDS  reagent  program  (Li  et  al.,  2006b).  The  envelopes  were 
cloned from a mixture of cocultured PBMC, uncultured PBMC, and plasma samples. 
These were sourced from only two countries in Africa. The WHO panel of primary 
isolates (Gao et al., 1994) contain one subtype C isolate, 92BR025, which is used in 
the later part of this thesis. 
The viruses described in this chapter are all replication-competent with the envelopes 
cloned directly from plasma samples. The 18 different envelope clones were derived 
from seropositive patients obtained from 8 different countries; 7 in Africa and also 
from within the United Kingdom. These chimeric viruses were then analysed for 
their  coreceptor  usage,  and  sensitivity  to  established  broadly  cross-neutralising 
monoclonal antibodies (bcnAbs), and compared with the subtype C reference strain 
panel described by Li et al. (Li et al., 2006b). 
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3.2  Patient samples 
Plasma samples from HIV-1 infected individuals were obtained from David Yirrell 
of the National Surveillance System in Scotland. Some of the sources of infection 
were  originally  acquired  from  Africa    (Yirrell  et  al.,  2004).  The  samples  were 
obtained from 20 different patients (numbered 20 to 39), all of which were typed as 
subtype C based on gag sequences. Samples from patient numbers 3 and 6 were 
previously  cloned  and  described  by  Aasa-Chapman  et  al.  (Aasa-Chapman  et  al., 
2004). The sample origin and the virus load at the time of sampling are listed in 
Table 3-1.  
Table 3-1. Sample origin and virus load at time of sampling 
Patient  Infection origin 
Plasma viral 
load 
(copies/ml) 
Source  Subtype 
3  Scotland, UK  293,000  plasma  C 
6  Mozambique  >100,000  plasma  C 
20  Zambia  36,300  plasma  C 
21  South Africa  79,700  plasma  C 
22  Malawi  76,900  plasma  C 
23  Gambia  22,600  plasma  C 
24  Congo  249,000  plasma  C 
25  Scotland, UK  130,000  plasma  C 
26  Zimbabwe  2,680,000  plasma  C 
27  Malawi  200,000  plasma  C 
28  Scotland, UK  329,000  plasma  C 
29  Zimbabwe  27,600  plasma  C 
30  Malawi  98,900  plasma  C 
31  South Africa  440,000  plasma  C 
32  Zimbabwe  71,000  plasma  C 
33  Zimbabwe  35,300  plasma  C 
34  Zimbabwe  21,800  plasma  C 
35  Zambia  194,000  plasma  C 
36  Scotland, UK  >750,000  plasma  C 
37  South Africa  541,000  plasma  C 
38  Nigeria  257,000  plasma  C 
39  Burundi  38,800  plasma  C 
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3.3  HIV-1 envelope cloning 
Viral RNA was first extracted from the plasma samples using the QIAamp Viral 
RNA Mini Kit (QIAGEN). First-strand cDNA was synthesised from the viral RNA 
and subsequently amplified in a one-step RT-PCR using the Titan One Tube RT-
PCR  Kit  (Roche  Diagnostics)  and  primers  o_envf  and  o_envr  according  to  the 
methods described in Section 2.5.3. Nested PCR were then carried out to clone out 
either gp120 or gp160 using primers 626L/125Y (for gp120) or fenv3/renv3 (for 
gp160). The amplified fragments were separated on an agarose gel, and bands of the 
expected sizes were excised and purified using the Qiagen Gel Extraction kit.  
The purified DNA fragments were first inserted into pcDNA3.1-TOPO vectors and 
transformed  into  chemically  competent  TOP10  E.  coli.  The  plasmids  were  then 
isolated and digested with either BstEII/MluI (for gp120) or EcoRI/XhoI (for gp160), 
and  subcloned  into  pHXB2∆env  (for  gp120)  or  pNL43∆env  (for  gp160)  HIV-1 
backbones. These restriction sites were encoded within the primers. pHXB2∆env 
allows  the  incorporation  of  heterologous  gp120  sequences  from  amino  acid  38 
(seven  amino  acids  after  the  signal  peptide)  to  six  amino  acids  prior  to  the 
gp120/gp41 junction, whilst pNL43∆env allows the incorporation of heterologous 
gp160 sequences (McKeating et al., 1996; Zheng and Daniels, 2001).  
Plasmid minipreps from multiple colonies of transformed TOP10 cells (Invitrogen) 
were screened for the correct inserts by restriction enzyme digestion. The resulting 
HIV-1 molecular clones encode replication-competent chimeric viruses containing 
envelopes  from  primary  isolates.  An  average  of  8  clones  from  each  of  the 
gp120/HXB2 and gp160/NL4.3 chimeric constructs from each patient sample was 
screened for the ability to infect NP2 cells. Figure 3-1 shows the agarose gels of the 124 
 
DNA fragments after digestion of the cloned products. Obtaining productive gp120 
chimeric viruses were more efficient than with gp160 chimeric viruses from all the 
patients. 
Plasmids  containing  the  correct  inserts  were  transfected  into  293T  cells  and 
replication competent viruses were harvested from the supernatant. Clones which 
successfully produced replication competent chimeric viruses are shown in Table 3-
2.  
Table 3-2. Clones that gave productive chimeric viruses
a 
Patient 
Number 
gp160/ 
NL4.3 viruses 
gp120/ 
HXB2 viruses 
3  -  CA6
b 
6  -  CB7
b 
20  -  C202 
21  -  - 
22  -  C222 
23  -  - 
24  -  - 
25  -  C250 
26  -  C261 
27  C27b, C27d  C271 
28  -  C281 
29  -  C291 
30  -  - 
31  -  - 
32  -  - 
33  C33.52
c  - 
34  -  C344 
35  -  C351 
36  -  C361 
37  C37.42
c  - 
38  C38d, C38g, C38.22
c  C381 
39  -  C391 
     
a. The envelopes (both gp120 and gp160) were cloned from the plasma samples from each patient and 
inserted into either NL4.3 or HXB2 backbones to produce replication competent chimeric viruses.  
Dashes indicate the failure to obtain productive chimeric viruses. 
b. These virus clones were produced by Craig Seymour. 
c. These virus clones were produced by Anna Forsman. 
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[A] 
       
[B] 
 
Figure 3-1. Agarose gels showing the DNA fragments after restriction enzyme 
digestion.   
Eight clones from each patient sample were screened for the correct inserts by restriction enzyme 
digestion. [A] Digestion of cloned gp120 envelopes in the HXB2 vector gave 2 fragments: a 1.5kb 
fragment for gp120, and an 11kb fragment for the vector backbone. All the clones produced inserts of 
the correct size. [B] Digestion of cloned gp160 envelopes in the TOPO vector gave 2 fragments: a 
2.5kb fragment for gp160, and a 4kb fragment for the vector. Only 5 out of the 8 clones (clones b, d, 
e, f, and g) produced inserts of the correct size. The above show a representative gel from each set of 
digested clones. 
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3.4  Sequencing of the cloned HIV-1 envelopes 
The envelopes were sequenced using an assortment of 11 different primers to ensure 
sufficient coverage of the cloned products (as described in Section 2.5.2), and to 
exclude any identical envelope clones during the picking of colonies. The sequences 
were then assembled using the Sequencher4 software and are shown in Figure 3-2. 
Accession numbers of the sequences that were uploaded onto Genbank are shown in 
Table 3-3.  
 Figure 3-2. (Cont. on next page) 
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Gp120 primary envelope isolates 
>CA6 
TGGGTCACCGTCTATTATGGGGTACCTGTGTGGAGGGAAGCAAAAGCTACTCTATTTTGTGCATCAGATGCTAAAGCATATGAGA
AAGAAGCGCATAATGTCTGGGCTACACATGCCTGTGTACCCACAGACCCCAACCCACAAGAAATTAACTTGGAAAATGTAACAGA
AAATTTTAACATGTGGAAAAATTACATGGTGGATCAGATGCATGAGGATGTAATCAGCTTATGGGATCAAAGCCTAAAGCCATGT
GTAAAATTGACTCCACTCTGTGTCACTTTAAGCTGTACAAATATTACCAGTAGTAATAGGACCAGTAGTAATGTTACTGCTACTG
ATGATAATGGGATGAAAAATTGCTCTTTCAATGTGACCACAGAAGTAAAAGACAAAAAGAAGCAAGAAAGGGCACTTTTTTATAG
GCTTGATATAGTACCAATTGAAAGCTCTAATGGGAACTCTACTGAGTATAGATTAATAAACTGTAATACTTCAACCATAGCACAA
GCCTGTCCAAAGATCTCTTTTGATCCAATACCTATACATTATTGTGCTCCTGCTGGTTATGCGATTCTAAAGTGTAATAATAAGA
CATTCAATGGAACAGGACCATGCAATAATGTCAGCACAGTGCAATGTACACATGGAATTAAGCCAGTGGTATCAACTCAACTACT
ATTAAATGGTAGCCTAGCAGAAGGAGAAATAATAATTAGATCTGAAAATCTGACCAACAATGCCAAAACAATAATAGCACATCTT
AATGAATCTATAGAAATAAATTGTACAAGACCAAACAACAATACAAGAAAAAGCATAAGGATAGGACCAGGACAAACATTCTATG
CAACAGGAGATATAATAGGAGACATAAGACAAGCACATTGTAACATTAGTGCAGAGAAATGGAACACAATGTTACAGAGGGTAAG
CAAAAAATTAAAAGAACACTTTAATAAAAACATAACATTTGCACCATCCTCAGGAGGGGATCTAGAAATTACAACACATAGCTTT
AATTGTGGAGGAGAATTTTTCTATTGCAATACATCACAATTGTTTAATACATCGCAATGGTTTACTAATGAAACAAATCTGACCA
GTCAGAATGCAAATTCATCCATCATCACACTCCAATGCAGAATAAAACAGATTATAAACATGTGGCAGGGGGTAGGACGAGCAAT
GTATGCCCCTCCCATTAAAGGAAACATAACATGCAGATCAAATATCACAGGATTACTATTGACACGTGATGGAGGAAACAATGCA
AGTGAGCCAGAGACATTTAGACCTGGAGGAGGAAATATGAAAGACAATTGGAGAAGTGAATTATATAAATATAAGGTAGTAGAAA
TTAACCCATTAGGAATAGCACCCACCAAGGCAAAGAGAGA 
>CB7 
TGGGTCACCGTCTATTATGGGGTACCAGTATGGAAGGAAGCAAGAGCTACTCTATTTTGTGCATCAGATGCTAAAGCATATGAGA
CAGAAGTGCATAATGTATGGGCTACACATGCCTGTGTACCCACAGACCCCAACCCACAAGAAATAGAGTTGGAAAATGTAACAGA
AAACTTTAATATGTGGAAAAATTACATGGTGGATCAAATGCATGAGGATGTAATCAGTTTATGGGATCAGAGCCTAAAGCCATGT
GTAAAATTGACCCCACTCTGTGTCACTTTAAACTGTACAGATACTGTTAATGGTACCATGTCTGAAGAAATGAAAAATTGCTCTT
TCAATATAACCACAGAAATAAGAGATAGGAAAAAGCAAGTAAGCGCACTTTTCTATAGACTTGATGTAGTATCACTTAATGGAAA
CTCTAACTCTAGTGAGTACAGATTAATAAATTGTAATACCTCAACCCTAGCACAAGCCTGTCCAAAGATCTCTTTTGACCCAATT
CCTATACATTACTGTGCTCCAGCTGGGTATGCGATTCTAAAATGTAATAATAAGACATTCAATGGATCAGGGCCATGCAATAATG
TCAGCACAGTGCAATGTACACATGGAATTAAGCCAGTGGTATCAACTCAATTACTGTTAAATGGCAGCCTAGCAGAAGAAATAAT
AATTAGATCTGAAAATCTGACAAACAATGCCAAAACAATAATAGTACATTTTAATAAATCTGTAGAAATTGTGTGTACAAGACCT
AATAATAATACAAGAAAGAGTGTGAGGATAGGACCAGGACAAACATTCTATGCAACAGGGGACATAATAGGAAATACAAGACAAG
CATATTGTAACATTAGTAAAGATAAATGGAATACAGCTTTACAAGGAGTAAGTGAAAAATTAAAAGAACACTTTAATAAAACAAT
AAAATTTAAACCATCCTCAGGAGGAGACCTAGAAATTACAACACATAGTTTTAATTGTAGAGGAGAATTTTTCTATTGCAATACA
TCAGGATTGTTTAATGGCACATACCTGAATAAGAATGAAACAAATTCAACCATCACGCTCCAATGCAGAATAAAACAAATTATAA
ACATGTGGCAGGGGGTAGGACGAGCAATATATGCCCCTCCCATTGAAGGAAACATAACATGTAAATCAAATATCACAGGACTACT
GTTGACACGTGATGGAGGAAACAGGGGTGAGAGTAATAATGAGACATTCAGACCTGGAGGAGGAGATATGAGAGACAATTGGAGA
AGTGAATTATATAAGTATAAAGTGGTAGAAATTAAACCATTAGGAATAGCACCCACCAAGGCAAAGAGAGA 
>C202 
TGGGTCACCGTCTATTATGGGGTACCTGTGTGGAGAGAAGCAAAAACTACTCTATTCTGTGCATCAGATGCTAAAGCATATGAGA
AAGAAGTGCATAATGTCTGGGCTACACATGCCTGTGTACCCACAGACCCCAGCCCACAAGAAATAGTTTTGGAGAATGTAACAGA
AAATTTTAACATATGGAAAAATGACATGGTGGATCAGATGCATGAGGATATAATCAGTTTATGGGATCAAAGCCTAAAACCATGT
GTACGGTTGACCCCACTATGTGTCACTTTAAAATGTAGTAATGCTAGGGTTATTAATAATACTGTTAATATTACTGATGCCTACA
ATGCTAGTGATACTGAAGAAATGAAAAATTGCTCTTTCAATATAACCACAGAACTAAGAGATAAGAAGGAGAAAGTGTATGCACT
CTTTTATAAACTTGATGTAGTACCACTTAAGGAGAAGAACAATACCTCTAGGGAGTATAGATTAATAAATTGTAATACCTCAACC
GTAACACAAGCCTGTCCAAAGGTCTCTTTTGACCCAATTCCTATACATTATTGTGCCCCAGCTGGTTATGCGATTCTAAAGTGTA
ATAATAAGACATTCAGTGGAAAAGGACCATGCAACAATGTCAGCACAGTACAATGTACACATGGAATTAAGCCAGTGGTATCAAC
TCAACTACTGTTAAATGGTAGCCTAGCTGAAGAGGAGATAATAATTAGATCTGAAGATCTGACTAACAATGTTAAGACAATAATA
GTACAGCTTAATAAACCTATAGAAATTATGTGTACAAGAGTCAGCAATAATACAAGAAGAAGCATAAGGATAGGGCCAGGACAAG
CATTCTATACAACAGGAGAAATAATAGGTGACATAAGAAACGCACATTGTAGCATTAGTACAGATGCCTGGAATGAAACTTTATA
CCAGGTAAGTGAAGAATTAAGAAAACACTTCTCTAATAACACAATAATAAGATTTGAACCATCTTCAGGAGGGGACCTAGAAATT
ACAACACATAGCTTTAATTGTAGAGGAGAATTTTTCTATTGCAATACAACAAAACTGTTTAATAGTACACACTGGCCTAATGGTA
CATCCGCATACAGGAATGGTACAGCAGACAATTACACCACACTCTCATGCAGAATAAAACAAATTATAAACATGTGGCAGAAGGT
AGGACGAGCAATGTATGCCCCTCCCATTGCAGGAAACATAACATGTAAATCAAATATCACAGGGCTACTATTGGTATGGGATGGA
GACAATAAAACAGATAATGGCATGAAGATAGAGACATTCAGACCTGGAGGAGGAGATATGAGGGACAATTGGAGAAGTGAATTAT
ATAAATATAAAGTGGTAGAAATTAAACCATTAGGAGTAGCACCCACTGGGGCAAAAAGAGA 
>C222 
TGGGTCACCGTCTATTATGGGGTACCTGTGTGGAAAGAAGCAAGCACTACTTTATTCTGTGCATCAGATGCTAAAGCATATGAGA
AAGAAGTGCATAATGTCTGGGCTACACGTGCCTGTGTGCCCACAGACCCCAACCCATATGAAACGTTTTTGGAAAATGTAACAGA
AAATTTTAACATGTGGAAAAATGACATGGTGGATCAGATGCATGAGGATATAATCAGTCTATGGGATGAAAGCCTAAAGCCATGT
GTAAAGTTGACCCCACTCTGTGTCACTTTAAACTGTACAGATGCTATCAATCAGACTGATACCACTCAGACCATAGCTAACCGTA
CCATAGCAAAAGACATGGAGGGACAAATAAAAAATTGCTCTTTCAATACAACCATAGAAATAAACAATAAGAAAGAGAAAGCGCG
TGCACTTTTTTATAGACTTGATGTAGTACCACTTGATAATGAGAAGAAGAGCAACAATAGTGGGAATCATAGCACCTATAGTGAG
TATAGATTAATAAATTGTAATACTTCAGCCATAACACAGGCCTGTCCAAAGGTCTCTTTTGATCCAATTCCTATACATTATTGTG
CTCCAGCTGGTTATGCGATTTTAAAGTGTAATAATAAGACTTTCAGTGGGACAGGACCATGCAATAATGTCAGCACAGTACAATG
TACACATGGAATTATGCCAGTGGTATCAACTCAACTACTGTTAAATGGTAGCATAGCAGAAGGAGAGATAATAATTAGATCTAAA
AATCTGAGTGACAATGCCAAAACAATAATAGTACAGCTTAACAGATCTGTAGAAATTACGTGTACAAGACCTGGCAATAATACAA
GGACAAGTATAAGGATAGGACCAGGACAAACATTCTATGCAACAGGAGACATAATAGGAGACATAAGACAAGCACATTGTAACAT
TACTAGAAAGAATTGGAGTGAAGCCTTAGAATGGGTAGCAGGAAAATTAGGAAAATACTTTCCTAATAAAACAATAAAATTTGAA
CCACACTCAGGAGGGGACCCAGAAATTACAAAACATAGCTTTAATTGTAGAGGGGAATTTTTCTATTGCGATACATCACAACTGT
TTAACTCATCACAACTGTTTAATAATACTAACGGTACAGTAAATAAGTCAGAAAACATCACACTCCCATGCAGAATAAGACAAAT
TGTAAACATGTGGCAGCAGGTAGGACGAGCAATATATGCCAATCCCATTGCAGGAAGCATAACATGTAAATCAAATATCACGGGA
CTACTATTGGTACGTGATGGAGGCACAAAAAATGACACAGAGAATAACACAGAGACATTCAGACCTGAAGGAGGAGATATGAGGG
ACAATTGGAGAAGTGAATTATATAAATATAAAGTGGTAGAAATTAAGCCATTGGGAGTAGCACCCACTGGGGCAAAAAGAGA Figure 3-2. (Cont. on next page) 
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>C250 
TGGGTCACCGTCTATTATGGGGTACCTGTGTGGAGGGAAGCAAAAGCTACTCTATTTTGTGCATCAGATGCTAAAGCATATGAGA
AAGAAGCGCATAATGTCTGGGCTACACATGCCTGTGTACCCACAGACCCCAACCCACAAGAAATTAACTTGGAAAATGTAACAGA
AAACTTTAACATGTGGGAAAATTGCATGGTGGATCAGATGCATGAGGATGTAATCAGCTTATGGGATCAAAGCCTAAAGCCATGT
GTAAAATTGACTCCACTCTGTGTCACCTTAAACTGTACAAATATTACCAGTAGTAATAGGACCAGTAGTAATGTTACTGCTACTG
ATGATAAAGGGATGAAAAATTGCTCTTTCAATGTGACCACAGAAGTAAAAGACAAAAAGAAGCAAGAAAGGGCACTTTTTTATAG
GCTTGATATAGTACCAATTGGAAGCTCTAATGGGAACTCTACTGAGTATAGATTAATAAACTGTAATACTTCAACCATAGCACAA
GCCTGTCCAAAGATCTCTTTTGATCCAATACCTATACATTATTGTGCTCCTGCTGGTTATGCGATTCTAAAGTGTAATAATAAGA
CATTCAATGGAACAGGACCATGCAATAATGTCAGCACAGTGCAATGTACACATGGAATTAAGCCAGTGGTATCAACTCAACTGCT
ATTAAATGGTAGCCTAGCAGAAGGAGAAATAATAATTAGATCTGAAAATCTGACCAACAATGCCAAAACAATAATAGCACATCTT
AATGAATCTATAGAAATAAATTGTACAAGACCAAACAATAATACAAGAAAAAGCATAAGGATAGGACCAGGACAAACATTCTATG
CAACAGGAGATATAATAGGAGACATAAGACAAGCACATTGTAACATTAGTGCAGAGAAATGGAACACAATGTTACAGAGGGTAAG
CAAAAAATTAAAAGAACACTTTAATAAAAACATAACATTTGCACCATCCTCAGGAGGGGATCTAGAAATTACAACACATAGCTTT
AATTGTGGAGGAGAATTTTTCTATTGCAATACATCACAATTGTTTAATACATCACATTGGTTTAATAATACAACAAATCAGACTG
AACCCATCACACTCCAATGCAGAATAAAACAGATTATAAACATGTGGCAGGGGGTAGGACGAGCAATGTATGCCCCTCCCATTAA
AGGAAACATAACATGCAGATCAAATATCACAGGATTACTATTGACACGTGATGGAGGAAACAATGCAAGTGAGCCAGAGACATTT
AGACCTGGAGGAGGAAATATGAAAGACAATTGGAGAAGTGAATTATATAAATATAAGGTAGTAGAAATTAACCCATTAGGAATAG
CACCCACTGGGGCAAAAAGAGA 
>C261 
TGGGTCACCGTCTATTATGGGGTACCTGTGTGGAAAGAAGCAAAAACTACTTTATTTTGTGCATCAGATGCTAAAGCATATGAAA
AAGAAGTGCATAATGTCTGGGCCACACATGCCTGTGTACCCACAGACCCCAATCCACAAGAAATGGTCTTGGAAAATGTAACAGA
AAATTTTAACATGTGGAAAAATGACATGGTAGATCAGATGCATGAAGATATAATTAGCTTATGGGATCAAAGCCTCAAACCATGT
GTAAAGTTGACCCCACTCTGTGTCACCTTAAACTGTACAAAGGCTGTAGGTACAGAGGCTACCTGTGGCAATGCTACCTGCAAGA
ACAACATAACTGATGAAATGAGAAATTGCTCTTTCAATGTAACTACAGAATTAAGAGATAAGAACAAGAAAGAAAGTGCACTTTT
TTATAGACTTGATATAACACCAATTGAAGAGAGTACTACTATTGATAATAATAGTACTAAGAGTAATTATAGTGAGTATAGATTA
ATAAATTGTAATACCTCAACCATAACACAAGCCTGTCCAAAGGTCTCTTTTAACCCAATTCCTATACATTATTGTGCTCCAGCTG
GTTATGCGATTCTAAAGTGTAATAATAAGACATTCAATGGAACAGGACCATGCAATAATGTCAGCACTGTACAATGTACACATGG
AATTAAGCCAGTGGTATCAACTCAATTCCTGTTAAATGGTAGTCTATCAGAAGGAGGGATAATAATCAGATTTGAAAATATATCA
AACAATGCCAAAACAATAATAGTACACCTTAATGAATCTGTAGAAATTGAGTGTATAAGGCCTGGCAATAGCACAAGGAAAAGTA
TGAGAATAGGACCAGGACAAACATTCTTTGCAACAGGGCAAGTAATAGGAGATATAAGACAAGCATTTTGTAAAATTAATGGAAG
TCAATGGAATAAAACTTTACACAGGGTAAGTGAAAAATTAAGAAAACACTTCAACAGAACAATAATATTTGATCAACCATCCGCA
GGAGGGGACTTGGAAATTCTAACCCATAGTTTTAATTGTAGAGGAGAGTTTTTCTATTGCAATACATCAAAACTGTTTAATGGTA
CATACAATGGTACATACACTGACAGTACAGGAAATAATACAAATGCAACCATCATACTCCCATGCAGAATAAAACAAATTATAAA
CATGTGGCAGGGGGTAGGACGAGCAATGTATGCCTCTCCCATTGCAGGAAACATAACATGTAGATCAAATATCACAGGACTATTA
CTGACACATGATGGAGGAGACACGAATAGAAACAATGAGACATTTAGACCTGCAGGAGGAGATATGAGGGACAATTGGAGAAGTG
AATTATATAAATATAAAGTGGTAGAAATCAAGCCATTAGGAATAGCACCCACTGGGGCAAAAAGAGA 
>C271 
TGGGTCACCGTCTATTATGGGGTACCTGTGTGGAGAGAAGCAAAAGCTACTCTATTCTGTGCATCAGATGCTAAAGCATATGAGA
AGGAAGTGCATAATGTCTGGGCTACACATGCCTGTGTACCCACGGACCCCGACCCACAAGAATTGGTTTTGGAAAATGTAACAGA
AAATTTTAATATGTGGAAAAATGATATGGTGGATCAGATGCATGAGGATATAATCAGTTTATGGGATCAAAGCCTAAAACCATGT
GTAAAGTTGACCCCACTCTGTGTCACTTTGAATTGTAGTGATGTTAAGGTTAGCAGGACCATGAGTGGCAATACCCCCGATAATA
GCACGGGTGCAATAATGAGAAATTGCTCTTTCAATGCAACCACAGAGCTAAAAGATAAGAAAGAGAAAATGTCTGCACTTTTTTA
TAGACTTGATATAGTACCAATCAAGGGGAACAATGAGAGCTCGAACTCTAGTGAATATAGATTAATAAATTGTAATACTTCAACC
ATAACACAGGCTTGTCCAAAGGTCTCCTTTGACCCAATTCCTATACATTATTGTGCTCCAGCTGGTTATGCGATTCTAAAGTGTA
ATGAGAAGAAATTCAATGGAACAGGACCATGCAAGAATGTTAGCACAGTACAATGTACACATGGAATTAAGCCAGTGGTATCAAC
TCAACTACTGTTGAATGGTAGCCTAGCAGAGGAAGACATAATAATTAGATCTGAAAATCTGACAGACAATGCCAAAACAATAATA
GTACATCTTAATGAATCTGTAGAAATTGTGTGTACAAGACCCAACAATAATACAAGGAAAAGTGTAAGGATAGGACCAGGACAAG
CCATCTATGCAACAGGAGCCATAATAGGAGATATAAGGCAGGCACATTGTAACATTAGTGAAAGGAATTGGACTACAACTTTACA
AAGGGTAAGTAAAGAATTAGGTTTAAGCTTTAATAAAACAAACATAACATTTGCACCGTCCGCAGGAGGGGACTTAGAAATTACA
ACACATAGCTTTAATTGTGGAGGAGAATTTTTCTATTGCAATACATCAGGACTGTTTAATAAGACATATAATACATCAGACCTAA
GTAATGATAAGAATAATACTGCAGGTACTGCAAACATCACACTCCAATGCAGAATAAAACAAATTATAAACATGTGGCAGGGGGC
AGGACGAGCAATGTACGCCCCTCCAATTGAAGGAAACATAACATGTAAATCAAATATCACAGGACTCCTATTGACACGAGATGGA
GGAATAAAAAATAATAGTAGGAATAATGAGACATTTAGACCTGGAGGAGGGAGCATGAGGGATAATTGGAGAAGTGAATTATATA
AATATAAAGTGGTAGAAATTCAACCATTAGGAGTAGCACCCCTGGGGCAAAAAGAGA 
>C281 
TGGGTCACCGTCTATTATGGGGTACCTGTGTGGAGGGAAGCAAAAGCTACTCTATTTTGTGCATCAGATGCTAAAGCATATGATA
AAGAAGCGCATAATGTCTGGGCTACACATGCCTGTGTACCCACAGACCCCAACCCACAAGAAATTAAATTGGAAAATGTAACAGA
AAATTTTAACATGTGGAAAAATTACATGGTGGATCAGATGCATGAGGATGTAATCAGCTTATGGGATCAAACCCTAAAGCCATGT
GTAAAATTGACTCCACTCTGTGTCACTTTAAACTGTACAAATACTACCAGTAGTAATAGGACCAGTAGTAATGTTACTGCTTCTG
ATGATAATGGGATGAAAAATTGCTCTTTCAATGTGACCACAGAAATAACAGACAAAAAGAAGCAAGAAAGGGCACTTTTTTATAA
GCTTGATATAGTACCAATTGAAAGCTCTAACTCTACTGAGTATAGATTAATAAACTGTAATACTTCAACCATAGCACAAGCCTGT
CCAAAGATCTCTTTTGATCCAATACCTATACATTATTGTGCTCCTGCTGGTTATGCGATTCTAAAGTGTAATAATAAGACATTCA
ATGGAACAGGACCATGCAATAATGTCAGCACAGTGCAATGTACACATGGAATTAAGCCAGTGGTATCAACTCAACTGCTATTAAA
TGGTAGCCTAGCAGAAGGAGAAATAATAATTAGATCTGAAAATCTGACCAACAATGCCAAAACAATAATAGCACATCTTAATGAA
TCTATAGAAATAAATTGTACAAGACCAAACAATAATACAAGAAAAAGCATAAGGATAGGACCAGGACAAACATTCTATGCAACAG
GAGATATAATAGGAGACATAAGACAAGCACATTGTAACATTAGTGCAGAGAGATGGAGCGCAACGTTACAGAGGGTAAGAAAAAA
ATTAAAAGAACACTTTAATAAAACAATAAAATTTGAACCATCCTCAGGAGGGGATCTAGAAATTACAACACATAGCTTTAATTGT
GGAGGAGAATTTTTCTATTGCAATACATCACAATTGTTTAATTCATCACATTGGTTTAATAACACAACAAATCAGACTGAACCCA
TCACACTCCAATGCAGAATAAAACAGATTGTAAACATGTGGCAGGGGGTAGGACGAGCAATGTATGCCCCTCCCATTAAAGGAAA
CATAACATGCAGATCAAATATCACAGGATTACTATTGACACGTGATGGAGGAAACAATGGAGGAAACAGTACAAATGAGGAAGAG
ACATTTAGACCTGGAGGAGGAAATATGAAAGACAATTGGAGAAGTGAATTATATAAATATAAGGTAGTAGAAATTAACCCATTAG
GAATAGCACCCACTGGGGCAAAAAGAGA Figure 3-2. (Cont. on next page) 
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>C291 
TGGGTCACCGTCTATTATGGGGTACCTGTGTGGAGAGAAGCAAAAGCTACTCTATTCTGTGCATCAGATGCTAAAGCATATGAGA
AAGAAGTGCATAATGTATGGGCTACACATGCCTGTGTGCCCACAGACCCCAACCCACAAGAAATGATTTTAGAAAATGTAACAGA
AAATTTTTACATGTGGGAAAATAATATGGTGGATCAGATGCATGAGGATATAATCAGTTTATGGGATCAAAGCCTAAAACCATGT
GTAAAGTTGACCCCACTCTGTGTCACTTTAGACTGTACAAATGTAACAAAAACTAATGATACAAATGCTAATACTACAAACTTTA
ATGTTAGCATGACTGAAGACATGAAAAATTGCTCTTTCAATGTAACCACAGAAATAGTAAATAAGGAAAAGAAAATGTATGCACT
TTTTTATAAACTTGATATAGAACCACTTAATAAGGGGAACAGCAGCAAGGGGGACGACAGCAGTCAGTATATATTAATAAATTGT
AAGACCTCAACCATAACCCAAGCCTGTCCAAAGGTCACTTTTGACCCAATTCCTATACATTATTGTGCTCCAGCTGGTTATGCGA
TTCTCAAGTGTAATAATAAGACATTCAATGGAACAGGACCATGCAATAATGTCAGCACAGTACAATGTACACATGGAATTAAGCC
AGTGGTATCAACTCAATTACTGTTAAATGGTAGCTTAGCAGAAGAAGATATAGTAATTAGATCTGAAAACCTGACAAACAATGCC
AAAACAATAATAGTACAACTTAAGACACCTGTAAACATTACATGTATAAGACCTGGCAATAATACAAGAAAAAGTATAAGGATAG
GACCAGGACAAACCTTCTTTGCAACAGGGGACATAATAGGAGACATAAGACGAGCACATTGTACCATTAATGAAAGTAGCTGGAA
TGAAACTTTAAAAGAGGTAGGAAAGAAATTAGCAGTTCTCTTCAATAAAACAAAAATAATATTTAACTCATCCTCAGGAGGGGAC
CCAGAGATTACAGCACATAGCTTTAATTGTAGAGGAGAATTTTTCTACTGTAATACATCAAAATTGTTTAAATACATATACAATG
GTACACACAATAGTACAGAAGGAAATTCACACAATGGTACCATCGTACTCCCATGCAGAATAAAACAATTTATAAACATGTGGCA
GGGAGTAGGACGAGCAATGTATGCCCCTCCCATCGCAGGAAACATAACATGTATCTCAAATATCACAGGACTACTGTTGACGCGC
GATGGCGGAAATAATAGTAGTAATAATGAGACATTCAGACCAGGAGGAGGAGATATGAGAGACAATTGGAGAAGTGAATTATACA
AGTACAAAGTAGTAGAAATTAAACCATTAGGAATAGCACCCACTGGGGCAAAAAGAGA 
>C344 
TGGGTCACCGTCTATTATGGGGTACCTGTGTGGAAAGAAGCAAAAACTACCTTATTCTGTGCATCAGATGCTAAAGGATATGAGA
GAGAGGTGCATAATGTTTGGGCTACACATGCCTGTGTGCCCACAGACCCCAACCCACAAGAATTAGTTTTGGAAAATGTAACAGA
AAATTTTAACATGTGGAAAAATGACATGGTGGATCAGATGCATGAGGATATAATCAGTTTATGGGATCAAAGCCTAAAGCCATGT
GTAAAGTTAACCCCTCTCTGTGTCACTTTAACATGTAACAATGTTACCCACAATGACACCAAGGTTGAGAATACCACAGTTACGG
TTGAGAATACCACAATTGGAGAAATAAAAAATTGCTCTTTCAATACAACCACAGAAATAAGAGATAAGCAACGGACGGAGTATGC
ACTTTTTTATAGACCTGATATAGTATCACTTAATAATAACAATACTTATAGATTAATAAATTGTAATAGCTCAACCATAACACAG
GCCTGTCCAAAGATCTCTTTTGACCCAATTCCTATACATTATTGTGCTCCAGCTGGTTATGCGATTCTAAAGTGTAATAATAAGA
CATTCAATGGGACAGGACCATGCTATAATGTCAGCACAGTACAATGTACACATGGAATCAAGCCAGTGGTATCAACTCAACTACT
GTTAAATGGTAGCCTAGCAGAGGAAGGGATAATAATTAGATCTGAAAATCTGACAAACAATGCTAAAACAACAATAGTACAGTTT
AATCAGTCTGTGGAAATTGTGTGTACAAGACCCAACAATAACACAAGAAAGAGTGTAAGGATAGGACCAGGACAAGCATTCTATG
CAACAGGTGGCATAATAGGAGACATAAGACAAGCACATTGTAAAATTAATGGAAGCAACTGGAATAGGACTTTACAAGAGGTAAA
GACAAAATTAGAAGAACACTTCCCTAATAAATCAATACACTTTCAGCCACACGCAGGAGGGGACCTAGAAATTACAACACATAGC
TTTAATTGTAGAGGAGAGTTTTTCTATTGCAATACATCAAAACTGTTTAATAGTACATACTGGTTTAAGGAGACAGGAGGTGAAA
ACATCACAACAATTCCATGTAGAATAAAACAAATTATAAACATGTGGCAGGAGGTAGGACGAGCAATGTATGCCCCTCCCATTGC
AGGAAACATAACATGTAAATCAAATATCACAGGACTACTATTAGAACGTGATGGAGGCAACCACACAGACAACAATGAGACATTC
AGACCTGGAGGAGGAAACATGAAGGACAATTGGAGAAGTGAATTATATAAATATAAAGTGGTAGAAATTAAGCCATTAGGATTAG
CACCCACTGGGGCAAAAAGAGA 
>C351 
TGGGTCACCGTCTATTATGGGGTACCTGTGTGGAAAGAAGCAAAAACTACTTTATTCTGTGCATCAGAGGCTAAAGTATATGAGA
GGGAGGTGCATAATATCTGGGCTACACATGCCTGTGTACCCACAGACCCCAACCCACAAGAGATGGTTTTGGAAAATGTAACAGA
AAACTTTAATATGTGGAAAAATGACATGGTGGATCAGATGCATGAGGATATAATCAGTTTATGGGATCAAAGCCTAAAGCCATGT
GTAAAGTTGACCCCACTCTGTGTCACTTTAAACTGTAGCGATGTAACAAACAAGACTACTGTTAGCAATGAGACCAGGGGTGAAA
TAAAAAATTGCTCTTTCAATGCAACCACAGAAATAAGAGATAAGACACGCAAAGAGCATGCACTCTTTTACAGACTAGATATAGT
ACCACTTGATGAGAATAATAAAAGCTCTTGTGAGAATTGCTCTAGTGAGTATAGATTAATAAATTGTAATACTTCAACTGTAACA
CAAGCCTGTCCAAAGGTCAATTTTGATCCAATTCCTATACATTACTGTGCTCCAGCTGGTTATGCGATTCTAAAGTGTAATAATA
AGACATTTAATGGGACAGGACCATGCCATAATGTCAGTACAGTACAATGTACACATGGAATTAAGCCAGTGGTATCAACTCAACT
ACTGTTAAATGGTAGCATAGCAGAAAAGGAGATAATAATTAGATCTGAAAATCTGACAGACAATGTTAAAACAATAATAGTACAT
CTTAATAAAACTATACCAATTGTGTGTACAAGACCCAACAATAATACAAGAAAAAGTGTAAGAATAGGACCAGGACAAACATTCT
ATGCAACAGGTGGCATAATAGGAGATATAAGACAAGCACATTGTAACATTAGTGGTTGGAATGAGACTTTACAAAAGGTAAGGAA
GAAATTAGAAGAACACTTCCCTAATAAAACAATAAGATTTCAACCATCCTCAGGAGGGGACCTAGAAATTACAACACATAGCTTT
AATTGTAGAGGAGAATTTTTCTATTGCAATACATCAAAACTGTTTAATGATAACGGCACAGAAAGTAATTCAAATTCAAGTTCAA
ACATCACAATTCCATGCAGAATAAAACAAATTATAAATATGTGGCAGGAAGTAGGACGGGCAATGTATGCCCCTCCCATTACAGG
AAACATAACATGTGAGTCAAATATCACAGGGATACTGTTAGTACGTGATGGAGGCGGAAATGAAAATAATACCACAGAGACATTC
AGACCTGGAGGAGGAAATATGAAGGACAATTGGAGAAGTGAATTATATAAATATAAAGTGGTAGAAATTAAGCCATTGGGAATAG
CACCCACTGGGGCAAAAAGAGA 
>C361 
TGGGTCACCGTCTATTATGGGGTACCTGTGTGGAAAGAGGCAAAAACTACTTTATTTTGTGCATCAGATGCTAAAGCATATGAGA
AAGAGGTACATAATGTCTGGGCTACACATGCCTGTGTACCCACAGACCCCAGTCCACAAGAACTGGTTTTGGGAAATGTAACAGA
AAATTTTAACATGTGGAAAAATGACATGGTAGATCAAATGAATGAGGATATAATCAGTTTGTGGGATCAAAGCCTCAAGCCATGT
GTAAAGTTGACCCCACTCTGTGTCACTTTAAACTGTACAAATGTTGTTCCCCACAATGGGACTATAACAAACCACGAAGGTGTTG
TTACCAACAATGAGACTGAAATGAGAAACTGCTCTTTCAATACAACCACAGAAGTAAAAGATAAGCGTAAGCAAGAAAGGGCACT
TTTTTATAGACTTGATATAGTACCACTTGACAACTCTAGTTATAGATTAATAAACTGTAATACCTCAACCATAACACAAGCCTGT
CCAAAGGTCACTTTTGACCCAATTCCTATACATTATTGTGCTCCAGCTGGCTATGCGATTCTAAAGTGTAATAATAAGACATTCA
GTGGAATAGGACCATGCAATAATGTCAGCACAGTACAATGCACACATGGAATTAAGCCAGTGGTATCAACTCAACTACTGTTAAA
TGGTAGCCTATCAGAAGAAGGGATAATAATTAGATCTGCAAATCTGACAGACAATGCCAAAACAATAATAGTACAATTTAATGAA
TCTGTGGAGATTGTGTGTACAAGACCTGGCAATAATACAAGAAAAAGTGTGAGGATAGGACCAGGACAAACATTCTATGCAACAG
GAGACATAATAGGAAATATAAGACAAGCACATTGTAACATCAATGAATCTAACTGGAGAACAGCTTTATCCAGGGTAAGTGAAAA
ATTAAAAGAACTCATTAATAAAACCATAACATTTAACCTACACTCAGGAGGGGACCTAGAGATTACAACACATAGCTTTAATTGT
GGAGGAGAATTTTTCTATTGCAATACATCAGAATTGTTTAATGGTACATACAATAATGATACAGGGACGTCTAATAATACCATCA
TACTCCCATGCAGAATAAAACAAATTATAAACATGTGGCAGAAGGTAGGACGAGCAATGTATGCCCCTCCCATTGCAGGAAACAT
AACATGTAGATCAAATATCACAGGACTACTATTGACACGTGATGGAGGAAAAGATGTAAATAATGAAACAGAGATAGTCAGACCT
GGAGGAGGGGATATGAGGGACAATTGGAGAAGTGAATTATATAAATATAAAGTGGTAGAAGTTAAGCCATTAGGAATAGCACCCA
CTGGGGCAAAAAGAGA Figure 3-2. (Cont. on next page) 
130 
 
>C381 
TGGGTCACCGTCTATTATGGGGTACCTGTGTGGAAAGAAGCGAAAGCTACTCTATTTTGTGCATCAGATGCTAAAGCATATGATA
CAGAAGTGCACAATGTCTGGGCTACACATGCCTGTGTACCCACAGACCCCAACCCACAAGAAATGGTTTTGGAAAATGTAACAGA
AAATTTTAACATGTGGAAAAATGACATGGTGGATCAGATGCATCAGGATATAATCAGTTTATGGGATCAAAGCCTAAAGCCATGT
GTACTGTTGACCCCACTCTGTGTTACTTTAAATTGTACAAATGCTAATGTGACCAGAACCAATGCCACAATGCAAGAAGAAATGA
AAAGTGAAATAAAAAATTGTTCTTTCAATATCACCACAGAAATGAGAGATAAGAGACAGAAAGTACATGCACTTTTTTATAGACT
TGATGTAGTACTAATAAATGAAACAATAGATAATACTAGTTACAGATTAATAAATTGTAATACCTCAGCCATAACACAAGCCTGT
CCAAAGGTCTCTTTTGACCCAATTCCTATACATTATTGTGCTCCAGCTGTTTATGCGATTCTAAAGTGTAATAATAAGACATTCA
ATGGAACAGGACCATGCAATAATGTCAGCACAGTGCAGTGTACACATGGAATTAAACCAGTGGTATCAACTCAATTATTGTTAAA
TGGTAGTATAGCAGAAAAAGAGATAATAATTAGATCTGAAAATCTGACAAACAATGCCAAAATAATAATAGTACATCTTAATGAA
TCTGTAGAAATTAATTGTACAAGACCCAACAACAATACAAGACAAAGTATAAGGATAGGACCAGGGCAAGCATTTTATGCAACAG
GAGATATAATAGGAGATATAAGACAAGCACATTGTAACATTAGTGCAAAACGATGGAACGAAACTTTAGAAAGGGTAAGACTAAA
ATTAAAGGAGCACTTCCCTGATAAAGCAATAACCTTTAATCACTCCTCAGGAGGGGATCTAGAAATTACAACACATAGCTTTAAT
TGTAGAGGAGAATTTTTCTATTGCAATACATCAGAACTGTTTAAGAATGGTACAAATAATGGTACCAATAGTACAGACTCAACAA
ATTCAACAACCATCACAATCCCATGCAGAATAAAACAAATTATAAATATGTGGCAGGGGGTAGGTCGAGCAATATATGCCCCTCC
CATTAAAGGAAACATAACATGTAACTCAAATATCACAGGACTACTGCTGACACGTGATGGAGGAAAAGGAGAAGAAAGTGATAAT
AAGACAGAGATATTCAGACCTGCAGGAGGAGATATGAGGGACAATTGGAGAAGTGAATTATATAAATACAAAGTGGTAGAAATCC
AGCCATTAGGAGTAGCACCCACTGGGGCAAAAAGAGA 
>C391 
TGGGTCACCGTCTATTATGGGGTACCTGTGTGGAAAGAAGCAAAAACTACTTTATTCTGTGCATCAGAGGCTAAAGCATATGAGA
GGGAGGTGCACAATATCTGGGCTACACATGCCTGTGTACCCACAGACCCCAACCCACAAGAGATGGTTTTGGAAAATGTAACAGA
AAACTTTAATATGTGGAAAAATGACATGGTGGATCAGATGCATGAGGATATAATCAGTTTATGGGATCAAAGCCTAAAGCCATGT
GTAAAGTTGACCCCACTCTGTGTCACTTTAAACTGTAGCGATGTAACAAACAAGACTACTGTTAGCAATGAGACCAGGGGTGAAA
TAAAAAATTGCTCTTTCAATGCAACCACAGAAATAAGAGATAAGACACGCAAAGAGCATGCACTCTTTTACAGACTAGATATAGT
ACCACTTAAGGAGACAACACTTAATGAGACTGGTACCAACTCTAGTGAGTATAGATTAATAAATTGTAATACTTCAACTGTAACA
CAAGCCTGTCCAAAGGTCAATTTTGATCCAATTCCTATACATTACTGTGCTCCAGCTGGTTATGCGATTCTAAAGTGTAATAATA
AGACATTTAATGGGACAGGACCATGCCATAATGTCAGTACAGTACAATGTACACATGGAATTAAGCCAGTGGTATCAACTCAACT
ACTGTTAAATGGTAGCATAGCAGAAAAGGAGATAATAATTAGATCTGAAAATCTGACAGACAATGTTAAAACAATAATAGTACAT
CTTAATAAAACTATACCAATTGTGTGTACAAGACCCAACAATAATACAAGAAAAAGTGTAAGAATAGGACCAGGACAAACATTCT
ATGCAACAGGTGGCATAATAGGAGATATAAGACAAGCACATTGTAACATTAGTGGTTGGAATGAGACTTTACAAAAGGTAAGGAA
GAAATTAGAAGAACACTTCCCTAATAAAACAATAAGATTTCAACCATCCTCAGGAGGGGACCTAGAAATTACAACACATAGCTTT
AATTGTAGAGGAGAATTTTTCTATTGCAATACATCAAAACTGTTTAATGATAACGGCACAGAAAGTAATTCAAATTCAAGTTCAA
ACATCACAATTCCATGCAGAATAAAACAAATTATAAATATGTGGCAGGAAGTAGGACGGGCAATGTATGCCCCTCCCATTGCAGG
AAACATAACATGTGAGTCAAATATCACAGGGATACTGTTAGTACGTGATGGAGGCGGAAATGAAAATAATACCACAGAGACATTC
AGACCTGGAGGAGGAAATATGAAGGACAATTGGAGAAGTGAATTATATAAATATAAAGTGGTAGAAATTAAGCCATTGGGAATAG
CACCCACTGGGGCAAAAAGAGA 
 
Gp160 primary envelope isolates 
>C27.b 
ATGAGAGTGAGGGGGACATCGAGGAATTGGCAACAATGGTGGATATGGGGCAGCTTAGGCTTATGGATGTTAATGATTTGTAGTG
GGAAGGAAAACTTGTGGGTCACAGTCTATTATGGGGTACCTGTGTGGAAAGATGCAAGTACTACTCTATTCTGTGCATCAGATGC
TAAAGCATATGAGAAAGAGGTGCACAATGTCTGGGCTACACATGCCTGTGTACCCACAGACCCCAACCCACAAGAACTTGTTTTA
AAAAATGTAACAGAAAATTTTAACATGTGGAAAAATGACATGGTGGATCAGATGCATGAAGATGTAATTAGTTTATGGGATCAGA
GCCTAAAGCCATGTGTAAAGTTGACCCCACTCTGTGTCACTTTAACCTGTACAAAGGCTAACATTACCAGTAATGTTACAGCTGC
CAGTAATGTTACAGTTGCCAGTCATGGTATCAGTAATATTACGGATGACATAAGAAATTGCTCTTTCAATACAACCACAGAACTA
AGAGATAAGAAAACAAGGATGTATGCACTTTTTTATAGACTTGATATAGTACCACTTGATGGGAATAATGAAAGTAAGGAGAATA
ATAAAAGTGCCACATATAGATTAATAAATTGTAATACCTCAACCATAACACAAGCCTGTCCAAAGATCTCTTTTGACCCGATTCC
TATACATTATTGTGCTCCAGCTGGTTTTGCGCTTCTAAAGTGTAATAATAAGACATTCAATGGGACGGGACCATGCCAGAATGTC
AGCACAGTACAATGTACACATGGAATTAAGCCAGTGGTATCAACTCAATTACTGTTAAATGGTAGCCTAGCAGAAGGAGAGATAA
TAATTAGATCTGAAAATCTGACAAACAATGCTAAAACAATAATAGTACATCTTAATGAATCTGTAGAAATTAATTGTGCAAGACC
CGGCAATAATACAAAGAAAAGTGTGAGGATAGGACCAGGACAAACATTCTATGCAACAGGAGACATAATAGGAGACATAAGACAA
GCACATTGTAACATTAGTAAAGATAATTGGACTAAGACTTTACAAAGGGTAGCGAAAAAATTACAGGAACACTTCCCTAGAACAA
TAAACTTTACTTCATCCTCAGGAGGGGACCTAGAAATTACAACACATACCTTTAATTGTAGAGGAGAATTTTTCTATTGCAATAC
ATCAGGCCTGTTTAATGGTACATTCAAGTTTAATGATACAGACATGACTAATGATACAGGAAACATCACACTTCCATGCAGAATA
AAACAAATTATAAACATGTGGCAGGAGGTAGGACGAGCAATGTATGCCCCTCCCATTGCAGGAAACATAACATGTAAATCAAATA
TCACAGGACTACTATTGCTACGGGATGGAGGGACAAATGTAACAAATGAAACAGAAATATTCAGACCTGGAGGAGGAGATATGAG
GGACAATTGGAGAAGTGAATTATATAAATATAAAGTGGTTGAAATTAAGCCATTGGGAATAGCACCCACTAAGGCAAAAAGGAGA
GTGGTGGAAAGACAAAAAAGAGCAGCAATAGGAGCTATGATCATTGGGTTCTTGGGAGCAGCAGGAAGCACTATGGGCGCAGCGT
CAATAGCGCTGACGGCACAGGCCAGACAAGTATTGTCTGGTATAGTGCAACAGCAAAGCAATTTGCTGAGAGCTATAGAGGCGCA
ACAGCATATGTTGCAACTCACAGTCTGGGGCATTAAGCAGCTCCAGGCAAGAGTCCTGGCTATAGAAAGATACCTAAAAGATCAA
CAGCTCCTAGGACTTTGGGGCTGCTCTGGAAAACACATCTGCACCACTGCTGTGCATTGGAATGTCAGTTGGAGTAATAAATCTC
TAGGAGAAATTTGGGATAACATGACCTGGATGCAGTGGGACAAAGAAATTAGTAACTACACAAACCAAATTTACAATTTGCTTGA
AGAATCACAAAACCAGCAGGAAAGAAATGAAAAAGATTTATTAGCATTGGACAGTTGGAATAGTTTGTGGACTTGGTTTGACATA
TCAAAATGGCTGTGGTATATAAGAATATTTATAATGATAGTAGGAGGCTTGATAGGTTTAAGAATAATTTTTGCTGTGCTTTCTA
TAGTAAAAAGAGTTAGGCAGGGATACTCACCTTTGTCGTTTCAGACCCTTGTCCCAAGCCCGAGGGAACCCGACAGGCTCGGAGG
AATCGAAGAAGAAGGTGGAGAGCAAGACAGAGACAGATCGCTGAGATTAGTGAGCGGATTCTTAGCGATTGTCTGGGACGACCTC
AGGAGCCTGTGCCTCTTCCTCTACCACCGATTGAGGGACTTCATATTGATTGCAGCGAGAGTGGTGGAGATTCTGGGACGCACGG
GGTGGGAAGCTCTTAAATATCTGGGAAGCATTGTGCAGTATTGGGGTCTGGAACTAAAAAAGAGTGCTATTAGTCTGCTTGATAC
CATAGCAATAGCAACAGCTGAGGGAACAGATAGGATTATAGACTTCATACGAAGATTTTTTAGAGGGATTTGCAACATACCTAGA
AGAATAAGACAGGGCTTTGAAGCAGCTTTGCAATAA Figure 3-2. (Cont. on next page) 
131 
 
>C27.d 
ATGAGAGTGAGGGGGACATCGAGGAATTGGCAACAATGGTGGATATGGGGCAGCTTAGGCTTATGGATGTTAATGATTTGTAGTG
GGAAGGAAAACTTGTGGGTCACAGTCTATTATGGGGTACCTGTGTGGAAAGATGCAAATACTACTCTATTCTGTGCATCAGATGC
TAAAGCATATGAAAAAGAGGTGCACAATGTCTGGGCTACACATGCCTGTGTACCCACAGACCCCAACCCACAAGAACTTGTTTTA
AAAAATGTAACAGAAAATTTTAACATGTGGAAAAATGACATGGTGGATCAGATGCATGAAGATGTAATTAGTTTATGGGATCAAA
GCCTAAAGCCATGTGTAAAGTTGACCCCACTCTGTGTCACTTTAACCTGTACAAAGGCTAACATTACCAGTAATGTTACAGCTGC
CAGTAATGTTACAGTTGCCAGTCATGGTATCAGTAATATTACGGATGACATAAAAAATTGCTCTTTCAATACAACCACAGAACTA
AGAGATAAGAAAACAAAGATGTATGCACTTTTTTATAGACTTGATATAGTACCACTTGATGGGAATAATGAAAGTAAGGAGAATA
ATAAAAGTGCCACATATAGATTAATAAATTGTAATACCCCAACCATAACACAAGCCTGTCCAAAGGTCTCTTTTGACCCGATTCC
TATACATTATTGTGCTCCAGCTGGTTTTGCGCTTCTAAAGTGTAATAATAAGACGTTCAGTGGGAAGGGACCATGCCAGAATGTC
AGCACAGTACAATGTACACATGGAATTAAGCCAGTGGTATCAACTCAATTACTATTAAATGGTAGCCTAGCAGAAGGAGAGATAA
TAATTAGATCTGAAAATTTGACAAACAATGCTAAAACAATAATAGTACATCTTAATGAATCTGTAGAAATTAATTGTGCAAGACC
CGGCAATAATACAAGGAAAAGTGTGAGGATAGGACCAGGACAAGCATTCTATGCAACAGGAGACATAATAGGAGACATAAGACAA
GCACATTGTAACATTAGTAAAGATAATTGGACTAAGACTTTACAAAGGGTAGCGAAAAAATTACAGGAACACTTCCCTAGAACAA
TAAACTTTACTTCATCCTCAGGAGGGGACCTAGAAATTACAACACATACCTTTAATTGTAGAGGAGAATTTTTCTATTGCAATAC
ATCAGGCCTGTTTAATGGTACATTCAAGTTTAATGATACAGACATGACTAATAATACAGGAAACATCACACTTCCATGCAGAATA
AAACAAATTATAAACATGTGGCAGGAGGTAGGACGAGCAATGTATGCCCCTCCCATTGCAGGAAACATAACATGTAAATCAAATA
TCACAGGACTACTATTGCTACGGGATGGAGGGACAAATGTAACAAATGAAACAGAAATATTCAGGCCTGGAGGAGGAGATATGAG
GGACAATTGGAGAAGTGAATTATATAAATATAAAGTGGTTGAAATTAGGCCATTGGGAATAGCACCCACTAAGGCAAAAAGGAGA
GTGGTGGAAAGACAAAAAAGAGCAGCAATAGGAGCTATGATCATTGGGTTCTTGGGAGTAGCAGGAAGCACTATGGGCGCAGCGT
CAATAGCGCTGACGGCACAGGCCAGACAAGTATTGTCTGGTATAGTGCAACAGCAAAGCAATTTGCTGAGAGCTATAGAGGCGCA
ACAGCATATGTTGCAACTCACAGTCTGGGGCATTAAGCAGCTCCAGGCAAGAGTCCTGGCTATAGAAAGATACCTAAAAGATCAA
CAGCTCCTAGGACTTTGGGGCTGCTCTGGAAAACACATCTGCACCACAAATGTGTCTTGGAATGTCAGTTGGAGTAATAAATCTC
TAGGAGAAATTTGGGATAACATGACCTGGATGCAGTGGGACAAAGAAATTAATAACTACACAAATCAAATATACACTTTGCTTGA
AGAATCACAAAACCAGCAGGAAAGAAATGAAAAAGATTTATTAGCATTGGACAGTTGGAATAGTTTGTGGACTTGGTTTGACATA
TCAAAATGGCTGTGGTATATAAGAATATTTATAATGATAGTAGGAGGCTTGATAGGTTTAAGAATAATTTTTGCTGTGCTTTCTA
TAGTAAAAAGAGTTAGGCAGGGATACTCACCTTTGTCGTTTCAGACCCTTGTCCCAAGCCCGAGGGAACCCGACAGGCTCGGAGG
AATCGAAGAAGAAGGTGGAGAGCAAGGCAGAGAAAGATCCACGAGATTAGTGAGCGGATTCTTAGCGATTGTCTGGGACGACCTC
AGGAACCTGTGCCTCTTCCTCTACCACCGATTGAGGGACTTCATATTGATTGCAGCGAGAGTGGTGGAGATTCTGGGACGCAGGG
GGTGGGAAGCACTTAAATATCTGAGAAGCATTGTGCAGTATTGGGGCCTGGAACTAAAAAAGAGTGCTATTAGTCTGCTTGATAC
CATAGCAATAGCAACAGCTGAGGGAACAGATAGGATTATAGACTTCATACGAAGATTTTGTAGAGGGATTTGCAACATACCTAGA
AGAATAAGACAGGGCTTTGAAGCAGCTTTGCAATAA 
>C33.52 
ATGAGAGTGATGGGGATACTGAGGAATTGTCCACAATGGTGGATATGGGGCATCTTAGGCTTTTGGATGTTAATGATTTGTAATG
GGAACTTGTGGGTCACAGTCTATTATGGGGTACCTGTGTGGAAGGAAGCAAAAACTACCTTATTCTGTGCATCAGATGCCAAAGG
ATATGAGAGAGAGGTGCATAATGTTTGGGCTACACATGCCTGTGTGCCCACAGACCCCAACCCACAAGAAATAGTTTTGGAAAAT
GTAACAGAAAATTTTAACATGTGGAAAAATGACATGGTGGATCAGATGCATGAGGATATAATCAATTTGTGGGATCAAAGCCTAA
AGCCATGTATAAGGTTGACCCCACTCTGTGTCACTTTAAACTGTAGTAATATCAAGAACACCACGGTTGATAATACCACAGATGG
AGAAATAAAAAATTGTTCTTTCAATGCAACCACAGAAATAAGAGATAGGCGACGGCAAGAGTATGCACTGTTTTATAGACCTGAT
ATAGTACCACTTGATGACCATGATAACAAAACCAATACCACTACTTATAGATTAATAAATTGTAATAGCTCAACCATAACACAAG
CCTGTCCAAAGATCTCTTTTGACCCAATTCCTATACATTATTGTGCTCCAGCTGGTTATGCGATTCTAAAGTGTAATAATAAGAC
ATTCAATGGAACAGGACCATGCCATAATGTCAGCACAGTACAATGTACACATGGAATTAGGCCAGTGGTATCAACTCAACTACTG
TTAAATGGTAGCCTAGCAGAGGAAGAAATAATAATTAGATCTGAAAATTTGACAAACAATGTCAAAACAATAATAGTACATCTTA
ATCAATCTGTAGGAATTGAGTGTATAAGACCCAACAATAACACAAGAAAGAGTATAAGGATAGGACCAGGACAAACATTCTATGC
AACAGGTGGCATAATAGGAGACATAAGACAAGCATATTGTAACATTAGTGAAGATAGCTGGGGTGAGACTTTGCAATGGGTAAAG
AAAAAATTAGAAGAACACTTCCCTAATAAAACAATGAAACTTGAACCATCTGCAGGAGGGGACCTAGAAATTACAACACATAGCT
TTAATTGTGGAGGAGAATTTTTCTATTGCAATACATCAAAACTGTTTAATAGTACATACTGGTTTAATGACACAGGAGGTAATGA
GACAGAAGGTAATGGGACCATCACAATTCCATGTAGAATAAAACAAATTATAAACATGTGGCAGGAGGTAGGACGAGCAATGTAT
GCCCCTCCCATTGAAGGAAACATAACATGTAAATCAAATATCACAGGACTATTATTAGTACGTGATGGAGGCAACGTAGAAGGCG
AGAACAGAACAGAGACATTCAGACCTGGAGGAGGAAACATGAAGGACAATTGGAGAAGTGAATTATATAAATATAAAGTGGTAGA
AATTAAGCCATTGGGAATAGCACCCACTGGTGCAAAAAGGAGAGTGGTGAAGAGAGAAAAAAGAGCAGTGGGAATAGGAGCTGTG
TTCCTTGGGTTCTTGGGAGCAGCAGGAAGCACTATGGGCGCGGCGTCAATAACGCTGACGGTACAGGCCAGACAACTGTTGTCTG
GTATAGTGCAACAGCAAAGTAATTTGCTGAGGGCTATAGAGGCGCAACAGCATATGTTGCAACTCACGGTCTGGGGCATTAAACA
GCTCCAGACAAGAGTCCTGGCTATAGAAAGATACCTGAAGGATCAACAGCTCCTAGGGATTTGGGGCTGCTCTGGAAAACTCATC
TGCACCACTTCTGTGCCTTGGAACACCAGTTGGAGTAATAAATCAAAAGAAGATATTTGGAATAACATGACCTGGATGCAGTGGG
ACAGAGAAATTAGTAATTACACAAACACAATATACAGGTTGCTTGAAGAATCGCAAACCCAGCAGGAACAAACTGAGAAAGATTT
ATTAGCATTGGACAGTTGGCAAAGTCTGTGGAGTTGGTTTAGCATATCAAATTGGCTGTGGTATATAAAAATATTCATAATGATA
GTAGGAGGCTTGATAGGTTTAAGAATAATTTTTGCTGTGCTATCTATAGTAAATAGAGTTAGGCAGGGATACTCACCTTTATCGT
TTCAGACCCTTATCCCAAACCCGAGGGGACCCGACAGGCCCGGAGGAATCGAAGAAGAAGGTGGAGAGCAAGACAGAGACAGATC
CGTGCGCTTAGTGAACGGATTCTTATCACTTGCCTGGGACGATTTGAGGAGCCTGTGCCTCTTCAGCTACCACCGATTGAGAGAC
TTCATATTGGTGACAGCGAGAGTGGCGGAACATCTGGGACGCTGCAGTCTCAAGGGACTACAGAGGGGGTGGGAAGCCCTTAAGT
ATTTAGGAAGTCTTGTGCAGTATTGGGGTCTGGAACTAAAAAAGAGTGCTATTAGTTTGCTTGATTCCACAGCAATAGTAGTAGC
TGAGGGAACAGATAGAATTATAGAATTCTGTGATTGGATGGCCTGCTGTAAGGGAAAGAATGAGACGAGCTGA 
   Figure 3-2. (Cont. on next page) 
132 
 
>C37.42 
ATGAGAGTGAGGGGGACATCGAGGAATTGGCAACAATGGTGGATATGGGGCAGCTTAGGCTTATGGATGTTAATGATTTGTAGTG
GGAAGGAAAACTTGTGGGTCACAGTCTATTATGGGGTACCTGTGTGGAAAGATGCAAATACTACTCTATTCTGTGCATCAGATGC
TAAAGCATATGAGAAAGAGGTGCACAATGTCTGGGCTACACATGCCTGTGTACCCACAGACCCCAACCCACAAGAACTTGTTTTA
AAAAATGTAACAGAAAATTTTAACATGTGGAAAAATGACATGGTGGATCAGATGCATGAAGATGTAATTAGTTTATGGGATCAAA
GCCTAAAGCCATGTGTAAAGTTGACCCCACTCTGTGTCACTTTAACCTGTACAAAGGCTAACATTACCAGTAATGTTACAGCTGC
CAGTAATGTTACAGTTGCCAGTCATGGTATCAGTAATATTACGGATGACATAAGAAATTGCTCTTTCAATACAACCACAGAACTA
AGAGATAAGAAAACAAAGATGTATGCACTTTTTTATAGACTTGATATAGTACCACTTGATGGGAATAATGAAAGTAAGGAGAATA
ATAAAAGTGCCACATATAGATTAATAAATTGTAATACCTCAACCATAACACAAGCCTGTCCAAAGGTCTCTTTTGACCCGATTCC
TATACATTATTGTGCTCCAGCTGGTTTTGCGCTTCTAAAGTGTAATAATAAGACATTCAGTGGGAAGGGACCATGCCAGAATGTC
AGCACAGTACAATGTACACATGGAATTAAGCCAGTGGTATCAACTCAATTACTGTTAAATGGTAGTCTAGCAGAAGGAGAGATAA
TAATTAGATCTGAAAATCTGACAAACAATGCTAAAACAATAATAGTACATCTTAATGAATCTGTAGAAATTAATTGTGCAAGACC
CGGCAATAATACAAGGAAAAGTGTGAGGATAGGACCAGGACAAGCATTCTATGCAACAGGAGACATAATAGGAGACATAAGACAA
GCACATTGTAACATTAGTAAAGCTAATTGGACTAAGACTTTACAAAGGGTAGCGAAAAAATTACAGGAACACTTCCAGAATAAAA
CAATAAACTTTACTTCATCCTCAGGAGGGGACCTAGAAATTACAACACATACCTTTAATTGTAGAGGAGAATTTTTCTATTGCAA
TACATCAGGCCTGTTTAATGGTACATTCAAGTTTAATGATACAGACATGACTAATGATACAGGAAACATCACACTTCCATGCAGA
ATAAAACAAATTATAAACATGTGGCAGGAGGTAGGACGAGCAATGTATGCCCCTCCCATTGCAGGAAACATAACATGTAAATCAA
ATATCACAGGACTACTATTGCTACGGGATGGAGGGACAAATGTAACAAATGAAACAGAAATATTCAGACCTGGAGGAGGAGATAT
GAGGGACAATTGGAGAAGTGAATTATATAAATATAAAGTGGTTGAAATTAAGCCATTGGGAATAGCACCCACTAAGGCAAAAAGG
AGAGTGGTGGAAAGACAAAAAAGAGCAGCAATAGGAGCTATGATCATTGGGTTCTTGGGAGCAGCAGGAAGCACTATGGGCGCAG
CGTCAATAGCGCTGACGGCACAGGCCAGACAAGTATTGTCTGGTATAGTGCAACAGCAAAGCAATTTGCTGAGAGCTATAGAGGC
GCAACAGCATATGTTGCAACTCACAGTCTGGGGCATTAAGCAGCTCCAGGCAAGAGTCCTGGCTATAGAAAGATACCTAAAAGAT
CAACAGCTCCTAGGACTTTGGGGCTGCGCTGGAAAACACATCTGCACCACAAATGTGTCTTGGAATGTCAGTTGGAGTAATAAAT
CTCTAGGAGAAATTTGGGATAACATGACCTGGATGCAGTGGGACAAAGAAATTAATAACTACACAAATCAAATATACACTTTGCT
TGAAGAATCACAAAACCAGCAGGAAAGAAATGAAAAAGATTTATTAGCATTGGACAGTTGGAATAGTTTGTGGAGTTGGTTTGAC
ATATCAAATTGGCTGTGGTATATAAAAATATTTATAATGATAGTAGGAGGCTTGATAGGTTTAAGAATAATTTTTGCTGTGCTTT
CTATAGTAAAAAGAGTTAGGCAGGGATACTCACCTTTGTCATTTCAGACCCTTACCCCAAGTCCGAGGGAACCCGACAGGCTCGG
AGGAATCGAAGAAGAAGGTGGAGAGCAAGGCAGAGAAAGATCCACGAGATTAGTGAGCGGATTCTTAGCGATTGTCTGGGGCGAC
CTCAGGAACCTGTGCCTCTTCCTCTACCACCGATTGAGGGACTCCATATTGATTGCAGCGAGAGTGGTGGAGATTCTGGGACGCA
GGGGGTGGGAAGCACTTAAATATCTGGGAGGCATTGTGCAGTATTGGGGTCTGGAACTAAAAAAGAGTGCTATTAGTCTGCTTGA
TACCATAGCAATAGCAACAGCTGAGGGAACAGATAGGATTATAGACTTCATACGAAGATTTTGTAGAGGGATTTGCAACATACCT
AGAAGAATAAGACAGGGCTTTGAAGCAGCTTTGCAATAA 
>C38.d 
ATGAGAGTGATGGGGACACAGAGGAATTATCTGCTATGGTGGATGTGGGGCATCTTAGGCTTTTGGATAATATATAGTGGGACAG
AAAAGACGTGGGTCACAGTCTATTATGGGGTACCTGTGTGGAGGGAAGCAAAAGCTACTCTATTTTGTGCATCAGATGCTAAAGC
ATATGATAAAGAAGCGCATAATGTCTGGGCTACACATGCCTGTGTACCCACAGACCCCGACCCACAAGAAATTTACTTGAAAAAT
GTAACAGAAAATTTTAACATGTGGAAAAATTACATGGTGGATCAGATGCACGAGGATGTAATCAGCTTATGGGATCAAAGCCTAA
AGCCATGTGTAAAATTGACTCCACTCTGTGTCACTTTAAACTGTACAAATACTACCAGTAGTAATAGGACCAGTAGTAATGTTAC
TGCTACTGATGATAATGGGACGAAAAATTGCTCTTTCAATGTGACCACAGAAATAACAGACAAAAAGAAGCAAGAAAGGGCACTT
TTTTATAGGCTTGATATAGTACCAATTGAAAACTCTACTGAGTATAGATTAATAAACTGTAATACTTCAACCATAGCACAAGCCT
GTCCAAAGATCTCGTTTGATCCAATACCTATACATTATTGTGCTCCTGCTGGTTATGCGATTCTAAAGTGTAATAATAAGACATT
CAATGGAACAGGACCATGCAATAATGTCAGCACAGTGCAATGTACACATGGAATTAAGCCAGTGGTATCAACTCAACTGCTATTA
AATGGTAGCCTAGCAGAAGGAGAAATAATAATTAGATCTGAAAATCTGACCAACAATGCCAAAACAATAATAGCACATCTTAATG
AATCTATAGAAATAAATTGTACAAGACCAAACAATAATACAAGAAAAAGCATAAGGATAGGACCAGGACAAACATTCTATGCAAC
AGGAGATATAATAGGAGACATAAGACAAGCACATTGTAACATTAGTGCAGAGAGATGGAACACAACGTTACAGAGGGTAAGAAAA
AAATTAAAAGAACACTTTAATAAAACCATAACATTTGAACCATCCTCAGGAGGGGATCTAGAAATTACAACACATAGCTTTAATT
GTGGAGGAGAATTTTTCTATTGCAATACATCACAATTGTTTAATTCATCACATTGGTTTAATACTACAACAAATCAGACTGAACT
CATCACACTCCAATGCAGAATAAAACAGATTATAAACATGTGGCAGGGGGTAGGACGAGCAATGTATGCCCCTCCCATTAAAGGA
AACATAACATGCAGATCAAATATCACAGGATTACTATTGACACGTGATGGAGGAAAAAATGAGACAGAGACATTTAGACCTGGAG
GAGGAAATATGAAAGACAATTGGAGAAGTGAATTATATAAATATAAGGTAGTAGAAATTAACCCATTAGGAATAGCACCCACTAA
GGCAAAAAGGAGAGTGGTGGAGAGAGAAAAAAGAGCAGCAATAGGGGCTGTGTTCCTTGGGTTCTTGGGAGCCGCAGGAAGCACT
ATGGGCGCGGCGTCGATAACGCTGACGGTACAGGCCAGACAATTGTTGTCTGGTATAGTGCAACAGCAAAGCAATTTGCTGAGGG
CTATAGAGGCGCAACAGCATATGTTGCAACTCACAGTCTGGGGTATTAAACAGCTCCAGACAAGAGTCTTGGCTCTAGAAAGATA
CCTAAAGGATCAACAGCTCCTAGGAATTTGGGGCTGCTCTGGAAAACTCATCTGCACCACTAATGTGCCTTGGAACTCTAGTTGG
AGTAATAAATCTGTAGATGATATTTGGCAAAACATGACCTGGATGCAGTGGGATAAAGAAATTAGTAATTATTCAGATATAATAT
ACACGTTGCTTGAAGAATCACAAAACCAGCAGGAAAGAAATGAAAAGGATTTATTAGCATTGGACAGTTGGAACAATCTGTGGAG
TTGGTTTAACATATCAAATTGGCTATGGTATATAAAAATATTCATAATGATAATAGGGGGCTTGATAGGTTTAAGAATAATTTTT
GCTGTACTCTCTATAGTGAATAGAGTTAGGCAGGGATACTCACCTTTGTCATTTCAGACCCATATCCCAAACCCGAGGGGACCCG
ACAGGCTCGGAGGAATCGAAGAAGAAGGTGGAGAGAAAGACAGAGACAGATCCATTCGATTAGTGAGCGGATTCTTAGCACTTGC
TTGGGACGATCTACGGAGCCTGTGCCTTTTCAGCTACCACCGATTGAGGGACTTCATATTAATTGTAACGAGAGCAGTGGAACTT
CTGGGACACAGCATTCTCAAGGGACTACAGAGGGGGTGGGAAGCCCTTAAGTATCTGAAAGGTCTTGGGCAGTACTGGGGTCTAG
AGCTAAAAAAGAGTGCTATTAGTCTGTTTGATACCGTAGCAATAGCAGTAGCTGAGGGAACAGATAGGATTATAGAAGCAATAAT
AAGAACTTGTAGAGCTATCTGTAACATACCTACAAGAATAAGACAGGGATTAGAAGCAGCTTTACAATAA  
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>C38.g 
ATGAGAGTGATGGGGACACAGAGGAATTATCTGCTATGGTGGATATGGGGCATCTTAGGCTTCTGGATAATATATAGTGGGACAG
AAAAGACGTGGGTCACAGTCTATTATGGGGTACCTGTGTGGAGGGAAGCAAAAGCTACTCTATTTTGTGCATCAGATGCTAAAGC
ATATGATAAAGAAGCGCATAATGTCTGGGCTACACATGCCTGTGTACCCACAGACCCCAACCCACAAGAAATTAACTTGAAAAAT
GTAACAGAAAATTTTAACATGTGGAAAAATTACATGGTGGATCAGATGCATGAGGATGTAATCAGCTTATGGGATCAAAGCCTAA
AGCCATGTGTAAAATTGACTCCACTCTGTGTCACTTTAAACTGTGCAAATATTACCAGTAGTAATAGGACCAGTAGTAATGTTAC
TGCTACTGATGATAATGGGATGAAAAATTGCTCTTTCAATGTGACCACAGAAATAACAGACAAAAAGAAGCAAGAAAGGGCACTT
TTTTATAAGCTTGATATAGTACCAATTAGTGGGAACTCTACTGAGTATAGATTAATAAACTGTAATACTTCAACCATAGCACAAG
CCTGTCCAAAGATCTCTTTTGATCCAATACCTATACATTATTGTGCTCCTGCTGGTTATGCGATTCTAAAGTGTAATAATAAGAC
ATTCAATGGAACAGGACCATGCAATAATGTCAGCACAGTGCAATGTACACATGGAATTAAGCCAGTGGTATCAACTCAACTGCTA
TTAAATGGTAGCCTAGCAGAAGAAGAAATAATAATTAGATCTGAAAATCTGACCAACAATGCCAAAACAATAATAGCACATCTTA
ATGAATCTATAGAAATAAATTGTACAAGACCAAACAATAATACAAGAAAAAGCATAAGGATAGGACCAGGACAAACATTCTATGC
AACAGGAGATATAATAGGAGACATAAGACAAGCACATTGTAACATTAGTGCAGAGAGATGGAACACAACGTTACAGAGGGTAAGC
AAAAAATTAAAAGAACACTTTAATAAAAGCATAATATTTGAACCATCCTCAGGAGGGGATCTAGAAATTACAACACATAGCTTTA
ATTGTGGAGGAGAATTTTTCTATTGCAATACATCACAATTGTTTAATACATCACATTGGTTTAATAATACAACAAATCAGACTGA
ACCCATCACACTCCAATGCAGAATAAAACAGATTGTAAACATGTGGCAGGGGGTAGGACGAGCAATGTATGCCCCTCCCATTAAA
GGAAACATAACATGCAGATCAAATATCACAGGATTACTATTGACACGTGATGGAGGAAACAATGCAAGTGCAAGTGAGGAGACAT
TTAGACCTGGAGGAGGAAATATGAAAGACAATTGGAGAAGTGAATTATATAAATATAAGGTAGTAGAAATTAACCCATTAGGAAT
AGCACCCACTAAGGCAAAAAGGAGAGTGGTGGAGAGAGAAAAAAGAGCAGCAATAGGGGCTGTGTTCCTTGGGTTCTTGGGAGCC
GCAGGAAGCACTATGGGCGCGGCGTCGCTAACGCTGACGGTACAGGCCAGACAATTATTGTCTGGTATAGTGCAACAGCAAAGCA
ATTTGCTGAGGGCTATAGAGGCGCAACAGCATATGTTGCAACTCACAGTCTGGGGTATTAAACAGCTCCAGACAAGAGTCTTGGC
TCTAGAAAGATACCTAAGGGATCAACAGCTCCTAGGAATTTGGGGCTGCTCTGGAAAACTCATCTGCACCACTAATGTGCCTTGG
AACTCTAGTTGGAGTAATAAATCTGTAGATGATATTTGGCAAAACATGACCTGGATGCAGTGGGATAAAGAAATTAGTAATTATT
CAGGTATAATATACACGTTGCTTGAAGAATCACAAAGCCAGCAGGAAAGAAATGAAAAGGATTTATTAGCATTGGACAGTTGGAA
CAATCTGTGGAGTTGGTTTAACATATCAAATTGGCTATGGTATATAAAAATATTCATAATGATAATAGGGGGCTTGATAGGTTTA
AGAATAATTTTTGCTGTACTCTCTATAGTGAATAGAGTTAGGCAGGGATACTCACCTTTGTCATTTCAGACCCATATCCCAAACC
CGAGGGGACCCGACAGGCTCGGAGGAATCGAAGAAGAAGGTGGAGAGAAAGACAGAGACAGATCCATTCGATTAGTGAGCGGATT
CTTAGCACTTGCTTGGGACGATCTACGGAGCCTGTGCCTTTTCAGCTACCACCGATTGAGAGACTTCATATTAATTGTAACGAGA
GCAGTGGAACTTCTGGGACACAGCATTCTCAAGGGACTACAGAGGGGGTGGGAAGCCCTTAAGTATCTGAAAGGTCTTGGGCAGT
ACTGGGGTCTAGAGCTAAAAAAGAGTGCTATTAGTCTGTTTGATACCATAGCAATAGCAGTAGCTGAGGGAACAGATAGGATTAT
AGAAGCAATAATAAGAACTTGTAGAGCTATCTGTAACATACCTACAAGAATAAGACAGGGCTTAGAAGCAGCTTTACAATAA 
>C38.22 
ATGAGAGTGATGGGGATCAAGAGGAGTTGTCAACGATGGTGGATATGGGGAATCTTAGGCTTTTGGATGATTTATAATGTGATAG
GGAATTTGTGGGTCACAGTCTATTATGGGGTACCTGTGTGGAAAGAAGCAAAAACTACTCTATTTTGTGCATCAGATGCTAAAGC
ATATGTTACAGAAGTGCACAATGTCTGGGCTACACATGCCTGTGTACCCACAGACCCCAACCCACAAGAAATGGTTTTGGAAAAT
GTAACAGAAAATTTTAACATGTGGAAAAATGACATGGTGGATCAGATGCATCAGGATATAATCAGTTTATGGGATCAAAGCCTAA
AGCCATGTGTACAGTTGACCCCACTCTGTGTTACTTTAAATTGTACAAATGCTAATGTGACCAGAACCAATGCCACAATGGAAGA
AGGAATGAAAAATGAAATAAAAAATTGTTCTTTCAATATCACCACAGAAATGAGAGATAAGAGACAGAAAGTACATGCACTTTTT
TATAGACTTGATGTAGTACTAATAAATGAAACAATAGATAATACTAGTTATAGATTAATAAATTGTAATACCTCAGCCATAACAC
AAGCCTGTCCAAAGGTCTCTTTTGACCCAATTCCTATACATTATTGTGCTCCAGCTGGTTATGCGATTCTAAAATGTAATAATAA
GACATTCAATGGAACAGGACCATGCAATAATGTCAGCACAGTGCAGTGTACACATGGAATTAAACCAGTGGTATCAACTCAACTA
TTGTTAAATGGTAGTCTAGCAGAAAAAGAGATAGTAATTAGATCTGAAAATCTGACAAACAATGCCAAAATAATAATAGTACATC
TTAATGAATCTGTAGAAATTAATTGTACAAGACCCAACAACAATACAAGACAAAGTATAAGGATAGGACCAGGGCAAGCATTTTA
TGCAACAGGAGATATAATAGGAGATATAAGACAAGCACATTGTAACATTAGTGCAAAACGATGGAACGAAACTTTAGAAAGGGTA
AGACTAAAATTAAAGGAGCACTTCCCTGATAAAGCAATAACCTTTAATCACTCCTCAGGAGGGGATCTAGAAATTACAACACATA
GCTTTAATTGTAGAGGAGAATTTTTCTATTGCAATACATCAGAACTGTTTAAGAATGGTACAAATAATGGTACCAATAGTACAGA
CTCAACAAATTCAACATCCATCACAATCCAATGCAGAATAAAACAAATTATAAATATGTGGCAGGGGGTAGGTCGAGCAATATAT
GCCCCTCCCATTAAAGGAAACATAACATGTAACTCAAATATCACAGGACTACTGCTGACACGTGATGGAGGAAAAGGAGAAGAAA
GTGATAATAAGACAGAGATATTCAGACCTGCAGGAGGAGATATGAGGGACAATTGGAGAAGTGAATTATATAAATACAAAGTGGT
AGAAATTCAGCCATTAGGAGTAGCACCCACTGAGGCGAAAAGGAGAGTGGTGGAGAGAGAAAAAAGAGCAGTGGGAATAGGAGCT
GTGTTTCTTGGGTTCTTGGGAGCAGCAGGAAGCACTATGGGCGCAGCGTCAATAACGCTGACGGTACAGGCCAGACAATTATTGT
CAGGCATAGTGCAACAGCAAAGTAATTTGCTGAGAGCTATAGAGGCGCAACAGCATATGTTGCAACTCACGGTCTGGGGCATTAA
GCAGCTCCAGACAAGAGTCCTGGCTATAGAAAGGTACCTAAAGGATCAACAGCTCCTAGGGATTTGGGGCTGCTCTGGAAAACTC
ATCTGCACCACTGCTGTGCCTTGGAACTCTAGTTGGAGTAATAAATCTCAAGATGAGATTTGGAATAACATGACCTGGATGCAGT
GGGATAGAGAAATTAGTAACTATACAAACACAATATACACGTTGCTTGCAGACTCGCAAAACCAGCAGGACAAAAATGAAAAGGA
GTTACTAGCATTAGATAGCTGGAAAAATCTGTGGAATTGGTTTAACATAACAAATTGGCTGTGGTATATAAAAATATTCATAATG
ATAGTAGGGGGCTTAATAGGTTTAAGAATAATTTTTGCTGTGATCTCTATAGTGAACAGAGTTAGGCAGGGATACTCACCATTGT
CGTTCCAGATCCTTACCCCAACCCCGAGGGGACCCGACAGGCCCGAAAGAATCGAAGAAGAAGGTGGAGAGCAAGACAAAGACAG
ATCCATTCGATTAGTGAGCGGATTCTTAGCACTTGCCTGGGACGATCTGCGGAGCCTGTGCCTCTTCAGCTACCACCGATTGAGA
GACTTACTATCGATTGCAGCGAGAGCAGTGGAACTTCTGGGACACAGCAGTCTCAAGGGGTTGAGACTAGGGTGGGAAGCCCTTA
AGTATCTGGGAAGCCTTGTGCTGTATTGGGGTCAGGAGCTAAAAAAGAGTGCTATTAGCTTGCTTGATACCACAGCAATAGCAGT
AGCTGGAGGGACAGATAGGATTATAGAAGTAGTATTAAGAATTGGTAGAGCTATCTACAACATACCTAGAAGAATCAGACAGGGC
TTAGAAAGGGCTTTGCTATAA 
 
Figure 3-2. Sequences of the cloned envelopes in fasta format 
    
134 
 
3.5  Sequence analysis of the cloned gp120 envelopes 
The  amino  acid  sequences  were  computationally  translated  from  the  DNA 
sequences, and all the  clones  had an uninterrupted env open reading  frame. The 
amino acid sequences of the gp120 regions were then aligned using the programme 
ClustalW2  (Larkin  et  al.,  2007)  and  compared  with  the  consensus  subtype  C 
sequence  on  the  Los  Alamos  National  Laboratory  (LANL)  HIV  database.  The 
aligned amino acid sequences are shown in Figure 3-3.  
The cysteine residues (C) at the bases of the V1, V2, V3, and V4 loops of gp120 
were highly conserved in the cloned samples. When compared with the consensus 
subtype C sequence, considerable amino acid sequence variability was seen in V1, 
V2, V4, V5 and a region  immediately  C-terminal of  V3.   Amino acid sequence 
variability within V3 itself was relatively low. The 34 amino acids immediately C-
terminal  to  V3  were  remarkably  variable,  as  is  typical  of  subtype  C  viruses 
(Gnanakaran et al., 2007; Li et al., 2006b).  
The  positions  of  potential  N-linked  glycosylation  (PNLG)  sites  are  known  to 
influence neutralisation patterns (Reitter et al., 1998), and these are shown in bold 
and underlined in Figure 3-3. PNLG occur at sites with an NX[ST]X motif, where X 
is any amino acid other than proline (P), followed by either serine (S) or threonine 
(T) within the square brackets. It appears that the V1, V2, V4 and V5 of gp120 were 
the most heavily glycoyslated regions. Fourteen PNLG sites were highly conserved 
(>90%)  in  the  subtype  C  env  clones  studied,  and  these  are  denoted  with  open 
triangles in Figure 3-3. The number of PNLG sites in each gp120 clone is shown in 
Table 3-3. The average number of PNLG sites in all the env clones is 26.7, with the 
lowest number being 23 (found in C202, C361 and CA7) and the highest number  
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being 30 (found in C37.42). This is similar to the numbers found in the subtype C 
reference clones as described by Li et al. (Li et al., 2006b), with the exception that 
the  reference  clones  contained  only  nine  conserved  PNLG  sites.  One  highly 
conserved  PNLG  is  in  the  N-terminus  of  V3,  which  was  shown  to  mask 
neutralisation  epitopes  in  the  V3  loop  of  subtype  B  viruses.  (Back  et  al.,  1994; 
Schonning et al., 1996). 
The  number  of  amino  acids  in  the  variable  loops  of  gp120  can  affect  the 
neutralisation  phenotype  (Etemad-Moghadam  et  al.,  1998;  Moore  and  Sodroski, 
1996; Wei et al., 2003). The numbers were highly varied amongst the clones, with 
values of up to 50% variability in some of the clones, and are comparable to the 
average number of amino acids within the variable loops in the subtype C reference 
panel (Li et al., 2006b). The only exception was the V3 loop, with all env clones 
possessing a constant number of 35 amino acids (Table 3-3) 
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                        ∆ 
CONSENSUS_C    WVTVYYGVPV WKEAKTTLFC ASDAKAYEKE VHNVWATHAC VPTDPNPQEI VLENVTENFN 
CA6            ---------- -R---A---- ---------- A--------- ---------- N--------- 
CB7            ---------- ----RA---- --------T- ---------- ---------- E---------  
C202           ---------- -R-------- ---------- ---------- -----S---- ---------- 
C222           ---------- ----S----- ---------- -------R-- -------Y-T F--------- 
C250           ---------- -R---A---- ---------- A--------- ---------- N--------- 
C261           ---------- ---------- ---------- ---------- ---------M ---------- 
C27.b          ---------- --D-S----- ---------- ---------- ---------L --K------- 
C281           ---------- -R---A---- -------D-- A--------- ---------- K--------- 
C291           ---------- -R---A---- ---------- ---------- ---------M I--------Y 
C344           ---------- ---------- -----G--R- ---------- ---------L ---------- 
C351           ---------- ---------- --E--V--R- ---I------ ---------M ---------- 
C361           ---------- ---------- ---------- ---------- -----S---L --G------- 
C37.42         ---------- --D-N----- ---------- ---------- ---------L --K------- 
C381           ---------- -----A---- -------DT- ---------- ---------M ---------- 
C38.22         ---------- ---------- -------VT- ---------- ---------M ---------- 
C38.d          ---------- -R---A---- -------D-- A--------- -----D---- Y-K------- 
C38.g          ---------- -R---A---- -------D-- A--------- ---------- N-K------- 
C391           ---------- ---------- --E-----R- ---I------ ---------M ---------- 94 
 
 
               |-------------V1----------- 
CONSENSUS_C    MWKNDMVDQM HEDIISLWDQ SLKPCVKLTP LCVTLNCTNA .......... TNATNTMG.. 
CA6            ----Y----- ---V------ ---------- -----S---I TSS....... NRTSSNVTAT 
CB7            ----Y----- ---V------ ---------- --------DT VN........ ........GT 
C202           I--------- ---------- ------R--- -----K-S-- RVI.NNTVN. ITDAYNASDT 
C222           ---------- ---------E ---------- --------D- INQTDTTQTI A-R-IAKDME 
C250           --E-C----- ---V------ ---------- ---------I TSS....... NRTSSNVTAT 
C261           ---------- ---------- ---------- --------K- VGT.....EA -CGNA-.CKN 
C27.b          ---------- ---V------ ---------- -----T--K- NITSNVTAAS NVTVASH-IS 
C281           ----Y----- ---V------ T--------- ---------T TSS....... NRTSSNVTAS 
C291           --E-N----- ---------- ---------- -----D---V TKT.....ND ---NT-NFNV 
C344           ---------- ---------- ---------- -----T-N-V THN.DTKVEN -TV-VENTTI 
C351           ---------- ---------- ---------- -------SDV TN........ .KT-VSNETR 
C361           ---------- N--------- ---------- ---------V VPH.....NG -ITNHEGVVT 
C37.42         ---------- ---V------ ---------- -----T--K- NITSNVTAAS NVTVASH-IS 
C381           ---------- -Q-------- ------L--- ---------- NVT......R ----MQEEMK 
C38.22         ---------- -Q-------- ------Q--- ---------- NVT......R ----MEE-MK 
C38.d          ----Y----- ---V------ ---------- ---------T TSS....... NRTSSNVTAT 
C38.g          ----Y----- ---V------ ---------- -------A-I TSS....... NRTSSNVTAT 
C391           ---------- ---------- ---------- -------SDV TN........ .KT-VSNETR 142 
 
 
 
               -------∆|---∆-------------------------V2-----------------------| 
CONSENSUS_C    ....EIKNCS FNITTELRDK KQKVYALFYR LDIVPLNE.. .......... NNSYRLINCN 
CA6            DDNG.M---- --V---VK-- -KQER----- -----IESSN G........N STE------- 
CB7            MSEE.M---- ------I--R -KQ-S----- --V-S--GNS .........N SSE------- 
C202           ...E-M---- ---------- -E-------K --V---K... EKNNT..... SRE------- 
C222           ...GQ----- --T-I-INN- -E-AR----- --V---DNEK KSNNSGNHST YSE------- 
C250           DDKG.M---- --V---VK-- -KQER----- -----IGSSN G........N STE------- 
C261           NITD-MR--- --V------- NK-ES----- ---T-IE-ST TIDNNSTKSN YSE------- 
C27.b          NITDD-R--- --T------- -TRM------ ------D... GNNESKENNK SAT------- 
C281           DDNG.M---- --V---IT-- -KQER----K -----IESS. .........N STE------- 
C291           SMTEDM---- --V---IVN- EK-M-----K ---E---KGN S....SKGDD SSQ-I----K 
C344           ...G------ --T---I--- QRTE------ P---S--... NNN....... ..T------- 
C351           ...G------ --A---I--- TR-EH----- ------D... ENNKSSCENC SSE------- 
C361           NNET-MR--- --T---VK-- RKQER----- ------DNSS .......... ...------- 
C37.42         NITDD-R--- --T------- -T-M------ ------D... GNNESKENNK SAT------- 
C381           ...S------ ------M--- R---H----- --V-LI--T. ........ID -T-------- 
C38.22         ...N------ ------M--- R---H----- --V-LI--T. ........ID -T-------- 
C38.d          DDNG.T---- --V---IT-- -KQER----- -----IEN.. .......... STE------- 
C38.g          DDNG.M---- --V---IT-- -KQER----K -----ISG.. .........N STE------- 
C391           ...G------ --A---I--- TR-EH----- ------K... ETTLNETGTN SSE------- 197 
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                                                  ∆           ∆ 
CONSENSUS_C    TSAITQACPK VSFDPIPIHY CAPAGYAILK CNNKTFNGTG PCNNVSTVQC THGIKPVVST 
CA6            --T-A----- I--------- ---------- ---------- ---------- ---------- 
CB7            --TLA----- I--------- ---------- --------S- ---------- ---------- 
C202           --TV------ ---------- ---------- ------S-K- ---------- ---------- 
C222           ---------- ---------- ---------- ------S--- ---------- ----M----- 
C250           --T-A----- I--------- ---------- ---------- ---------- ---------- 
C261           --T------- ---N------ ---------- ---------- ---------- ---------- 
C27.b          --T------- I--------- -----F-L-- ---------- --Q------- ---------- 
C281           --T-A----- I--------- ---------- ---------- ---------- ---------- 
C291           --T------- -T-------- ---------- ---------- ---------- ---------- 
C344           S-T------- I--------- ---------- ---------- --Y------- ---------- 
C351           --TV------ -N-------- ---------- ---------- --H------- ---------- 
C361           --T------- -T-------- ---------- ------S-I- ---------- ---------- 
C37.42         --T------- ---------- -----F-L-- ------S-K- --Q------- ---------- 
C381           ---------- ---------- ----V----- ---------- ---------- ---------- 
C38.22         ---------- ---------- ---------- ---------- ---------- ---------- 
C38.d          --T-A----- I--------- ---------- ---------- ---------- ---------- 
C38.g          --T-A----- I--------- ---------- ---------- ---------- ---------- 
C391           --TV------ -N-------- ---------- ---------- --H------- ---------- 257 
 
                                         ∆                             ∆                               ∆            |---------∆---------V3-------------- 
CONSENSUS_C    QLLLNGSLAE EEIIIRSENL TNNAKTIIVH LNESVEIVCT RPNNNTRKSI RIGPGQTFYA 
CA6            ---------- G--------- --------A- ----I--N-- ---------- ---------- 
CB7            ---------- .--------- ---------- F-K------- ---------V ---------- 
C202           ---------- --------D- ---V-----Q --KPI--M-- -VS----R-- ------A--T 
C222           -------I-- G------K-- SD-------Q --R----T-- --G----T-- ---------- 
C250           ---------- G--------- --------A- ----I--N-- ---------- ---------- 
C261           -F------S- GG----F--I S--------- -------E-I --G-S----M --------F- 
C27.b          ---------- G--------- ---------- -------N-A --G---K--V ---------- 
C281           ---------- G--------- --------A- ----I--N-- ---------- ---------- 
C291           ---------- -D-V------ ---------Q -KTP-N-T-I --G------- --------F- 
C344           ---------- -G-------- ------T--Q F-Q------- ---------V ------A--- 
C351           -------I-- K--------- -D-V------ --KTIP---- ---------V ---------- 
C361           --------S- -G-----A-- -D-------Q F--------- --G------V ---------- 
C37.42         ---------- G--------- ---------- -------N-A --G------V ------A--- 
C381           -------I-- K--------- -----I---- -------N-- -------Q-- ------A--- 
C38.22         ---------- K--V------ -----I---- -------N-- -------Q-- ------A--- 
C38.d          ---------- G--------- --------A- ----I--N-- ---------- ---------- 
C38.g          ---------- ---------- --------A- ----I--N-- ---------- ---------- 
C391           -------I-- K--------- -D-V------ --KTIP---- ---------V ---------- 319 
 
` 
               -------------|∆                        •                         
CONSENSUS_C    TGDIIGDIRQ AHCNISEDKW NKTLQKVSKK LKEHFPN.KT IKFEPSSGGD LEITTHSFNC 
CA6            ---------- ------AE-- -TM--R---- -----NK.N. -T-A------ ---------- 
CB7            ------NT-- -Y----K--- -TA--G--E- -----NK.T. ---K------ ---------- 
C202           --E------N ---S--T-A- -E--YQ--EE -RK--S-NTI -R-------- ---------- 
C222           ---------- -----TRKN- SEA-EW-AG- -GKY---.-- -----H---- P---K----- 
C250           ---------- ------AE-- -TM--R---- -----NK.N. -T-A------ ---------- 
C261           --QV------ -F-K-NGSQ- ----HR--E- -RK--NR.TI -FDQ--A--- ---L------ 
C27.b          ---------- ------K-N- T----R-A-- -Q----..R- -N-TS----- ------T--- 
C281           ---------- ------AER- SA---R-R-- -----NK.T. ---------- ---------- 
C291           ---------R ---T-N-SS- -E--KE-G-- -AVL-NK.TK -I-NS----- P---A----- 
C344           --G------- ---K-NGSN- -R---E-KT- -E-----.-S -H-Q-HA--- ---------- 
C351           --G------- ------G..- -E-----R-- -E-----.-- -R-Q------ ---------- 
C361           ------N--- -----N-SN- RTA-SR--E- ---LINK.TI TFN.LH---- ---------- 
C37.42         ---------- ------KAN- T----R-A-- -Q---Q-.-- -N-TS----- ------T--- 
C381           ---------- ------AKR- -E--ER-RL- ------D.-A -T-NH----- ---------- 
C38.22         ---------- ------AKR- -E--ER-RL- ------D.-A -T-NH----- ---------- 
C38.d          ---------- ------AER- -T---R-R-- -----NK.T. -T-------- ---------- 
C38.g          ---------- ------AER- -T---R---- -----NK.S. -I-------- ---------- 
C391           --G------- ------G..- -E-----R-- -E-----.-- -R-Q------ ----------378 
 
 
 
Figure 3-3 (cont. on next page) 
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             |-∆------∆----------V4--------------| 
CONSENSUS_C    RGEFFYCNTS KLFNS..TYN STNS...... ...TITLPCR IKQIINMWQE VGRAMYAPPI 
CA6            G--------- Q---TSQWFT NETNLTSQNA NSSI---Q-- ---------G ---------- 
CB7            ---------- G---GTYLNK NETNSTIT.. ......-Q-- ---------G ----I----- 
C202           ---------T -----THWP- G-SAYRNG.T ADNYT--S-- ---------K ---------- 
C222           -------D-- Q----SQLF- N--GTVN... KSEN------ -R--V----Q ----I--N-- 
C250           G--------- Q---TSHWF- N-TNQTEP.. ....---Q-- ---------G ---------- 
C261           ---------- ----GTYNGT Y-D-TGN..N TNA--I---- ---------G -------S-- 
C27.b          ---------- G---GTFKF- D-DMTND... .TGN------ ---------- ---------- 
C281           G--------- Q----SHWF- N-TNQTEP.. ....---Q-- ----V----G ---------- 
C291           ---------- ---KYIYNGT HNSTEGN..S HNG--V---- ---F-----G ---------- 
C344           ---------- -----TYWFK E-GG...... .ENIT-I--- ---------- ---------- 
C351           ---------- ----DNG-ES NS--...... .SSN--I--- ---------- ---------- 
C361           G--------- E---GTYN.. ..-DTG...T SNN--I---- ---------K ---------- 
C37.42         ---------- G---GTFKF- D-DMTND... .TGN------ ---------- ---------- 
C381           ---------- E--KNG.-N- G---TDS..T NST---I--- ---------G ----I----- 
C38.22         ---------- E--KNG.-N- G---TDS..T NSTS--IQ-- ---------G ----I----- 
C38.d          G--------- Q----SHWF- T-TNQTEL.. ....---Q-- ---------G ---------- 
C38.g          G--------- Q---TSHWF- N-TNQTEP.. ....---Q-- ----V----G ---------- 
C391           ---------- ----DNG-ES NS--...... .SSN--I--- ---------- ----------439 
 
 
               • ∆    •/∆         |------V5------| 
CONSENSUS_C    AGNITCKSNI TGLLLTRDGG K......NNT ETFRPGGGDM RDNWRSELYK YKVVEIKPLG 
CA6            K-----R--- ---------- N....NASEP --------N- K--------- ------N--- 
CB7            E--------- ---------- N...RGES-N ---------- ---------- ---------- 
C202           ---------- -----VW--D NKT.DNGMKI ---------- ---------- ---------- 
C222           --S------- -----V---- TKN.DTE--- -----E---- ---------- ---------- 
C250           K-----R--- ---------- N....NASEP --------N- K--------- ------N--- 
C261           ------R--- ------H--- ....DTNR-N -----A---- ---------- ---------- 
C27.b          ---------- -----L---- TNV.TN..E- -I-------- ---------- ---------- 
C281           K-----R--- ---------- NNGGNST-EE --------N- K--------- ------N--- 
C291           ------I--- ---------- ....NNSS-N ---------- ---------- ---------- 
C344           ---------- -----E---- NHT.DNN... --------N- K--------- ---------- 
C351           T-----E--- --I--V---- GNE.NNT..- --------N- K--------- ---------- 
C361           ------R--- ---------- -...DVN-E- -IV------- ---------- -----V---- 
C37.42         ---------- -----L---- TNV.TN..E- -I-------- ---------- ---------- 
C381           K-----N--- ---------- -GE.ESD-K- -I---A---- ---------- ------Q--- 
C38.22         K-----N--- ---------- -GE.ESD-K- -I---A---- ---------- ------Q--- 
C38.d          K-----R--- ---------- -......-E- --------N- K--------- ------N--- 
C38.g          K-----R--- ---------- N...NASASE --------N- K--------- ------N--- 
C391           ------E--- --I--V---- GNE.NNT..- --------N- K--------- ----------495 
 
 
CONSENSUS_C    IAPTKAKR 
CA6            -------- 
CB7            -------- 
C202           V---G--- 
C222           V---G--- 
C250           ----G--- 
C261           ----G--- 
C27.b          -------- 
C281           ----G--- 
C291           ----G--- 
C344           L---G--- 
C351           ----G--- 
C361           ----G--- 
C37.42         -------- 
C381           V---G--- 
C38.22         V---E--- 
C38.d          -------- 
C38.g          -------- 
C391           ----G---503 
 
Figure 3-3. Amino acid alignments of cloned gp120 envelopes. 
Nucleotide sequences of the gp120 env gene from subtype C patient samples were translated, aligned, 
and compared with the subtype C consensus sequence with ClustalW2. Numbering of amino acid 
residues is according to the HXB2 numbering sequence. Dashes denote sequence identity, while dots 
represent gaps introduced to optimize alignments. V1, V2, V3, V4 and V5 regions (shaded boxes) 
designate hypervariable HIV-1 gp120 domains. Potential N-linked glycosylation sites (NXYX motif,  
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where X is any amino acid other than proline and Y is either serine or threonine) are in bold and 
underlined.  Highly  conserved  sites  of  potential  N-linked  glycosylation  are  denoted  with  open 
triangles. Shaded residues with a solid bullet are positions 356, 440, and 448, which were previously 
determined to be important for CCR3 usage.   
 
 
CONSENSUS_C    VGIGAVFLGF LGAAGSTMGA ASITLTVQAR QLLSGIVQQQ SNLLRAIEAQ QHMLQLTVWG 
C27.b          AA---MII-- ---------- ---A--A--- -V-------- ---------- ---------- 
C38.d          AA-------- ---------- ---------- ---------- ---------- ---------- 
C38.g          AA-------- ---------- --L------- ---------- ---------- ---------- 
C37.42         AA---MII-- ---------- ---A--A--- -V-------- ---------- ---------- 
C38.22         ---------- ---------- ---------- ---------- ---------- ----------  60 
 
CONSENSUS_C    IKQLQTRVLA IERYLKDQQL LGIWGCSGKL ICTTAVPWNS SWSNKSQEDI WDNMTWMQWD 
C27.b          -----A---- ---------- --L------H ------H--V ------LGE- ---------- 
C38.d          ---------- L--------- ---------- ----N----- ------VD-- -Q-------- 
C38.g          ---------- L----R---- ---------- ----N----- ------VD-- -Q-------- 
C37.42         -----A---- ---------- --L---A--H ----N-S--V ------LGE- ---------- 
C38.22         ---------- ---------- ---------- ---------- -------DE- -N--------  120 
 
CONSENSUS_C    REISNYTDTI YRLLEDSQNQ QEKNEKDLLA LDSWKNLWNW FDITNWLWYI KIFIMIVGGL 
C27.b          K------NQ- -N---E---- --R------- ----NS--T- ---SK----- R--------- 
C38.d          K-----S-I- -T---E---- --R------- ----N---S- -N-S------ ------I--- 
C38.g          K-----SGI- -T---E--S- --R------- ----N---S- -N-S------ ------I--- 
C37.42         K--N---NQ- -T---E---- --R------- ----NS--S- ---S------ ---------- 
C38.22         -------N-- -T--A----- -D----E--- ---------- -N-------- ----------  180 
 
CONSENSUS_C    IGLRIIFAVL SIVNRVRQGY SPLSFQTLTP .NPRGPDRLG RIEEEGGEQD RDRSIRLVSG 
C27.b          ---------- ---K------ --------V- .S--E----- G--------- ----L----- 
C38.d          ---------- ---------- -------HI- .--------- G-------K- ---------- 
C38.g          ---------- ---------- -------HI- .--------- G-------K- ---------- 
C37.42         ---------- ---K------ ---------- .S--E----- G--------G -E--T----- 
C38.22         ---------I ---------- ------I--- .T------PE ---------- K---------  240 
 
CONSENSUS_C    FLALAWDDLR SLCLFSYHRL RDFILIAARA VELLGRSSLR GLQRGWEALK YLGSLVQYWG 
C27.b          ---IV----- -----L---- ---------V --I--..... ..RT------ ----I----- 
C38.d          ---------- ---------- ------VT-- -----H-I-K ---------- --KG-G---- 
C38.g          ---------- ---------- ------VT-- -----H-I-K ---------- --KG-G---- 
C37.42         ---IV-G--- N----L---- --S------V --I--..... ..R------- ---GI----- 
C38.22         ---------- ---------- --LLS----- -----H---K --RL------ ------L---  300 
 
CONSENSUS_C    LELKKSAISL LDTIAIAVAE GTDRIIELIQ RICRAIRNIP RRIRQGFEAA LQ 
C27.b          ---------- -------T-- ------DF-R -FF-G-C--- ---------- -- 
C38.d          ---------- F--V------ -------A-I -T----C--- T-----L--- -- 
C38.g          ---------- F--------- -------A-I -T----C--- T-----L--- -- 
C37.42         ---------- -------T-- ------DF-R -F--G-C--- ---------- -- 
C38.22         Q--------- ---T-----G -------VVL --G---Y--- ------L-R- -L  300 
 
 
Figure  3-4.  Amino  acid  alignments  of  the  gp41  sequence  from  the  gp160 
envelope clones. 
The  amino  acid  sequence  of  the  gp41  portions  from the subtype  C  gp160  envelope  clones  were 
aligned  together  with  the  consensus  C  sequence  obtained  from  the  LANL  HIV  database  using 
ClustalW2. The underlined sequences denote the MPER of gp41 containing the equivalent of the 2F5 
and 4E10 epitope. The 2F5 epitope is missing in the subtype C sequences, whereas the 4E10 epitope 
is present.  
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Table 3-3. Genbank accession numbers, number of PNLG sites, and number of 
amino acids in variable loops 
Virus 
Clone
1 
Genbank 
accession 
number 
No. of N-linked 
glycosylation sites 
No. of amino acids in variable loops 
V1  V2  V3  V4  V5 
Consensus_C    25  17  38  35  22  7 
CA6  FJ977089  26  25  42  35  33  9 
CB7  FJ977090  23  16  41  35  25  10 
C202  FJ977078  23  28  42  35  32  12 
C222  FJ977079  26  30  50  35  30  12 
C250  FJ977080  27  25  42  35  27  9 
C261  FJ977081  28  28  50  35  31  9 
C27.b*  FJ977091  29  33  47  35  29  10 
C281  FJ977082  27  25  40  35  27  13 
C291  FJ977083  28  28  46  35  31  9 
C344  FJ977084  26  29  38  35  26  9 
C351  FJ977085  27  21  47  35  26  10 
C361  FJ977086  23  28  37  35  26  10 
C37.42*  FJ977094  30  33  47  35  29  10 
C381  FJ977087  28  24  41  35  30  12 
C38.d*  FJ977092  28  25  38  35  27  7 
C38.g*  FJ977093  27  25  39  35  27  10 
C38.22*  FJ977095  28  24  41  35  30  12 
C391  FJ977088  27  21  47  35  26  10 
               
Mean    26.7  25.8  43.4  35.0  28.6  10.2 
               
1  Replication-competent  molecular  clone  containing  gp120,  or  gp160  (indicted  with  asterisk,  *), 
cloned directly from patient plasma and inserted into an HIV-1HXB2, or HIV-1NL4.3 (*), based vector. 
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3.6  Phylogenetic studies of cloned gp120 envelopes 
The amino acid sequences of the cloned envelopes were compared with the subtype 
reference  alignments  on  the  LANL  HIV  database,  which  consist  of  at  least  4 
representative  strains  from  each  subtype  and  recombinants  in  the  M-group. 
Phylogenetic  studies of all the envelope  nucleotide  sequences confirmed that the 
newly isolated clones grouped within subtype C. Two reference subtype C strains, 
92BR025.8 from Brazil and SK164B1from South Africa (Gao et al., 1996; Kiepiela 
et al., 2004), clustered closely to our cloned sequences (Figure 3-5). 
A phylogenetic tree was then constructed using the GTR (General time reversible) 
PhyML algorithm (Guindon and Gascuel, 2003) with bootstrap replications of 1000. 
The tree was rooted with three subtype D strains (NDK, ELI and 94UG114) and is 
shown in Figure 3-6. In addition to the 18 viral env sequences used in this study, 
sequences from the subtype C reference panel were also included for comparison. 
Some  of  the  new  subtype  C  envelopes  clustered  closely  to  the  reference  panel, 
indicating close relationships. For example, C361, C222 and C381 were found to be 
quite  similar  to  ZM109F.PB4,  ZM135M.PL10a  and  ZM233M.PB6  respectively. 
However, a few strains were well separated from the reference panel. These are the 
C281 and C344 clusters, as well as isolates C261, C291, C351, and CB7. These 
isolates can be used as further strains in testing for the neutralisation breadth of a 
candidate antibody. In terms of geographical clustering, the isolates C281, C250 and 
CA6 were all from Scotland, UK and formed one cluster. The Nigerian isolate C38.d 
and C38g were also clustered together. However, 4 isolates from different regions 
were clustered together, and these were C27.b, C37.42, C351 and C391. 
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Figure  3-5.  Phylogenetic  clustering  of  the  cloned  gp120  envelopes  with  the 
subtype reference alignments.  
Phylogenetic  clustering  was  performed  together  with  the  subtype  reference  alignments  using  the 
Neighbour  Treemaker  function  on  the  LANL  HIV  database  website.  The  cloned  envelopes  were 
found  to  cluster  together  with  other  subtype  C  viruses  from  the  database.   
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Figure 3-6. Phylogenetic relationships of subtype C env clones. 
Newly  characterised  subtype  C  sequences  (with  a  C-prefix)  are  compared  with  the  subtype  C 
reference clones from Li et al. 2006. Horizontal branch lengths are drawn to scale (the scale bar 
represents  0.05  nucleotide  substitutions  per  site),  but  vertical  separation  is  for  clarity  only.  The 
phylogenetic tree was rooted with subtype D env sequences (NDK, ELI and 94UG114).  
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3.7  Titration of chimeric viruses and coreceptor usage 
The  chimeric  viruses  obtained  after  the  transfection  were  first  titrated  on  NP2 
indicator cell lines (Soda et al., 1999) that stably express CD4 and the coreceptor 
CCR5  (NP2/CD4/CCR5)  to  determine  the  infectivity  of  the  chimeric  viruses,  as 
described in Section 2.3.5. Infected NP2 cells were stained blue in a p24 β-gal assay, 
and these were counted under the light microscope. The titres of the virus stocks 
were then determined by calculating the focus-forming units (FFU) per ml of virus 
used and the results are shown in Table 3-4. The envelope clones C27d, C33.52, and 
C271  produced  chimeric  viruses  of  insufficient  titre  to  be  useful  in  further 
characterisations, and were not included in the table.  
To determine if the primary envelopes were able to use other coreceptors to enter the 
cells, the same virus stocks were then titrated on other NP2/CD4 cells expressing 
either CXCR4, CCR3, CCR8, or APJ. To determine if the chimeric viruses were 
coreceptor independent, they were also titrated on NP2/CD4 cells not expressing any 
coreceptor. The titre in FFU/ml were determined as above and shown in Table 3-4.  
All the 18 chimeric viruses were found to use CCR5 as the main coreceptor and were 
mostly mono-tropic. None of the cloned envelopes, except for C344, were able to 
use  CXCR4  efficiently.  The  envelope  clone  C344  was  multi-tropic  for 
R3/X4/R4/R8. Three other virus clones; C261, C281 and C381, were dual-tropic for 
CCR5 and CCR3 usage. The virus clone C202 was the only virus, other than C344, 
to use CCR8 as a coreceptor. None of the virus clones was found to use APJ as a 
coreceptor.  
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Table 3-4. Coreceptor usage of envelope clones 
Virus clone
1 
Infectivity (x 10
3 FFU/ml) for NP2/CD4 
Classification
2 
% CCR3 
usage 
compared 
to CCR5  CCR5  CXCR4  CCR3  CCR8  APJ 
 
                 
CA6  31  -
3  0.2  nt
4  nt    R5  0.6 
CB7  1,800  -  10  nt  nt    R5  0.6 
C202  32  0.4  2  5.5  -    R5/R8  6.3 
C222   2,100  0.1  1.6  3.2  -    R5  0.08 
C250  73  1.5  4.1  4.1  -    R5  5.6 
C261  21  0.8  2.5  0.7  -    R5/R3  12 
C27.b*  2,800  -  21  1.0  -    R5  0.8 
C281  300  0.5  95  1.9  0.3    R5/R3  32 
C291  1,100  0.5  15  1.6  0.2    R5  1.4 
C344  38  7.6  11  9.2  0.7    R5/X4/R3/R8  29 
C351  1,200  0.4  34  1.5  0.4    R5  2.8 
C361  43  0.7  2.4  1.5  0.2    R5  5.6 
C37.42*  3  -  -  -  -    R5  0 
C381  7.7  0.5  1.0  0.6  0.3    R5/R3  13 
C38.d*  6.7  -  -  -  -    R5  0 
C38.g*  12  -  0.6  -  -    R5  5.0 
C38.22*  500  -  9.8  nt  nt    R5  2.0 
C391  4,100  0.5  230  2.0  0.2    R5  5.6 
       
Median      3.9 
1  Replication-competent  molecular  clone  containing  gp120,  or  gp160  (indicted  with  asterisk,  *), 
cloned directly from patient plasma and inserted into an HIV-1HXB2, or HIV-1NL4.3 (*), based vector. 
2 Viruses were classified as dual- (or multi-)-tropic if their titre on alternative coreceptors were within 
1 log10 of the titre obtained on the dominant coreceptor line. 
3 -, <100 (FFU/ml). 
4 nt, not tested. 
 
The median percentage of CCR3 usage compared to CCR5 was 3.9% in this study of 
18 cloned subtype C viruses. It was observed that the proportion of viruses that were 
able to use both CCR3 and CCR5 were lower in this study of subtype C envelopes, 
compared  to  the  previous  findings  on  subtype  B  envelopes  where  >70%  of  the 
viruses  tested  were  able  to  use  CCR3  efficiently  (Aasa-Chapman  et  al.,  2006a). 
Other groups have also reported high CCR3 usage for subtype B viruses (Agrawal et  
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al., 2009; Peters et al., 2004). This may indicate a different pattern of coreceptor 
usage between different subtypes of HIV-1.  
To investigate this further, the CCR3 usage patterns in subtypes B and C envelope 
reference panels (Li et al., 2005; Li et al., 2006b) were similarly studied. The median 
value of CCR3 usage compared to CCR5 in the panel of 11 subtype B envelopes was 
9.8%, compared to a much lower median value of 0.05% in the panel of 12 subtype 
C envelopes (Table 3-5 and Table 3-6). The median values for the CRF07_BC and 
CRF02_AG reference strains panels were 0.18% and 0.53% respectively (Table 3-7 
and Table 3-8). Therefore, CCR3 usage in subtype B viruses appears to be higher 
than  in  other  subtypes.  A  student’s  t-test  performed  on  the  data  confirmed  that 
viruses in the subtype B reference strain panels had a significantly higher usage of 
CCR3 compared to CCR5 than the viruses in the subtype C reference strain panel, 
with a p value of 0.015. 
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Table 3-5. CCR3 use by the Tier 2 subtype B reference strain panel of gp160 
clones
1 
Virus  Source
2 
Infectivity (x 10
3 FFU/ml) for 
NP2/CD4 
% CCR3 usage 
compared to 
CCR5  CCR5  CCR3 
         
6535.3  ccPBMC  645  93  14 
QH0692.42  ccPBMC  7,050  290  4.1 
SC422661.8  plasma  2,350  230  9.8 
PVO.4  ccPBMC  2,165  145  6.7 
TRO.11  ccPBMC  149  23  16 
AC10.0.29  ccPBMC  135  110  81 
RHPA4259.7  plasma  1,550  305  19.7 
REJO4541.67  plasma  860  7.8  0.9 
TRJO4551.58  plasma  2,150  4.5  0.2 
WITO4160.33  plasma  149  23  15 
CAAN5342.A2  plasma  1,635  28  1.7 
         
Median
3        9.8 (0.2-81) 
         
 
1Li et al. (2005) Human immunodeficiency virus type 1 env clones from acute and early subtype B 
infections  for  standardized  assessments  of  vaccine-elicited  neutralizing  antibodies.  J.  Virol., 
79:10108-25. 
2ccPBMC, co-cultured PBMC. 
3Median level of CCR3 usage (and range) in percentage (%) for the panel. 
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Table 3-6. CCR3 use by the Tier 2 African subtype C reference strain panel of 
gp160 clones
1 
Virus  Source
2 
Infectivity (x 10
3 FFU/ml) for 
NP2/CD4 
% CCR3 usage 
compared to 
CCR5  CCR5  CCR3 
         
Du156.12  ccPBMC  640  0.14  0.02 
Du172.17  ccPBMC  95  0.06  0.06 
Du422.1  ccPBMC  1,685  0.16  0.01 
ZM197M.PB7  ucPBMC  38  0.02  0.05 
ZM214M.PL15  plasma  7,050  43  0.61 
ZM233.PB6  ucPBMC  410  0.05  0.01 
ZM249M.PL1  plasma  89  0.18  0.20 
ZM53M.PB12  ucPBMC  735  0.37  0.05 
ZM109F.PB4  ucPBMC  2,745  10.8  0.39 
ZM135M.PL10a  plasma  625  0.13  0.02 
CAP45.2.00.G3  plasma  15  0.01  0.07 
CAP210.2.00.E8  plasma  198  0.02  0.01 
         
Median
3        0.05 (0.01-0.61) 
         
 
1Li et al. (2006) Genetic and neutralization properties of subtype C human immunodeficiency virus 
type  1  molecular env  clones  from  acute  and  early  heterosexually  acquired  infections  in  southern 
Africa. J. Virol., 80:11776-90. 
2ccPBMC, co-cultured PBMC; ucPBMC, uncultured PBMC. 
3Median level of CCR3 usage (and range) in percentage (%) for the panel. 
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Table 3-7. CCR3 use by the Tier 2 CRF07_BC reference strain panel of gp160 
clones
1 
Virus  Source
2 
Infectivity (x 10
3 FFU/ml) for 
NP2/CD4 
% CCR3 usage 
compared to 
CCR5  CCR5  CCR3 
         
CH038.12  ccPBMC  9,125  116  1.3 
CH064.20  ccPBMC  1,150  0.18  0.02 
CH070.1  ccPBMC  17,400  61  0.35 
CH091.9  ccPBMC  4,550  5.9  0.13 
CH110.2  ccPBMC  3,100  3.9  0.13 
CH111.8  ccPBMC  0.40  0.03  7.5 
CH181.12  ccPBMC  1,505  0.21  0.01 
CH120.6  ccPBMC  1,380  7.7  0.56 
CH119.10  ccPBMC  3,100  23  0.74 
CH117.4  ccPBMC  1,420  1.5  0.10 
CH115.12  ccPBMC  2,485  0.04  0.002 
CH114.8  ccPBMC  215  0.50  0.23 
         
Median
3        0.18 (0.002-7.5) 
         
 
1Registry of Molecularly Cloned HIV-1, SIV and SHIV gp160 Genes for Use as Env-Pseudotyped 
Viruses  in  Neutralizing  Antibody  assays  (http://www.hiv.lanl.gov/content/nab-reference-
strains/html/home.htm 
2ccPBMC, co-cultured PBMC. 
3Median level of CCR3 usage (and range) in percentage (%) for the panel. 
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Table 3-8. CCR3 use by the Tier 2 CRF02_AG reference strain panel of gp160 
clones
1 
 
Virus  Source
2 
Infectivity (x 10
3 FFU/ml) for 
NP2/CD4 
% CCR3 usage 
compared to 
CCR5  CCR5  CCR3 
         
T257-31  ccPBMC  1,505  6  0.40 
928-28  ccPBMC  55  0  0 
271-11  ccPBMC  131  5.9  4.5 
T33-7  ccPBMC  383  14  3.7 
263-8  ccPBMC  110  26  26 
T250-4  ccPBMC  240  0.02  0.008 
T251-18  ccPBMC  1,025  30  2.9 
T278-50  ccPBMC  748  0.56  0.07 
T255-34  ccPBMC  12  0.01  0.08 
235-47  ccPBMC  7.5  0.04  0.53 
266-60  ccPBMC  490  4.2  0.86 
         
Median
3        0.53 (0-26) 
         
 
1Registry of Molecularly Cloned HIV-1, SIV and SHIV gp160 Genes for Use as Env-Pseudotyped 
Viruses  in  Neutralizing  Antibody  assays  (http://www.hiv.lanl.gov/content/nab-reference-
strains/html/home.htm 
2ccPBMC, co-cultured PBMC. 
3Median level of CCR3 usage (and range) in percentage (%) for the panel. 
 
 
Three amino acid residues were found to be linked to the use of CCR3 as a co-
receptor  by  subtype  B  envelopes  (Aasa-Chapman  et  al.,  2006b).  These  were 
asparagine  N356,  arginine/serine  R/S440  and  asparagine  N448  (numbering 
according to HXB2 sequence, and these positions are shaded in Figure 3-3). The two 
asparagine positions are PNLG sites, and if removed, the viruses were found to be 
mono-tropic for CCR5. The four CCR3-using subtype C envelopes (C261, C281,  
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C344, and C381) contain both PNLG sites, except for C381 which possess only the 
latter PNLG site (N448). Interestingly, none of the subtype C envelopes tested in this 
study possess either an arginine or serine in position 440. The subtype C virus clones 
tested here do not follow the rules that were previously determined for subtype B 
viruses  (Aasa-Chapman  et  al.,  2006b).  Other  determinants  must  therefore  be 
involved in CCR3 coreceptor usage in subtype C viruses.  
3.8  Neutralisation phenotype of cloned envelopes 
The  18  cloned  replication-competent  subtype  C  viruses  were  tested  for  their 
neutralization  sensitivity  to  four  well-established  bcnAbs,  and  to  soluble  CD4 
(sCD4). The bcnAbs tested were the mAbs b12 and 2G12 which target the CD4 
binding site and the glycan shield of gp120 respectively, and mAbs 2F5 and 4E10 
which  recognize  adjacent  epitopes  in  the  membrane-proximal  external  region  of 
gp41 (Muster et al., 1993; Purtscher et al., 1994; Sanders et al., 2002a; Scanlan et al., 
2002; Stiegler et al., 2001; Trkola et al., 1996b; Zhou et al., 2007; Zwick et al., 
2001). Only gp160 subtype C cloned viruses were tested for sensitivity to 2F5 and 
4E10. The cloned viruses were also tested for their sensitivity to two different patient 
serum samples and an uninfected normal human serum (NHS) as negative control. 
These neutralisation assays were tested on TZM-bl cells using the luciferase assay as 
described in Section 2.3.9. The maximum concentration of antibody tested was 50 
µg/ml and a 1:10 dilution for serum samples. Two subtype B lab-adapted strains 
(NL4.3  and  MN)  and  a  sensitive  Tier-1  subtype  C  strain  (93MW965.26)  were 
included for comparison. The relative light units (RLU) from the luciferase assay 
were measured in a luminometer. The percentage of RLU in test wells compared to 
in virus only control wells (after subtraction of background luminescence) was used 
to determine the inhibitory effects of the antibody or serum, and this was then plotted  
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against the concentration of the antibody or dilution of the serum used. These graphs 
are shown in Figure 3-7. The inhibitory concentration of antibody required to cause 
50% neutralisation of the virus (IC50) are listed Table 3-9. 
3.8.1  Neutralisation by soluble CD4 
The  sensitivity  of  the  chimeric  viruses  to  neutralisation  by  sCD4  was  tested  to 
understand the conformational traits of the CD4 binding site of the cloned envelopes. 
This  is  important  for  Chapter  5  where  some  of  these  viruses  were  tested  for 
sensitivity to VHH that targets the CD4bs.  
The results showed that many of the cloned viruses were sensitive to inhibition by 
sCD4 alone, with only 3 of the cloned viruses (CA6, C281, and C38.g) not inhibited 
at 50 µg/ml of sCD4, suggesting some form of epitope exposure in and around the 
CD4 binding site of gp120 in the sensitive isolates. Resistance to neutralisation by 
sCD4 have been observed among primary isolates (Daar et al., 1990; Pugach et al., 
2004). Out of these 3 viruses, only CA6 was sensitive to b12 neutralisation, which 
suggest conformational differences around the CD4 binding site. The mAb b12 was 
able  to  neutralise  only  6  of  the  viruses  at  50  µg/ml.  The  virus  clone  C351  was 
particularly sensitive to b12, with IC50 value of <0.02 µg/ml. This is significantly 
more  sensitive  to  the  other  viruses  in  the  subtype  B  and  C  reference  panels. 
Interestingly, llama antibody fragments that target the CD4 binding site were able to 
neutralise 3 isolates (C38.22, C222, and C261) which were not neutralised by b12 
(Forsman et al., 2008).  
3.8.2  Neutralisation by monoclonal antibodies 
The  cloned  viruses  were  resistant  to  neutralisation  by  the  glycan-specific  2G12, 
except  for  C38.g.  Similar  broad  resistance  to  2G12  has  been  reported  for  other  
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subtype C viruses (Binley et al., 2004; Gray et al., 2006). The cloned viruses were 
insensitive to the mAb 2F5, due to the absence of the DKW motif on subtype C 
viruses. The mAb 4E10 was able to neutralise all the subtype C cloned envelope 
viruses tested. None of the viruses contain the NWFNIT epitope previously thought 
to be required for 4E10 recognition (Zwick et al., 2001), although they all contain 
the WFXI motif that has been reported to be essential for recognition (Binley et al., 
2004; Li et al., 2005).  
When compared to the neutralisation results obtained with the subtype C reference 
panels (Li et al., 2006b), the sensitivity of the subtype C reference envelopes with 
2G12  and  2F5  were  similar  to the  cloned  subtype  C  envelopes  in  this  study.  In 
contrast, all the subtype C viruses in the reference panel were neutralised by sCD4, 
and a higher proportion were neutralised by b12, compared to the lower sensitivity to 
both sCD4 and b12 by the viruses created in this study. In addition, the geometric 
mean titre (GMT) of 7.6 µg/ml  for the  mAb 4E10 was 7 times higher than that 
obtained in the subtype C reference panels. The viruses obtained in this study were 
therefore slightly more resistant to neutralisation than those in the Li et al. subtype C 
standard reference panel (Li et al., 2006b).  
3.8.3  Neutralisation by human serum samples 
The subtype C viruses in this study were also tested on two serum samples (QC1 and 
QC2) obtained from chronic subtype B HIV-1 patients, together with a serum pool 
from uninfected individuals. These results were compared with the two subtype B 
lab adapted strains (NL4.3 and MN), and a Tier-1 subtype C isolate (93MW965.26). 
All the cloned viruses in this study were broadly sensitive to QC1, and 11 of the 18 
viruses were sensitive to QC2. Most of the cloned viruses were less sensitive than  
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93MW965.26 to neutralisation by the sera. From the results, some of the viruses 
tested were clearly more sensitive than others, and they can be grouped according to 
their sensitivity to the QC sera. The viruses C261, C291, C344, C351, C361, C381 
and C391 were highly sensitive and easily neutralised by high dilutions of QC sera. 
These have similar sensitivity to 93MW965.26, and more sensitive than MN and 
NL4.3 and can  be  classified together with the easily  neutralised  “Tier-1”  viruses 
(Mascola et al., 2005). In contrast, the less sensitive virus clones CA6, CB7, C27.b, 
C37.42,  C38.d,  C38.g,  and  C38.22  require  high  concentrations  of  QC1  to  be 
neutralised, and were not neutralised by QC2.  These are a 100-fold less sensitive 
than 93MW965.26 and 10-fold  less  sensitive than  MN and NL4.3, and they  can 
therefore be classified as “Tier-2” viruses (Mascola et al., 2005).  
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Figure 3-7. (cont. on next page) 
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Figure  3-7.  sCD4,  mAb  and  serum 
neutralisation  of  subtype  C  cloned 
viruses in TZM-bl cells.  
The percentage of RLU in test wells compared 
to virus only control wells (after subtraction of 
background  luminescence)  was  determined. 
Data points represent the mean and error bars 
the  standard  error.  All  cloned  viruses  were 
tested for neutralisation by sCD4, b12 and 2G12 
(left  panels),  in  addition  to  2  different  patient 
plasma  serum  (QC1  and  QC2)  and  infected 
normal  human  serum  (NHS;  right  panels). 
Cloned gp160 viruses were tested with 2F5 and 
4E10 as well.  
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Table 3-9. Neutralisation profiles 
  IC50 in TZM-bl cells
b 
  Conc. (µg/ml)    Reciprocal serum dilution 
                   
Virus clone
a  sCD4  IgG1b12  2G12  2F5  4E10    QC1  QC2  Normal 
pool 
                   
NL4.3  0.15  0.02  1.9  0.8  2.3    517  84  <10 
MN  nd  nd  nd  nd  nd    345  169  <10 
93MW965.26  nd  nd  nd  nd  nd    13,723  1,590  10 
                   
CA6  >50  6.2  >50  nd  nd    76  <10  14 
CB7  1.0  0.19  >50  nd  nd    86  <10  <10 
C202  5.3  >50  >50  nd  nd    301  115  11 
C222   1.1  >50  >50  nd  nd    370  65  <10 
C250  32  1.8  >50  nd  nd    528  382  24 
C261  1.1  >50  >50  nd  nd    5,667  665  12 
C27.b*  1.5  19  >50  >50  8.2    12  <10  <10 
C281  >50  >50  >50  nd  nd    216  38  21 
C291  0.5  >50  >50  nd  nd    6,166  1,650  19 
C344  25  >50  >50  nd  nd    3,798  1,103  22 
C351  2.3  <0.02  >50  nd  nd    2,147  358  16 
C361  0.49  >50  >50  nd  nd    12,204  2,251  18 
C37.42*  6.9  43  >50  >50  11    13  <10  <10 
C381  0.32  >50  >50  nd  nd    9,410  1,187  <10 
C38.d*  9.3  >50  25  >50  4.0    99  19  11 
C38.g*  >50  >50  >50  >50  7.7    44  <10  11 
C38.22*  29  >50  >50  >50  7.5    32  <10  <10 
C391  2.3  >50  >50  nd  nd    1,146  180  14 
                   
GMT
c  5.3      >50  7.6    301  65  11 
                   
a Clones marked with an asterisk are gp160 env clones 
b  Neutralisation  values  are  the  concentration  or  dilution  at  which  RLU  were  reduced  by  50% 
compared to virus control wells. QC1 and QC2 are serum samples from individuals infected with 
subtype B HIV-1. 
c Geometric mean titre against the 18 replication competent subtype C  viruses containing cloned 
primary isolate Env. 
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3.9  Discussion  
3.9.1  Genotype of cloned subtype C envelopes 
The sequences of the cloned subtype C envelopes showed variations in the lengths of 
the variable loop regions, as well as variations in the positions and number of PNLG 
sites,  thus  demonstrating  the  heterogeneity  of  these  cloned  subtype  C  envelopes. 
Variations  in  these  regions  have  been  shown  to  mask  epitopes  and  influence 
neutralisation patterns (Cao et al., 1997; Reitter et al., 1998; Wei et al., 2003; Wyatt 
et al., 1995). In this study sample, the V3 loop was relatively conserved, followed by 
a region of 34 amino acids downstream that was highly variable. This is similar to 
other  observations  on  newly  transmitted  subtype  C  and  R5  subtype  B  viruses 
(Engelbrecht  et  al.,  2001;  Milich  et  al.,  1997;  Ping  et  al.,  1999).    As  with  Li’s 
subtype C envelope reference panel, all the viruses in this study contain a highly 
conserved PNLG near the start of the V3 loop (position 301, HXB2 numbering) that 
is known to mask V3 epitopes on subtype B viruses (Back et al., 1994; Schonning et 
al., 1996). Based on the phylogenetic studies, many of the cloned viruses in this 
study clustered into separate groups from those in the subtype C reference strain 
panel.  
3.9.2  Coreceptor usage of cloned subtype C envelopes 
All the subtype C envelopes in this study used CCR5 as a coreceptor, as is typical of 
newly  transmitted  subtype  B  and  C  viruses  regardless  of  the  stage  of  infection 
(Cecilia  et  al.,  2000;  Connor  et  al.,  1997b;  Li  et  al.,  2006a;  Ping  et  al.,  1999; 
Williamson et al., 2003; Zhang et al., 1993). Previous findings had shown that CCR3 
usage  is  prevalent  in  in  vivo  replicating  samples;  such  as  brain  tissue  samples 
(Agrawal et al., 2009; He et al., 1997; Peters et al., 2004), but was diminished after  
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PBMC coculture (Aasa-Chapman et al., 2006a). The panel of subtype C envelopes 
which were cloned directly from plasma samples in this study had a median CCR3 
usage of 3.9%, compared to a median of 0.05% in the subtype C reference panel that 
were  cloned  from  a  mixture  of  plasma,  uncultured  and  cocultured  PBMC.  This 
observation has therefore validated our previous findings with regards to diminished 
CCR3 usage in PBMC cocultures. 
All previous studies on CCR3 usage were performed predominantly on subtype B 
isolates. Coreceptor use was found to be dependent on the third variable (V3) region 
of gp120 (Choe et al., 1996), and the determinants were mapped to three residues on 
gp120 (Aasa-Chapman et al., 2006b). However, the R3/R5 subtype C viruses in this 
study did not possess all the requisite amino acid residues needed for CCR3 use. 
R3/R5  subtype  C  viruses  possibly  possess  a  different  conformational  pattern  for 
coreceptor binding compared to subtype B viruses. 
In these subtype C patient samples, we observed that CCR3 usage is much lower 
than previous studies performed on subtype B samples. To corroborate this finding, 
the CCR3 usage of the envelopes in the subtype B, C, CRF07_BC and CRF02_AG 
standard reference panels was investigated. The use of CCR3 as a coreceptor to enter 
cells  was  100-fold  more  in  subtype  B  envelopes  than  in  the  other  subtypes  and 
recombinant forms. The reasons as to why subtype B envelopes are more prone to 
use CCR3 as a coreceptor than other subtypes should be further investigated, and the 
amino acid residues required for CCR3 usage can be determined in future studies. 
These results may have implications in the development of CCR5 entry inhibitors 
and provide insight into alternative entry pathways for each HIV- subtype.  
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While a  manuscript was  being prepared with the results of this chapter, a paper 
describing very similar results was very recently published. Nedellec et al. reported 
identical results where they found increased CCR3 usage in subtype B viruses, and 
lower incidence of CCR3 usage in subtypes A, C and D viruses (Nedellec et al., 
2009).  They  have  also  used  the  NP2  cell  assay  to  determine  coreceptor  usage. 
However, instead of cloning HIV-1 envelopes into replication competent chimeric 
viruses, they have used pseudotyped viruses.   
3.9.3  Neutralisation profile of cloned subtype C envelopes 
The  neutralisation profile of the subtype  C  viruses  in this  study  is slightly  more 
resistant to neutralisation by the sCD4 and the common bcnAbs than Li’s subtype C 
reference panel. For example, the IC50 GMT titre with the mAb 4E10 was nearly a 
10-fold higher for the viruses in this study. Li et al. (Li et al., 2006b) noted a trend in 
which HIV-1 envelopes cloned from cocultured PBMC viruses were more sensitive 
than those cloned from plasma viruses. None of the cloned viruses in this study was 
obtained from PBMC cultures. The envelopes in this study were all cloned directly 
from patient plasma samples and can be classified as Tier-2 viruses as they were 
more resistant to neutralisation by antibodies (Mascola et al., 2005).  
Although  some  of  the  isolates  in  this  study  were  phylogenetically  similar  to the 
subtype C reference panels, a few of them (in particular C261, C291, C351, and 
CB7) clustered into distinct groups. These isolates can be used as further strains for 
use  in  testing  the  neutralisation  breadth  of  a  candidate  antibody  or  for  vaccine 
studies, and were used in our studies on llama antibody fragments (termed VHH) 
which target the CD4 binding site of gp120 (Forsman et al., 2008) and also in the 
investigation of the neutralisation breadth of serum samples in East London patients.   
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3.9.4  Summary 
In summary, the env genes were amplified from 15 patients with subtype C HIV-1 
from  a  few  countries  in  Africa  and  in  the  UK.  These  were  inserted  into  HIV-1 
vectors to create replication-competent viruses, and 18 of these were characterised 
here. Some of the chimeric viruses in this study were more resistant to neutralisation 
and  were  phylogenetically  distinct  from  Li’s  subtype  C  reference  panel.  These 
cloned subtype C viruses are therefore useful to supplement the standard reference 
strains  for  use  in  characterising  the  neutralisation  potency  of  antibodies.  These 
viruses were used to study the neutralisation breadth of VHH in Chapter 5. This is 
also the first study on CCR3 usage by subtype C viruses. The use of CCR3 as a 
coreceptor was found to be less prevalent in subtype C viruses, and indeed in the 
other subtype reference panels, than  in the commonly  studied  subtype  B strains. 
Even in cases where CCR3 use was determined, the required amino acid residues 
required for CCR3 interaction differed from those for subtype B envelopes.  
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4  Anti-gp41 VHH 
4.1  Introduction 
Of the four broadly cross-neutralising monoclonal antibodies (bcnAbs) described to 
date, two of them target the gp41 portion of the HIV-1 envelope glycoprotein (refer 
to Introduction in Section 1.2.4.2). These are the human mAbs 2F5 and 4E10, which 
were generated from individuals naturally infected with a subtype B HIV-1 strain 
(Buchacher et al., 1994; Muster et al., 1993; Stiegler et al., 2001; Zwick et al., 2001). 
While  4E10  is  able  to  neutralise  most  subtype  C  strains  of  HIV-1,  2F5  is  often 
ineffective against subtype C HIV-1 as it lacked an epitope on the MPER of subtype 
C gp41 (Li et al., 2006b). This finding is confirmed by the results as detailed in 
Chapter 3. The gp41 portion is also more conserved than gp120, possibly making 
gp41  a  better  target  than  gp120  when  it  comes  to  generating  broad  neutralising 
antibodies, although such instances have been extremely rare (refer to Section 1.2.4). 
As subtype C HIV-1 accounts for more than half of the infections in the world and is 
currently infecting more people than any other subtype (Hemelaar et al., 2006), there 
is a need to focus on generating and characterising neutralising antibodies that are 
effective against subtype C HIV-1.  
Although the bcnAbs described to date were all obtained from HIV-1 infection in 
humans, rather than from immunisation (Pantophlet and Burton, 2006), we decided 
to exploit the non-conventional immune system of the camelids to generate novel 
antibodies against a subtype C envelope. Camelid VHH are small in size (about 15 
kDa), have a preference  for cleft recognition due to their  long protruding CDR3 
loops (De Genst et al., 2006; Vu et al., 1997), and are easily expressed  in  large 
quantities using yeast cultures (van de Laar et al., 2007). These qualities make VHH  
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a  good  candidate  for  use  as  a  microbicide  (refer  to  Chapter  1  for  detailed 
introduction). 
This chapter will describe the selection of anti-gp41 VHH  isolated  from a  llama 
immunised with recombinant trimeric CN54 gp140 derived from a subtype C HIV-1. 
The  selection of  anti-gp120 VHH  from the same  llama was performed  by  Anna 
Forsman  and  described  elsewhere  (Forsman  et  al,  2008).  The  anti-gp41  VHH 
isolated in this study were then characterised for their ability to neutralise HIV-1 and 
an attempt at epitope mapping was made.  
4.2  Llama 48 immunisation and phage library construction 
The work described in this section was undertaken by staff at Ablynx NV, Ghent, 
Belgium. Llama immunisations were carried out as part of the European Microbicide 
Project (EMPRO). One llama (L48) was immunised with recombinant gp140 from 
the HIV-1 CN54 strain, which is a subtype B’/C recombinant (CRF07_BC) that was 
originally isolated in China, which is entirely subtype C in envelope apart from the 
very N-terminus (Rodenburg et al., 2001; Su et al., 2000). This strain was chosen as 
the immunogen as it was a non-subtype B virus and the recombinant glycoprotein 
(Chen et al., 2005b) was available in large amounts within the EMPRO consortium.  
The llama received six intramuscular injections at weekly intervals (as described in 
Section 2.6.1). The humoral immune response was evaluated in ELISA on gp120 or 
gp140 coated plates, using serum samples from day 0 and 43 post immunisation, and 
shown  in  Figure  4-1.  The  ELISA  showed  the  presence  of  anti-HIV-1  envelope 
antibodies  in  the  llamas,  thus  indicating  successful  immunisation.  The  immune 
response  against  gp140  was  almost  twice  as  high  as  gp120,  indicating  a  robust 
recognition of the gp41 region.   
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Figure 4-1. Anti-envelope antibody response in llama 48.  
Llama  48  (L48)  was  immunised  with  recombinant  CN54  gp140,  which  was  introduced 
intramuscularly in 6 weekly doses. Blood samples were taken on days 0 and 43 post-immunisation 
and the serum anti-gp120 and anti-gp140 response was evaluated in ELISA on solid-phase CN54 
gp120 and CN54 gp140. The immune response against gp140 was almost twice as much than in 
gp120, indicating a robust recognition of the gp41 region.  
 
To  enable  the  recovery  of  VHH  repertoires  of  extensive  diversity,  B  cells  were 
isolated  from  both  blood  and  lymph  nodes  from  the  immunised  llamas.  Blood 
samples were collected at day 39 and 43 post immunisation. In addition, a lymph 
node biopsy was taken  at day 39.  For each  llama, total RNA was  isolated  from 
peripheral blood lymphocytes as well as lymph node lymphocytes, and subsequently 
pooled.  Oligo  dT-primed  cDNA  was  synthesised  and  the  VHH  repertoire  was 
amplified and cloned into the pAX050 phagemid vector, followed by transformation 
into E. coli TG1 cells. The library derived from llama 48 was found to contain 1.4 × 
10
7 clones, and 62% were found to contain an insert of the correct size. To obtain 
recombinant bacteriophages expressing the VHH as fusion proteins with the phage 
gene III product, the transformed TG1 cells were grown to logarithmic phase and 
then  infected with  helper phage  M13KO7. The  phage particles were precipitated 
with polyethylene glycol to remove free VHH.  
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4.3  Characterisation  of  recombinant  gp41  and  gp41Δ  with 
monoclonal antibodies 
The recombinant gp41 and gp41∆ used in this study were obtained from BioDesign, 
Inc  and  the  Centralised  Facility  for  AIDS  Reagents  (CFAR)  respectively.  The 
recombinant gp41 was made from constructs based on IIIB HIV-1 (subtype B) and 
contains the full length gp41 sequence, whereas recombinant gp41∆ was made from 
MN  HIV-1  (subtype  B)  and  contains  only  the  ectodomain  region  of  gp41.  Both 
recombinant proteins are monomeric.  
To determine the integrity and presence of essential epitopes, these antigens were 
probed with  various  mAbs  in ELISAs. Most important of these were the  human 
mAbs 2F5 and 4E10, which were used during the panning process for the selection 
of VHH from the phage library (described in the next section). The other two human 
mAbs were 50-69D, which recognises a conformational dependent epitope on gp41, 
and  98-6D,  which  recognises  a  linear  epitope  (aa  644-663)  on  gp41.  The 
recombinant  proteins  were  coated  overnight  at  a  concentration  of  1  µg/ml,  and 
probed with serial dilutions of the mAbs. ELISAs were carried out as described in 
Section 2.4.13. The ELISA results are  shown  in  Figure 4-2, which confirms the 
presence of both the 2F5 and 4E10 epitopes on gp41 and gp41∆. Additionally, the 
mAbs 50-69D and 98-6D were able to bind to gp41, thus demonstrating that the 
recombinant protein was properly folded.  
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Figure 4-2. Binding of mAbs 2F5, 4E10, 50-69D and 98-6D to gp41 and gp41∆ in 
ELISA 
Maxisorp plates were coated overnight with gp41 [A, C] and gp41∆ [B] at a concentration of 1 µg/ml, 
and probed with serially diluted mAbs 2F5, 4E10 [A, B] and 50-69D, 98-6D [C]. These were then 
detected  with an AP-conjugated goat anti-human IgG antibody. Chemiluminescence  was detected 
with  the  addition  of  substrate  and  luminescence  readings  (in  RLU)  were  normalised  to  readings 
obtained from blank control wells. The results showed that all 4 mAbs bind to gp41 and, 2F5 and 
4E10 bound to gp41∆ in a dose-dependent manner. The 2F5 and 4E10 epitopes were therefore present 
on the recombinant gp41, and the proteins were correctly folded.  
 
4.4  Panning for anti-gp41 VHH from phage libraries 
This section describes the panning  for anti-gp41 VHH using phage display. This 
process  was  divided  into  three  sections,  representing  three  different  strategies  to 
select for VHH that target gp41. The first method employed trypsin and glycine to  
172 
 
elute out all phages that bind to gp41. The second method employed the mAbs 2F5 
and 4E10 in competitive elution to dislodge phages that recognised the MPER of 
gp41. The final method involved the panning of phages that recognised the gp41 
portion of trimeric gp140, with the prior removal of phages that recognised gp120 by 
preincubating the phage library with gp120.  
4.4.1  Panning of phage libraries on gp41 with trypsin and glycine 
elutions 
VHH targeting gp41 of the HIV-1 envelope were selected by panning the phage 
library for 1 h on recombinant gp41, which were coated onto plates at concentrations 
of 5, 1, and 0.2 µg/ml. The full-length and truncated recombinant gp41s were used 
for selections. Blank control wells containing PBS only were also included. Bound 
phages were washed extensively with PBS to remove unspecific binding of phages, 
and the phages were eluted with either trypsin or glycine in parallel. Treatment with 
trypsin will elute out all phages bound to gp41 through the digestion of the gene III 
product, whilst treatment with glycine will elute out phages due to low pH changes. 
The eluted phages were harvested and titrated on E. coli TG1 cells. Selections where 
a larger number of clones were eluted out compared to blank control wells were 
taken forward to a second round of selections. In the second round of selections, only 
1 and 0.2 µg/ml concentrations of gp41 and gp41∆ were used. This was based on the 
results after the first round of selections where 5 µg/ml of antigen was found to 
produce  an  excessive  number  of  eluted  phages.  After  two  rounds  of  panning, 
selections where a dose-dependent enrichment of clones was observed were chosen 
and individual VHH were expressed. (Full methods described in Section 2.6.2)  
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Figure  4-3  shows  the  outcome  of  the  titration  after  the  selections  on  gp41  and 
gp41∆. In general, no correlation was observed between the number of clones eluted 
by trypsin or glycine, nor with the use of either gp41 or gp41∆. Selections where a 
larger number of clones were eluted compared to blank controls were taken forward 
to a second round of panning, as marked by the block arrows in Figure 4-3 [A]. 
These were all selected on 0.2 µg/ml of gp41 and gp41∆. Phages eluted in the blank 
controls were able to bind unspecifically to the wells and represent the background 
noise levels. The outputs from the trypsin and glycine elutions that were selected on 
gp41 and gp41∆ were combined (denoted with ‘Φ41a’ and ‘Φ41b’ respectively in 
Figure 4-3) and used in the first round of panning in the next section.  
The titration of the eluted phages after the second round of panning was similarly 
carried  out.  All  the  selections  again  gave  a  greater  number  of  eluted  phages 
compared to blank controls, as shown in Figure 4-3 [B]. Outputs from the 1 µg/ml 
gp41 and 0.2 µg/ml gp41∆ produced a good number of eluted phages and were 
brought forward to the next stage of picking and expression of individual clones.  
From each of the outputs, the eluted phage repertoires were allowed to infect E. coli 
TG1 cells and plasmids containing the VHH gene fragments were harvested through 
miniprep. The plasmids were digested with BstEII and SfiI and  inserted  into the 
pAX051  expression  vector  before  transforming  back  into  electrocompetent  TG1 
cells (refer to methods in Section 2.6.3). Ninety-six clones were picked from each 
output and the VHH harvested from the periplasmic fractions. The clones were also 
DNA fingerprinted with HinFI to determine the heterogeneity of the selected clones. 
This is shown in Figure 4-4. 
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Figure 4-3. Titrations of eluted phage after trypsin and glycine elutions  
The phage library was panned on immobilised gp41 and gp41∆ of different concentrations, and bound 
phages were eluted with either trypsin or glycine. In all cases, the number of phages eluted was higher 
than in the blank control wells. There was no visible difference between selections carried out on 
gp41 or gp41∆, nor elutions performed using either trypsin or glycine. [A] After the titration of eluted 
phages from the first round of selection, the outputs from the 0.2 µg/ml concentration was brought 
forward to a second round of panning, as shown by the block arrows. The phage outputs from both 
trypsin and glycine elutions on gp41 and gp41∆ (denoted with ‘Φ41a’ and ‘Φ41b’ respectively) were 
used in the first round of panning for the next section. [B] After the titration of eluted phages from the 
second round of selection, the outputs from the 1 µg/ml gp41 and 0.2 µg/ml gp41∆ were brought 
forward to the next stage for the picking and expression of individual clones. There was an error in 
the serial dilution of the outputs of 1 µg/ml gp41∆/glycine (bottom panel of [B]) which gave zero 
titres but the outputs of 0.2 µg/ml gp41∆/glycine were fine.  
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Figure 4-4. DNA fingerprint of selections from trypsin and glycine elutions 
The final outputs from the selections were subcloned into expression vectors for VHH production. 
Ninety-six different clones were picked for VHH expression, and their DNA was fingerprinted by 
digestion with HinFI. These were then separated on agarose gel electrophoresis and visualised. The 
heterogeneity of the band sizes show that the clones selected were fairly diverse. A representative 
sample of the digested clones is shown here. 
 
4.4.2  Panning of phage libraries on gp41 with competitive elution 
by the monoclonal antibodies 2F5 and 4E10 
In the previous section, all phages that bound to gp41 were eluted out with trypsin or 
glycine. In this section, selections using a similar setup were carried out, except that 
phages were eluted out with competitive elution by the human mAbs 2F5 and 4E10. 
A high concentration (100 µg/ml) of the mAbs was used to saturate the binding site 
on the gp41 antigen and potentially dislodge phages that recognise the MPER of 
gp41.  The  negative  (or  irrelevant)  control  used  was  the  human  mAb  Remicade, 
which is an anti-TNFα IgG1, also at a concentration of 100 µg/ml. As before, both 
gp41 and gp41∆ were used as the selecting antigens, but at concentrations of 1 and 
0.2 µg/ml for the first round of panning. In addition to the phage library from llama 
48, the  outputs  from  the  first  round of  selections  on  gp41  and  gp41∆  that  were 
obtained in the previous section (denoted with ‘Φ41a’ and ‘Φ41b’ in Figure 4-3) 
were also used as starting libraries. These libraries were enriched with phages that 
can bind to gp41 after one round of panning.  
As before, the eluted phages were harvested and titrated on E. coli TG1 cells. The 
titrations after the first round of selections are shown in Figure 4-5 [A]. The elutions 
with the original phage library from llama 48 gave better titrations than those phage  
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libraries obtained from the outputs of the previous selections (Φ41a and Φ41b), as a 
dose-dependent output could be seen. The indistinct titration results could be due to 
the  5-fold  dilutions  that  were  carried  out,  instead  of  the  10-fold  dilutions  used 
previously. The outputs of the selections on both gp41 and gp41∆ were similar and 
could  not  be  easily  differentiated,  although  there  was  a  slight  dose  dependent 
reduction in eluted phages from those selected from Φ41a and Φ41b. All the outputs 
from 0.2 µg/ml of gp41∆ were brought forward to the second round of panning, and 
the outputs from gp41 were discarded.  
Figure 4-5 [B] shows the titrations of the eluted phages from the second round of 
selections. As in the first round of panning, the eluted phages were indistinct from 
that obtained with Remicade as control. A dose dependent reduction in eluted phages 
corresponding  to  a  reduction  in  antigen  concentration  was  also  not  present. 
Nevertheless, the outputs from 0.2 µg/ml of gp41∆ were carried forward to the next 
stage of picking and expression of individual clones.  
As before, the eluted phage repertoires from each of the final outputs were allowed 
to infect E. coli TG1 cells and the plasmids containing the VHH gene fragments 
were harvested through miniprep. The plasmids were digested with BstEII and SfiI 
and  inserted  into  the  pAX051  expression  vector  before  transforming  back  into 
electrocompetent TG1 cells (refer to methods in Section 2.6.3). Ninety-six clones 
were picked  from each output and the VHH was harvested  from the periplasmic 
fractions.  The  clones  were  also  DNA  fingerprinted  with  HinFI  to  determine  the 
heterogeneity  of  the  selected  clones,  and  shown  in  Figure  4-6.  Compared  to the 
previous  selections,  VHH  obtained  from  2F5  and  4E10  elutions  were  less 
heterogeneous.   
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Figure 4-5.Titrations of eluted phage after 2F5 and 4E10 elutions 
The phage libraries from llama 48 and outputs, Φ41a and Φ41b from the previous selections, were 
used as inputs in the first round of panning on immobilised gp41 and gp41∆. Bound phages were 
eluted with 2F5, 4E10 and Remicade as control. In contrast to the previous selections, these selections 
using 2F5 and 4E10 gave high background levels with Remicade. A dose dependent dilution was also 
not distinct. [A] After the first round of selections, only elutions from 0.2 µg/ml of gp41∆ were 
carried forward to the second round of panning. [B] After the second round of selections, the elutions 
from 0.2 µg/ml of gp41∆ were brought forward to the next stage for the picking and expression of 
individual clones.   
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Figure 4-6. DNA fingerprint of selections from 2F5 and 4E10 elutions 
The final outputs from the selections were subcloned into expression vectors for VHH production. 
Ninety-six different clones were picked for VHH expression, and their DNA was fingerprinted by 
digestion with HinFI. These were then separated on agarose gel electrophoresis and visualised. The 
digested  fragments  show  only  slight  variations in the  band  sizes,  thus  suggesting  that  the  clones 
obtained  in  these  selections  were  less  diverse  than  those  obtained  in  the  previous  selections.  A 
representative sample of the digested clones is shown here. 
 
4.4.3  Panning  of  phage  libraries  on  CN54  gp140  with  gp120 
subtraction 
In this last method to select for anti-gp41 VHH, the phage library from llama 48 was 
allowed to incubate with immobilised CN54 gp140 (at a concentration of 0.5 µg/ml) 
on a plate. The phage library was first diluted 100- and 1000-fold to produce an 
optimal concentration of phages, and then allowed to preincubate with 10 µg/ml of 
CN54 gp120 for 1 h to mop up phages that recognise gp120 before putting onto the 
gp140 coated plates.  Another plate without gp120 preincubation was also run  in 
parallel. Blank control wells without gp140 were also included. The bound phages 
were  eluted  with  trypsin,  as  previous  experience  showed  that  this  gave  a  more 
complete eluate.  
The eluted phages were then titrated on TG1 cells as before. Figure 4-7 [A] shows 
the titration after the first round of selection. The number of eluted phages in the 
1/100 dilutions were more than those in the 1/1000 dilutions. However, they were 
not significantly more than the blank control wells and the presence of gp120 did not 
seem to affect the number of phages eluted. Nevertheless, the eluted phages from  
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both the 1/100 dilution with and without gp120 preincubation were moved to the 
second  round  of  panning.  For  consistency  in  the  second  round  of  panning,  the 
outputs from the panning without gp120 preincubation were also brought forward. 
Figure 4-7 [B] shows the titration after the second round of selection. There was a 
dose  dependent  reduction  in  the  number  of  eluted  phages  corresponding  to  the 
dilution factor of the input phage, but the background levels were still very high. The 
number  of  eluted  phages  between  those  with  gp120  preincubation  appear  to  be 
similar to those without gp120 preincubation. Both the outputs from the plate with 
gp120 preincubation were brought forward for picking and expression of individual 
clones.   
As before, 96 clones were picked from each output and the VHH were harvested 
from the periplasmic fractions. The clones were also DNA fingerprinted with HinFI 
to determine the heterogeneity of the selected clones, and shown in Figure 4-8. The 
selected clones appear to be fairly heterogeneous, according to the variation in sizes 
of the DNA bands.  
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Figure 4-7. Titrations of eluted phage after panning on gp140 
The  phage  library  (of  two  different  dilutions)  was  panned  on  immobilised  CN54  gp140  after 
preincubation with CN54 gp120. Phages bound to gp120 will not bind to gp140, thus leaving phages 
that recognise  gp41  to  bind  to  the immobilised  gp140.  [A]  After  the  first round  of  panning,  the 
number of eluted phages was less with an increase in dilution factor. However, background levels 
were high as seen in the blank wells. Phages eluted in the 100-fold dilution were brought forward to 
the next round. Phages eluted in the wells without gp120 preincubation were also brought forward in 
the second round of panning for consistency. [B] The results of the titration in the second round of 
panning were similar to the first round. There was a dose-dependent reduction in eluted phages, but 
background levels were also high. Elutions from the wells with gp120 preincubation were brought 
forward to the next stage of picking and expression of individual clones. 
 
 
 
 
 
Figure  4-8.  DNA  fingerprint  of  selections  from  gp140  panning  with  gp120 
subtraction 
The final outputs from the selections were subcloned into expression vectors for VHH production. 
Ninety-six different clones were picked for VHH expression, and their DNA was fingerprinted by 
digestion with HinFI. These were then separated on agarose gel electrophoresis and visualised. The 
digested fragments show slight variations in the band sizes, thus suggesting that the clones obtained in 
these selections were fairly heterogeneous. A representative sample of the digested clones is shown 
here. 
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4.4.4  Summary of anti-gp41 VHH selections 
From each selection output, 96 different clones were picked and grown in 96-well 
microtitre plates. A total of 10 different outputs were obtained after the selection 
process. The phage library expressing the VHH repertoire from llama 48 (ΦL48 in 
Figure 4-9) was the starting material for 8 of the selections, and 2 of the selections 
started off with the outputs from the first round of panning on gp41 (Φ41b in Figure 
4-9). Two of the selections were panned on gp140, and another 2 were panned on 
gp41. The rest of the 6 selections were panned on gp41∆. Six of the selections were 
eluted with either trypsin or glycine, whilst 4 of the selections were eluted by using 
2F5 and 4E10. A schematic overview of the whole selection process is shown in 
Figure 4-9.  
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Figure 4-9. Schematic showing the overview of the selection process 
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4.5  Screenings of the selected anti-gp41 VHH 
The 960 individual clones selected in the previous sections were grown overnight in 
E.  coli  TG1  cells  in  1  ml  of  medium  in  96  deep-well  plates.  For  each  clone, 
approximately 90 µl of E. coli periplasmic extract containing the expressed VHH 
was prepared and screened for its ability to bind to gp41 and to neutralise HIV-1. 
The methods are described in Section 2.6.3. 
4.5.1  Screening of anti-gp41 VHH in ELISA 
The first step in the screening of the selected anti-gp41 VHH was to test their ability 
to bind to gp41 in ELISA (full methods described in Section 2.4.13). These were 
assayed on plates precoated with gp41∆. As only a limited amount of periplasmic 
extract containing VHH was produced, there was enough material to carry out the 
ELISA only once, but in duplicate. Two µl of periplasmic extract from each clone 
was diluted  into 48 µl of PBS, and these were  introduced into each well of the 
maxisorp plate in duplicate. Each VHH clone was also tested in a blank control well 
which was precoated with only PBS. Bound VHH were detected with a mouse anti-
c-myc mAb, and then with an AP-conjugated goat anti-mouse IgG antibody. Chemi-
luminescence was detected with the addition of substrate, and the relative light units 
(RLU) for each clone were averaged and the blank control values subtracted. These 
were then plotted against the position numbers of the clones on the 96-well plates 
(refer to Figure 4-10).  
The graphs [A] to [J] correspond to the outputs shown in the schematic diagram 
(Figure 4-9). Many of the VHH clones were found to bind to gp41 very strongly. To 
establish the number of positive clones from each output, a cut-off RLU value was 
determined. This value was defined as 2 standard deviations above the average blank  
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control values on each plate, and worked out to have an average RLU value of 1500. 
In cases where the blank control value was very low, a minimum RLU value of 1500 
was imposed.   
Table 4-1 gives the summary of the results of the ELISA screening of the selected 
anti-gp41 VHH. From the outputs, an average of 84 out of 96 clones on each plate 
was found to be positive for binding to gp41, or an 88% success rate.  
Table 4-1. Summary of results from ELISA screening 
Output
a  Number of positive 
clones  Percentage value
b   
A  80/96  83%   
B  88/96  92%   
C  86/96  90%   
D  91/96  95%   
E  87/96  91%   
F  93/96  97%   
G  93/96  97%   
H  87/96  91%   
I  61/96  64%   
J  74/96  77%   
Average
b  84/96  88%   
a The alphabet outputs corresponds to the outputs from the selections as shown in Figure 4-9. 
b The percentage values were rounded to the nearest whole number.   
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Figure 4-10 (cont. next page)    
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Figure 4-10. Screening of anti-gp41 VHH from periplasmic extracts in ELISA 
VHH from the various outputs were tested for their ability to bind to gp41 in ELISA. The blank 
control adjusted RLU values were plotted against the clone numbers from each output.   
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4.5.2  Screening of anti-gp41 VHH in neutralisation 
Although it was encouraging to find 840 (out of 960) VHH that were positive for 
binding to gp41, the ELISA screenings did not eliminate enough VHH to enable 
further characterisations of just a handful of VHH. A functional screen, through the 
use of neutralisation assays, was carried out to assess if any of the VHH were good 
neutralisers.  All the 960 individual VHH were screened for their ability to neutralise 
HIV-1 IIIB, based on the rationale that IIIB is generally sensitive to neutralisation. 
HIV-1 CN54 was not included in the neutralisation screening, due to difficulties in 
propagating  the  isolate  in  PBMC  to  a  high  enough  titre,  and  a  molecular  clone 
bearing the full envelope of CN54 was also found to be unviable. 
The HIV-1 neutralisation screen of VHH was evaluated in NP2/CD4/CXCR4 target 
cells. The periplasmic extracts containing the VHH were tested along with negative 
control  periplasmic  extracts  without  any  VHH.  Due  to  the  limited  amounts  of 
periplasmic extracts obtained, 50 µl of each clone was tested in one well only. Since 
the periplasmic extracts were estimated to contain approximately 10 µg/ml of VHH, 
the approximate amount of VHH assayed per well is 0.5 µg (or a final concentration 
of 2.5 µg/ml of VHH). At 72 h post infection, cells were fixed and stained for HIV-1 
p24 protein in a β-galactosidase assay. FFU were counted microscopically and the 
reduction in FFU in test wells compared to virus control wells was determined for 
each clone. (Methods described in Section 2.6.6) 
The results from the NP2 neutralisation assay showed that all the 960 VHH obtained 
were  either  not  neutralising  or  just  weakly  neutralising.  The  percentage 
neutralisation averaged 30-40%, reaching a maximum neutralising value of 65% for 
only a handful of clones. None of the VHH was able to neutralise IIIB to more than  
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90%. From previous experience in the laboratory, periplasmic extracts containing 
VHH that targeted gp120 can achieve neutralisation values of 90%.  However, as 
periplasmic extracts can also contain cell debris and other proteins, this might have 
contributed to the high background levels, and making the interpretation of results 
difficult.  Negative  control  periplasmic  extract  was,  on  its  own,  able  to  cause  an 
average of 15% neutralisation on HIV-1 IIIB. Nevertheless, the 12 VHH clones to 
give the highest neutralisation values were chosen for futher characterisation, after 
verifying that they also bound to gp41 in ELISA. These VHH then had their DNA 
sequenced to ensure that they were not identical clones. 
4.5.3  Summary of anti-gp41 VHH screening 
The results from the ELISA binding screening showed that 840 of the selected VHH 
clones were able to bind to gp41. The panning of the phage library from llama 48 
had therefore worked very well indeed. However, the results from the neutralisation 
screen on HIV-1 IIIB were very disappointing, as none of them were found to be 
strongly neutralising. Nevertheless, the 12 best neutralisers were chosen and verified 
that they were also positive for binding in the ELISA screen. These 12 VHH were 
sequenced and 4 were chosen for further characterisation. Their translated sequences 
are shown below in Figure 4-11.  
The  VHH  4F1  and  4G6  were  obtained  from  output  H,  which  were  obtained  by 
panning the phage library from llama 48 on gp41∆ with 4E10 elution; whilst the 
VHH 5A1 and 5G1 were obtained from output G, which were similarly panned but 
with 2F5 elution. Despite the difference in elution methods, the VHH 4F1, 4G6 and 
5G1 share similar sequences, especially in the CDR3. The VHH 5A1, on the other 
hand, was vastly different in all the CDRs when compared to the other three.   
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4F1             EVQLVESGGGLVQPGGSLRLSCAVSGTPFSFTGVAWFRQAPGKQREPVAVMTSTG-TTNY 59 
4G6             QVKLEESGGGLVQPGGSLRLSCAVSGITFRFTGVAWFRQAPGKQREPVAVMTSTG-TTNY 59 
5A1             QVQLVESGGGLVQAGDSLRLSCAASGRSFNSYTMGWFRQNPGKEREFVAAIHFNGYTTWY 60 
5G1             EVQLVESGGGLVQPGGSLRLSCAVSGISFSFTGVAWFRQAPGKQREKIAVMTSGG-TTAY 59 
                :*:* ********.*.*******.** .*    :.**** ***:** :*.:   * ** * 
 
4F1             EDSVKGRFTISRDNAKRTVYLQMNSLKPEDTAVYYCFVEDS---EAGGLEITGYWGQGIQ 116 
4G6             EDSVKGRFTISRDNAKRTVYLQMNSLKPEDTAVYYCFVEDS---EAGGLEITGYWGQGIQ 116 
5A1             ADSVKGRFTSSRDDAKSTVYMQMNSLKPEDTAVYYCAAKQFGSWRSTGVSEYNYWGRGTP 120 
5G1             EDSVNGRFSISRDNAKRTVYLQMNSLKPEDTAVYYCFVEDS---EAGGLEITGYWGQGIQ 116 
                 ***:***: ***:** ***:*************** .::    .: *:.  .***:*   
 
4F1             VTVSS 121 
4G6             VTVSS 121 
5A1             VTVSS 125 
5G1             VTVSS 121 
                ***** 
Figure 4-11. Amino acid sequences of the four anti-gp41 VHH 
The 4 VHH chosen were obtained by panning the phage library from llama 48 on gp41∆. 4F1 and 
4G6 were obtained with 4E10 elution, and 5A1 and 5G1 were obtained with 2F5 elution. These VHH 
bound to gp41 in ELISA screenings and were able to neutralise HIV-1 IIIB to 50%. After sequencing 
these VHH, they were translated and aligned using ClustalW2. Even though they were obtained from 
different selection procedures, the VHH 4F1, 4G6 and 5G1 share similar sequences whereas 5A1 is 
distinct from the rest. The CDRs are shown shaded.  
 
 
4.6  Large scale expression of VHH 
To be able to further characterise the individual VHH, they have to be expressed in 
greater quantities and purified. After the expression of VHH in E. coli TG1 cells and 
subsequent purification by means of the C-terminal 6-Histidine-tag in nickel column 
beads, the result of the purification was monitored by SDS-PAGE. The full methods 
are described in Section 2.6.4. From the gel image, the eluates from the purification 
process  contain  a  clean  and  prominent  band  near  the  19kDa  mark,  which 
corresponds to the approximate size of the VHH.   
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Figure 4-12. Expression and purification of VHH 
Recombinant VHH were expressed in E. coli TG1 cells and purified by means of the C-terminal 6-
Histidine-tag. The purification was monitored by SDS-PAGE followed by Coomassie blue staining. 
Shown is a representative analysis of the purification of a VHH. The first and last lanes contain the 
molecular weight marker (SeeBlue Plus 2, Invitrogen), followed by unpurified E. coli periplasmic 
extracts, the unbound flow-through fraction, followed by 2 washes, and finally 2 eluates. The flow-
through seems to contain some uncaptured VHH, as with Wash 1. By Wash 2, all unbound proteins 
were washed out. The two eluates gave a clear distinct band near the 19 kDa mark.  
 
4.7  Neutralisation of HIV-1 by anti-gp41 VHH 
The purified VHH were tested again in neutralisation assays, because previous tests 
were  carried  out  using  periplasmic  extracts  which  contain  cell  debris  and  other 
proteins. As the TZM-bl cell assay was later developed and set up in our laboratory, 
this  assay  was  used  instead  of  the  NP2  cell  assay,  which  involves  the  time-
consuming and laborious counting of FFUs microscopically. This assay is described 
in  Section  2.3.9.  The  TZM-bl  neutralisation  assay  employs  a  luciferase  read-out 
using a luminometer and is a relatively high-throughput process. This assay utilises  
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TZM-bl cells, which are HeLa cells expressing endogenous CXCR4 and engineered 
to  express  CD4  and  CCR5  and  to  contain  a  Tat-induced,  LTR-driven  firefly 
luciferase reporter gene. The assay measures neutralisation as a reduction of Tat-
induced luciferase expression (Derdeyn et al., 2000; Montefiori, 2004; Platt et al., 
1998; Wei et al., 2002).  
Virus was incubated with serial dilutions of VHH (up to a maximum of 50 µg/ml) 
for 1 h and subsequently incubated with TZM-bl cells. At 48 h post infection, cells 
were lysed with the addition of Promega luciferase assay reagent. Luminescence was 
measured and background luminescence subtracted. The percentage of relative light 
units  (RLU)  in  test  wells,  compared  to  in  virus  only  control  wells,  was  then 
determined. The lowest VHH concentration required to achieve 50% reduction of 
infectivity  (IC50)  compared  to  a  virus  control  was  calculated  using  the  XLfit  4 
software  with  sigmoidal  regression  analysis.  To  ensure  reproducible  results,  the 
neutralisation activity of each VHH was assayed in duplicate and on two separate 
occasions. Against each virus included in the study, a negative control VHH (VHH 
#3 that is directed against an irrelevant epitope; at 50 µg/ml) was included in at least 
two wells.  
The  virus  isolates  tested  in  this  assay  included  IIIB,  MN,  93MW965.26  and 
96ZM651.02.  The  TCLA  isolates  IIIB  and  MN  are  commonly  used  subtype  B 
viruses, and are known to be generally sensitive to antibody-mediated neutralisation 
(Moore et al., 1993; Wrin et al., 1995). The subtype C isolates are 93MW965.26 and 
96ZM651.02,  which  are  Tier  1  and  2  viruses  respectively.  The  Tier  1,  2  and  3 
classification  is  based  on  the  sensitivity  of  the  envelope  pseudotyped  viruses  to 
neutralisation, with Tier 1 viruses being the most sensitive to neutralisation (Mascola  
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et al., 2005). It was not possible to test the VHH for neutralisation to the autologous 
virus HIV-1 CN54 as virus yields in PBMC cultures were of low titres and cloning 
of the env gene did not produce any infectious clones. 
The graphs  in  Figure 4-13 show the results of the  neutralisation assays with the 
respective  viruses,  and  Table  4-2  shows  the  IC50  values  of  the  anti-gp41  VHH. 
Surprisingly, only the 5G1 VHH was able to neutralise both IIIB and MN to 50%. 
On closer inspection of the graphs, all the VHH showed some neutralising activity 
only when quantities were higher than 17 µg/ml. The 5G1 VHH gave IC50 values of 
49.2 µg/ml and 37.8 µg/ml with IIIB and MN respectively.  
The anti-gp41 VHH fared better against the subtype C isolates, particularly against 
the  Tier  2  isolate  96ZM651.02.  All  the  four  VHH  were  able  to  neutralise 
96ZM651.02 with IC50 values between 6.2 – 45.1 µg/ml, but only 4G6 and 5G1 were 
able to neutralise 93MW965.26.  
In  summary,  the  anti-gp41  VHH  were  not  able  to  potently  neutralise  the  Tier  1 
subtype  B  viruses  tested  at  concentrations  up  to  50  µg/ml.  This  contradicts  the 
results of the NP2 assay which was carried out in the screening of the selected VHH. 
On the other hand, these VHH were found to neutralise the two subtype C viruses 
tested, especially against 96ZM651.02 which  is  a Tier 2  virus. These results are 
discussed in Section 4.12. 
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Figure 4-13. Anti-gp41 VHH neutralisation of HIV-1 in TZM-bl cells 
The percentage of RLU in test wells compared to in virus only control wells (after subtraction of 
background luminescence) was determined for VHH concentrations up to a maximum of 50 µg/ml. 
None of the VHH were able to neutralise either IIIB or MN to 50%. All of the VHH were able to 
neutralise 96ZM651.02, but only 4G6 and 5G1 were able to neutralise 93MW965.26. 
 
Table 4-2. Anti-gp41 VHH IC50 (µg/ml) titres against HIV-1 
VHH 
IC50 against virus isolates (µg/ml) 
IIIB  MN  93MW  96ZM 
4F1  >50  >50  >50  22.4 
4G6  >50  >50  35.4  12.0 
5A1  >50  >50  >50  45.1 
5G1  49.2  37.8  43.9  6.2 
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4.8  Enzyme linked immunosorbent assays (ELISA) 
4.8.1  VHH titrations 
The  purified  VHH  were  also 
checked to determine if they bind to 
gp41  in  ELISA.  These  were  first 
titrated  on  Maxisorp  plates  coated 
with 1 µg/ml of gp41 to determine 
the best range of VHH concentration 
to  use  in  ELISA,  starting  from  1 
µg/ml  of  VHH  and  5-fold  serially 
diluted thereafter.   
Figure 4-14 shows the graph of the 
purified VHH titration on gp41. The 
various  VHH  gave  a  peak 
luminescence  signal  at  1000  ng/ml, 
which drops down to a minimum at 
around 8 ng/ml. The negative control 
VHH produced only a background signal in the ELISA.  
4.8.2  VHH binding to recombinant gp41 and gp140  
The four different purified VHH were then tested for binding in ELISA against four 
different  antigens,  this  time  in  2-fold  dilution  starting  from  1  µg/ml.  The  four 
antigens  were  recombinant  gp41  IIIB,  and  recombinant  trimeric  gp140  obtained 
from isolates 92UG037 (subtype A), Bx08 (subtype B), and 96ZM651.02 (subtype 
C). The CN54 immunogen was not included as supplies were exhausted at this stage 
Figure  4-14.  Titration  of  anti-gp41  VHH  in 
ELISA 
The purified VHH were titrated on gp41 coated plates. The 
results  showed  a  dose-dependent  signal,  with  maximum 
peak values at around 1 µg/ml of VHH and dropping to a 
low  at  around  8  ng/ml.  The  negative  control  VHH 
produced background level signals.  
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of the project. The plates were first coated overnight with 1 µg/ml of the antigens, 
and the ELISA was carried out as described in Section 2.6.5. The mAb 2F5, which 
recognise the MPER of gp41, was included as a positive control.  
Figure 4-15 shows the graphs from the ELISAs. As expected, all the VHH and 2F5 
bound  to  gp41  in  a  dose-dependent  manner.  When  comparing  the  curves  with 
recombinant  gp140,  a  striking  difference  emerged.  The  mAb  2F5  was  able  to 
recognise  92UG037  and  Bx08,  which  are  isolates  from  subtypes  A  and  B 
respectively,  but  none  of  the  VHH  were  able  to  bind  to  these  two  antigens. 
Interestingly, all the VHH were able to bind to gp140 96ZM651.02. The mAb 2F5 
was not able to bind to 96ZM651.02 as the 2F5 epitope are often not present on 
subtype C isolates (Li et al., 2006b).  
The results of the ELISA correspond well with the results from the neutralisation 
tests  in  the  previous  section.  VHH  binding  to  gp140  96ZM651.02  results  in  the 
neutralisation ability of the corresponding virus isolate. Absence of binding to gp140 
Bx08 corresponds to low neutralisation ability of subtype B isolates IIIB and MN. 
Although the VHH were unable to bind to trimeric forms of gp41 presented in the 
context of gp140 Bx08, the VHH were able to bind to monomeric forms of gp41 
IIIB. This could be due to the more ‘exposed’ structure of gp41 compared to gp140. 
It should also be noted that these VHH were selected through panning on gp41 MN, 
and not on gp140. In summary, the results from the neutralisation and ELISA tests 
show that the VHH seem to have a preference for subtype C isolates. This is perhaps 
not too surprising as the llama was immunised with subtype C gp140 CN54. 
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Figure  4-15.  Binding  of  anti-gp41  VHH  to  recombinant  gp41  and  gp140  in 
ELISA 
Plates were first coated overnight with the respective antigens at 1 µg/ml. The VHH were introduced 
as described in the text. All the VHH were able to bind to gp41 IIIB and gp140 96ZM651.02 in a dose 
dependent manner, but they were unable to bind to gp140 92UG037.A9 and Bx08. The mAb 2F5 was 
used as a positive control, and it bound to all except gp140 96ZM651.02 where the epitope was 
absent. 
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4.8.3  VHH competition in ELISA 
In  an  initial  attempt  to  map  the 
epitopes of the anti-gp41 VHH and 
to determine if they bind to similar 
epitopes, the VHH were allowed to 
compete for each other in binding in 
an  ELISA.  In  order  to  distinguish 
and detect the test sample from the 
other VHH, each of the VHH was 
biotinylated  using  a  procedure 
described  in  Section  2.7.1.2.  To 
check  for  successful  biotinylation, 
the biotinylated VHH were titrated 
on gp41 coated Maxisorp plates and 
detected  with  an  AP-conjugated 
streptavidin. Unbiotinylated VHH at 
the  highest  concentration  was  also 
included  in  the  titration.  From  the 
titration graph in Figure 4-16, a concentration-dependent signal was observed, and 
they were all higher than their respective unbiotinylated samples. The biotinylation 
of the VHH samples was therefore successful.  
The VHH were then checked to see if they competed with each other for binding to 
similar  epitopes.  The  procedure  is  described  in  Section  2.6.9.  Briefly,  titrated 
amounts of unbiotinylated VHH and mAb 2F5 were allowed to bind to gp41 coated 
Maxisorp plates in separate wells and in duplicate. The anti-gp120 VHH, A12, was 
Figure 4-16. Titration of biotinylated VHH 
To check that each VHH was successfully biotinylated, 
a titration was carried out in ELISA and the VHH was 
detected  with  an  AP-conjugated  streptavidin. 
Unbiotinylated  VHH  at  the  highest  concentration  was 
included  in  the  titration.  From  the  graph,  all  the 
biotinylated  VHH  were  successfully  biotinylated  and 
produced a signal which was above the unbiotinylated 
samples.   
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added  as  an  irrelevant  negative  control.  A  fixed  amount  of  biotinylated  VHH 
(optimised at 5 µg/ml) was introduced to all the wells and allowed to compete for 
binding  to  epitopes  on  gp41.  The  amount of  gp41-bound  biotinylated  VHH  was 
detected  with  an  AP-conjugated  streptavidin,  and  the  luminescence  was  detected 
after the addition of substrate.  
The graphs in Figure 4-17 show the results of the competition ELISA. The negative 
control A12 VHH does not bind to gp41, and hence it did not impede the binding of 
the biotinylated test samples to give a flat curve in each graph. This observation was 
also true for 2F5, and hence  none of the VHH competes  for binding to the 2F5 
epitope. Each of the biotinylated test sample will compete with its corresponding 
unbiotinylated VHH. Hence lower levels of biotinylated VHH was detected when a 
greater concentration of its own unbiotinylated VHH was present in each well, thus 
producing the dose-dependent curves seen.  
Of the four different VHH tested, 5A1 was the only VHH which did not compete 
with  the  other  VHH  for  binding  to  the  same  epitope.  The  presence  of  high 
concentrations of the other three VHH did not inhibit the binding of 5A1 to gp41. 
The 4F1, 4G6 and 5G1 VHH all compete with each for binding to a similar epitope 
on gp41.  
In summary, the 4F1, 4G6 and 5G1 VHH all recognised a similar epitope on gp41, 
whereas  the  5A1  VHH  recognised  a  different  epitope on  gp41. This  was  hardly 
surprising as the sequences of the CDRs for 4F1, 4G6 and 5G1 were quite similar, 
compared to 5A1 which was quite different from the rest (Figure 4-11).  
    
199 
 
 
Figure 4-17. Competitive binding to gp41 in ELISA 
Titrated amounts of unbiotinylated VHH and 2F5 were allowed to bind to gp41 coated plates. The 
anti-gp120  VHH,  A12,  was  included  as an  irrelevant negative  control  VHH.  A  fixed  amount  of 
biotinylated VHH was added to all the wells for competitive binding to gp41 and then detected with 
AP-conjugated streptavidin. The biotinylated VHH will compete for binding to its own corresponding 
unbiotinylated sample. None of the VHH tested was able to compete with 2F5 for binding. The 4F1, 
4G6  and  5G1  VHH  competed  with  each  other  for  binding  to  gp41,  whereas  5A1  recognised  a 
different epitope compared to the rest. 
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4.9  Western blots using anti-gp41 VHH 
To verify that the VHH were able to recognise gp41 in a specific manner, western 
blots were carried out according to procedures described in Section 2.6.7. Briefly, 
about 10 ng of gp41 was resolved, without the boiling of samples, in multiple lanes 
in SDS-PAGE and then blotted onto a PVDF membrane. The individual lanes were 
cut out and probed with the different VHH in separate receptacles. The mAb 50-
69D, which reacts to a conformational dependent epitope on gp41, was used as a 
positive control; and an irrelevant VHH, E7, was used as a negative control. The 
western blots were visualised using ECL detection reagent and x-ray film. 
Figure 4-18[A] shows the individual lanes blotted with gp41. The four different anti-
gp41  VHH  gave  distinct  prominent  bands  near  the  39  kDa  marker,  indicating  a 
specific  recognition  of  recombinant  gp41.  The  positive  control  mAb  produced 
multiple  bands,  which  might  be  an  indication  of  impurities  in  the  sample.  The 
negative control E7 VHH did not give a signal in the western blot.  
In a variation of the above method, the VHH were then resolved in SDS-PAGE and 
blotted  onto  a  PVDF  membrane.  Even  though  the  VHH  were  subjected  to  high 
temperatures  and  chemically  denatured,  the  VHH  have  a  remarkable  ability  to 
renature itself (Dumoulin et al., 2002; Perez et al., 2001; van der Linden et al., 1999). 
The VHH were tested for their ability to capture recombinant gp41 in solution form. 
Captured gp41 were detected with the mAb 50-69D and visualised on an x-ray film 
and shown in Figure 4-18[B]. All the four different VHH were able to capture gp41, 
as indicated by a prominent band at the 14 kDa mark, which is the approximate size 
for a VHH. The negative control VHH (E7) was not able to capture gp41, as shown 
by the absence of a band.  
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Both western blots thus showed that the isolated anti-gp41 were able to bind to and 
capture gp41 in a specific manner. 
 
Figure 4-18. Western blots of anti-gp41 VHH 
[A] Recombinant gp41 were blotted onto a PVDF membrane in six separate lanes, and the lanes were 
then cut out. These were then individually probed with various antibodies and VHH and detected with 
ECL reagent. All the VHH produced a single prominent band near the 39 kDa mark, except for the 
negative control E7 VHH. The positive control mAb 50-69D produced a prominent band near the 39 
kDa mark, but also detected other impurities in the sample. [B] The VHH were blotted onto a PVDF 
membrane in the lanes as shown. These were then allowed to capture gp41 in solution form, which 
was in turn probed with the anti-gp41 mAb 50-69D. The results show that the anti-gp41 VHH were 
able to capture gp41 in solution form, but not the negative control E7 VHH. 
 
4.10  Epitope mapping 
In an attempt to map the binding epitopes of the four different anti-gp41 VHH, they 
were tested for their ability to bind to a set of 15-mer peptides, with 11 amino acid 
overlaps between sequential peptides. The sequences of these peptides were based on 
the MN strain. To ensure complete coverage of the gp41 sequence, a total of 42 
different peptides were tested. These peptides were coated overnight onto Maxisorp  
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plates at a concentration of 10 µg/ml, and an ELISA was carried out as described in 
Section 2.6.10. 
None of the VHH was able to bind to any of the peptides in the set. A few positive 
controls  using  known  mAbs  with  established  binding  epitopes  showed  that  the 
experiment was working properly. This was repeated three times and the results were 
consistently negative.     
Through the Collaboration for AIDS Vaccine Discovery (CAVD), we have access to 
reagents and technologies developed by other groups. One of these groups, Pepscan 
Presto  BV  (The  Netherlands),  has  developed  a  proprietary  set  of  combinatorial 
peptide arrays covering the sequences of gp160 from the subtype A and C isolates 
92UG037 and 93MW965 respectively. Their peptide arrays contain 15 to 18-mer 
linear and cyclic peptide fragments that overlaps by 19 amino acids. The data of their 
results are presented in Figure 4-19.  
The  positions  of  the  gp160  peptides  are  laid  out on  the  horizontal  axis,  and  the 
vertical  axis  indicates  the  presence  of  binding.  The  VHH  produced  a  high 
background signal to peptides from 92UG037 and these are not shown. All the VHH 
produced  a  binding  signal  to  peptides  covering  the  gp41  portion  of  93MW965. 
However, multiple peaks were observed for all the VHH samples, indicating that 
they do not bind to a singular linear epitope. In all instances of 4F1, 4G6 and 5G1, 
three to four prominent peaks were detected on  linear peptides  from 93MW965. 
These  were  highlighted  in  circles  in  Figure  4-19.  The  5A1  VHH  produced  high 
background signals and with peaks that were different to the rest. 
The  consensus  binding  sequences  of  the  three  VHH  were  found  to  be 
SITLTVQARQLLS and LTVWGIKQL. These amino acids correspond to positions  
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534-546 and 568-576 on the HXB2 Env numbering system. To a lesser extent, these 
VHH were also found to recognise WEREIDNYTH, which corresponds to position 
numbers 631-640.  
 
 
 
Figure 4-9 (cont. next page).    
204 
 
 
 
 
Figure 4-19. Results of epitope mapping from Pepscan 
Linear and cyclic peptides from gp160 93MW965 are shown lined up on the horizontal axis, and 
binding of the VHH to the peptides would be shown as peaks on the vertical axis. All the VHH tested 
were found to bind to the gp41 peptides. Similar peaks (circled above) were identified for 4F1, 4G6 
and 5G1, whereas those from 5A1 produced inconclusive results.  
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An attempt was made to understand 
the relationship of these epitopes on 
the structure of g41. Unfortunately, 
the crystal structure of a native gp41 
in the context of an envelope spike 
is  as  yet  unsolved.  The  predicted 
structure of gp41 was obtained from 
Zolla-Pazner’s  review  (Zolla-
Pazner, 2004) and adapted to show 
the  relative  positions  of  the 
identified  epitopes.  These  are 
marked  with  red  boxes  in  Figure 
4-20.  Interestingly,  the  identified 
epitopes  for  the  three  VHH  (4F1, 
4G6,  and  5G1)  occupy  adjacent 
positions  on  gp41,  thus  adding 
strength to the results obtained from 
epitope  mapping.  The  binding 
epitopes for 5A1 were not similarly 
identified.  
 
   
Figure  4-20.  Illustration  of  epitope  positions 
on gp41 
The epitopes identified by Pepscan were mapped onto the 
above illustrated structure of gp41. It was found that the 
possible  epitopes  occupy  adjacent  positions  on  gp41. 
Figure  adapted  from  Nat  Rev  Immunol  4(3):199-210. 
(Zolla-Pazner, 2004)  
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4.11  Conformational dependent epitope 
To confirm that the VHH bind to a conformational dependent epitope on gp41, a 
denaturing  ELISA  was  carried  out  as  described  in  Section  2.6.11.  Briefly,  two 
aliquots of gp41 at 1 µg/ml were coated onto Maxisorp plates. However, one of the 
gp41 aliquot was treated with 1% SDS, 50 mM DTT and then boiled for 5 minutes to 
denature the protein. The  four different VHH were then allowed to bind to both 
samples of gp41 and run  in parallel. Two  mAbs were  included as controls; 2F5 
recognises a  linear epitope whilst 50-69D recognises a conformational dependent 
epitope on gp41.  
The results of the ELISA are shown in Figure 4-21. On the plate with untreated 
gp41, all the VHH and mAbs were able to bind to gp41 as per usual. However, none 
of the VHH and 50-69D were able to bind to the denatured gp41. Only 2F5, which 
does not require a conformational dependent epitope, was able to bind to denatured 
gp41. Therefore, all the VHH were found to recognise a conformational dependent 
epitope. 
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Figure 4-21. VHH binding to denatured gp41 in ELISA 
Two ELISA plates were set up in parallel, one coated with gp41 and the other coated with denatured 
gp41. The VHH were allowed to bind to both forms of gp41. The mAbs 2F5 and 50-69D, which 
recognise a linear and conformational dependent epitope respectively, were included as controls. On 
the plate with untreated gp41, all the VHH and mAbs were able to bind. However, none of the VHH 
and  50-69D  except  2F5  was  able  to  bind  to  the  denatured  gp41.  Therefore,  all  the  four  VHH 
recognised a conformational dependent epitope. 
 
4.12  Discussion 
In  this  chapter,  a  phage  library  containing  the  antibody  repertoire  from  a  llama 
immunised  with  a  subtype  C  trimeric  gp140  CN54  was  panned  on  recombinant 
gp41. A total of 10 different selection methods were used. This consisted of using 
recombinant gp41, gp41∆ or gp140 as the selecting antigen, and different elution 
methods using trypsin, glycine or antibody competition were used. Although 88% of 
all the selected VHH were found to bind to gp41, all of them displayed very weak 
neutralising ability in the initial neutralisation screen using NP2 cells.  
Four anti-gp41 VHH, 4F1, 4G6, 5A1 and 5G1, were brought forward for further 
characterisation. These 4 were panned on gp41∆, but 4F1 and 4G6 were eluted with  
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4E10, whereas 5A1 and 5G1 were eluted with 2F5. However, the 4F1, 4G6 and 5G1 
VHH were found to be quite similar based on their amino acid sequences, whereas 
5A1 possessed CDRs which were comparatively different. 
The VHH were tested for their ability to neutralise a few strains of HIV-1 in the 
newer  TZM-bl  cell  assay.  Differences  between  assays  have  been  previously 
observed  in  our  laboratory,  and  also  in  the  global  collaboration  working  on  the 
standardisation of HIV-1 neutralisation assays (Polonis et al., 2008). Discrepancies 
between results obtained in different neutralisation assays may be expected for non-
potent mAbs. This is because the different assays employ different target cells, virus 
inputs,  incubation  times,  as  well  as  the  use  of  the  polycation  DEAE-dextran  to 
enhance the level of infection in TZM-bl cells. 
In the TZM-bl assay, all the 4 VHH were unable to neutralise the two neutralisation- 
sensitive TCLA isolates IIIB and MN to high potency (<10 µg/ml). Instead, these 
VHH were found to be more potent against subtype C isolates (i.e. 93MW965.26 and 
96ZM651.02). The mAb 4E10 was also found to neutralise at similar levels (10-50 
µg/ml) against subtype C viruses (Binley et al., 2004), indicating similar neutralising 
potencies.  Binding  tests  in  ELISA  showed  that  these  VHH  do  not  bind  well  to 
trimeric gp140 from subtype A and B, but they bound to trimeric gp140 subtype C 
and  monomeric subtype  B gp41. This observation was perhaps  not surprising as 
these  VHH  were  isolated  from  a  llama  that  was  immunised  with  a  subtype  C 
envelope. A positive correlation between the subtype-specific antigen binding with 
subtype-specific neutralisation was therefore observed, as also reported elsewhere 
(Crooks et al., 2008; Fouts et al., 1997; Moore et al., 2006). In future work, more  
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isolates from subtypes B and C can be tested for sensitivity to neutralisation by these 
VHH. 
In an attempt to identify their binding epitopes, all the VHH were found to bind to a 
conformational  dependent  epitope.  Nevertheless,  epitope  mapping  using  peptides 
from the 93MW965 strain has revealed the possible binding site on gp41 for 4F1, 
4G6 and 5G1, which also cross-compete with each other for binding on gp41. The 
epitope for 5A1 was unable to be determined, but competition studies have shown 
that 5A1 does not compete for binding with the other three VHH. The exact binding 
epitopes  for  these  VHH  could  perhaps  be  determined  in  the  future  by  alanine 
scanning of gp41.  
In summary, four anti-gp41 VHH were isolated from a llama immunised with gp140 
CN54 which showed a preference for neutralising subtype C HIV-1 isolates. These 
VHH do not recognise the MPER of gp41, but bind to a conformational dependent 
epitope on gp41.  
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5  C8- and D7- Family Specific VHH Libraries 
5.1  Introduction 
In  addition  to  llama  (L48)  that  was  immunised  with  recombinant  gp140  CN54 
(described  in  Chapter  4),  another  llama  (L44)  was  separately  immunised  with 
recombinant gp120 CN54 and a phage display VHH library was created. These were 
all  carried  out  as  part  of  the  European  Microbicide  Project  (EMPRO),  in 
collaboration with Ablynx NV, Ghent, Belgium.  
Anna Forsman, a former PhD student in the lab, has described the isolation of three 
VHH (C8, D7 and  A12 VHH)  from  llama 44 that were able to  inhibit different 
subtypes of HIV-1 (Forsman et al., 2008). These three VHH were able to block CD4 
binding to HIV-1 gp120 and were able to neutralise various subtype B and C isolates 
of HIV-1 to high potency. These VHH were selected after two rounds of panning on 
gp120 IIIB with competitive elution with soluble CD4 (sCD4).  
In the continuing quest for more broadly neutralising antibodies against the HIV-1 
envelope, it will be useful to select for variants of an antibody that has already been 
shown  to  be  broadly  neutralising.  A  “family-specific”  approach  was  therefore 
devised to allow the amplification of a “family” of affinity variants that had been 
generated in vivo in the llama, and followed by the subsequent selection for such 
variants. In this chapter, two family-specific VHH libraries containing members that 
are similar to the parental C8 and D7/A12 VHH were created. These members were 
amplified from the immune library that was originally created from llama 44. The 
C8-family specific library only produced identical members to the C8 VHH, whereas 
the creation of the D7/A12-family (thereafter named as D7- family) specific library  
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was a success. This method of creating a family-specific library is a novel approach 
to VHH or antibody selection. Members of this family were then characterised and 
an attempt at identifying the crucial amino acid residues involved in binding were 
made. 
 
5.2  Library creation 
5.2.1  Primer design 
To create a family-specific phage display library where the members have similar 
antigen  recognition  ability  as  the  parental  VHH,  the  sequences  of  the  members 
should  share  some  homology  to the  parental  VHH.  Because  the  H  chain  CDR3 
possesses the greatest flexibility and conformational variability of the CDRs, it could 
have  the  greatest  influence  on  antigen  binding  (Nuttall  et  al.,  2000).  In  order to 
extract out VHH with similar properties as the  parental VHH, C8- and D7/A12- 
specific primers that recognised the last stretch of amino acids (4-6 codons) in the 
CDR3 were designed. 
Figure  5-1  shows  the  sequences  of  the  C8,  A12  and  D7  VHH,  with  the  CDR3 
sequences highlighted in grey. The A12 and D7 share similar sequences and are part 
of the same family. Degenerate reverse primers were designed to correspond to the 
underlined sequences, with one primer to capture both D7- and A12-like sequences.  
The sequences of the primers were: C8, 5'- TGA GGA GAC GGT GAC CTG GGT 
CCC CTG GCC CCA GTC TGT ATA GTC GC -3' and D7, 5'- TGA GGA GAC 
GGT GAC CTG GGT CCC CTG GCC CCA GTM GTW RTA ATC YGA AT TCG 
-3'. The underlined region of the primers corresponds to the specific CDR3 of the 
VHH. The forward primer used was specific for the FR1 region of VHH.  
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               -- FR1 primer 
PMP9C8          GCCGTGCAGCTGGTGGATTCTGGGGGAGGCTTGGTGCAGGCTGGGGGGTCTCTGAGACTC 60 
PMP9A12         GCGGTGCAGCTGGTGGAGTCTGGGGGAGGATTGGTGCAGGCTGGGGGCTCTCTGAGACTC 60 
PMP9D7          GCGGTGCAGCTGGTGGAGTCTGGGGGAGGATTGGCGCAGGCTGGGGGCTCTCTGAGACTC 60 
 
PMP9C8          TCCTGTGTAGTTTCTGGAAGCATCTTCAGTATCAATGCCATGGGCTGGTACCGCCAGGCC 120 
PMP9A12         TCCTGTACAGCCTCTGGACGCATCAGCAGTAGCTATGATATGGGCTGGTTCCGCCAGGCT 120 
PMP9D7          TCCTGTACAGTTTCTGGACGCACCAGTAGTAGCCATGATATGGGCTGGTTCCGCCAGGCT 120 
 
PMP9C8          CCAGGGAAGCAGCGCGATTTGGTCGCACGTATTAGT---GGTGATAGTAGTACTTACTAT 177 
PMP9A12         CCAGGGAAGGAGCGTGAGTTTGTAGCGGCTATTAGTTGGAGTGGTGGTACCACAGACTAT 180 
PMP9D7          CCAGGAAAGGAGCGTGAGTTTGTAGCGGCTATTAGCTGGAGTGGTGGTACCACAAACTAT 180 
 
PMP9C8          ATAGACTCCGTGAAGGGCCGATTCACCATCTCCAGAGACAACGCCGCGAACACGGTGTAT 237 
PMP9A12         GCAGACTCCGTGAAGGGGCGATTCGCCATCTCCAAAGACAACGCCAAGAACGCAGTGTCC 240 
PMP9D7          GCAGACTCCGTGAAGGGGCGATTCGCCATCTCCAAAGACAACGCCAAGAACGCAGTCTCC 240 
 
PMP9C8          CTGCAAATGAACAGCCTGAAACCTGAGGACACAGCCGTCTATTACTGTGCAGC---GCGA 294 
PMP9A12         CTGCAAATGAACAGCCTGAAACCCGAGGACACGGCCGTTTATTACTGTGCAGCTAAGTGG 300 
PMP9D7          CTGCAAATGAACAGCCTGAAACCTGAGGACACGGCCGTTTATTACTGTGCAGCTAAGTGG 300 
 
                                 -- C8 primer 
PMP9C8          CGATTGCC----TATAGGC-----------------GACTATACAGACTGGGGCCAGGGG 333 
PMP9A12         CGACCGCTACGTTATAGTGACTACCCTTCGAATTCGGATTACTACGACTGGGGCCAGGGG 360 
PMP9D7          CGACCGCTACGTTATAGTGATAACCCTTCGAATTCAGATTATAACTACTGGGGCCAGGGG 360 
                                            -- D7 primer 
 
PMP9C8          ACCCAGGTCACCGTCTCCTCA 354 
PMP9A12         ACCCAGGTCACCGTCTCCTCA 381 
PMP9D7          ACCCAGGTCACCGTCTCCTCA 381 
 
Figure 5-1. Nucleotide sequences of the parental VHH 
The nucleotide sequences of the parental VHH were aligned and displayed above, with the CDR3 
sequences highlighted in grey. Two unique degenerate reverse primers (shown above with arrows for 
the C8 and D7 primers), which corresponds to the underlined sequences, were designed to extend into 
the CDR3 region to create the family specific phage library. 
 
5.2.2  C8- and D7- family specific phage library construction 
The procedures for the creation of the C8- and D7/A12- like (D7 for short) dedicated 
libraries  were  described  in  Section  2.7.2  and  were  carried  out  by  Ablynx  NV. 
Briefly,  the  primers  designed  above  were  used  to  amplify  out  VHH  genes  with 
similar CDR3 sequences from the cDNA library that was originally isolated from the 
PBL pools of llama 44. The amplified fragments were then digested and gel purified, 
before  insertion  into  a  phagemid  vector  (pAX050)  for  display  on  filamentous 
bacteriophage. The family-specific phage libraries was then titrated out, and the size 
of the libraries was determined to be 5.7 x 10
6 and 2.0 x10
6 clones for the C8- and 
D7-specific library respectively. Through colony PCR on a selection of clones, the  
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percentage of functional inserts within the library were determined to be 100% and 
91.3% for the C8- and D7-specific library respectively. 
5.3  Preparation of the recombinant gp120 antigen 
5.3.1  Recombinant gp120 92BR025 expression and purification 
As the aim of the EMPRO project was to obtain antibodies that can better target 
subtype C HIV-1, selecting for VHH that can recognise a subtype C envelope will be 
highly desirable. The only readily available subtype C recombinant gp120 was from 
the CN54 isolate, but there were doubts about the antigenic profile of this isolate. 
Anna Forsman (a former PhD student in the lab) has demonstrated that recombinant 
gp120 CN54 does not bind efficiently to soluble CD4 and did not mediate infection 
when expressed on a virus particle. As there was a need to create a subtype C gp120 
recombinant protein for use as an antigen in the panning process, she has cloned the 
full-length gp120 from a subtype C primary isolate (92BR025) which was obtained 
from the WHO-UNAIDS collection of primary isolates (Gao et al., 1994). These 
primary isolates represent strains that were circulating in areas chosen for vaccine 
trials. The gp120 92BR025.C1 clone was able to mediate infection when expressed 
on the HXB2 backbone and was chosen for recombinant protein expression. 
The procedure for recombinant gp120 92BR025 expression is described in Section 
2.7.1.1.  Briefly,  amplified  gp120  fragments  were  cloned  into  a  mammalian 
expression vector, and recombinant gp120 was expressed in 293T cells infected with 
a T7 RNA polymerase recombinant vaccinia virus to enhance expression. Secreted 
envelope protein was harvested 48 h post-transfection and purified by means of the 
6-Histidine-tag  which  was  incorporated  into  the  reverse  primer.  Expression  of 
recombinant gp120 in the cell culture supernatant was captured onto ELISA plates  
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by the sheep antibody D7324. Since the D7324 antibody recognises the C-terminus 
of  gp120,  this  method  captures  antigens  that  are  fully  translated  and  secreted. 
Captured  gp120  was  detected  using  human  anti-HIV-1  sera.  A  negative  control 
supernatant (mock transfected cells) and gp120 CN54 of known concentration were 
also included in the ELISA.  
Figure 5-2 shows the results of the ELISA from gp120 92BR025 expression. A dose-
dependent curve was observed for both gp120 92BR025 and CN54. Based on the 
luminescence signals of both curves, the approximate amount of gp120 92BR025 
expressed in the supernatant was determined to be approximately 3 µg/ml.  
 
   
 
 
 
Figure  5-2.  Detection  of  gp120 
92BR025 expression in ELISA 
Serial dilutions of cell culture supernatant 
were incubated on D7324 coated plates to 
capture  gp120,  which  was  detected  with 
human  anti-HIV  serum  followed  by  an 
AP-conjugated  goat  anti-human  IgG 
antibody.  A  serial  dilution  of  gp120 
CN54,  starting  from  50  µg/ml,  was  also 
included  as  a  positive  control.  A  mock 
expression  was  included  as  a  negative 
control.   
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The recombinant gp120 92BR025 was then purified with nickel columns using the 
method described in Section 2.6.4.2. The purified samples were dialysed overnight 
in PBS with a 90 kDa cut-off membrane. Figure 5-3 shows the image of the SDS-
PAGE of the samples after purification. Most of the supernatant proteins (between 
40 – 70 kDa) were removed, but the presence of impurities was still observed after 
His-tag  purification.  Dialysis  of  the  purified  samples  did  not  remove  all  the 
impurities, as shown in the highlighted ellipse. 
 
Figure 5-3. SDS-PAGE of gp120 92BR025 purification 
The products before and after nickel column purification were analysed in SDS-PAGE. The culture 
supernatant and the flow-through showed the presence of huge quantities of culture proteins. After 
elution of the His-tag proteins, some of the impurities were still present in the sample. These are 
marked in the ellipse above. These impurities were not removed even after dialysis of the sample. The 
recombinant gp120 92BR025 with the His-tag is marked with the bold arrow.  
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5.3.2  Biotinylation of recombinant gp120 
Antigen that is coated onto a solid substrate can cause antibodies to ‘stick’ onto the 
substrate,  leading  to  avidity  effects.  In  a  new  strategy  to  isolate  VHH of  higher 
affinity without the associated avidity effects, the phages were allowed to bind to the 
antigen in solution form, instead of coated onto plastic plate. The bound phages were 
captured by means of a biotin-avidin interaction on avidin coated plates. For that to 
occur, the antigen of interest needs to be biotinylated. 
The gp120 of both IIIB and 92BR025 were biotinylated according to the method 
described  in Section 2.7.1.2, which  involves the attachment of  biotin to any  free 
NH2  groups  on  a  protein.  To  check  that  the  biotinylation  of  the  antigens  have 
succeeded, both ELISA and Western blots were carried out.  
In  the  ELISA,  Maxisorp  plates  were  coated  with  both  the  biotinylated  and 
unbiotinylated  forms  of  gp120.  Biotin  was  detected  with  a  streptavidin-PO 
conjugate. The substrate was added and A490 measured. Figure 5-4 shows the graph 
from  the  ELISA.  Both  biotinylated  gp120  IIIB  and  92BR025  produced  higher 
signals than the corresponding unbiotinylated samples and the blank control wells, 
indicating  that  both  recombinant  gp120  were  successfully  biotinylated.  The 
recombinant gp120 were also probed with HRP-conjugated streptavidin in Western 
blots and visualised with ECL reagent on an X-ray film.  
Figure 5-5 shows the image of the Western blot. Biotinylated gp120 IIIB gave a 
clear  prominent  band  near  the  130  kDa  marker,  whereas  biotinylated  gp120 
92BR025 only gave a faint band at the same position. The presence of other bands in 
the  92BR025  sample  indicated  that  impurities  were  present,  as  was  already 
highlighted in the previous section.  
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The  biotinylated  gp120  samples  were  also  probed  with  the  C8  and  D7  VHH  in 
ELISA, and these VHH were able to bind. Hence, the epitopes for C8 and D7 were 
not disrupted during the biotinylation process (Data not shown). 
 
Figure 5-4. Detection of biotinylated gp120 in ELISA 
Both biotinylated and unbiotinylated gp120 IIIB and 92BR025 
were  coated  onto  Maxisorp  plates  and  detected  with 
streptavidin in ELISA. The results show that the biotinylated 
samples  gave  a  higher  signal  than  unbiotinylated  samples, 
which  were  comparable  to  the  readings  from  blank  control 
wells.  
 
Figure  5-5.  Western  blot  of  biotinylated  gp120 
IIIB and 92BR025 
Biotinylated  gp120  IIIB  and  92BR025  of  two  different 
concentrations  were  blotted  onto  PVDF  membranes  and 
probed with streptavidin. Biotinylated gp120 IIIB produced a 
clean  band  near  the  130  kDa  mark,  whereas  92BR025 
produced only a faint band (shown circled). Impurities were 
also  present  in  the  biotinylated  gp120  92BR025  sample,  as 
shown by the presence of bands near the 72 kDa mark.  
218 
 
5.4  Biopanning  and  selection  of  C8-  and  D7-  family  specific 
phage libraries 
The  C8-  and  D7-family  specific  phage  libraries  that  were  created  above  were 
sequentially panned on either  biotinylated gp120 IIIB or 92BR025. Recombinant 
gp120 IIIB was used in the selection protocol due to its availability, purity and good 
binding to sCD4 in ELISA. HIV-1 IIIB is, however, a CXCR4-using TCLA isolate 
and does not represent the majority of the transmitted HIV-1 isolates. In addition, 
IIIB is a subtype B virus; a subtype which accounts for only about 10% of infections 
worldwide.  Nevertheless,  since  the  parental  C8  and  D7/A12  VHH  were  isolated 
from  selections  using  gp120  IIIB,  this  antigen  was  also  used  in  the  following 
selection. 
To  facilitate  selection  of  VHH  that  could  recognise  HIV-1  primary  isolates,  as 
opposed to the TCLA virus HIV-1 IIIB, the family specific phage libraries were also 
panned on recombinant gp120 derived from the subtype C primary isolate 92BR025 
described in the previous sections. The phage libraries were panned twice on each 
subtype to enrich for VHH that can recognise that particular subtype of HIV-1. 
In an attempt to remove avidity effects during the binding of phages to the antigen, 
the phages were allowed to bind to low concentrations of antigen in solution form in 
pre-blocked plastic plates. This solution was then transferred to neutravidin coated 
plates to capture the biotinylated gp120 antigen. Neutravidin is a neutrally charged 
derivative  of  the  avidin  molecule  that  binds  to  biotin  with  minimal  nonspecific 
binding. Selections with biotinylated gp120 92BR025 were found to produce high 
background levels, and this might be due to the presence of impurities in the sample.  
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We decided that the sheep antibody D7324 (which recognises the C-terminus of 
gp120) would be coated onto plates to capture the phages bound to gp120 92BR025.  
This method of allowing the phages to bind to antigen in solution form is in contrast 
to the previous selections where the phages were allowed to bind to antigen that was 
pre-coated on Maxisorp plates. After the transfer of bound phages to the plates, the 
wells were then washed eight times to dislodge unbound phages and antigen. We 
assumed that the family specific phage library would have similar properties as the 
parental C8 and D7 VHH, and should therefore all recognise the CD4 binding site-
related epitopes of gp120. Therefore, trypsin was used to elute out all bound phages, 
instead of a competitive sCD4 elution used in the selections for C8 and D7. After 
two rounds of selections on each biotinylated antigen, the outputs that gave the best 
enrichment of binders from the optimum concentration of antigen were harvested. 
These procedures are detailed in Section 2.7.3. 
5.4.1  Bio-panning on biotinylated gp120 IIIB and 92BR025 
In  the  first  round  of  selection,  the  family  specific  phage  library  was  allowed  to 
incubate with serially diluted biotinylated gp120 IIIB and 92BR025 ranging from 10 
nM to 0.01 nM. Blank controls containing PBS only were also included. These were 
then  transferred  to  neutravidin  and  D7324  coated  plates  respectively,  and  bound 
phages were captured through the attachment of the antigen onto the plates. After the 
removal of unbound phages through washing, the bound phages were eluted with 
trypsin. Eluted phages were titrated onto E. coli, as described in Section 2.6.2.2, and 
shown in Figure 5-6 [A]. In each selection, there was an enrichment in the number of 
clones eluted, compared to the blank control wells. However, the selections using 
gp120 92BR025 appear to give a higher background compared to using gp120 IIIB.   
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The eluted phages from the first round of selection were amplified in E. coli TG1 
cells,  and  the  phages  were  rescued  to  be  used  as  inputs  in  the  second  round  of 
selection  following  the  methods  described  in  Section  2.6.2.  The  same  selection 
procedure was carried out as before, except that the amount of antigen used was 
decreased. The eluted phages were again titrated on E. coli, then on agar plates and 
shown in Figure 5-6 [B]. Two outputs from each selection were chosen for VHH 
expression by subcloning the selected repertoire into the pAX051 expression vector 
(refer to methods in Section 2.6.3). Ninety-six clones were picked from each output 
and the VHH harvested from the periplasmic fractions. 
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Figure 5-6. Titration on eluted phages from C8- and D7-family specific libraries  
The C8 and D7 family specific phage libraries were sequentially panned with biotinylated gp120 IIIB 
or 92BR025 in 2 rounds of selections. [A] In the first round of selection, the eluted phages (1Φ, 2Φ, 
3Φ, and 4Φ) were brought forward to a second round of panning, as shown in the block arrows above. 
[B] After the titration of eluted phages from the second round of selection, the outputs from two of 
each selection were brought forward to the next stage of picking and expression of individual clones 
(as shown in the block arrows). In all cases, the number of phages eluted was more than the blank 
control wells.     
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A representative sample of the selected clones was DNA fingerprinted with HinFI to 
determine  their  heterogeneity.  This  is  shown  in  Figure  5-7.  Compared  to  the 
fingerprints generated in Chapter 4, the selected clones here appear to show much 
less variation from each other. This is to be anticipated since all the selected clones 
have homologous sequences that belong to the same family.  
A  total  of  8  different  plates  containing  96  different  clones  each  were  selected, 
containing 4 plates each from the C8 and D7 family specific library. A schematic of 
the selection process and the outputs are shown in Figure 5-8. 
 
 
Figure 5-7. DNA fingerprint of selected clones from family specific libraries 
The final outputs from the selections were subcloned into expression vectors for VHH production. 
Ninety-six different clones were picked for VHH expression, and their DNA was fingerprinted by 
digestion with HinFI. These were then separated on agarose gel electrophoresis and visualised. The 
similarity of the fragment sizes show that the clones selected were not very diverse. A representative 
sample of the digested clones is shown here. 
  
223 
 
 
Figure 5-8. Schematic of the C8- and D7- family specific libraries selection 
 
5.4.2  Polyclonal sequencing of the outputs 
To determine if the family specific phage library construction and the panning of 
sister  clones  were  successful,  a  sequencing  reaction  was  carried  out  on  the 
polyclonal outputs of each selection. Since the outputs from each selection contain 
the  selected  VHH  repertoire,  sequencing  of  the  polyclonal  outputs  will  produce 
variations in the nucleotide sequence if the outputs were of a high diversity. 
Figure 5-9 shows the sequences of the polyclonal outputs aligned with the sequence 
of the parental VHH. In the selections from the C8-specific library, all the outputs 
were identical in sequence to the parental C8 VHH. This meant that only identical 
clones  were  produced  during  the  construction  of  the  C8-family  specific  phage 
library. This could be due to the C8-primer being too specific and only pulled out  
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sequences identical to C8 during the construction of the C8-family specific phage 
library, or no other clones like C8 were present in the llama.   
Fortunately, the polyclonal outputs from the D7-family selections showed variations 
in  its  translated  sequences  and  are  denoted  with  an  ‘X’  to  represent  an 
undeterminable amino acid sequence in Figure 5-9. On closer inspection, many of 
these variations occur within the CDRs, indicating that the selections had managed 
to  pull  out  sister  clones  which  were  fairly  diverse  and  could  represent  affinity 
matured clones.  
In  summary,  selections  on  the  C8-family  specific  phage  library  produced  only 
identical clones to the parental C8 VHH. On the other hand, selections on the D7-
family specific phage library have succeeded in producing a family of homologous 
clones with similar sequences as the parental D7/A12 VHH.  
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Figure 5-9. Polyclonal sequencing of the selected outputs 
The  polyclonal  outputs  from  the  selections  were  sequenced  and  the  nucleotide  sequence  was 
translated and aligned using ClustalW2. Positions marked with an ‘X’ refer to an undeterminable 
amino acid, probably due to variations in that particular position. Outputs from the C8-family were 
found to be identical to the parental C8 VHH, whereas variations were observed in the CDRs in the 
outputs of the D7-family.   
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5.4.3  Sequencing of the individual VHH 
Sequencing of all the individual clones selected from the D7-specific family was 
carried out to determine the diversity of the VHH in this library. Out of the 376 
clones picked, there were 49 unique amino acid sequences. Many identical clones 
were observed in both the selection strategies, using either biotinylated gp120 IIIB or 
92BR025, and therefore the antigen subtype did not help  in the enrichment of a 
particular  set  of  clones.  One  may  postulate  that  there  were  at  least  49  unique 
members  with  sequences  similar  to  D7  and  A12  in  the  original  phage  library 
repertoire  from  llama  44.  All  the  VHH  showed  high  sequence  homology  to  the 
parental  D7  VHH,  and  variations  in  the  sequences  were  observed  in  both  the 
framework regions, as well as the CDRs of the VHH. 
A total of 31 unique VHH were chosen, based on the differences in their amino acid 
sequences, for large scale expression and purification of the VHH to enable further 
characterisation. The DNA encoding the VHH fragments were all subcloned into the 
pAX051 expression vector providing a C-terminal 6x Histidine tag for purification. 
The methods are described in Section 2.6.4. 
 
5.5  Variations in Neutralisation potencies 
The 31 individual VHH from the D7-family specific library were tested for their 
neutralisation  activity  by  assaying  on  T-cell  line  adapted  viruses,  recombinant 
replication-competent  chimeric  viruses  and  psuedoviruses  expressing  envelopes 
cloned from plasma of infected individuals. The neutralisation activity was evaluated 
on the TZM-bl cell line that express CD4, the co-receptors CXCR4 and CCR5, as 
well as a Tat-induced luciferase reporter when infected with HIV-1. The TZM-bl  
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assay is described in Section 2.3.9, and the highest VHH concentration tested was at 
25 µg/ml.  The lowest VHH concentration required to achieve 50% reduction of 
infectivity (IC50) compared to virus control were determined.  
The numbers of VHH tested from the 2B10, 2C7 and 2C9 outputs (refer to Figure 5-
8) were 11, 9 and 11 respectively. These were chosen based on differences in their 
amino  acid  sequences,  especially  in  the  CDR  regions.  A  comparison  of  the 
neutralisation potency with the b12 mAb was also included, which is one of the most 
extensively studied bcnAb to HIV-1, which also binds to an epitope that overlaps the 
CD4bs of gp120 (Zhou et al., 2007). A total of seven different strains of viruses were 
used, of which 3 were subtype B viruses (IIIB, QH0692.42, PVO.4) and 4 were 
subtype C viruses (C222, C27d, 92BR025, ZM214M). The QHO692.42, PVO.4 and 
ZM214M isolates are psuedoviruses which are Tier-2 CCR5 using envelopes, and 
are part of the subtype standard reference panels (Li et al., 2005; Li et al., 2006b). 
The C222 and C27d primary isolates were described in Chapter 3, and 92BR025 is a 
PBMC isolate obtained from the WHO-UNAIDS panel of primary isolates (Gao et 
al., 1994). The envelopes  from these  isolates were cloned  into HIV-1 backbones 
producing chimeric replication competent viruses.  
From the results in Table 5-1, the VHHs can be broadly categorised into three groups 
according to their ability to neutralise different strains of HIV-1. Most of the VHH 
showed similar neutralisation potencies. For instance, all the VHH tested were able 
to neutralise HIV-1 IIIB and C27d at less than 1 µg/ml, whereas none were able to 
neutralise  PVO.4  and  ZM214M.  All  the  VHH  were  also  able  to  neutralise 
QHO692.42 to moderate levels with IC50 values of between 10-25 µg/ml.    
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However, two of the subtype C viruses tested revealed significant differences in the 
neutralising potencies of the VHH. Most of the VHH were able to neutralise both 
C222 and 92BR025 to high potencies with IC50 values of less than 1 µg/ml and 5 
µg/ml respectively. This group of VHH is termed the broad neutralisers. The A12 
VHH belongs to this group. A group of 7 different VHH was unable to neutralise 
both C222 and 92BR025, and are termed ‘narrow’ neutralising VHH. The D7 VHH 
belongs to this group. Three of the VHH were able to neutralise C222 with IC50 
values of less than 15 µg/ml, but they were not able to neutralise 92BR025. This 
group was termed ‘intermediate’ neutralisers.  
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Table 5-1. VHH and mAb b12 IC50 (ug/ml) titres against HIV-1 
 
VHH
a 
Subtype B    Subtype C 
IIIB  QH0692.42  PVO.4    C222  92BR025  C27d  ZM214M 
B
r
o
a
d
 
2B10A2  0.07  19.73  >25    0.13  2.01  0.02  >25 
2B10C2  0.16  18.66  >25    0.12  1.57  0.03  >25 
2B10D5  0.57  19.63  >25    0.96  1.95  nd  >25 
2B10D7  0.12  21.63  >25    0.20  1.42  0.03  >25 
2B10D11  0.18  15.48  >25    0.36  4.47  0.03  >25 
2B10G5  0.40  16.10  >25    0.04  0.28  0.05  >25 
2B10H1  0.29  17.21  >25    0.08  0.74  0.04  >25 
2B10H3  0.29  19.14  >25    0.06  0.39  0.04  >25 
2C7B8  0.15  10.78  >25    0.27  0.78  0.14  >25 
2C7D2  0.17  20.71  >25    0.28  0.60  0.14  >25 
2C7E3  0.07  12.16  >25    0.13  0.48  0.03  >25 
2C7G11  0.16  16.08  >25    0.24  1.76  0.08  >25 
2C9A8  0.30  nd  >25    0.41  2.40  0.07  >25 
2C9B11  0.24  nd  >25    0.30  3.41  0.24  >25 
2C9C5  0.12  nd  >25    0.16  1.23  0.12  >25 
2C9D9  0.37  nd  >25    0.61  3.64  0.30  >25 
2C9E4  0.35  nd  >25    0.50  1.76  0.14  >25 
2C9E7  0.30  20.87  >25    0.34  0.90  0.15  >25 
2C9F1  0.13  19.31  >25    0.48  0.95  0.13  >25 
2C9F10  0.13  18.70  >25    0.16  0.61  0.12  >25 
2C9H5  0.17  17.28  >25    0.19  0.73  0.03  >25 
I
n
t
e
r
-
m
e
d
i
a
t
e
 
2C7F7  0.34  17.31  >25    4.53  >25  0.24  >25 
2C7H5  0.12  16.50  >25    10.20  >25  0.06  >25 
2C9E2  0.20  19.39  >25    4.08  >25  0.16  >25 
N
a
r
r
o
w
 
2B10B10  0.54  19.40  >25    >25  >25  nd  >25 
2B10E2  0.46  15.90  >25    >25  >25  nd  >25 
2B10E8  0.49  18.54  >25    >25  >25  nd  >25 
2C7D1  0.24  16.29  >25    >25  >25  0.17  >25 
2C7D5  0.13  20.04  >25    >25  >25  0.08  >25 
2C7E11  0.21  17.27  >25    >25  >25  0.09  >25 
2C9F6  0.18  14.54  >25    >25  >25  0.15  >25 
  A12  0.09  13.00  >25    0.07  0.23  0.02  >25 
  D7  0.30  17.00  >25    >25  >25  0.03  >25 
  b12  0.21  0.70  >25    >25  >25  0.02  12.29 
a. The VHH are grouped into 3 categories according their neutralising potencies against C222 and 
92BR025. The neutralisation potencies are shaded in different shades, with darker shades indicating 
higher potencies.  
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5.6  Sequence analysis of the CDRs 
All the 31 VHH possessed unique sequences with variations within the framework 
regions (FR)  as well  as  in the  complementarity determining regions (CDRs). To 
understand the basis of the variations in neutralising potencies amongst the members 
of the D7-specific VHH family, the amino acid sequences of the CDRs of the VHH 
were grouped according to their three neutralising categories, and these are shown in 
Table  5-2.  Only  the  sequences  of  the  CDRs  are  shown  as  these  are  crucial  in 
determining antigen recognition. The positions of the CDRs residues are as follows: 
24-33 for CDR1, 52-59 for CDR2 and 99-116 for CDR3. Variations in the amino 
acid residues are highlighted in grey.  
When  comparing  between  the  broad  and  narrow  neutraliser  categories,  the  only 
region that is distinct between them is the presence of an Tyr-Tyr-Asp (YYD)116 
motif at the C-terminal end of the CDR3 region for the broad neutralisers. There is 
an absence of this motif in all the narrow neutralisers. Mutation of this YYD116 
motif  to  YYY,  YNY or  YND  seems  to  hinder  the  neutralising  abilities  of  these 
particular viruses. Within the broad neutraliser category, mutations in the other CDR 
or framework residues did not hinder neutralising abilities.  
To demonstrate that the YYD116 motif is crucial for the broad neutralising ability of 
the VHH, we compared the sequences of all the VHH obtained from this family. In 
Figure  5-10(A), the  sequences  of  both  2C7D2  and  2C9E2  are  exactly  the  same, 
except for a single YYD116 to YYY116 mutation. This single mutation resulted in a 
change in neutralisation category from broad to intermediate. Similarly for 2B10G5 
and  2C7D1,  a  single  YYD116  to  YNY116  mutation  resulted  in  a  neutralisation 
category change from broad to narrow, as shown in Figure 5-10(B). The 2C7H5 and  
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2C7E11 VHH belong to the intermediate and narrow neutralisation category, and 
they both exhibit a YND116 mutation. Although these two VHH contain a few other 
mutations  in  its  sequence,  these  mutations  are  also  found  in  the  other  broad 
neutraliser (or YYD) variants and therefore do not affect its neutralising potential, as 
shown  in  Figure  5-10(C).  The  2C9E2  VHH  possesses  a  S63F  mutation  in  the 
framework region, in addition to the presence of a YYY motif that caused a change 
from  broad  to  poor  neutralisation  ability.  This  is  shown  in  Figure  5-10(D).  The 
YYY, YNY and YND motifs are therefore associated with less broad neutralising 
potential when compared to the YYD motif. 
Certain residues within the CDRs were found to show mutations in high frequencies. 
These  are  residues  24,  28,  31,  and  32  within  CDR1,  residue  59  in  CDR2,  and 
residues 106, 108, 115 and 116 in CDR3. Except for residues 115 and 116 which are 
part  of  the  YYD  motif,  mutations  in  all  the  other  residues  did  not  affect  the 
neutralisation ability of the VHH, and are therefore not as critical to function.  
However, the presence of a YYD motif in itself is not sufficient to confer broad 
neutralising ability to the VHH against these subtype C strains tested. Even though 
the 2C7F7 VHH contains a YYD  motif,  it  falls under the  intermediate category. 
From Table 5-2, 2C7F7 contain three other point mutations within the CDRs. There 
is one unique H/Y32F mutation within the CDR1 that is not found in any of the other 
VHH  within  the  family.  A  unique  phenylalanine  residue,  that  is  nonpolar  and 
hydrophobic, has replaced the polar histidine or tyrosine residues that are usually 
found in that position. This particular mutation might therefore affect the folding or 
binding of 2C7F7 and thus affect its neutralisation ability. 
    
232 
 
Table 5-2. Sequence comparison of the CDRs 
VHH
a  CDR1(24-33)
b  CDR2(52-59)
b  CDR3(99-116)
b 
 
Broad Neutralisers 
 
2B10D5 
2B10C2 
2C9A8 
2C9B11 
2B10A2 
2B10D11 
2C7E3 
2C9C5 
2C9F10 
2C7D2 
2B10G5 
2C9E7 
2B10H3 
2C7B8 
2B10D7 
2B10H1 
2C9F1 
2C9H5 
2C7G11 
2C9D9 
2C9E4 
A12 
 
VSGRTSSSHD 
VSGRTSSSHD 
VSGRTSSSHD 
VSGRTSSSHD 
VSGRTSSSHD 
VSGRISSSHD 
ASGRISSSHD 
ASGRISSSHD 
APGRISSSHD 
ASGRISSSHD 
ASGRISSSHD 
AFGRISSSHD 
ASGRISSSHD 
ASGRISSSYD 
ASGRISSSYD 
ASGRISSSYD 
ASGRISSSYD 
ASGRISSSYD 
ASGRISSSYD 
ASGRISSMYD 
ASGRISSMYD 
ASGRISSSYD 
 
SWSGGTTD 
SWSGGTTD 
SWSGGTTD 
SWSGGTTD 
SWSGGTTN 
SWSGGTTD 
SWSGGTTN 
SWSGGTTN 
SWSGGTTN 
SWSGGTTD 
SWSGGTTD 
SWSGGTTD 
SWSGATTD 
SWSGGATD 
SWSGGTTD 
SWSGGTTD 
SWSGGTKD 
SWSSGTTD 
SWSGGTTD 
SWSGGTTA 
SWSGGTTA 
SWSGGTTD 
 
KWRPLRYSDNPSNSDYYD  
KWRPLRYSDNPSNSDYYD  
KWRPLRYNDNPSNSDYYD  
KWRPLRYNDNPSNSDYYD  
KWRPLRYSDNPSNSDYYD  
KWRPLRYSDNPSNSDYYD  
KWRPLRYSDSPSNSDYYD  
KWRPLRYSDSPSNSDYYD  
KWRPLRYSDSPSNSDYYD  
KWRPLRYSDDPSNSDYYD  
KWRPLRYSDDPSNSDYYD  
KWRPLRYSDDPSNSDYYD  
KWRPLRYSDDPSNSDYYD 
KWRPLRYSDYPSNSDYYD  
KWRPLRYSDYPSNSDYYD  
KWRPLRYSDYPSNSDYYD  
KWRPLRYSDYPSNSDYYD  
KWRPLRYSDYPSNSDYYD  
KWRPLRYSDSPSNSDYYD  
KWRPLRYSDDPSNSDYYD  
KWRPLRYSDDPSNSDYYD  
KWRPLRYSDYPSNSDYYD  
 
Intermediate Neutralisers 
 
2C7H5 
2C9E2 
2C7F7 
 
ASGRISSSHD 
ASGRISSSHD 
ASGRTSSSFD 
SWSGGTTD 
SWSGGTTD 
SWSGGTTD 
KWRPLRYSDDPSNSDYND 
KWRPLRYSDDPSNSDYYY 
KWRPLRYSDNPSNSDYYD 
Narrow Neutralisers 
 
2B10E8 
2C7E11 
2B10E2 
2C9F6 
2B10B10 
2C7D1 
2C7D5 
D7 
 
VSGRTSSSHD 
ASGRVSSSHD 
ASGRISSSYD 
ASGRISSSYD 
ASGRISSSYD 
ASGRISSSHD 
ASGRLSSMYD 
VSGRTSSSHD 
SWSGGTTD  
SWSGGTTD  
SWSGGTTD  
SWSGGTTD  
SWSGGTTD  
SWSGGTTD  
SWGGGSTT  
SWSGGTTN  
KWRPLRYSDNPSNSDYND  
KWRPLRYSENPSNSDYND  
KWRPLRYSDYPSNSDYNY  
KWRPLRYSDYPSNSDYYY  
KWRPLRYSDYPSNSDYNY  
KWRPLRYSDDPSNSDYNY  
KWRPLRYSDNPSNSDYND  
KWRPLRYSDNPSNSDYNY  
aAmino  acid  sequences  of  the  CDRs  are  grouped according  to  their  three  different neutralisation 
categories. Grey highlights refer to regions with sequence variations. The YYD motifs at the end of 
the CDR3 are bolded and underlined. Variations of this motif are bolded.  
bThe numbers in brackets refer to the amino acid positions of the CDRs within the VHH sequence.  
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[A] 
 
2C7D2           EVQLVESGGGLVQAGGSLRLSCTASGRISSSHDMGWFRQAPGKEREFVAAISWSGGTTDY 60 
2C9E2           EVQLVESGGGLVQAGGSLRLSCTASGRISSSHDMGWFRQAPGKEREFVAAISWSGGTTDY 60 
 
2C7D2           ADSVKGRFAISKDNAKNAVSLQMNSLKPEDTAVYYCAAKWRPLRYSDDPSNSDYYDWGQ 119 
2C9E2           ADSVKGRFAISKDNAKNAVSLQMNSLKPEDTAVYYCAAKWRPLRYSDDPSNSDYYYWGQ 119 
 
 
[B] 
 
2B10G5          EVQLVESGGGLVQAGGSLRLSCTASGRISSSHDMGWFRQAPGKEREFVAAISWSGGTTDY 60 
2C7D1           EVQLVESGGGLVQAGGSLRLSCTASGRISSSHDMGWFRQAPGKEREFVAAISWSGGTTDY 60 
 
2B10G5          ADSVKGRFAISKDNAKNAVSLQMNSLKPEDTAVYYCAAKWRPLRYSDDPSNSDYYDWGQ 119 
2C7D1           ADSVKGRFAISKDNAKNAVSLQMNSLKPEDTAVYYCAAKWRPLRYSDDPSNSDYNYWGQ 119 
 
 
[C] 
 
2B10G5          EVQLVESGGGLVQAGGSLRLSCTASGRISSSHDMGWFRQAPGKEREFVAAISWSGGTTDY 60 
2C7H5           EVQLVESGGGLVQAGGSLRLSCTASGRISSSHDMGWFRQAPGKEREFVAAISWSGGTTDY 60 
2C7E11          EVQLVESGGGLVQAGGSLRLSCTASGRVSSSHDMGWFRQAPGKEREFVAAISWSGGTTDY 60 
 
2B10G5          ADSVKGRFAISKDNAKNAVSLQMNSLKPEDTAVYYCAAKWRPLRYSDDPSNSDYYDWGQ 119 
2C7H5           ADSVKGRFAISKDNAKSAVSLQMNSLKPEDTAVYYCAAKWRPLRYSDDPSNSDYNDWGQ 119 
2C7E11          ADSVKGRFAISKDNAKNAVSLQMNSLKPEDTAVYYCAAKWRPLRYSENPSNSDYNDWGQ 119 
 
 
[D] 
 
2B10D7          EVQLVESGGGLVQAGGSLRLSCTASGRISSSYDMGWFRQAPGKEREFVAAISWSGGTTDY 60 
2C9F6           EVQLVESGGGLVQAGGSLRLSCTASGRISSSYDMGWFRQAPGKEREFVAAISWSGGTTDY 60 
 
2B10D7          ADSVKGRFAISKDNAKNAVSLQMNSLKPEDTAVYYCAAKWRPLRYSDYPSNSDYYDWGE 119 
2C9F6           ADFVKGRFAISKDNAKNAVSLQMNSLKPEDTAVYYCAAKWRPLRYSDYPSNSDYYYWGQ 119 
 
 
 
Figure 5-10. Full sequences of relevant VHH illustrating important mutants 
The full sequences of relevant VHH are shown above, with mutations highlighted in grey. [A] A 
YYD to YYY mutation resulted in 2C9E2 turning into an intermediate neutraliser. [B] A YYD to 
YNY resulted in 2C7D1 turning into a narrow neutraliser. [C] A YYD to YND mutation resulted in 
2C7H5  and  2C7E11  turning  into  an  intermediate  and  narrow  neutraliser  respectively.  The  other 
mutations highlighted in its sequence are also present in other YYD variants, and do not contribute to 
the neutralisation category as defined in this study. [D] A YYD to YYY mutation resulted in 2C9F6 
turning into a narrow neutraliser. The presence of an S63F mutation in the FR is unlikely to affect 
neutralisation breadth.  
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5.7  VHH show diverse kinetic measurements 
To determine if there was a relationship between the binding kinetics of the VHH to 
gp120 and the neutralisation breadth of the VHH against HIV-1, the affinities of the 
VHH to recombinant gp120 IIIB were measured using surface plasmon resonance 
techniques. Surface plasmon resonance measures the angle by which polarised light 
is reflected from a gold-covered glass surface, to which molecules of interest are 
immobilised usually through a dextran layer linked to the gold. The angle by which 
the polarised light is reflected is used to calculate the density above the glass surface, 
enabling real-time analysis of the interactions between the immobilised molecule and 
molecules  added  to  the  fluid-phase.  Kinetic  measurements  were  performed  on  a 
BIAcore machine by Bart Hoorelbeke at Ablynx NV, who is our collaborator on the 
EMPRO project. 
Recombinant gp120 IIIB was coupled to the biosensor chip using standard amine 
coupling  techniques,  and  the  periplasmic  extracts  containing  VHH  from  all  the 
clones of 2B10 were measured for their dissociation rate constants (kd). Due to time 
constraints and limitations in access to the BIAcore facility, we were only able to test 
the VHH outputs from 2B10 only. A remarkably high proportion of the VHH clones 
(98%) from 2B10 were able to bind to recombinant gp120 IIIB. The kd or off-rates 
ranged from 5.91x10
-4 s
-1 to 2.47x10
-5 s
-1, representing a range of over 20-fold. This 
showed that the biological active members within the D7 sub-family library of VHH 
were fairly diverse, despite such variations not being evident in the DNA fingerprint 
using HinFI digestion.  
Twelve VHH were subsequently chosen, based on their wide range of off-rates, to be 
purified and further analysed in the BIAcore. The association and dissociation rate  
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constants  (ka  and  kd)  were  determined  and  used  to  calculate  the  equilibrium 
dissociation constants (KD). These are shown  in Table 5-3, and the D7 and  A12 
VHH were included for comparison.  
Interestingly, VHH with low off-rates of 1x10
-4 s
-1 and below possess a YYD116 
motif, which is associated with a broad neutralising ability. VHH with high off-rates 
of  1x10
-4  s
-1  and  above  do  not  possess  the  YYD116  motif  and  display  a 
corresponding lack in broad neutralising ability. A lower off-rate would mean that 
the VHH ‘sticks’ longer onto the antigen, hence VHH with the YYD116 motif were 
able to ‘stick’ longer onto gp120 IIIB compared to those VHH without the YYD116 
motif.  These  also  have  a  corresponding  greater  affinity  (a  lower  dissociation 
equilibrium constant or KD) for gp120 IIIB. A greater affinity for gp120 in the VHH 
with the YYD116 motif might therefore have a direct correlation with it having a 
broader neutralisation potential.  
However, the kinetics of the D7 VHH seems to contravene the above observation. 
The D7 VHH has a YNY motif that is associated with a narrow neutralising ability, 
but  yet  its  off-rates  were  in  the  range  of  those  VHH  in  the  broad  neutralising 
category. A greater sampling of the VHH needs to be carried out to confirm this 
observation.    
    
236 
 
Table 5-3. VHH kinetic constants and affinities 
 VHH   kD (1/s) 
a  KD (nM)
b  Motif116
c  Neut. 
Category
d 
2B10D11   2.47E-05  0.22  YYD  Broad 
2B10H1   2.52E-05  0.17  YYD  Broad 
2B10C2   2.76E-05  0.23  YYD  Broad 
2B10G5   3.09E-05  0.21  YYD  Broad 
2B10H3   3.12E-05  0.19  YYD  Broad 
2B10A2   6.80E-05  ND  YYD  Broad 
2B10D7   7.37E-05  0.57  YYD  Broad 
2B10D5   7.61E-05  0.66  YYD  Broad 
2B10B4   8.56E-05  0.52  YYD  Broad 
2B10E8   1.12E-04  1.1  YND  Narrow 
2B10E2   3.18E-04  1.9  YNY  Narrow 
2B10B10   3.39E-04  1.7  YNY  Narrow 
A12  2.98E-05  0.1  YYD  Broad 
D7   6.88E-05  0.1  YNY  Narrow 
a Dissociation rate constant, 
b Equilibrium dissociation constant, 
c Amino acid motif at position 116, 
d 
Neutralisation category as shown in Table 5-1.  
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5.8  Inhibition of sCD4 binding 
The parental D7 and A12 VHH was previously determined to compete with sCD4 
for binding to gp120 in both ELISA and surface plasmon resonance (Forsman et al., 
2008). Even though a general trypsin elution was employed during the panning of 
the VHH from the family-specific libraries, the selected VHH from this study were 
all assumed to have similar recognition properties and recognise a CD4bs-related 
epitope of gp120. A competition ELISA was therefore carried out to determine if the 
selected VHH behaved in a similar manner.  
A fixed amount of gp120 IIIB was first allowed to bind to titrated amounts of VHH, 
and the ability of the bound VHH to inhibit the binding of gp120 to sCD4-precoated 
plates was measured. Therefore, greater amounts of a CD4bs recognising VHH will 
prevent gp120 from binding to the plates and lead to lower levels of gp120 detection. 
A sample of 15 different VHH from the different outputs representing a range of 
different affinities was tested in this assay. The parental D7 VHH and the CD4bs 
recognising mAb b12 were also included in this assay, together with an irrelevant 
negative control VHH (VHH #3). The results are shown in a graph in Figure 5-11. 
VHH which possess a YYD116 motif are show in solid lines and those without the 
motif are in dashed lines. The negative control VHH showed no effect in affecting 
gp120 binding to sCD4. Together with the D7 VHH and positive control mAb b12, 
the 15 different VHH isolated in this study were all found to inhibit binding of gp120 
to sCD4 in a dose dependent manner. This is possible if the VHH bind to an epitope 
which sterically overlaps the CD4bs and hinders the binding of sCD4, or if VHH 
binding locks gp120 in a conformation that prevents binding of sCD4. It is quite 
likely that this family of VHH all recognise related epitopes on gp120 but bind with  
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different off-rates. Unliganded D7 VHH has been crystallised and a high-resolution 
structure of D7 was obtained by W. Weissenhorn’s laboratory, and a crystal structure 
of D7 liganded to gp120 is being sought.  
 
 
Figure 5-11. VHH inhibition of sCD4 binding to gp120 IIIB in ELISA 
A range of VHH were tested for their ability to inhibit sCD4 binding to gp120 IIIB in ELISA. Dashed 
lines refer to VHH without the YYD motif, and solid lines refer to VHH with the YYD motif. All the 
VHH from the D7 subfamily were able to inhibit sCD4 binding to gp120 IIIB, in a manner similar to 
the mAb b12. The presence of the YYD motif did not produce a clear difference in the inhibition 
pattern that can be determined in this ELISA. The negative VHH does not inhibit gp120 binding to 
sCD4 even at high concentrations.  
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5.9  Discussion 
In  this  study,  I  have  successfully  created  a  D7  family-specific  library  of  HIV-1 
neutralising VHH, although the C8-family only produced identical clones. This was 
achieved  through  the  use  of  primers  that  target  the  tail  of  the  CDR3  sequence, 
thereby  isolating  VHH  with  homologous  sequences  from  the  diverse  repertoire 
naturally present in the immunised llama. The design of the primer was based on the 
sequence of the D7/A12 VHH, which was previously found to be able to neutralise 
various HIV-1 isolates of subtypes B and C. The D7 family-specific library was then 
panned  on  picomolar  concentrations  of  recombinant  gp120  in  solution  form  to 
reduce potential avidity effects. In yet another indication that the library creation and 
panning had worked, a very high proportion (98%) of the selected VHH was specific 
for gp120, as determined with a high-throughput BIAcore machine. Although the 
main objective was to isolate VHH members that were able to target the CD4bs of 
gp120, a general trypsin elution method was employed to elute out all bound phages 
to gp120. It was assumed that all members of the family will be able to recognise an 
epitope overlapping the CD4bs, in a manner similar to the parental D7 VHH. This 
property  of  the  family-specific  library  was  confirmed  with  a  competition  ELISA 
experiment where all of isolated VHH tested were able to prevent soluble CD4 from 
binding to gp120.  
Through this technique, 49 unique VHH belonging to the same family were isolated 
from a single llama. However, the members of this VHH subfamily do not show 
identical properties. Even though they share the ability to recognise gp120 at an 
epitope overlapping the CD4bs, they do so with different off-rates. From the subset 
of clones tested in surface plasmon resonance, the VHH within the D7-family show a 
20-fold variation in off-rate. The upper peak in off-rate (kd) reached was 2.47x10
-05  
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s
-1 for the 2B10D11 VHH, which was twice lower than the parental D7 value of 6.88 
x10
-05 s
-1. Interestingly, the affinity (KD) of D7 was twice better at 0.1nM, compared 
to 0.22nM for 2B10D11. It is worth noting that antibody affinities in this range are 
close to the suggested affinity ceiling for in vivo maturated antibodies (Batista and 
Neuberger, 1998; Foote and Eisen, 1995), which might explain the absence of VHH 
with even better affinities in the original immune library. Camelid VHH also usually 
bind to their target with affinities comparable to those of conventional antibodies 
(Harmsen and De Haard, 2007; Muyldermans et al., 2001). Nevertheless, the affinity 
and  avidity  of  these  VHH  can  often  be  enhanced  by  reconstructing  them  as  a 
conventional bivalent antibody or as multimers (Power and Hudson, 2000). 
The  VHH  within  the  family  also  showed  variations  in  their  ability  to  neutralise 
different strains of HIV-1. Although most of the VHH possessed similar potencies as 
the parental D7 VHH against some of the HIV-1 strains tested, 3 primary isolates of 
HIV-1  stood  out.  The  selected  VHH  displayed  different  neutralisation  potencies 
(IC50 values) when tested on C27d, C222 and 92BR025, and the VHH were grouped 
accordingly.  When  the  sequences  were  analysed  according  to  the  neutralisation 
categories, it was interesting to find that certain amino acid residues were important 
for potent neutralising ability. An YYD116 motif at the tail of the CDR3 was found 
to correlate with good neutralising activity. Changes in the YYD motif changed the 
neutralising  activity  to  ‘poor’  against  the  viruses  tested  in  this  study,  whereas 
mutations in the other CDRs or the FRs did not affect neutralising ability. This motif 
is also directly related to its off-rates in BIAcore studies and is therefore crucial to its 
function. More viruses will  be tested to determine  if additional differentiation  in 
neutralisation  ability  can  be  observed.  We  have  thus  exploited  the  naturally 
occurring  pool  of  related  sequences  to  help  elucidate  this  correlation  between  
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sequence and antigen-antibody interactions. Back mutations to the YYD motif via 
site-specific mutagenesis are currently being carried out on the VHH that are narrow 
neutralisers to determine if this changes their neutralisation breadth. Unfortunately, 
time  constraints  do  not  permit  inclusion  of  this  analysis  in  my  thesis.  Structural 
studies  on  VHH  and  its  binding  to  antigen  are  currently  in  progress  to  further 
elucidate antigen-binding reactions. 
In  conclusion,  we  have  used  a  novel  approach  to  create  a  family-specific  VHH 
library whereby members of the family showed similarity in its ability to recognise a 
particular antigen, eliminating the need for competitive elutions. However, variations 
exist within the members of the family in terms of their binding affinities, as well as 
neutralisation ability across different strains of  viruses. The creation of a diverse 
pool  of  VHH  from  a  single  parental  clone  has  enabled  the  broadening  in 
neutralisation breadth and potencies. This approach can also be used on other llamas 
or be based on new sequences once new broadly neutralising antibodies have been 
identified. By analysing the sequences of the VHH, we were able to associate certain 
amino acid residues as crucial for broad neutralisation ability. This will be useful for 
future engineering of potent heavy chain antibody fragments against HIV-1, as well 
as offering new tools for development of inhibitors, vaccines and research reagents.  
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6  Discussion and Summary 
When this project was started in 2005, subtype B viruses were the  most studied 
subtype even though subtype C viruses were the cause of the majority of the new 
infections in the world. Since HIV-1 envelopes of different subtypes are very diverse 
and show different neutralisation patterns, we decided to study subtype C HIV-1 
envelopes and to characterise new antibodies that can neutralise them.  
To this end, I have described in Chapter 3 on the cloning of 18 subtype C HIV-1 env 
genes directly  from patients and their  insertion  into vectors to create replication-
competent  chimeric  viruses.  The  genotypes  of  these  envelopes  were  then 
phylogenetically characterised and variations in their variable loops and positions of 
potential  N-linked  glycosylation  sites  were  analysed.  The  sequences  of  these 
envelopes were uploaded onto Genbank. 
I have also determined that these cloned subtype C envelopes have a much lower 
incidence  in  ability  to  use  CCR3  as  a  coreceptor than  in  the  commonly  studied 
subtype B envelopes. Envelopes from the subtype B, C, CRF07_BC and CRF02_AG 
standard reference panels were then studied for their ability to use other coreceptors 
for  virus  entry,  and  we  found  that  subtype  B  envelopes  have  a  100-fold  higher 
incidence  of  using  CCR3  as  a  coreceptor  compared  to  the  other  subtype  and 
recombinant  forms.    Unfortunately,  similar  findings  were  recently  reported  by 
another group (Nedellec et al., 2009).  
Although  some  of  the  determinants  in  gp120  for  CCR3  coreceptor  usage  were 
previously mapped for subtype B viruses (Aasa-Chapman et al., 2006b), these were 
found to be inapplicable for envelopes from other subtypes. As the sequences for the  
243 
 
cloned subtype C envelopes are known, future work could be developed to determine 
the amino acids that are important for CCR3 binding.  
The  patient  samples  used  in  this  study  were  mostly  obtained  from  Africa  and 
represent current replicating strains. The creation of this panel of subtype C viruses 
adds to the other subtype C panels (Brown et al., 2005; Li et al., 2006b) that were 
created  after the start of this project, and the panel described in this study will be a 
useful  resource  for  antibody  neutralisation  studies  as  some  of  the  envelopes  are 
genetically and phenotypically diverse from the standard panel strains. The subtype 
C envelopes created here were used to test the neutralisation breadth of the VHH that 
were created in Chapters 4 and 5, as well as in other studies by Forsman et al. and 
McKnight et al. (Forsman et al., 2008; McKnight, personal communication). The 
characterisation  of  these  subtype  C  envelopes  for  their  sensitivity  to  antibody 
neutralisation might also have implications in the design and assessment of vaccine 
candidates.  For  instance,  novel  broadly  neutralising  antibodies  or  novel  entry 
inhibitors to be used in clinical trials can be tested against these subtype C primary 
isolates to determine the candidates’ neutralisation potency and breadth.  
In  this  thesis,  the  unique  properties  of  the  llama  single-chain  antibodies  were 
exploited  to  produce  VHH  that  retain  all  the  antigen-binding  properties  of 
conventional antibodies. Advantages of using such VHH include their longer than 
average CDR3 loops that can bind into clefts, ease of cloning and expression, as well 
as being robust and stable (refer to Section 1.3.2). 
Chapter 4 described the isolation of four different anti-gp41 VHH from a llama that 
was  immunised  with  recombinant  trimeric  gp140  CN54.  These  were  found  to 
neutralise  subtype  C  viruses  better  than  subtype  B  viruses  and  recognised  a  
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conformational dependent epitope on gp41. Although the neutralisation potency of 
these VHH were not as strong as the well characterised mAbs 2F5 and 4E10, these 
VHH can  be  modified  into bivalent or multivalent forms and engineered to give 
higher binding affinities. All the anti-gp41 neutralising antibodies described to date 
were isolated from humans naturally infected with HIV-1, and this may be the first 
instance of  isolating anti-gp41  neutralising antibodies  from an  immunised animal 
(Haynes and  Montefiori, 2006; Pantophlet and  Burton, 2006;  Zwick and Burton, 
2007). 
The  VHH  produced  in  Chapter  5  were  based  on  our  earlier  success  in  isolating 
neutralising VHH that target the CD4 binding site of gp120 (Forsman et al., 2008). 
Using  a  novel  cloning  strategy,  a  D7/A12  family-specific  library  of  VHH  was 
successfully produced and described in this chapter. This newly isolated family of 
VHH were all able to compete with sCD4 for binding to gp120, and displayed a 
range of binding affinities to gp120. Based on their ability to neutralise different 
strains of HIV-1, this family of VHH can be classified into “Broad”, “Intermediate” 
and  “Narrow”  neutralisers.  The  last  three  amino  acid  residues  of  the  CDR3  are 
implicated in these differences in affinities and neutralisation abilities. Mutational 
studies are currently  being carried out to verify this, as well as to determine the 
binding epitope on gp120.  
The creation of  homologue antibodies  in the  family-specific  library of VHH  has 
allowed the mining of antibodies of interest from a diverse pool that has undergone 
affinity maturation in vivo, removing the painstaking task of antibody engineering. 
This panel of VHH can also be used for the identification and characterization of 
conserved epitopes on HIV-1 envelope proteins that can serve as templates for the  
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design of new immunogens in reverse immunology, and also as research reagents for 
potential use as therapeutics in combination with other antiretroviral drugs.  
As mentioned earlier, these VHH can be easily manipulated to make them better 
candidates for microbicide or vaccine development. For example, these VHH can be 
humanised and reconstructed into conventional antibodies to remove any potential 
immunogenicity in humans (Desmyter et al., 2001; Men et al., 2004). VHH can also 
undergo in vitro affinity maturation to produce VHH with greater affinities to their 
antigens. Such methods include the use of ribosome display, which is a cell-free 
system  for  the  in  vitro  selection  of  proteins  through  the  formation  of  protein-
ribosome-mRNA  (PRM)  complexes,  and  then  harvesting  the  captured  RNA  for 
further  rounds  of  selections.  When  used  in  combination  with  low-fidelity  DNA 
polymerase to generate random mutations, in vitro protein evolution can be achieved 
(Zahnd et al., 2007).  
In Chapters 4 and 5 of this thesis, the isolated VHH were first selected by panning on 
recombinant antigens and individual colonies were then picked for further screening. 
Due  to  the  hundreds  (sometimes  thousands)  of  clones  selected,  the  individual 
screening of the selected clones were often limited to testing for binding in ELISA. 
Although it would be desirable to screen for neutralisation instead of binding, since 
binding to recombinant envelope does not always correlate with neutralisation of 
virions (Pantophlet and Burton, 2006; Zanetti et al., 2006; Zhu et al., 2006), the 
testing  of  hundreds  of  clones  in  neutralisation  assays  against  a  panel  of  various 
viruses would involve thousands of assays and prove to be impractical. Although the 
TZM-bl  assay offers  medium-throughput in 96-well  formats, a  higher-throughput  
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neutralisation assay is needed to effectively screen the hundreds of selected VHH 
against a variety of HIV-1 isolates to identify interesting VHH.  
Thus far, VHH have been utilised to target gp41 and the CD4bs on gp120 in HIV-1 
research. For future work, VHH can also be employed to target CD4-induced sites 
(including the coreceptor binding site) on gp120. Although the antibodies targeting 
the  CD4-induced  sites  are  usually  non-neutralising,  presumably  due  to  steric 
hindrance by conventional immunoglobulins which are too bulky to bind onto virus-
associated  functional spike, several  Fab  fragments to CD4-induced epitopes have 
been shown to be able to neutralise primary isolates (Burton et al., 2004; Labrijn et 
al., 2003). VHH, which are even smaller than Fabs, might be ideal candidates to 
interrogate the coreceptor binding site.  
In  conclusion,  this  study  has  investigated  and  characterised  subtype  C  HIV-1 
envelopes  from  primary  isolates,  which  are  responsible  for  the  majority  of  new 
infections in the world today. The unique properties of llama antibody fragments 
were exploited in this study to isolated VHH that can neutralise HIV-1 infection 
derived from these subtype C envelopes, as well as envelopes from other isolates and 
subtypes. These anti-gp41 and anti-CD4 binding site VHH may be the first reported 
incidence of neutralising antibody isolation from an immunised animal instead of a 
natural infection in humans. These neutralising VHH can be utilised for further use 
in microbicide and vaccine research. 
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